A study of a proline specific seprase activity from mammalian serum by O'Brien, Pamela
A Study of a Proline Specific 
Seprase Activity 
from Mammalian Serum
Thesis submitted for the degree of 
Doctor of Philosophy
by
Pamela O’Brien, B.Sc.
Supervised by 
Dr. Brendan F. O’Connor
School of Biotechnology 
Dublin City University 
Ireland
August 2006
Declaration
I hereby certify that this material, which I now submit for assessment on the 
programme o f study leading to the award o f Doctor o f Philosophy, is entirely my 
own work and has not been taken from the work of others save and to the extent that 
such work has been cited and acknowledged within the text o f my work.
Signed: O "ferign ID No.: 98399080
Pamela O’Brien
Date: ^ 0 0 6
I
Dedications
I would like to dedicate this thesis, the hard work and long hours that went into 
completing it to .......
Brendan for giving me the opportunity to take on this challenge. Your enthusiasm 
helped me through those ‘groundhog days’ and made the whole experience an 
enjoyable and memorable one.
My parents and big sister Jen. Thank you for all your encouragement and support 
over the years. My student days are now over! Thank god I hear you say!
Daragh, thank you for being there to listen, encourage and support me when I needed 
you. Thank you for being you!
Zelda, for keeping me company in the lab and for our chats! It kept me going on 
those long days.
The DCU gang. Our coffee breaks, lunches and nights out were always entertaining -  
cheers! And for those who opened their labs up to me - 1 thank you!
To Paraic and Paul....what can I say boys. Thank you both for all your help in 
decoding the genetic code for me! You have both provided me with great 
entertainment, in and out o f the lab! Paraic, your theories were enlightening.
To Roman and Pat. Your help and guidance when I started this project was greatly 
appreciated.
And to the girls, Aoife, Anita and Niamh. For your friendship and most importantly 
for introducing me to the joys o f Harry Potter back in the BT days!
Thank you!
II
Papers
Collins PJ, McMahon G, O'Brien P, O’Connor B. (2004) Purification, identification 
and characterisation o f seprase from bovine serum. Int J  Biochem Cell Biol. 
36(11):2320-2333.
O’Brien, P and O’Connor B. Review: Seprase, A strategically important Matrix 
Serine Protease. BBA Reviews. [Manuscript in preparation].
O’Brien P, O’Donoghue A, McMahon G, Craik C, O’Connor B. Characterisation o f  
the active site o f Seprase, a novel post proline cleaving endopeptidase. Proc Natl 
Acad Sci. [Manuscript in preparation].
Posters
O’Brien P, Collins PJ, O’Donoghue A, Craik CS, and O’Connor B. Identification 
and Characterisation o f Seprase from Bovine Serum. IACR Annual meeting, 
Galway. March 2006.
O'Brien P and O'Connor B. Molecular Cloning and Characterisation o f  Seprase. 
National IRCSET Symposium, Croke Park, Dublin. November 2005.
O'Brien P and O'Connor B. The Purification and Characterisation o f  Seprase from  
Bovine Serum. National IRCSET Symposium, Croke Park, Dublin. November 2004.
O'Brien P and O'Connor B. The Purification and Characterisation o f Seprase from  
Bovine Serum. National IRCSET Symposium, Royal Hospital Kilmainham, Dublin. 
November 2003.
Presentations
O’Brien P and O’Connor B. (2005) “Seprase -  A potential Biomarker fo r  Breast 
C a n c e r Breast Check, Mater Misericordiae Hospital, Dublin.
O’Brien P and O’Connor B. (2006) “Review o f  the Clinical Research Study on 
Seprase levels in IDC.” Breast Check, Mater Misericordiae Hospital, Dublin.
Publications
Ill
Abbreviations
A600 Absorbance at 600 nm
AA Amino Acid
Ac Acetyl
AEBSF 4-(2-aminoethyl)-benzenesulfonyl fluoride
ACC 7-amino-4-carbamoylmethylcoumarin
AFC 7-amino-4-trifluoromethylcoumarin
AFP alpha- feto protein
otiAPpro cfc-antiplasmin, ‘pro’ form, 464 amino acid residues
c ^ A P a c t  Cfc-antiplasmin, mature form, 4 5 2  amino acid residues
AMC 7-amino-4-methylcoumarin
AMCC 7-amino-4-methyl-3-carbamoylmethylcoumarin
AP cfc-antiplasmin
APCE Antiplasmin Cleaving Enzyme
APMSF 4-amidino-phenylmethane-sulphonyl fluoride
APSF 4-amidino phenylsulfonyl fluoride
BCA Bicinchoninic Acid
BCIP 5-Bromo-4-chloro-3-indolyl phosphate, toluidine salt
B isacry 1 B isacry lamide
BoroPro Prolineboronic acid
bp Base-pair
BSA Bovine Serum Albumin
BT Benzothiazol
Bz Benzoyl
CA Cancer antigen
CAPS N-cyclohexyl-3-aminopropanesulfonic acid
cDNA copy Deoxyribonucleic acid
CEA Carcinoembryonic antigen
cmk Chloromethyl-ketone
CMV Cytomegalovirus
CN 2-nitrile
Cone. Concentration
CPC Calcium Phosphate Cellulose
DABCYL 4-(4-dimethylaminophenylazo)benzoyl
DAPI 4’,6-diamidino-2-phenylindole
DEPC Diethyl Pyrocarbonate
DIC Differential Interference Contrast
DICI Diisopropylcarbodiimide
DFP Diisopropyl fluorophosphates
dl-hO Deionised water
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DPIV Dipeptidyl peptidase IV
DPPIV Dipeptidyl peptidase IV
DTT Dithiothreitol
EBV Epstein Barr Virus
EC Enzyme commission
eds. Editors
ECM Extracellular matrix
EDANS 5-[(2-aminoethyl)amino]-naphthalene-l-sulfonic acid
EDTA Ethylenediaminetetra acetic acid
EH Eadie-Hofstee
EtOH Ethanol
FAPa Fibroblast Activation Protein-alpha
FGF-2 Fibroblast growth factor 2
FITC Fluorescein isothiocyanate
FLAG Octapeptide - DYKDDDDK
Fmoc 9-fluorenylmethyloxy carbonyl
FPLC Fast Protein Liquid Chromatography
FRET Fluorescence Resonance Energy Transfer
HATU 0-(7-Azabenzotriazole-1 yl)-N,N,N’N ’-tetramethyluronium
hexafluorophosphate 
HC1 Hydrochloric Acid
HCV Hepatitis C virus
HIC Hydrophobic Interaction Chromatography
HOBt N-hydroxy benzotriazole
V
HPLC
HR
HW
IC50
IDC
IEF
IgG
IMAC
IPF
IPTG
JTP-4819
kcat
Ki
Km
\c  aPP
LB
LB
Log
LOX
mAb
MCS
MeOH
MMP
MOPS
mRNA
MW
NaCl
NaOH
NBT
ND
NEM
NPY
NT A
High Performance Liquid Chromatography
High Resolution
Hanes-Woolf
Inhibitor conc. resulting in 50% loss in enzymatic activity 
Infiltrating ductal carcinoma 
Isoelectric focusing 
Immunoglobulin G
Immobilised metal affinity chromatography
Idiopathic pulmonary fibrosis
Isopropyl-j$-D-thiogalactopyranoside
(S)-2-[[(S)-2-(hydroxyacetyl)-l-pyrrolidinyl]carbonyl]-N-
[phenylmethyl] - 1 -pyrrolidinecar-boxamide
Turnover number
Inhibition Constant
Michaelis constant
Apparent Km
Lineweaver-Burk
Luria Bertani
Logarithm
Human melanoma cell line 
Monoclonal antibody 
Multiple cloning site 
Methanol
Matrix metallo-proteinase
3-(N-Morpholino)propanesulfonic acid
Messenger RNA
Molecular Weight
Sodium Chloride
Sodium Hydroxide
Nitro blue tetrazolium chloride
Not determined
N-ethylmaleimide
Neuropeptide Y
Nitrilotriacetic acid
VI
OA Osteoarthritis
OD Optical density
ORF Open reading frame
P Statistical significance
PAGE Polyacrylamide gel electrophoresis
PAP 1 Pyroglutamyl Peptidase I
PBS Phosphate buffered saline
PCR Polymerase Chain Reaction
PDB Protein data bank
PE Prolyl Endopeptidase
PEP Prolyl Endopeptidase
pH log o f  the reciprocal o f  the hydrogen ion concentration
pi Isoelectric point
PIPES Piperazine-1,4-bis(2-ethanesulfonic acid)
PMSF Phenylmethylsulphonyl fluoride
PO Prolyl oligopeptidase
POP Prolyl oligopeptidase
PVDF Polyvinylidene fluoride
Pyrr Pyrrolidide
RBS Ribosome binding site
RCO Acyl
RET Resonance energy transfer
RFU Relative Fluorescence Units
RNA Ribonucleic acid
rRNA Ribosomal RNA
RPMI Roswell Park Memorial Institute medium
RT-PCR Reverse transcription PCR
S9 Prolyl oligopeptidase family of serine proteases
SDS Sodium dodecyl sulphate
SEM Standard Error Mean
Serpin Serine protease inhibitor
SIMP Serine Integral Membrane Protein
SMC Smooth Muscle Cell
S-S Disulphide bridges
Suc- Succinyl
Tann Annealing Temperature
TAE Tris-Acetate/EDTA solution
TBS Tris Buffered Saline
TBS-T Tris Buffered Saline solution containing Tween 20
TE Tris/EDTA solution
T/E Trypsin/EDTA solution
TEMED N, N, N, N ’-tetramethyl ethylenediamine
TIS T riisopropylsilane
TFA Trifluoroacetic acid
Tm Temperature o f melting point
TRH Thyrotropin-releasing hormone
TRITC Tetramethylrhodamine isothiocyante
Tris Tris (hydroxymethyl) amino methane
tRNA Transfer RNA
uPA Urokinase plasminogen activator
uPAR Urokinase plasminogen activator receptor
UV Ultraviolet
v/v Volume per volume
V max Maximal enzyme velocity
WGA Wheat germ agglutinin
WG Wire guided
WLE Wide local excision
w/v Weight per volume
Xaa Any amino acid
X-Gal 5-bromo-4-chloro-3-indolyl-j3-D-galactopyranoside
Yaa Any amino acid
Z- Af-benzy lo xycarbony 1
Zaa Any amino acid
ZIP Z-Pro-prolinal insensitive Z-Gly-Pro-AMC degrading
peptidase
Vili
Units
A Ampere
A Angstrom ( 1 .0  x 1 0 ‘ 10 metres)
Da Dalton
g g-force (relative centrifugal force - ref)
g Gram
h Hour
Hz Hertz
k Kilo
kb Kilo base
L Litre
m Metre
M Molar
min Minute
mM Millimolar
°C Degrees Celsius
pH Logarithm of reciprocal hydrogen-ion concentration
pi Isoelectric point
rpm Revolutions per minute
sec Second
V Volts
Prefixes
k kilo (1 x 1 0 3)
c centi (1 x 1 0 '2)
m milli (1 x 1 0 '3)
\x micro (1 x 1 O'6)
n nano ( l x l 0‘9)
p pico (1 x 1 0 ' 12)
IX
Amino Acid Abbreviations
Ala A Alanine
Arg R Arginine
Asn D Asparagine
Asp N Aspartic acid
Cys C Cysteine
Gin Q Glutamine
Glu E Glutamic Acid
Gly G Glycine
His H Histidine
Ile I Isoleucine
Leu L Leucine
Lys K Lysine
Met M Methionine
Nie n Norleucine
Phe F Phenylalanine
Pro P Pro line
Ser S Serine
Thr T Threonine
Trp W Tryptophan
Tyr Y Tyrosine
Val V Valine
Abbreviations IV
Table of Contents XI
List of Figures XVIII
List of Tables XXIV
Abstract XXVI
Table of Contents
1.0 Introduction 1
1.1 Cancer 2
1.1.1 Cancer Development 3
1.2 Fibroblast Activation Protein a  / Seprase 7
1.3 Classification o f Seprase 7
1.4 Structure o f Seprase and Biochemical Aspects 8
1.4.1 Catalytic Classification 16
1.4.2 Biochemical Aspects of Seprase 18
1.5 Purification and Activity Detection o f Seprase 21
1.6 Distribution o f Seprase 22
1.7 Biological and Pathological Roles 27
1.7.1 Tumour Suppressor 27
1.7.2 Tumour Promoter 28
1.7.3 Seprase Complexes in cellular invasiveness 31
1.7.4 Antiplasmin Cleaving Enzyme (APCE) 33
1 .8  Substrate Specificity 36
1.8.1 Modifications o f  bioactive peptides 38
1.9 Possible Clinical Significance o f Seprase 40
1.9.1 Seprase provides target specificity to anti-tumour agents 40
1.9.2 Inhibition of Seprase protease activity 41
1.9.3 Disruption o f signalling 42
1.10 Bio markers 44
1.11 Aims of the project 48
Declaration I
Dedications II
Publications III
XI
2.0 Materials and Methods 50
2.1 Protein concentration 51
2.1.1 Quantitative determination by Biuret Assay 51
2.1.2 Quantitative determination by Standard BCA Assay 51
2.1.3 Quantitative determination by Coomassie Assay 51
2.2 Fluorescence Spectrometry using 7-Amino-4-Methyl-Coumarin
(AMC) 52
2.2.1 AMC Standard Curves 52
2.2.2 Inner Filter Effect 52
2.3 Enzyme Assays 53
2.3.1 Substrate Preparation 53
2.3.2 Quantitative Z-Gly-Pro-AMC degrading activity
measurements 5 3
2.3.2.1 Cuvette 53
2.3.2.2 Microtitre Plate 54
2.3.3 Quantitative Z-Pro-Prolinal Insensitive Z-Gly-Pro-AMC
(ZIP) degrading activity measurements 54
2.3.4 Non-quantitative Z-Gly-Pro-AMC degrading activity
measurements 5 5
2.4 An optimised purification procedure for Bovine Serum Seprase 56
2.4.1 Bovine Serum Preparation 56
2.4.2 Phenyl Sepharose Hydrophobic Interaction
Chromatography 56
2.4.3 Calcium Phosphate Cellulose Chromatography 57
2.4.3.1 Resin preparation 57
2.4.3.2 Column Chromatography 57
2.4.4 Cibacron Blue 3GA Chromatography 58
2.4.5 Sephacryl S-300 Size Exclusion Chromatography 58
2.4.6 Preparation o f dialysis tubing 59
2.5 Polyacrylamide Gel Electrophoresis 59
2.5.1 Preparation of SDS Gels 59
2.5.2 Sample Preparation 60
2.5.3 Sample Application 60
2.5.4 SDS PAGE Gel staining 61
XII
2.6 Identification o f this Z-Pro-Prolinal Insensitive Peptidase 62
2.6.1 Determination o f N-Terminal Protein Sequence 62
2.6.1.1 SDS Polyacrylamide Gel Electrophoresis 62
2.6.1.2 PVDF Electroblotting 62
2.6.2 Protein G Affinity Chromatography 63
2.6.3 Gelatin Sepharose Chromatography 63
2.6.4 UV Zymogram Development 64
2.6.4.1 Native Polyacrylamide Gel Electrophoresis 64
2.6.4.2 UV Zymogram Assessment 64
2.6.5 Gelatin Zymogram Development 64
2.6.6 Wheat germ Agglutinin (WGA) Lectin Affinity
Chromatography 65
2.7 Biochemical Studies 66
2.7.1 Temperature Studies 66
2.7.1.1 Determination o f Optimum Assay temperature 66
2.7.1.2 Thermal profile, (T5o) 66
2.7.1.3 Thermal Stability 66
2.7.1.4 Thermal Inactivation o f Seprase 67
2.7.2 Determination of pH Optimum 67
2.7.3 Determination o f the Second Order Rate Constant, (K2)
for DFP Inhibition o f Seprase 68
2.7.4 Inhibition Studies using synthesised Dipeptidyl Phosphonate
Esters 69
2.7.4.1 Partial Purification Procedure for Bovine Serum Prolyl
Oligopeptidase 69
2.7.4.1.1 Phenyl Sepharose Hydrophobic Interaction 
Chromatography I 69
2.7.4.1.2 Phenyl Sepharose Hydrophobic Interaction 
Chromatography II 69
2.7.4.1 .3 Cibacron Blue 3GA Chromatography 70
2.7A2 Inhibitor Analysis 71
2.8 Substrate Specificity Studies 73
2.8.1 Substrate Specificity using Combinatorial Dipeptide
Library 73
XIII
2.8.1.1 Preparation of the Seprase Sample 73
2.8.1.2 Construction o f the Dipeptide Substrate Library 74
2.8.1.3 Dipeptide Substrate Library Screening 75
2.8.2 Kinetic Analysis 76
2.8.2.1 Km Determination for Z-Gly-Pro-AMC 76
2.8.2.2 Ki(app) Determination using Selected Synthetic 
Peptides 76
2.9 Tissue Localisation Studies 78
2.9.1 Tissue preparation 78
2.9.2 Preparation o f cleared lysate sample from mammalian
cells 7 9
2.10 Molecular Cloning o f Seprase 81
2.10.1 Bacterial strains, primers and plasmids 81
2.10.2 Media, solutions and buffers 87
2.10.3 Isolation and purification o f DNA and RNA 90
2.10.3.1 Isolation o f RN A 90
2.10.3.2 Isolation o f plasmid DNA 90
2.10.3.2.1 1-2-3 Method 91
2.10.3.2.2 GenElute Plasmid Miniprep Kit 91
2.10.3.2.3 Qiagen plasmid Mini Kit 92
2.10.3.3 Isolation o f DNA from agarose gels 93
2.10.3.3.1 Glass wool gel extraction 93
2.10.3.3.2 PerfectPrep Kit 93
2.10.3.4 Purification and concentration o f DNA 
samples 93
2.10.3.5 Quantification of DNA and RNA 94
2.10.4 Agarose Gel Electrophoresis 94
2.10.5 Competent Cells 95
2.10.5.1 Rubidium chloride method 95
2 . 1 0.5.2 Transformation o f competent cells 96
2.10.5.3 Determining competent cell efficiency 96
2.10.6 Bacterial Storage 96
2.10.7 Enzymes 97
2.10.7.1 Reverse transcription 97
XIV
2.10.7.2 Polymerase chain reaction 97
2.10.8 Gene manipulation 98
2.10.8.1 Antarctic Phosphatase Reaction 98
2.10.8.2 Cloning o f PCR Products 99
2.10.9 DNA Sequencing 99
2.10.10 Bio-Informatics 99
2.10.11 Prokaryotic Expression System 101
2.10.11.1 Protein Expression 101
2.10.11.1.1 Standard expression culture 1 01
2.10.11.1.2 Preparation of cleared lysate 101
2.1 0.11.2 Protein purification using the Standard
IMAC procedure 1 02
2.10.11.2.1 Standard IMAC procedure 102
2.10.11.2.2 Recharging the Ni-NTA resin 102
2.10.12 Mammalian Expression System 103
2.10.12.1 Cell Culture Methods 103
2 . 1 0 . 1 2 . 1 . 1  Culture o f Cells in Suspension 103
2.10.12.1.2 Culture o f Adherent Cells 103
2.10.12.2 Cell Counts 104
2.10.12.3 Cell Storage and Recovery 105
2.10.12.4 Transfection o f Cells using Electroporation 105
2.10.12.5 Stable Transfections 106
2.10.12.6 Western Blot 107
2.10.12.6.1 Preparation o f Cellular Protein 107
2.10.12.6.2 Western Blot Analysis 107
2.10.12.7 Immunocytochemistry 108
2.11 Clinical Research Study o f Human Serum 109
3.0 Purification and Characterisation of Seprase from Bovine Serum 111
3.1 Protein Determination 1 1 2
3.2 AMC Standard Curve and Inner Filter Effect 114
3.3 An Optimised Purification procedure for Bovine Serum
Seprase (ZIP) 117
XV
3.3.1 Phenyl Sepharose Hydrophobic Interaction
Chromatography (HIC) 118
3.3.2 Calcium Phosphate Cellulose Chromatography 121
3.3.3 Cibacron Blue 3GA Chromatography 123
3.3.4 Sephacryl S-300 HR Size Exclusion Chromatography 124
3.4 Purity Assessment 127
3.5 Identification of the Z-Pro-Prolinal Insensitive Peptidase 129
3.5.1 UV Zymogram Development 131
3.6 Gelatin Zymography 134
3.7 Wheat Germ Agglutinin (WGA) Lectin Affinity
Chromatography 135
4.0 Biochemical Analysis of Seprase 139
4 .1 Temperature Studies 140
4.1.1 Determination of Optimum Assay Temperature 140
4.1.2 Thermal Profile, (T50) 141
4.1.3 Thermal Stability 142
4.1 .4 Thermal Inactivation of Seprase 143
4.2 Influence o f pH 144
4.3 Determination o f the Second Order Rate Constant, (K2) for
DFP Inhibition o f Seprase 145
4.4 Inhibition Studies 149
4.4.1 Partial Purification Procedure for Bovine Serum Prolyl
Oligopeptidase 149
4.4.1.1 Phenyl Sepharose Hydrophobic Interaction 
Chromatography I 149
4.4.1.2 Phenyl Sepharose Hydrophobic Interaction 
Chromatography II 151
4.4.1.3 Cibacron Blue 3GA Chromatography 153
4.4.2 Inhibitor Analysis 155
XVI
5.0 Substrate Specificity Studies 160
5.1 Substrate Specificity using Combinatorial Dipeptide Library 162
5.2 Kinetic Analysis 169
5.2.1 Km determination for Z-Gly-Pro-AMC 169
5.2.2 Competitive inhibition o f Seprase by synthetic peptides 174
5.2.2.1 Effect o f Tri- and Tetra-peptides on
Seprase Activity 182
6.0 Localisation Studies 186
6 .1 Localisation Studies 187
6.1.1 Bovine Tissue Studies 187
6.1.2 Cell Localisation Studies 193
7.0 Molecular Cloning of Seprase 195
7.1.1 Cloning o f human Seprase gene 196
7.1.2 Cloning o f human Seprase gene into pcDNA3
and pcDNA3-HA 206
7.1.3 Cloning o f human Seprase gene into pQE30-Xa 217
7.1.4 Cloning o f human Seprase gene into pIRES-hrGFP II 224
8.0 Clinical Research Study of Human Serum 228
9.0 Summary and Recommendations 235
References 238
Appendices 256
XVII
List of Figures
Chapter 1
Figure 1.1.1 Microecology o f the tumour-host invasion field 4
Figure 1.1.2 Summary o f intracellular signalling 5
Figure 1.4.1 General structure of Serine-Integral Membrane peptidases
(SIMP) 8
Figure 1.4.2 Three-Dimensional Structure o f Seprase 9
Figure 1.4.3 ct//3 hydrolase domain o f  Seprase 1 0
Figure 1.4.4 Eight bladed /3-propeller domain o f Seprase 11
Figure 1.4.5 Amino acid sequence alignment o f eukaryotic Seprase
C-terminal 13
Figure 1.4.6 Superposition o f Seprase with DPPIV showing detailed
view o f the residues around the Glu motif 14
Figure 1.4.7 Schematic representation of the catalytic mechanism of
Serine Proteases 17
Figure 1.4.8 Catalytic Triad of Seprase 18
Figure 1.6 .1 Detection o f Seprase antigen and enzyme activity in
human tissue 23
Figure 1.6.2 Detection of Seprase antigen expression in IPF 25
Figure 1.7.1 Model o f Seprase supramolecular complexes 30
Figure 1.7.2 Co-localisation o f Seprase and f t integrin 31
Figure 1.7.3 Co-localisation and RET of Seprase and uPAR on LOX
cells 33
Figure 1.7.4 Summary o f fibrinolytic system 34
Figure 1.8.1 Seprase binding model 38
Figure 1.10.1 The roadmap for cancer bio marker development 46
Chapter 2
Figure 2.2.1 Chemical Structure of JTP-4819 52
Figure 2.5.1 Coloured Markers 60
Figure 2.7 Chemical Structure o f the Dipeptidyl Phosphonate esters 71
XVIII
Figure 2.8 Diagram illustrating 7-amino-4-carbamoylmethylcoumarin
(ACC)-labelled dipeptide library construction using standard 
Fmoc protocols where SPPS corresponds to solid 
phase peptide synthesis 7 5
Figure 2.10.1 pCR2.1 vector 85
Figure 2.10.2 pQE30-Xa vector 85
Figure 2.10.3 pcDNA3 and pcDNA3-HA vectors 86
Figure 2.10.4 pIRES-hrGFP II vector 86
Figure 2.10.5 DNA Ladders 95
Figure 2.10.12.2 Diagram o f Haemocytometer 104
Chapter 3
Figure 3.1.1 BSA Standard Curve 1 1 2
Figure 3.1.2 BSA Standard Curve 113
Figure 3.1.3 BSA Standard Curve 113
Figure 3.2.1 AMC Standard Curve 115
Figure 3.2.2 AMC Standard Curve 115
Figure 3.2.3 Serum Quenched AMC Standard Curve 116
Figure 3.2.4 Post Phenyl Sepharose Quenched AMC Standard Curve 116
Figure 3.3.1 Fractionation of the Two Z-Gly-Pro-AMC Hydrolysing
Activities in Bovine Serum by Phenyl Sepharose 
Hydrophobic Interaction Chromatography 1 20
Figure 3.3.2 Differentiation o f the Two Distinct Z-Gly-Pro-AMC
Degrading Activities in Bovine Serum by the inclusion 
o f JTP-4819 120
Figure 3.3.3 Elution profile of Seprase during Calcium Phosphate
Cellulo se Chromatography 1 22
Figure 3.3.4 Elution profile o f Seprase during Cibacron Blue 3GA
Chromatography 123
Figure 3.3.5 Elution profile of Seprase during S-300 Gel Filtration
Chromatography 125
Figure 3.4.1 SDS-Gel o f Purification Procedure 128
Figure 3.4.2 SDS-Gel o f Purification Procedure 128
Figure 3.5.1 Coomassie- Stained PVDF Membrane B lot 129
XIX
Figure 3.5.2 SDS PAGE Gel o f Partial purified ZIP sample 130
Figure 3.5.3 Native PAGE analysis o f ZIP Proteolytic Analysis 131
Figure 3.5.4 UV Zymogram and Silver Staining o f native ZIP 132
Figure 3.5.5 Peptides sequenced and identified as Seprase 133
Figure 3.5.6 Seprase amino acid sequence 13 3
Figure 3.6.1 Gelatinolytic Activity o f Seprase, detected by Zymography 134
Figure 3.7.1 Elution profile o f Seprase Activity during WGA Lectin
Affinity Chromatography 136
Chapter 4
Figure 4.1.1 Determination o f the Optimum Assay temperature
for Seprase 140
Figure 4.1.2 Thermal profile o f Seprase 141
Figure 4.1.3 Determination o f the Thermal Stability o f Seprase 142
Figure 4.1.4 Thermal Inactivation o f Seprase 143
Figure 4.2 Influence o f pH on Seprase activity 144
Figure 4.3.1 Standard Curve for DFP Analysis 147
Figure 4.3.2 K2 determination for DFP Inhibition o f Seprase 147
Figure 4.4.1 Elution profile o f PO activity during Phenyl Sepharose
Hydrophobic Interaction Chromatography I 150
Figure 4.4.2 Elution profile of PO activity during Phenyl Sepharose
Hydrophobic Interaction Chromatography II 151
Figure 4.4.3 Cibacron Blue 3GA Chromatography of PO activity 153
Figure 4.4.4 Structure o f 8h Inhibitor 155
Figure 4.4.5 Inhibitor Profile Effect o f the compound 8 Series 156
Figure 4.4.6 Inhibitor Profile Effect o f the compound 9 Series 157
Figure 4.4.7 Inhibitor Profile Effect o f the compound 10 Series 158
Chapter 5
Figure 5.1.1 Schematic representation o f an Enzyme-Substrate
Complex 163
Figure 5.1.2 Pj Positional Scanning Profile for Seprase 164
Figure 5.1.3 P2 Positional Scanning Profile from 0-60 minutes
for Seprase 165
XX
Figure 5.1.5
Figure 5.2.1 
Figure 5.2.2 
Figure 5.2.3 
Figure 5.2.4 
Figure 5.2.5
Figure 5.2.6
Figure 5.2.7
Figure 5.2.8
Figure 5.2.9
Figure 5.2.10
Figure 5.2.11
Figure 5.2.12
Figure 5.2.13
Figure 5.2.14
Figure 5.2.15
Figure 5.1.4
Figure 5.2.16
P2 Positional Scanning Profile from 12-60 minutes 
for Seprase 166
Positional Scanning combinatorial dipeptide library 
profiles 168
Michaelis-Menten curve for purified Seprase 170
Lineweaver-Burk plot for purified Seprase 170
Eadie-Hofstee plot for purified Seprase 171
Hanes-Woolf plot for purified Seprase 171
Kjapp determination for Z-Gly-Met-Phe using 
Lineweaver-Burk plot 175
Kjapp determination for Z-Gly-Pro-Phe using Lineweaver- 
Burk plot 175
Kiapp determination for Z-Ala-Pro-Phe using Lineweaver- 
Burk plot 176
Kiapp determination for Z-Ala-Met-Phe using Lineweaver- 
Burk plot 176
K app determination for Z-Ala-Nle-Phe using Lineweaver- 
Burk plot 177
Kjapp determination for Z-Gly-Met-Phe-His using Lineweaver- 
Burk plot 177
K app determination for Z-Gly-Nle-Phe-His using Lineweaver- 
Burk plot 178
K app determination for Z-Ala-Pro-Phe-His using Lineweaver- 
Burk plot 178
K app determination for Z-Ala-Nle-Phe-His using Lineweaver- 
Burk plot 179
Kjapp determination for Z-His-Pro-Phe-His using Lineweaver- 
Burk plot 179
Kjapp determination for Ala-Ser-Gly-Pro-Ser-Ser using 
Lineweaver-Burk plot 180
K app determination for Ala-Ser-Nle-Pro-Ser-Ser using 
Lineweaver-Burk plot 1 80
XXI
C hapter 6
Figure 6.1.1 Total Seprase Activity in Bovine Tissue 188
Figure 6.1.2 Specific Activity o f Seprase in Bovine Tissue 188
Figure 6.1.3 Total Prolyl Oligopeptidase Activity in Bovine Tissue 189
Figure 6.1.4 Specific Activity o f Prolyl Oligopeptidase in Bovine Tissue 189
Figure 6.1.5 Specific Activity o f Seprase in Si Fraction 190
Figure 6.1.6 Specific Activity o f Prolyl Oligopeptidase in Si Fraction 190
Figure 6.1.7 Z-Gly-Pro-AMC Hydrolysing Activity Profile for Mammalian
Cells 193
Figure 6.1.8 Total Seprase Activity in Mammalian Cell Lines 193
C hapter 7
Figure 7.1.1 RNA Analysis 196
Figure 7.1.2 Cloning o f human Seprase gene 197
Figure 7.1.3 Control PCR Reactions 198
Figure 7.1.4 Human Seprase mRNA sequence 199
Figure 7.1.5 The Cloning of rSeprase in two parts strategy 2 0 0
Figure 7.1.6 Verification Digest o f pPOBl 2 0 1
Figure 7.1.7 pPOBl Plasmid Map 2 0 2
Figure 7.1.8 DNA Sequencing of pPOBl 203
Figure 7.1.9 Alignments of Sequences 205
Figure 7.1.10 Verification Digest o f pPOBl 2 207
Figure 7.1.11 pPOBl2 Plasmid Map 208
Figure 7.1.12 DNA Sequencing o f pPOBl 2 209
Figure 7.1.13 Verification Digest for pPOBl5-18 2 1 0
Figure 7.1.14 pPOBl5-18 Plasmid Map 2 1 1
Figure 7.1.15 Expression profile o f transfected cell lines 2 1 2
Figure 7.1.16 mRNA Analysis o f stable transfected cell lines 213
Figure 7.1.17 Western Blot Analysis o f rSeprase expression 214
Figure 7.1.18 Alignment o f Mammalian Expression Clones 5’ Upstream
Sequence 215
Figure 7.1.19 Immunocytochemistry o f stably transfected cell lines 216
Figure 7.1.20 Verification digest o f pQPOB5 218
Figure 7.1.21 pQPOB5 Plasmid Map 219
XXII
Figure 7.1.22 Sequence of pQPOB5 aligned with that o f Seprase 219
Figure 7.1.23 Expression and Purification o f rSeprase in E. coli XL10-Gold 
and BL21(DE3) 221
Figure 7.1.24 E. coli codon bias relative to rSeprase 223
Figure 7.1.25 Verification Digest for pIRPOB 1 and pIRPOB2 225
Figure 7.1.26 pIRPOBl and pIRPOB2 Plasmid Map 225
Figure 7.1.27 Alignment o f pIRES-hrGFP II Mammalian
Expression Clones 226
Chapter 8
Figure 8.1 Total Activity o f Serum Samples from frill cohort
of patients 232
Figure 8 .2  Specific Activity of Serum Samples from full
cohort o f patients 232
XXIII
List of Tables
Chapter 1
Table 1.4 
Table 1.8
Table 1.10
Chapter 2
Table 2.5.1 
Table 2.5.2 
Table 2.7 
Table 2.8 
Table 2.9.1 
Table 2.9.2 
Table 2.10.1 
Table 2.10.2 
Table 2.10.3 
Table 2.10.4 
Table 2.10.12.6
Chapter 3
Table 3.3.1 
Table 3.7.1
Table 3.7.2
Chapter 4
Table 4.4.1
Table 4.4.2
Biochemical properties o f Seprase 20
Kinetic constants for the hydrolysis o f fluorogenic dipeptide 
substrates by Seprase 37
Conditions associated with elevated tumour marker levels 
in serum 45
SDS PAGE Gel Preparation 59
Silver Staining Procedure 61
Structure o f the Dipeptidyl Phosphonates Esters 71
Peptide preparation for Kj (app) Determinations 77
Bovine Tissue Samples 79
Mammalian Cell Lines 80
Bacterial Strains 81
Primers (obtained from MWG-Biotech AG) 82
Sequencing Primers (obtained from MWG-Biotech AG) 83 
Plasmids 84
Incubation Conditions for Antibodies used 108
Purification o f Seprase from Bovine Serum 126
Purification o f Seprase from Bovine Serum using the 
WGA Affinity Lectin Column 137
Comparison o f important biochemical properties o f both 
enzymes 138
Partial Purification o f Prolyl Oligopeptidase from 
Bovine Serum 154
Overall Inhibitory Studies on Seprase and prolyl 
Oligopeptidase 159
XXIV
Chapter 5
Table 5.2.1 Kinetic parameters for Seprase 172
Table 5.2.2 K,app values for selected peptides 181
Chapter 6
Table 6.1.1 Levels o f Seprase and PO Activities in various
Bovine samples 191
Chapter 7
Table 7.1.1 Summary o f cloning strategy o f pcDNA3 and pcDNA3-HA
vectors 2 1 2
Chapter 8
Table 8.1 Characteristics of the patient cohort supplying
serum samples 231
Table 8.2 Test o f Normality o f Clinical Samples 233
Table 8.3 Group Statistics o f Clinical Samples 233
Table 8.4 Independence Samples Test 233
XXV
Abstract
Seprase or Fibroblast activation protein (FAP) is an integral membrane serine 
peptidase, which has been shown to have gelatinase activity. It appears to act as a 
proteolytically active 170-kDa dimer, consisting o f  two 97-kDa subunits. It is a 
member o f  the group type II integral serine proteases, which include dipeptidyl 
peptidase IV  (DPPIV/CD26) and related type II trans-membrane prolyl serine 
peptidases, which exert their mechanisms o f action on the cell surface. DPPIV and 
Seprase exhibit multiple functions due to their abilities to form complexes with each 
other and to interact with other membrane-associated molecules. Localization o f  
these protease complexes at cell surface protrusions, called invadopodia, may have a 
prominent role in processing soluble factors and in the degradation o f extracellular 
matrix components that are essential to the cellular migration and matrix invasion 
that occur during tumour invasion, metastasis and angiogenesis.
Seprase was isolated and purified from bovine serum, yielding a specific activity o f  
166.41 units/mg. The purified soluble Seprase was shown to have both exopeptidase 
and endopeptidase activity. The soluble form o f  the glycoprotein was shown to bind 
to the Wheat Germ Agglutinin (WGA)-Lectin Affinity Chromatography. Biochemical 
studies show that Seprase has a pH  optimum o f 8.0 and it is thermostable (up to 40 
°C). The second order rate constant, k2 fo r  DFP inhibition o f Seprase was determined 
to be 3.31 x 103 Af V 7. Positional scanning o f  the Pi dipeptide library determined 
that Seprase has a marked preference fo r  proline in the Si subsite. Data obtained 
during screening o f  the P2 sub-library revealed a much broader specificity in the S2 
binding pocket o f  bovine Seprase. In the S2 subsites, this study shows that Seprase has 
a preference fo r  Nor leucine, Alanine, Leucine, Glycine, Arginine, Methionine and 
does not tolerate aromatic, strongly basic or acidic residues. The kinetic constant Km 
determined fo r  purified Seprase was 82.10¡jM. Seprase was found to have an average 
kCat /  Km ratio o f 1.17 x 105 M 1 s'1 fo r  cleavage o f  the fluorimetric substrate Z-Gly- 
Pro-AMC. Tissue localisation studies identified Seprase activity in bovine large 
intestine, serum, kidney, liver and spleen and also in the breast cancer cell line 
Hs578T. Seprase was successfully cloned into prokaryotic and eukaryotic expression 
systems. Clinical studies on serum samples from breast cancer patients indicated that 
Seprase levels are elevated in patients with invasive ductal carcinoma.
XXVI
Chapter 1 
Introduction
Cancer is a class o f diseases or disorders characterized by uncontrolled division o f cells 
and the ability of these cells to invade other tissues, either by direct growth into adjacent 
tissue through invasion or by implantation into distant sites by metastasis. The word 
cancer comes from the Greek word ‘Karkinos’ meaning crab, which refers to the 
metaphorical claws reaching out to invade surrounding tissues. ‘Cancer’ generally refers 
to a malignant tumour or neoplasm. Malignant tumours possess potentially lethal 
abnormal characteristics enabling them to invade and to metastasise, or spread, to other 
tissues.
Each year there are over 19,000 new cancer cases and 11,000 cancer deaths in Ireland 
(The National Cancer Registry Ireland www.ncri.ie). The four commonest types o f 
cancer are breast, colorectal, lung and prostate. For women in Ireland, incidence rates of 
breast, colorectal, lung, lymphoma cancers and melanoma o f the skin are significantly 
higher than the rates for other women in the EU. For women, breast cancer is the leading 
type of cancer and the leading cause of cancer-related death. Breast cancer currently 
affects over 1,700 women in Ireland every year (The Irish Cancer Society 
www.cancer.ie).
The earlier breast cancer is diagnosed and treated, the better the long-term prospects for 
women with the disease. It is important when patients are diagnosed with cancer that 
doctors know whether the disease is local or has spread to other locations. It is this 
ability to spread to other tissues and organs that makes cancer a possibly life-threatening 
disease. Therefore it is of great interest to scientists and clinicians to understand what 
makes metastasis possible for a cancerous tumour.
1.1 Cancer
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Cancer development is a multi-step process driven in most part by genetic change. 
Mutation of genes can be either inherited or acquired. Irreversible damage to DNA leads 
to the formation of a cell containing DNA errors, which can multiply to form additional 
mutated cells. Under normal conditions DNA repair may revert the cell back to a normal 
cell. In other cases programmed cell death or apoptosis is initiated. Failure in each case 
usually results in carcinogenesis.
However, it is becoming increasingly apparent that the tumourigenic phenotype must 
overcome the suppressive effects of the surrounding microenvironment. Solid tumours 
consist of neoplastic cells and stroma. The neoplastic cell population is embedded in and 
supported by a connective tissue framework called the stroma (from the Greek word 
meaning mattress), which provides mechanical support and nutrition to the neoplastic 
cells.
Under normal conditions tissues communicate through a complex network of 
interactions which are necessary for cellular differentiation and to create complex tissue 
structures. This may be (i) physically, through direct contact or through the intervening 
extracellular matrix (ECM) or (ii) biochemically through soluble/insoluble signalling 
molecules. These intracellular signals may become disrupted, for example, by the 
activation of fibroblasts due to wound healing (Liotta et al., 1991). These conditions are 
normally temporary and reversible. However, when inflammation is sustained, 
continuous upregulation of enzymes (such as matrix metalloproteinases MMPs) by 
stromal fibroblasts can disrupt the ECM, and invading immune cells can overproduce 
factors that promote abnormal proliferation. The transition from normal to invasive 
carcinoma is preceded by, or is concomitant with, activation of the local host stroma (see 
Figure 1.1.1) (Liotta and Kohn, 2001).
1.1.1 Cancer Development
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Figure 1.1.1 Microecology of the tumour-host invasion field
Transition of the invasive carcinoma is preceded by the activation o f host fibroblasts, immune cells and 
endothelial cells. Invasion occurs in a localised area of cross-talk and cooperation between the stromal 
cells and the pre-malignant epithelium (depicted as zones demarked by dashed lines). Cytokine and 
enzyme exchange between the participating cells stimulates migration of both cell types towards each 
other and modifies the adjacent extracellular matrix/basement membrane (ECM). The result is the 
breakdown of normal tissue (Liotta and Kohn, 2001)
Wound healing and tumour development are dynamic progressive processes that involve 
the interaction of several tissue types and have many mechanistic similarities. The 
composition of tumour stroma markedly resembles that of wound granulation tissue, 
although a distinguishing feature of the tumour stroma is the absence of platelets and a 
lower density o f inflammatory cells (Sieweke and Bissell, 1994). In cancer, these 
changes in the stroma drive invasion and metastasis (formation of secondary tumours), 
the hallmarks of malignancy (see Figure 1.1.2). Bissell and Radisky (2001) describe how 
tumours activate some of the normal wound-healing responses. Tumour cells produce 
many of the same growth factors that activate the adjacent stromal tissues as in 
wounding or fibrosis. Activated fibroblasts and infiltrating immune cells (macrophages) 
secrete proteases (MMPs) and cytokines such as FGF-2 (fibroblast growth factor-2). 
These factors potentiate tumour growth, stimulate angiogenesis and induce fibroblasts to 
undergo differentiation into myofibroblasts (cells that share the characteristics of 
fibroblasts) and into smooth muscle (Bissell and Radisky, 2001).
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Dingemans et al., (1993) transplanted colon carcinomas into granulation tissue which 
induced an invasive phenotype, thereby demonstrating that cancer invasion is stimulated 
by wound-healing stroma.
Integrity
û
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Precancer
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Figure 1.1.2 Summary of Intracellular Signalling
Signalling from the normal epithelial cells to the stroma and back (black thin arrows) maintains the 
integrity of the epithelial tissue (thick arrow). During epithelial carcinogenesis, the signalling changes 
(dotted blue arrow) and this causes cancer-associated changes in the stroma. The new cross-talk (dotted 
black arrows) between the cancer cells and the stroma leads to invasion (thick arrow). Adapted from De 
Wever and Mareel, (2003).
Cell surface proteases play an important role in facilitating cell invasion into the 
extracellular matrix. Proteases associate at plasma membrane protrusions, called 
invadopodia, which contact and dissolve the matrix. Invadopodia degrade a variety of 
immobilised substrates including fibronectin, laminin and type I collagen (Monsky et al., 
1994). Integral membrane proteases may contribute significantly to ECM degradation by 
metastatic cells by virtue of their localisation at invadopodia which are in contact with
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the ECM. Integral membrane proteases can be defined as a group o f cell surface 
glycoproteins that contain extracellular domains of either metallo- or serine-proteases, a 
transmembrane domain and a short cytoplasmic tail. Examples of such transmembrane 
glycoproteins include meprin, matrix metalloproteinase, DPPIV, fibroblast activation 
protein a  (FAPa) and Gbase. Abundant expression of these enzymes is associated with 
poor prognosis (Iwasa, 2005).
This study will take a detailed look at the serine protease Seprase / fibroblast activation 
protein a  (FAPa), a 170kDa gelatinase, which belongs to the S9b peptidase family 
(Abbott and Gorrell, 2002; Barrett et al., 1998).
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1.2 Fibroblast Activation Protein a / Seprase
Fibroblast activation protein a  (FAPa) and/or Seprase (surface expressed protease) are a 
170kDa integral membrane gelatinase. FAPo: is an inducible cell surface glycoprotein 
that was originally identified in cultured fibroblasts using monoclonal antibody F19 
(Garin-Chesa et al., 1990; Rettig et al., 1993). Seprase was originally identified as a 
glycoprotein peptidase selectively expressed on the surface of invadopodia and was 
isolated from a human malignant melanoma cell line LOX by Pineiro-Sanchez et al., 
(1997). The expression of Seprase correlates with the invasiveness of human melanoma 
and carcinoma cells. Molecular cloning of FAPo' and Seprase revealed that they are the 
same cell surface serine protease which is found on chromosome 2q23 (Chen et al., 
2003; Chen and Kelly, 2003; Mathew et al., 1995; Pineiro-Sanchez et al., 1997; Scanlan 
et al., 1994). For the clarity of this review, the protease is referred to as Seprase 
throughout.
1.3 Classification of Seprase
Seprase (EC 3.4.21.-) belongs to the small family of serine integral membrane 
peptidases (SIMP). These peptidases are inducible, specific for proline-containing 
peptides and macromolecules and active on the cell surface (Chen et al., 2003). Post- 
prolyl peptidases modify bioactive peptides and change their cellular functions. This 
class of peptidases have important roles in cancer (Busek et al., 2004; Chen et al., 2003; 
Chen, 2003; Chen and Kelly, 2003; Rosenblum and Kozarich, 2003). This group of 
enzymes also includes prolyl endopeptidase, dipeptidyl peptidase 8 and dipeptidyl 
peptidase IV-/3 (Rosenblum and Kozarich, 2003). However, the best studied of this class 
of enzymes is dipeptidyl peptidase IV (DPPIV or CD26) (EC 3.4.14.5) (Rosenblum and 
Kozarich, 2003). Studies have shown the importance of DPPIV in regulating tumour cell 
behaviour and function (Bauvois, 2004). Seprase shows up to 52% homology to DPPIV, 
both being members of the S9b peptidase family (Goldstein et al., 1997). Seprase is, 
therefore, a member of the DPIV-like gene family (Abbott and Gorrell, 2002) grouped in 
subfamily S9B of the peptidase family S9 (prolyl oligopeptidase family), clan SC 
(Barrett et al., 1998). Even though all SIMP members are known to cleave prolyl peptide
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(Pro-Xaa) bonds there are conflicting reports on possible dipeptidyl peptidase activity 
associated with Seprase but its main distinguishing feature is its gelatinase activity 
(Gorrell et al., 2001; Park et al., 1999). An early report had suggested that DPPIV had 
gelatinase activity (Bermpohl et al., 1998); however, more recent reports suggest 
otherwise (Gorrell et al., 2001; Park et al., 1999). The roles Seprase plays are only 
beginning to be understood but insights into the potential functions of Seprase can be 
obtained from the vast amount of work done on DPPIV.
1.4 Structure of Seprase and Biochemical Aspects
Active Seprase is a 170kDa homodimer that contains two N-glycosylated 97-kDa 
subunits. The 760-amino acid Seprase protein (GenBank GI 1888316) is a type II 
integral membrane protein with a large C-terminal extracellular domain. Seprase has 
been shown to be shed from the cell surface and recent studies by our group have 
identified a serum form of the protease (Collins et al., 2004). A second group has 
recently identified the soluble form of Antiplasmin Cleaving Enzyme (APCE) as 
Seprase (Lee et al., 2005a). The crystal structure of the extracellular domain of Seprase 
has recently been solved (see Figure 1.4.2) (Aertgeerts et al., 2005). This provides 
information for the substrate specificity of Seprase. The Seprase monomer has 5 
potential N-glycosylation sites, 13 cysteine residues, 3 segments that correspond to 
highly conserved catalytic domains of serine proteases, a hydrophobic transmembrane 
segment and a short cytoplasmic tail (6 amino acids) (see Figure 1.4.1).
G-W-S-Y-G
G-W-S-Y-G
Figure 1.4.1 General structure of Serine-Integral Membrane Peptidases (SIMP)
SIMP prototypes such as Seprase and DPPIV are proteolytically active as dimers and have a cytoplasmic 
domain (C); transmembrane domain (TM); glycosylation-rich region (GR); cysteine-rich region (CR); and 
catalytic region (CAT). X represents the disulphide bonds. Adapted from Chen et al., (2003).
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Figure 1.4.2 Three-Dimensional Structure of Seprase
The ribbon diagram illustrates the dimeric structure of Seprase (pdb accession code 1Z68). The 
extracellular domain consists o f 2 domains, an eight bladed /3-propeller domain (indicated in blue) and an 
hydrolase domain (indicated in green) that contains the catalytic triad. The catalytic residues are 
shown, catalytic Serine 624, Aspartic Acid 702 and . (Aertgeerts et al., 2005)
Each subunit contains two topologically distinct domains; the /3-propeller (residues 54- 
492) and the o//3-hydrolase domain (residues 27-53 and 493-760) (see Figure 1.4.2). The 
catalytic triad is located at the interface o f the /3-propeller and the c^/3-hydrolase domain. 
The arrangement of the catalytic triad in the order nucleophile-acid-base is a 
characteristic of the of ¡3 hydrolase domain (Ollis et al., 1992). This domain features 
mostly parallel /3-sheets connected by a-helices on either surface of the sheet (see Figure 
1.4.3). Each blade of the /3-propeller domain comprises a three- or four-stranded anti­
parallel /3-sheet (see Figure 1.4.4). The sheets are twisted and radially arranged around 
their ventral tunnel. The eight bladed /3-propeller domain is situated on top of the 
catalytic triad and may serve as a “gate” to selectively filter protein access to the 
catalytic triad (Aertgeerts et al., 2005; Cheng et al., 2002). The /3-propeller domain in
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Prolyl Oligopeptidase has been shown to regulate proteolysis (Fulop et al., 1998). The 
oscillating propeller blades have been shown to act as a gating filter during catalysis, 
letting small peptides substrates into the active site while excluding large proteins to 
prevent accidental proteolysis in the cytosol (Fulop et al., 2000). The active site is 
accessible in two ways, through a cavity formed between the /3-propeller and the 
hydrolase domain. The side opening has a diameter of ~24A in contrast to the narrower 
/3-propeller opening (~14A).
Figure 1.4.3 oilfi hydrolase domain of Sep rase
The ribbon diagram illustrates the a//3 hydrolase domain (residues 27-53 and 493-760) of Seprase (pdb 
accession code 1Z68). The otJ& hydrolase domain contains the catalytic triad. The catalytic residues are 
shown, catalytic Serine 624, Aspartic Acid 702 and (Aertgeerts et al., 2005). a-helices are
indicated in red, /3-sheets are indicated in blue and the hydrogen bonds are indicated in green. For amino 
acid information see Appendix B. Generated using DeepView (Section 2.10.10).
10
Figure 1.4.4 Eight bfaded ^-propeller domain of Seprase
The ribbon diagram illustrates the eight bladed /3-propeller domain (residues 54-492) of Seprase (pdb 
accession code 1Z68). Generated using DeepView (Section 2.10.10).
DPPIV shows similar structure homology to Seprase (see Figure 1.4.1). In DPPIV the 
N-terminal hydrophobic sequence represents an uncleavable signal peptide that also 
functions as a membrane-anchoring domain (Barrett et al., 1998; Ogata et a l, 1989). In 
Seprase the N-terminal domain possibly has a similar role as a signal peptide although 
there is no published data to support this. A highly conserved residue Asp599 in DPPIV 
has been shown to be important in enzyme processing such as proper folding, 
dimerisation and transport (Chen et al, 2003). A mutation in this residue (D599A) 
specifically decreased the cell surface expression of DPPIV in stably transfected mouse 
fibroblasts. Seprase also has this conserved Asp599 residue (see Figure 1.4.5); therefore, 
it is possible to conclude that this residue is also important in the processing of the 
Seprase enzyme.
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The Seprase gene has been observed in several species (see Figure 1.4.5). A mouse 
homologue has been identified (Niedermeyer et al., 1998) as well as a Xenopus laevis 
homologue (Brown et al., 1996). The mouse Seprase gene spans approximately 60kb 
and contains 26 exons ranging in size from 46bp to 195bp. This genomic organisation is 
similar to that of the human Seprase gene (Niedermeyer et al., 1998). The catalytic 
serine residue arranged within the consensus sequence G-X-S-X-G is split between two 
exons. Gly-Trp is located at the very end of exon 21 and Ser-Tyr-Gly at the beginning o f 
exon 22. This arrangement differs from the typical serine protease where the complete 
serine consensus site is encoded within one exon. The study of the mouse homologue 
has shown alternative splicing and 3 distinct Seprase splice variants have been detected 
in tissues (Niedermeyer et al., 1997). An alternative spliced Seprase was later identified 
in the human melanoma cell line LOX which encodes a novel truncated iso form 
(Goldstein and Chen, 2000). The splice variant encodes for a 239 amino acid 
polypeptide with a molecular weight of 27kDa that precisely overlaps the carboxyl- 
terminal catalytic region of the wild type Seprase.
An alignment of eukaryotic Seprase C-terminal amino acid sequences is shown in Figure 
1.4.5. Sequence similarity is represented in gray scale shading, with black being the 
highest similarity. Figure 1.4.5 illustrates that the C-terminal catalytic region o f Seprase 
is highly homologous throughout the different species.
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Figure 1.4.5 Amino acid sequence alignment of eukaryotic Seprase C-terminal
Alignment of amino acid sequences for the C-terminal of Seprase; deduced sequences Homo sapiens 
(AAC51668), Mus musculus (AAH19190), Xenopus laevis (AAC59872) and the putative sequence Bos 
Taurus (XP 603457). Alignment was performed using MultAlin and edited using GenDoc (Section 
2.10.10). Sequence similarity is represented by grey scaling, with black being the highest similarity. The 
amino acids of the catalytic triad (Ser624, Asp702, His734) are indicated (*). The serine protease consensus 
motif G-X-S-X-G is underlined. For amino acid information see Appendix B.
The charged N-terminal end of substrate peptides is recognised by two glutamates (Glu 
motif). Comparison of the crystal structure of Seprase and DPPIV revealed one major 
difference in the vicinity of the Glu motif (Glu203-Glu204 for Seprase; Glu205-Glu206 for 
DPPIV) within the active site o f the enzyme (see Figure 1.4.6). The importance o f the 
Glu motif in DPPIV catalysis has been confirmed by single point mutations that abolish 
the enzyme’s aminopeptidase activity (Abbott et al., 1999). Detailed comparison o f 
Seprase and DPPIV revealed that the Ala657 residue in Seprase, instead of Asp663 as in 
DPPIV, reduces the acidity in this pocket. This change could explain the lower affinity 
for N-terminal amines by Seprase (Aertgeerts et al., 2005). Mutant proteins were 
developed to determine the importance of these two residues. Studies have shown that in 
DPPIV, the replacement of Asp663 by an alanine Ala663 results in a ~4-fold decrease in
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catalytic efficiency for N-terminal dipeptides, with a concomitant increase in efficiency 
to cleave Z-Gly-Pro-AMC (which has been shown not to be cleaved by DPPIV). This 
mutation caused the wild type DPPIV catalytic efficiency for Z-Gly-Pro-AMC to be 
increased from 9.0 M '1s '1 to 1.6 x 103 M 'V 1. On the other hand, mutation of Ala657 to an 
Asp657 in Seprase resulted in reducing the kcJKm for cleavage of Z-Gly-Pro-AMC by 
~350-fold (Aertgeerts et al., 2005).
Figure 1.4.6 Superposition of Seprase with DPPIV showing a detailed view of the 
residues around the Glu motif.
The interactions in DPPIV between the active site residues and the N-terminus of the hexapeptide (NPY6, 
YPSKPD, blue), present in the crystal structure of DPPIV {yellow), are shown as dashed lines. Residues in 
Seprase are orange. Amino acid residues are labelled in italic and bold for DPPIV and Seprase, 
respectively (Aertgeerts et al., 2005).
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Structural comparison o f the active sites of Seprase and DPPIV revealed similar S2-S2 
specificity pockets. The Si subsite (numbered according to Schechter and Berger (1967) 
see Figure 5.1.1) in Seprase is flat and could accommodate most amino acids. The S2 
active site pocket is lined by Trp623 and Tyr745. These residues would be expected to 
interact with large aliphatic side chains of peptide substrates. The Si specificity pocket 
in Seprase is a well defined hydrophobic pocket lined by Tyr625, Val650, Trp653, Tyr656, 
Tyr660 and Val705. This site optimally accommodates a proline residue. Large 
hydrophobic and aromatic residues can be modelled in the hydrophobic S2 pocket, 
defined by residues Arg123, Phe350, Phe351, Tyr541, Pro544, Tyr625 and Tyr660 (Aertgeerts et 
al., 2005).
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In its membrane form, the majority of Seprase, including its catalytic domain, is exposed 
to the extracellular environment (see Figure 1.4.1). The catalytic domain consists of the 
catalytic serine (S624) flanked by glycines in the classical consensus sequence for an 
active site serine, G-X-S-X-G. This conserved serine protease motif is present as G-W- 
S-Y-G. The catalytic serine in conjunction with aspartate (D702) and histidine (H734) 
comprises the catalytic triad (Goldstein et al., 1997; Pineiro-Sanchez et al., 1997; 
Scanlan et al., 1994) (see Figure 1.4.8). The orientation of these residues is similar to 
members o f the prolyl oligopeptidase family and its structural organisation is similar to 
that o f DPPIV. Therefore, this enzyme is classified as a non-classical serine protease. An 
interesting observation made in DPPIV is that a single substitution of either Gly residue 
in the motif resulted in the retention of the newly synthesised enzyme in the 
endoplasmic reticulum and rapid degradation (Barrett et al., 1998). This suggests that 
both residues are also essential for correct folding and transport of the enzyme to the cell 
surface. The three catalytic amino acids play an essential role in catalysis. The histidine 
acts as a general acid-base catalyst activating the nucleophilic group, the hydroxyl group 
of the serine acts as a nucleophile in the attack on the peptide bond while the aspartic 
acid stabilizes charged tetrahedral intermediates formed in the reaction (Fink, 1987; 
Rennex et al., 1991).
The mechanism of action of serine proteases (Figure 1.4.7) involves an acyl-enzyme 
intermediate. Both the formation and decomposition of the acyl-enzyme proceed through 
the formation of a negatively charged tetrahedral intermediate (Polgar, 2002).
1.4.1 Catalytic Classification
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Figure 1.4.7 Schematic Representation of the Catalytic Mechanism of Serine 
Proteases
(Polgar, 2002)
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Figure 1.4.8 Catalytic Triad of Seprase
Ribbon diagram o f the catalytic triad of Seprase (pdb accession code 1Z68). The catalytic triad residues 
are indicated Serine 624, Aspartic Acid 702 and . Hydrogen bonds are indicated in green.
For amino acid information see Appendix B. Generated using DeepView (Section 2.10.10).
1.4.2 Biochemical Aspects of Seprase
Post translational modification of the protein such as N-glycosylation occurs and it is 
thought that the N-terminus may be blocked (Pineiro-Sanchez et al., 1997). The resolved 
crystal structure of Seprase shows that there are 5 potential glycosylation sites on the 
asparagine residues 49, 92, 227, 314 and 679. Four are located in the /3-propeller domain 
and one is located in the hydrolase domain (Aertgeerts et al., 2005). The glycosylated 
form of Seprase has both post-prolyl dipeptidyl peptidase and gelatinase activities while 
the non-glycosylated form lacks any detectable activity (Sun et al., 2002).
Reports show that the gelatinase activity of Seprase was completely blocked by serine- 
protease inhibitors, including diisopropyl fluorophosphate (DFP) and 
phenylmethylsulfonyl fluoride (PMSF) (Aoyama and Chen, 1990; Collins et al., 2004). 
Seprase could be affinity labelled by [3H]-DFP, but the proteolytically inactive 97kDa 
subunit could not (Pineiro-Sanchez et al., 1997). This confirmed the existence of a serine 
protease active site on the dimeric form of the enzyme. This was further demonstrated 
by the loss of proteolytic activity upon the dissociation of its 97kDa subunits following
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treatment with acid, heat, or cysteine and histidine modifying agents (Pineiro-Sanchez et 
al., 1997). Therefore, it can be concluded from this that Seprase activity is determined 
by the association o f the subunits to form a proteolytically active dimer (Aertgeerts et 
al., 2005). The proteolytic activity of membrane bound Seprase was found to be 
maximal at neutral pH and was enhanced by a mixture of 2mM EDTA and 2mM DTT 
(which inhibits metal-dependent proteases and activates cysteine proteases respectively) 
(Aoyama and Chen, 1990). However, a previous study of the soluble form of Seprase 
demonstrated that EDTA had no effect on the proteolytic activity and, contrary to 
previous reports DTT had a detrimental effect, with 5mM DTT causing a 10% loss of 
activity (Bimey and O'Connor, 2001). Table 1.4 summarises some of the biochemical 
properties of Seprase.
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Source MW
(kDa)
Pi pH
optim um
T em p eratu re
optim um
(°C)
Am ino Acid Identity 
to H um an Seprase 
(% )
G enB ank
accession
nu m ber
Reference
Homo sapiens
Malignant Melanoma 170 - dimer 5.0 7.0 - 100% AAC51668 (Aoyama and Chen, 1990; Monsky et al., 1994;
cel Is; LOX cells 97- subunit Pineiro-Sanchez et al., 1997)
Recombinant; cDNA from 95 -  subunit - 8.5 - 100% - (Sun et al., 2002)
WI38 cells
Bovine Serum 96 - subunit 5.68 7.5 - - - (Bimey and O'Connor, 2001; Collins et al., 2004)
Chicken embryo 160 -  dimer - 7.6 37 - - (Kelly, 1999)
97 -  subunit
Mus musculus - - - - 89% AAH19190 (Niedermeyer et al., 1997)
Xenopus laevis - - - - 50% AAC59872 (Brown e ta l., 1996)
Table 1.4 Biochemical Properties o f Seprase
Summary o f the published biochemical properties o f Seprase. Those marked with (-) have not been published.
2 0
Seprase has been mainly purified from cell membranes and shed vesicles o f LOX human 
amelanotic melanoma cells (Aoyama and Chen, 1990; Monsky et al., 1994). It has also 
been purified from 9-day old chicken embryos (Kelly, 1999). Size exclusion 
chromatography (S-200) and affinity chromatography using wheat germ agglutinin 
(WGA)-agarose are two of the most widely used resins for Seprase purification 
(Aoyama and Chen, 1990; Pineiro-Sanchez et al., 1997). Immunoafflnity purification o f 
Seprase has also been utilised, with the mAb F19 pre-coated onto Sepharose CL-4B 
beads (Rettig et al., 1994). Soluble forms and iso forms of these membrane proteases are 
beginning to be found in biological fluids (Chen et al., 2003; Collins et al., 2004). 
Recently our group have published the purification scheme for the soluble form of 
Seprase from bovine serum (Collins et al., 2004). This purification procedure involved a 
combination of hydrophobic interaction chromatography, hydroxylapatite, and cibacron 
blue chromatography followed by size exclusion chromatography.
Until recently, the most sensitive assay available for Seprase detection involved gelatin 
zymography which exploits the established gelatinase activity associated with Seprase 
(Pineiro-Sanchez et al., 1997). However, this is not a quantitative assay. A semi- 
quantitative assay was developed based on the degradation o f radio labelled gelatin 
substrate and subsequent qualitative measurement of the released fragments (Kelly, 
1999). Seprase was reported to possess prolyl dipeptidyl peptidase activity (Abbott et al., 
1993; Chen et al., 2003; Niedermeyer et al., 1998; Sun et al., 2002) and Ala-Pro-AFC 
was seen as a potential sensitive fluorogenic substrate. Interestingly, conflicting results 
exist with reports that Seprase has no such prolyl dipeptidyl peptidase cleavage activity 
(Ghersi et al., 2002; Pineiro-Sanchez et al., 1997). Recently our group have also reported 
on the post prolyl cleaving endopeptidase activity of the soluble form of Seprase using 
the fluorimetric substrate Z-Gly-Pro-AMC (Collins et al., 2004).
1.5 Purification and Activity Detection of Seprase
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1.6 Distribution of Seprase
Studies have shown that Seprase is transiently expressed in certain normal fetal 
mesenchymal tissues, during wound healing and in reactive stroma responding to 
epithelial cancers and some sarcomas (Garin-Chesa et al., 1990; Rettig et al., 1993). 
Normal adult tissues as well as malignant epithelial, neural and haematopoietic cells are 
generally Seprase-negative. The initial identification of Seprase involved the study o f six 
surface glycoproteins that were differentially expressed during normal development, 
proliferative activation and malignant transformation of mesenchymal cells and tissues. 
The monoclonal antibody (mAb) F I9 was used to define the human cell-surface 
glycoprotein Seprase (Rettig et al., 1988). The F I9 antigen (now know as Seprase) was 
found to be expressed on cultured fibroblasts derived from various organs, several foetal 
mesenchymal tissues, scar tissue and a proportion of sarcoma cell lines. In normal adult 
tissues expression of the F 19 antigen was restricted to occasional fibroblasts and to a set 
of pancreatic islet cells (Rettig et al., 1988). The pattern observed in this initial study 
suggests that Seprase is a cell-surface marker for proliferating mesenchymal cells and 
that its expression may be induced by normal growth factors or during malignant 
transformation (Rettig et al., 1988).
Another early study describes the induction of F19 in the reactive mesenchyme of 
epithelial tumours (carcinomas) (Garin-Chesa et al., 1990). Fibroblasts positive for the 
F I9 antigen (Seprase) using immunohistochemical studies were found in primary and 
metastatic carcinomas including colorectal, breast, ovarian, bladder, and lung 
carcinomas. This study also analysed dermal incision wounds and found that FI9 was 
strongly induced during scar formation. These studies suggest that the F19+ phenotype 
correlates with specialised fibroblast functions in wound healing, inflammation and 
malignant tumour growth (Garin-Chesa et al., 1990). Another important observation 
from this study is that the cellular immunostaining patterns obtained with the tumour 
tissue suggests that Seprase is localised exclusively in the cell membrane/cytoplasm of 
fibroblastic cells. This cellular staining is consistent with the cell surface localisation of 
Seprase in cultured fibroblasts (Garin-Chesa et al., 1990).
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Since these early reports, more studies have shown that Seprase is expressed in reactive 
human tumour stromal fibroblasts (Park et al., 1999). Studies have confirmed the 
expression of Seprase in primary breast infiltrating ductal carcinoma, colon 
adenocarcinoma and lung adenocarcinoma and also in metastatic colon adenocarcinoma 
in the hepatic system (see Figure 1.6.1) (Dolznig et al., 2005; Park et al., 1999).
Tumor Normal
Figure 1.6.1 Detection of Seprase antigen and enzyme activity in human tissue
A and B, immunohistochemical detection of Seprase using mAb FI 9 in a colon carcinoma (A) or matched 
control normal colon tissue from the same patient (B) (bars = lOOum). (Park et al., 1999).
Several groups have shown Seprase to be expressed in the reactive stromal fibroblasts o f 
human breast cancer and its absence from normal breast tissue (Ariga et al., 2001; 
Garin-Chesa et al., 1990; Rettig et al., 1994; Scanlan et al., 1994). In addition to this, 
Seprase is also expressed by infiltrating ductal carcinoma (IDC) cells in breast cancer 
patients while it is not expressed by normal breast epithelia (Dolznig et al., 2005; Kelly 
et al., 1998; Park et al., 1999). Stromal expression of Seprase in IDC of the breast was 
associated with longer survival of patients (Ariga et al., 2001). Further work has shown 
that Seprase expression is not confined to stromal fibroblasts but that the protease is also 
expressed in some types of malignant cells of epithelial origin (Chen et al., 2003; Iwasa 
et al., 2005; Jin et al., 2003; Okada et al., 2003). Reports differ in the cellular 
localisation o f FAPa and Seprase depicted by immunohistochemistry (Chen et al., 2003; 
Kelly et al., 1998). The apparent difference is thought to be partially due to the use o f
23
antibodies that recognise, with varying affinity, different epitopes exhibited by FAPa 
(derived from activated fibroblasts) and Seprase (derived from invasive cancer cells).
Expression patterns of Seprase were examined in cervical carcinoma and cervical 
intraepithelial neoplasm (Jin et al., 2003). This embraces both carcinoma in situ and the 
precursor lesions known as dysplasia or ‘disordered differentiation’. Some micro- 
invasive carcinomas and all invasive carcinomas showed Seprase immunoreactivity in 
the cancer cells (Jin et al., 2003). The findings in this study show a direct correlation 
between gelatinase expression and the malignant phenotype. Thus Seprase may be an 
early marker of tumour progression characterising Seprase expression with invasive 
growth. A separate study to support this concept was performed by Iwasa et al., (2005) 
which examined Seprase expression in colorectal cancer specimens. Immunoblotting 
showed higher levels of Seprase protein in the cancer tissue than in normal colorectal 
tissue (p<0.001). The results also revealed a significant correlation between Seprase 
expression and lymph node metastasis (p=0.033).
Expression patterns of Seprase in human gastric cancer were investigated using 
immunohistochemistry and the study showed that there were distinct differences in its 
expression between the intestinal- and diffuse-type gastric cancer (Okada et al., 2003). 
Results also showed, as in Iwasa et al., (2005), a correlation between Seprase expression 
and depth of invasion. In intestinal cancer, the stromal expression o f Seprase 
significantly correlated with liver metastasis (p=0.0002) and lymph node metastasis 
(pO.OOOl). In contrast, in diffuse-type cancer there was no correlation between stromal 
Seprase expression and lymph node metastasis (p=0.0821) (Okada et al., 2003). A 
separate study looked at the expression of Seprase at the mRNA and protein level. This 
study found that Seprase expressing carcinoma tissues were more prominently found in 
the scirrhous type than in other types of gastric carcinoma (Mori et al., 2004).
Immunohistochemical studies have shown Seprase expression was induced in patients 
with idiopathic pulmonary fibrosis (IPF) (Acharya et al., 2006). Its expression pattern is 
restricted to fibroblasts in areas of ongoing tissue injury (see Figure 1.6.2).
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Figure 1.6.2 Detection of Seprase antigen expression in IPF
Serial lung tissue sections immunostained with Seprase (A) and an isotope-matched control antibody (B). 
Note areas of thickened interstitium interspersed with normal alveolar architecture. Seprase expression is 
only seen in areas of fibrosis (bar = 1mm for both A and B) (Acharya et al., 2006).
Seprase was recently identified for the first time on chondrocyte membranes under 
conditions that promoted cartilage resorption and elevated expression in cartilage from 
osteoarthritis patients (OA) (Milner et al., 2006). The results from this study supported a 
role for Seprase in the mechanisms leading to cartilage degeneration in OA. Gene 
expression profiling in the murine model showed a 7-fold increase in Seprase expression 
in inflamed, compared to non-inflamed paws.
A study by Huber et al. (2003) found that Seprase was expressed in benign and 
malignant melanocytic skin tumours. This is in contrast to the findings in benign 
epithelial tumours, in which little or no expression of Seprase was observed on stromal 
fibroblasts (Dolznig et al., 2005; Garin-Chesa et al., 1990). Normal adult skin, however, 
did not have any detectable Seprase activity. These contradictory results could be 
explained if melanocytic naevi (moles) are considered as precursor lesions for melanoma 
development, characterised by a constitutively-active tumour stroma (Huber et al., 2003; 
Huber et al., 2006). Gene expression studies have identified Seprase to be uniquely 
overexpressed in aggressive fibromatosis (Skubitz and Skubitz, 2004). Aggressive 
fibromatosis is locally invasive but rarely metastasises. There are histologic similarities 
between this disease and the proliferative phase of wound healing.
To further support the concept that Seprase is expressed during wound healing, studies 
have shown that stellate cells at the tissue remodelling interface of cirrhosis in humans, 
express Seprase (Levy et al., 1997; Levy et al., 1999). Hepatic stellate cells (HSCs) are a 
known major source of ECM degrading enzymes and protease inhibitors of hepatic 
tissue remodelling (Alcolado et al., 1997). It is thought that Seprase may contribute to 
the (HSC)-induced extracellular matrix changes (ECM) of cirrhosis. Seprase expression 
was also detected in the hepatic parenchyma of patients with chronic hepatitis C virus 
(HCV) infection. In fact, Seprase expression correlates with the degree of fibrosis in 
HCV (p<0.0001) (Levy et al., 2002). This adds considerable weight to the assertion that 
Seprase has a role in the pathogenesis of chronic liver disease.
Another study involving the Xenopus laevis Seprase homologue describes its increased 
expression during hormone-induced tail resorption, indicating a possible role in tissue 
remodelling (Brown et al., 1996). An extension of this concept is that Seprase has been 
found to be expressed during mouse embryo development (Niedermeyer et al., 2001). 
Seprase deficient mice showed no overt developmental defects and were viable. To 
analyse Seprase expression at various stages of embryonic development, mice deficient 
in Seprase but expressing /3-galactosidase under the control o f the Seprase promoter 
were developed (Seprase'7' lacZ). These Seprase'7' lacZ mice expressed /3-galactosidase 
at active tissue remodelling during embryogenesis supporting a role for Seprase in tissue 
remodelling processes (Niedermeyer et al., 2001).
Overall, Seprase has been seen to be expressed in stromal fibroblasts of more than 90% 
of all epithelial tumours including lung, colorectal and breast carcinomas (primary and 
metastatic) (Garin-Chesa et al., 1990). It has also been shown to be expressed in post­
natal non-tumour tissues (Chen et al., 2003), in a proportion of bone and soft tissue 
sarcoma tumour cells (Dolznig et al., 2005), in granulation tissue o f healing wounds, and 
on pancreatic cells (Rettig et al., 1988). However, normal adult tissue, benign and 
premalignant epithelial lesions are generally Seprase negative. Seprase-positive cells 
were found in close proximity to the endothelial cells o f the tumour capillaries and 
surround the tumour nodules (Garin-Chesa et al., 1990; Rettig et al., 1988; Welt et al., 
1994). These results suggest that Seprase may have a critical role to play in altering the
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micro-environment to promote tumour growth, thus enhancing the theory that metastatic 
effects may depend on proteolytic enzymes derived not only from tumour cells but also 
from stromal cells.
1.7 Biological and Pathological Roles
High levels o f Seprase activity have been positively correlated with the invasive 
behaviour of many malignantly transformed cells but its function in malignancy is still 
unknown (Aoyama and Chen, 1990; Kelly et al., 1994; Monsky et al., 1994)
1.7.1 Tum our Suppressor
There is compelling evidence that Seprase may play a role as a tumour suppressor 
(Ramirez-Montagut et al., 2004; Welt and Ritter, 1999; Wesley et al., 1999). Initial 
studies have focused on DPPIV. Expression of DPPIV is lost as normal melanocytes 
progress to malignant melanoma. Experiments showed that the re-expression of DPPIV 
was able to change the mouse melanoma cells to a more differentiated and normal 
phenotype with a return to dependence on exogenous growth factors (Wesley et al., 
1999). Wesley et al. (1999) observed that the re-establishment o f dependence on 
exogenous growth factors occurred even when a catalytically inactive mutant of DPPIV 
was expressed. This group attributed this to the expression of endogenous Seprase which 
was co-induced when the mutant DPPIV was expressed. More recent studies have 
provided direct evidence for Seprase as a tumour suppressor. It was observed that the 
expression o f Seprase decreased the tumourigenicity of mouse melanoma cells in 
animals and restored contact inhibition and growth factor dependence (Ramirez- 
Montagut et al., 2004). Another interesting finding from this study is that the catalytic 
mutant of Seprase contributed to the tumour suppression in the absence of an active 
protease. In addition to this, the study showed that while DPPIV expression induced 
Seprase expression, the converse was not so; i.e. Seprase expression did not induce 
DPPIV expression. Therefore, it was concluded that the tumour-suppressive activities o f 
wild-type and mutant Seprase are most likely due to functions residing in Seprase.
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The role of Seprase in breast cancer was investigated using human breast cancer cell 
lines that normally express Seprase (MDA-MB-435 and MDA-MB-436) (Goodman et 
al., 2003). Anti-sense suppression o f Seprase rendered these cells sensitive to serum 
starvation while control transfectants with high levels of Seprase expression grew well 
in the absence of serum. Goodman concluded that the breast cancer cells with high 
levels of Seprase expression are less dependent on exogenous serum factors for growth 
and have gained independence from normal growth regulatory controls. Independence 
from normal growth regulation is a key characteristic of malignantly transformed cells 
that distinguishes them from normal cells.
Seprase expression was also engineered in the human breast cancer cell line MDA-MB- 
231, which lacks normal Seprase expression (Huang et al., 2004). A mouse model was 
utilised to show that Seprase expressing tumours grew more rapidly and were highly 
vascular when compared to tumours of control transfectants which lacked Seprase 
expression (Huang et al., 2004). This group did find that when these cells were grown in 
vitro, those cells that did express Seprase grew at the same rate as those that did not. 
This indicated that Seprase had a more noticeable effect on tumour cell growth in the 
mouse mammary fat pad environment. For tumours to grow and integrate into 
surrounding normal tissue, they must attract a blood supply (angiogenesis), which 
sustains growth. This study was the first evidence for a pro-angiogenic function for 
Seprase and it can be concluded that Seprase expression promotes growth of breast 
cancer tumours at least in part by driving angiogenesis (Huang et al., 2004). This 
conclusion is supported by studies showing that Seprase mRNA is up-regulated by 
endothelial cells undergoing re-organisation and capillary morphogenesis (Aimes et al., 
2003). Both these findings together suggest that Seprase expression by breast cancer 
cells favourably alters the tumour microenvironment to promote tumour growth.
1.7.2 Tumour Promoter
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Similar growth-promoting effects of Seprase have been described (Cheng et al., 2002; 
Wang et al., 2005a). Murine Seprase was transfected into HEK293 human embryonic 
kidney cells and it was shown that tumours derived from Seprase expressing cells grew 
more rapidly than the control transfectants. This group also demonstrated in an animal 
model, that antibodies found to inhibit the dipeptidase activity of Seprase, also 
suppressed the growth of tumours which were derived from cells expressing Seprase. 
Wang et al. (2005b) found that the over-expression of Seprase in the human hepatic 
stellate cell (HSC) cell line LX-2 increased cell adhesion, migration and invasion. 
Interestingly, this group found that Seprase protease activity was not necessary for these 
functions. These findings further support a pro-fibrogenic role for Seprase by indicating 
that, in addition to its enzymatic functions, Seprase has important non-enzymatic 
functions (Wang et al., 2005b). Overall, it can be concluded from these studies that 
Seprase activity mediates in some way the increased tumour growth.
There is an obvious discrepancy between Seprase function in tumour promotion and 
tumour suppression. It is proposed by some that Seprase expression has a profound 
effect on cells that do not normally express Seprase and that the context in which 
Seprase is expressed determines the biological response to Seprase (promotion or 
inhibition of growth) (Kelly, 2005). A model has been created that explains all the 
findings so far. It describes how Seprase associates with membrane-bound signalling 
molecules causing transmission of growth stimulatory or inhibitory signals (see Figure
1.7.1 for an example of stimulatory signals). The factor that determines this must reside 
in the signalling molecules that are available for interaction with Seprase on the cells. 
Therefore it was concluded that Seprase carries out its biological functions in a cell- 
context dependent manner through a combination of its protease activity and its ability 
to form complexes with other cell surface molecules (see Section 1.7.3) (Kelly, 2005).
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Figure 1.7.1 Model of Seprase supramolecular complexes
Model o f a Seprase supramolecular complex with proteolytic, adhesive, and stimulatory signalling 
capabilities. Seprase dimers form heteromeric complexes with DPPIV dimers (Ghersi et al., 2002; Scanlan 
et al., 1994). Seprase can also form close association with f t integrins and uPAR (Artym et al., 2002). It is 
known that uPAR can bind to integrin through the a3 chain (Zhang et al., 2003). However, the 
binding interactions that associate Seprase, uPAR, and the integrins are not defined and may not be as 
depicted. Model taken from (Kelly, 2005). See Section 1.7.3 for Seprase complexes in cellular 
invasiveness.
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Seprase associates with c<3i(3i integrin, DPPIV, MMP-2, membrane-type 1 MMP and uPA 
at the invadopodia o f human malignant cells and so may interact with these proteinases 
and receptors and with associated cascades (Artym et al., 2002; Milner et al., 2006; 
Monsky et al., 1994; Mueller et al., 1999).
The integrin family o f transmembrane adhesion proteins have been shown to exhibit 
multiple functions, including adhesion to ECM and their localisation at invadopodia 
(Mueller et al., 1999). One theory is that integrins are involved in recruiting proteases to 
these sites of cell invasion. The QfjjSi integrin has been shown to associate with Seprase 
and it is thought that c$/31 may participate in the formation of functional invadopodia by 
docking Seprase (see Figure 1.7.2).
1.7.3 Sep rase complexes in cellular invasiveness
P1 seprase
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Figure 1.7.2 Co-localisation of Seprase and integrin
Panel A , C o-localisation  o f  S eprase and f t  integrin a t invadopodia o f  LO X  cells using 
im m unofluorescence and im age analysis, (a) d irec tly  labelled  FIT C  (green )-m A b C 27 against f t  in tegrin 
and rhodam ine (red)-m A b D28 against S eprase co -localise in the sam e invadopodia (arrowheads), (b) 3D  
lum inescence profiles illustrate f t  integrin and S eprase stain ing  in tensities in the m icrog raph  show n above 
each profile. Arrows indicate invadopodia. Panel B , d iagram m atic rep resen ta tion  o f  integrin a 3f t  and 
S ep rase localisation as w ould  be  seen in a vertical section  through  an invadopodium . (M ueller et al., 1999)
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Seprase and DPPIV can form a complex localised at invadopodia of fibroblasts on 
collagenous fibres, that has both gelatinolytic and gelatin binding activities, which 
facilitates cell migration (Chen, 2003; Chen and Kelly, 2003; Ghersi et al., 2003; Ghersi 
et al., 2006). Seprase and DPPIV are highly homologous with both enzymes having the 
same domain structure (see Figure 1.4.1). Seprase shows 50% amino acid identity with 
dipeptidyl peptidase IV over the entire sequence, with almost 70% identity in the 
catalytic domain (Goldstein et al., 1997; Pineiro-Sanchez et al., 1997; Scanlan et al., 
1994). The Ser-Asp-His catalytic triad is conserved in both enzymes and their genes 
map to the same region of the human chromosome 2. Despite their shared structural 
features, Seprase and DPPIV differ in their tissue distribution and expression (Welt et 
al., 1994). Seprase can form heteromeric complexes with DPPIV and the formation of 
the DPPIV-Seprase complex, which exhibits both prolyl peptidase activity and 
gelatinase activity, is necessary for cell migration on a collagen substrate (Ghersi et al., 
2002). It is possible that the two enzymes cooperate for efficient degradation of 
substrates and its consequent biological functions. The exact natures of the homodimer 
and heterodimer complexes of Seprase are poorly understood.
A recent study has shown that Seprase-Urokinase-type plasminogen activator receptor 
(uPAR) membrane complexes are associated with the invadopodia o f LOX cells, 
suggesting their co-operative roles in tumour invasion (see Figure 1.7.3) (Artym et al., 
2002). Urokinase plasminogen activator (uPA), a serine protease, converts the tissue 
zymogen plasminogen into plasmin. Plasmin has the ability to degrade most proteins in 
the ECM, including type IV collagen, laminin and fibronectin. In model systems, both 
the inhibition of uPA activity and the prevention of uPA binding to its receptor have 
been shown to limit the formation of metastasis (Iwasa et al., 2005). Thus, Seprase may 
also be a potential candidate for anti-metastatic therapies. The interaction of uPA and the 
integrins have been shown to regulate both adhesive and signalling activities of integrins 
(Mueller et al., 1999). The formation of the Seprase-uPAR membrane complexes is 
dependent upon both the cytoskeleton and integrins, specifically the P\ integrin (Artym 
et al., 2002).
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Figure 1.7.3 Co-localisation and R ET of Seprase and uPAR on L O X  cells
Lox cells were attached to glass coverslips and were examined by immunofluorescence microscopy. Cells 
were labelled with FITC-conjugated anti-Seprase D28 mAb (B) and TRITC-conjugated anti-uPAR mAb 
(C). Columns 1-4: Differential Interference Contrast (DIC), fluorescence of anti-Seprase, fluorescence o f 
anti-uPAR and resonance energy transfer (RET) (Artym et al., 2002)
1.7.4 Antiplasmin Cleaving Enzyme (APCE)
As mentioned in Section 1.4 Lee et al. (2005a) have recently identified the soluble form 
of Antiplasmin Cleaving Enzyme (APCE) as Seprase. Cfc-antiplasmin (AP) is a plasma 
glycoprotein o f the serpin (serine protease /«hibitor) superfamily and is the primary 
physiological inhibitor of plasmin, a key enzyme in fibrin degradation (Lee et al., 1997). 
The fibrinolytic system leads to the generation o f plasmin from plasminogen through the 
action of Tissue or Urokinase Plasminogen Activator (t-PA or uPA). Studies into Cfc- 
antiplasmin have shown that it is present in the blood in a larger “pro”-form, a^APpR0 
and in a smaller mature form of c^ A P a c t . c^ A P p r o  has 464 amino acid residues, with 
Met as the N-terminus and the mature form o^APact, having 452 amino acid residues, 
with an N-terminal asparagine (Bangert et al., 1993; Lee et al., 2004). Both forms have 
been shown to be present in the blood (66% c^APact ; 34% c^APpro) and they both 
form a stable complex with plasmin. However the “pro”-form has remarkably less 
capacity of cross-linking fibrin (see Figure 1.7.4) (Koyama et al., 1994). When c^APact 
is cross-linked to fibrin (during clot formation), it retains the ability to effectively inhibit 
plasmin and protect fibrin from proteolysis. The processing of c^ A P p r o  to otiA P Ac t  was 
shown to involve a plasma protease that cleaved the Prol2-Asnl3 bond of the onA P p r o  
protein (Lee et al., 2005a). This protease was called Antiplasmin Cleaving Enzyme 
(APCE).
33
Tissue/Urokinase Plasminogen 
Activator (t-PA) (uPA)
r > 
Plasmin Digestion ^ (Plasminogen P  1
«2 A P pro
Inhibition /  y
o f Plasm in . ^  y  *
/  *^  SCross-linkage 
a 2APAcT V  with Fibrin
Fibrin degradation 
Products
Antiplasmin Cleaving 
Enzyme (APCE)
Figure 1.7.4 Summary of Fibrinolytic System
Plasmin is generated from plasminogen through the action o f Tissue or Urokinase Plasminogen Activator 
(t-PA or uPA). Plasmin digests Fibrin giving rise to degradation products. c^ APpro is processed to 
c^ APact by the action of APCE. c^APAcr can cross-link with both Plasmin and Fibrin. During clot 
formation, a 2A P ACT becomes cross-linked to fibrin, where it retains the ability to effectively inhibit 
plasmin and protect fibrin from proteolysis.
APCE was purified from human plasma using an initial ammonium sulphate 
fractionation, followed by hydrophobic, anion exchange, T-gel thiophilic, and 
immunoaffinity chromatographies (Lee et al., 2004). The fact that APCE is found in 
human plasma and cleaves c^ APpro suggests that one of its physiologic functions is the 
regulation of c^ APacx availability for plasmin inhibition within cross-linked fibrin (Lee 
et al., 2004). Plasmin is resistant to c^-antiplasmin inhibition when it is associated with 
the plasma membrane (Del Rosso et al., 2002). A study analysing the regulation o f liver 
regeneration by the plasmin/cfc-AP system suggested that this system plays an important 
role in the hepatic repair via proteolysis of the matrix elements and the clearance o f 
cellular debris from the injured site (Okada et al., 2004). Altered fibrin turnover may be
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responsible for tumour-promoting effects by various means (Gemer et al., 2001). In 
clinical situations where fibrin formation is likely, the development of an agent that 
inhibits APCE might result in decreased amount of OzAPact available for cross-linking 
to fibrin as thrombi develop or as inflammation progresses. Abnormalities o f 
haemostasis during tumour growth and metastasis have been observed and it has been 
shown that the ECM of neoplastic tissue is abnormally rich in fibrin bundles and is 
mixed with other stromal components (Del Rosso et al., 2002). Degradation of fibrin, 
fibrinogen and the ECM proteins by plasmin, in addition to the concomitant activation 
of the Urokinase Receptor by Urokinase Plasminogen Activator, was suggested to 
facilitate tumour cells invasion and metastasis (Gemer et al., 2001). It has also been 
shown that elevated plasma levels of cross-linked fibrinogen indicated cancer-related 
fibrin deposition and fibrinolysis (Gemer et al., 2001).
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The identification of key substrates recognised by Seprase may provide a better 
understanding of the physiological role and of the pathways that control the activation o f 
stromal fibroblasts during tumourigenesis. Seprase has been shown to have two 
proteolytic activities. Firstly it is a gelatinase (Aoyama and Chen, 1990; Monsky et al., 
1994; Pineiro-Sanchez et al., 1997) and secondly an N-terminal post-prolyl amino 
peptidase that can cleave Ala-Pro-AFC. Table 1.8 illustrates the kinetic constants 
obtained in studies o f dipeptide substrates. Most serine proteases have no absolute 
substrate specificity (Fulop et al., 1998). They can cleave peptide bonds with a variety of 
side chains adjacent to the scissile bond. The Sj-Pi hydrogen bond is a very important 
factor in the proper substrate orientation and the transition state stabilisation. Proline 
residues do not possess main chain NH groups and therefore the architecture of the Si 
binding site is evolved to be much more specific in Seprase (Fulop et al., 1998).
A study by Collins et al. (2004) revealed that the soluble serum form of Seprase has a 
preference for N-blocked amino substrates of Gly-Pro-X and is most effective when X is 
Phe or Met and least effective when X is His or Glu. This study reported an affinity 
constant (Km) of 270jiM for bovine serum Seprase with the substrate Z-Gly-Pro-AMC. 
Extensive substrate specificity studies suggested that this peptidase has an extended 
substrate binding region in addition to the primary specificity Si (see Figure 5.1.1). The 
analysis also revealed that at least five subsites were involved in enzyme-substrate 
binding, with the smallest peptide cleaved being a tetrapeptide.
Substrate specificity studies using zymography have shown that Seprase degrades 
gelatin and thermally denatured type I and type IV collagens but not laminin, 
fibronectin, fibrin or casein (Monsky et al., 1994; Pineiro-Sanchez et al., 1997). The 
gelatinase activity distinguishes Seprase from DPPIV, which does not have gelatinase 
activity (Gorrell et al., 2001; Park et al., 1999). However, an earlier report by Bermpohl 
et al. (1998) suggested that DPPIV does have gelatinase activity. Both the gelatinase and 
dipeptidyl peptidase activities o f Seprase are mediated by an active site serine624 (Park et 
al., 1999; Pineiro-Sanchez et al., 1997).
1.8 Substrate Specificity
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Substrate kcat (S '*) K m OiM) kcat/Km ( M 'V 1) References
Ala-Pro-AFC ND 250 ND Recombinantly expressed murine Seprase (Cheng et al., 2005)
Ala-Pro-AFC 2.0 200 1.0 x 104 Recombinantly expressed human Seprase with an N-terminal histidine tag (Sun 
et al., 2002)
Ala-Pro-AFC ND >200 2.1 x 104 Wild type human Seprase (Aertgeerts et al., 2005)
Ala-Pro-AFC 14.2 244 5.8 x 104 Recombinantly expressed human Seprase with an N-terminal Flag tag (Edosada 
et al., 2006b)
Ala-Pro-AFC 1.08 323 3.34 x 103 Recombinantly expressed human Seprase (Lee et al., 2005a)
Ala-Pro-AFC 0.99 272 3.64 x 103 Wild type human APCE (Lee et al., 2005a)
Gly-Pro-AFC 5.6 248 2.3 x l O 4 Recombinantly expressed human Seprase with an N-terminal Flag tag (Edosada 
et al., 2006b)
Gly-Pro-AFC ND >200 4.3 x l O 3 Wild type human Seprase (Aertgeerts et al., 2005)
Gly-Pro-AMC ND >1000 3.0 x 103 Wild type human Seprase (Aertgeerts et al., 2005)
Z-Gly-Pro-AMC ND 270 ND Soluble bovine form o f  Seprase (Collins et al., 2004)
Z-Gly-Pro-AMC ND ND 5 3  x 104 Wild type human Seprase (Aertgeerts et al., 2005)
Z-Gly-Pro-AMC 0.51 101 5.0 x 103 Recombinantly expressed human Seprase (Lee et al., 2005a)
Z-Gly-Pro-AMC 0.54 124 4.35 x 103 Recombinantly expressed human Seprase (Lee et al., 2005a)
Z-Gly-Pro-AMC ND ND 7.4 x 103 Recombinantly expressed human Seprase with an N-terminal Flag tag (Edosada 
et al., 2006b)
FRET peptide 1.20 29 4.14 x 104 Recombinantly expressed human Seprase (Lee et al., 2005a)
FRET peptide 1.05 26 4.03 x 104 Wild type human APCE (Lee et al., 2005a)
Table 1.8 Kinetic Constants for the hydrolysis o f fluorogenic dipeptide substrates by Sep rase
N D -n o t de term ined . FR E T  peptide: A rg -L ys(D A B C Y L )-T hr-S er-G ly -P ro -A sn-G ln-G L n-G ln -G lu(E D A N S )-A rg
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1.8.1 Modifications of bioactive peptides
The endopeptidase activity of Seprase may function to regulate bioactive peptides. A 
proline near the end o f a peptide produces a significant bend. The natural substrates of 
Seprase are unknown, although the serum form has been shown to cleave the Pro 12- 
Asnn bond of otz antiplasmin (c^APpro) producing the Asn-Cfc antiplasmin (c^APAcr) 
(Lee et al., 2004). The cleaved protein binds fibrin more efficiently and slows clot lysis 
by plasmin more effectively than full-length oti antiplasmin (c^APpro). Based on the 
Seprase cleavage site in c^APpro, the specificity of Seprase in the P4-P4 positions were 
defined (Edosada et al., 2006a). The study confirmed that Seprase requires a Proline in 
the P| position and Glycine (or D-amino acids) at the P2 position (see Figure 1.8.1) 
(Collins et al., 2004; Edosada et al., 2006a). Seprase was shown to have a broader 
tolerance at the P4, P3, Pi’, and P2’ positions. In the P3 position, Seprase had a preference 
for Ala and Ser. Less activity was observed against charged and aromatic amino acid 
residues, suggesting a preference for small, uncharged amino acids at the P3 position. 
Seprase seems to have a broader specificity at the P4 position. Compared to the previous 
study mentioned above, it was found that Seprase had a preference for Phe or Met at the 
Pi position and least tolerance of His or Glu (Collins et al., 2004; Edosada et al., 2006a).
Figure 1.8.1 Seprase binding model
The model shows a peptide with the P3-Pi’ sequence Ser-D-Ala-Pro-Ile bound to Seprase. The surface 
depicts the structure of Seprase (pdb accession code 1Z68) with carbon atoms shown in white, oxygens in 
red, and nitrogens in blue. The carbon atoms of the peptide are in yellow and the side chain of the P2 D- 
Ala residue is highlighted in cyan. (Edosada et al., 2006a)
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Seprase has been shown to have a preference for N-blocked amino substrates. Studies 
have shown that Seprase cleaves formyl-, benzyloxycarbonyl- and biotinyl- blocked 
substrates, which DPPIV cleaved poorly (Edosada et al., 2006b). The substrate 
preferences as defined by Edosada et al. (2006b) were used to design a peptidyl- 
chloromethyl ketone (cmk) that inhibited Seprase but not DPPIV.
A fluorescence resonance energy transfer (FRET) peptide (see Table 1.8) was developed 
that contained the APCE-sensitive Prol2-Asnl3 bond within the Thr9-Glnl6 sequence 
of Met-cfcAP (of2APpro) (Lee et al., 2004). Hydrolysis of the Pro-Asn bond separates the 
fluorophore, EDANS, from the quenching group, DABCYL, to give an increase in 
fluorescence. Kinetic data using the FRET peptide has shown Seprase to have high 
affinity and kinetic efficiency, indicating that residues in the P4-P4’ region contribute to 
the substrate specificity (Lee et al., 2005a). The k c a t / K m  value for cleavage o f the FRET 
peptide is ~8-fold higher than for Z-Gly-Pro-AMC and ~12-fold higher than for Ala- 
Pro-AFC (see Table 1.8) (Lee et al., 2004).
Combined results from the Edosada et al. (2006a) study also provided a composite 
c^AP-derived peptide substrate for Seprase namely, Ala-Ser-Gly-Pro-Ser-Ser. 
Comparing the kinetic parameters for the parental (TSGP-NQ) and composite c^AP- 
derived peptide substrate (ASGP-SS) shows that the K m value for the cleavage of the 
composite substrate was 3.3 fold higher than the parental substrate (Km = 4.3^M and 
\.3\iM respectively). However, a concomitant 3.4 fold increase in kcat was observed, 
yielding a nearly equivalent catalytic efficiency (kcat/Km ) for each peptide (kcat/ K m = 1.3 
x 106 M V  and 1.2 x 106 M V ).
Identification of the natural substrates of Seprase and the functions of Seprase activated 
peptides remains an important area to be investigated.
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1.9 Possible Clinical Significance of Seprase
Invasion with or without metastatic spread of cancer to distant sites has already occurred 
in a significant number of patients by the time their disease is detected (Fidler, 2002). 
Significant improvement in a patient’s survival may be achieved by halting the invasion 
process and containing the metastatic spread and growth of the disease. There are 
various possibilities on how this can be pursued.
1.9.1 Seprase provides target specificity to anti -  tumour agents
Surface expressed Seprase represents an additional potential target for 
immunolocalisation and immunotherapy of epithelial cancers. Since a large proportion 
of carcinomas contain an abundance of Seprase positive stroma, it is possible that they 
would be accessible to circulating mAb. Several groups have developed antibodies 
directed against Seprase. Antibodies were developed using the Seprase specific mAbF19 
as a model and humanising the antibody (Hofheinz et al., 2003; Mersmann et al., 2001; 
Samel et al., 2003; Scott et al., 2003; Tahtis et al., 2003).
A phase I study investigated the effects of the mAbF19 targeted against metastatic colon 
cancer (Welt et al., 1994). This study concluded that there were no toxic effects 
associated with intravenous administration of iodine131 labelled mAbF19 ( I31I-mAbF19). 
Increased expression of Seprase in primary and metastatic colorectal carcinomas with 
limited expression in normal adult tissue was also observed during this study. This 
highly selective expression pattern allowed for imaging of carcinoma lesions as small as 
1 cm in diameter. A logical concern with regards to the development of stromal targeting 
for cancer therapy is the notion that the stromal response to cancer (at the cellular and 
molecular level (Welt et al., 1994)) is similar to that of wound healing and Seprase is 
known to be expressed in healing dermal incisions (Rettig, 1988). However, the patients 
involved in this study would have had extensive scarring due to surgery but did not show 
any localisation of m I-mAbF19 at these sites. Another phase I trial and limited phase II 
trial have been conducted with an unconjugated, humanized version of monoclonal 
antibody FI9 to Seprase called sibrotuzumb (Hofheinz et al., 2003; Scott et al., 2001).
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Results from this trial found that sibrotuzumb was well tolerated and relatively safe and 
a pharmacokinetic model has been developed for it (Kloft et al., 2004). Similar to the 
results obtained in the previous phase I trial (Welt et al., 1994), trace labelling with 1311 
and detection imaging revealed that sibrotuzumb specifically accumulated in the 
tumours and not in the normal tissues (Scott et al., 2003). These studies suggest that 
mAbF19 has diagnostic and therapeutic applications and could be constructed to provide 
novel immune and non-immune effector functions (Kelly, 2005; Welt et al., 1994).
1.9.2 Inhibition of Seprase protease activity
The protease activity of Seprase is another appealing target for inhibiting the promotion 
of tumour growth by Seprase. Seprase is inhibited by the serine protease inhibitors DFP 
(0.005mM), PMSF (ImM), AEBSF (5mM) and APSF (0.5mM) (Aoyama and Chen, 
1990; Collins et al., 2004; Pineiro-Sanchez et al., 1997; Scanlan et al., 1994). The 
170kDa protease was sensitive to others inhibitors, such as NEM and HgCk, that bind 
the sulfhydryl group of amino acid residues of the proteases (Aoyama and Chen, 1990). 
The inhibition studies performed suggest that Seprase contains a catalytically active 
serine residue.
A series of dipeptide proline diphenyl phosphonates were designed against DPPIV and 
Seprase (Gilmore et al., 2006). The most potent inhibitor for both enzymes was found to 
be Gly-Prop(OPh)2, which exhibited overall second-order rate constants of inactivation 
of 5.24 x 105 M 'min 1 and 1.06 x 104 M 'min 1 against DPPIV and Seprase respectively. 
In the case of Seprase, it was found that the nature of the P2 residue of the inhibitor had a 
less pronounced effect on the second order rate constants, in contrast to DPPIV. It was 
found for DPPIV that the second order rate constants varied by one order of magnitude 
between the most effective [Gly-ProP(Oh)2] and the least effective [Ala-ProP(Oh)2] 
inhibitors. This group also found that Gly-Prop(Oh)2 and Tyr-Prop(Oh)2 exerted a 
considerable dose dependent anti-invasive effect on the LOX melanoma cell line, in 
vitro.
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The inhibition of the catalytic activity of Seprase with anti-catalytic antibodies has been 
investigated. It was found that the tumour-promoting effects of Seprase expression were 
inhibited by the use o f these antibodies (Cheng et al., 2002; Ghersi et al., 2002). This 
group also observed the over-expression of Seprase, leading to increased 
tumourigenicity, compared to a mutated S624A Seprase (Cheng et al., 2005). In this 
same study, Seprase activity was shown to be inhibited by Val-boroPro, a boronic acid 
inhibitor, with an IC50 of 4 x 10*8mol/L (Cheng et al., 2005). However, this inhibitor was 
also found to inhibit DPP IV , DPP-7, -8 and -9 (Edosada et al., 2006b; Flentke et al., 
1991). N-acyl-Gly-Pro dipeptides were identified as Seprase selective substrate motifs 
and a second boronic acid inhibitor was designed, Ac-Gly-BoroPro (Edosada et al., 
2006b) and it inhibited these prolyl peptidases with Kj values ranging from ~9- to 5400- 
fold higher than that for Seprase inhibition (Ki = 23nM for Seprase) (Edosada et al., 
2006b). This indicated that the Ac-Gly-Pro motif conferred significant Seprase 
selectivity and suggests that this could possibly be used to test Seprase as a therapeutic 
target.
These studies together suggest that Seprase activity plays an important role in the 
promotion of tumour growth and that the Seprase protease is a good potential target for 
therapies designed to slow tumour growth.
1.9.3 Disruption of signalling
The targeting of antigens selectively expressed on the surface of tumour stromal 
fibroblasts or tumour capillary endothelial cells is currently being explored for the 
immunotherapy of cancer (Fassnacht et al., 2005; Lee et al., 2005b; Tahtis et al., 2003). 
By targeting or preventing the generation of tumour stroma or angiogenic blood vessels, 
tumour lesions may be deprived of the essential support services or nutrients required for 
survival and growth (Dvorak, 1986). For reasons discussed above, Seprase is an 
important antigen for targeted therapy of the tumour stroma.
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Garin-Chesa et al., (1990) propose that radio labelled or toxin-conjugated mAbs or 
inflammatory mAb isotypes detecting Seprase may be used to induce cell damage in the 
Seprase positive supporting tumour stroma. This would lead to tumour cell necrosis 
(death) and inflammatory cell infiltrates. Recruitment of additional Seprase positive 
reactive fibroblasts would renew the target cell population and aid formation of fibrous 
capsules enclosing and isolating epithelial tumour cells.
Studies in murine models have shown that immunologic targeting o f the tumour 
vasculature, a key element of tumour stroma, can lead to protective immunity in the 
absence of significant pathology (Lee et al., 2005b). Targeting the tumour stroma, 
instead of tumour cells, reduces the incidence of immune evasion. This is due to the fact 
that stromal cells are diploid, unlike tumour cells, and are therefore more genetically 
stable and exhibit limited proliferative capacity.
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Genes that are expressed in a highly tissue- or disease-specific manner provide possible 
targets for (i) anti-cancer therapeutics (ii) the early detection of cancer and (iii) 
monitoring of disease during and after treatment (Brown et al., 2005). Tumour markers 
are substances occurring in blood, tissue, saliva or urine, that are associated with cancer 
and whose measurement or identification is useful in patient diagnosis or clinical 
management. These soluble molecules are usually glycoproteins detected by monoclonal 
antibodies. The ideal tumour marker should be (1) specific for the cancer for which it is 
testing; (2) not present in any other conditions; and (3) the concentration should change 
with the amount of malignant tissue present. An ideal tumour maker could be used for 
screening, diagnosis and the monitoring of disease progression and should be easily and 
reproducibly measured.
To date there is no serum or saliva tumour marker(s) for breast cancer screening. There 
are three main methods of screening for breast cancer: mammography, clinical breast 
examination and breast self-examination. A mammogram is a breast x-ray that is the 
most proven screening test for reducing the risk of dying from breast cancer. It is 
important to remember that breast cancer cannot be diagnosed by mammography alone. 
In addition, a patient may be asked to have further testing (e.g., ultrasound or biopsy) 
because something on the mammogram needs more evaluation. One study found that 11 
percent of mammograms performed in the United States require additional evaluation 
and the lesion turns out to be benign in more than 90 percent of these cases (Brown et 
al., 1995).
Currently there are no ideal tumour markers which are recommended for screening of 
the general population and most are restricted to monitoring cancers once they have been 
detected and diagnosed using other methods. A new prognostic marker is also needed to 
identify patients who are at the highest risk for developing metastasis. Most tumour 
markers have too many false positives from benign conditions to make screening 
feasible. Many only clearly identify malignancy once the cancer is sufficiently advanced 
to make this detection o f limited use. Table 1.10 shows the currently used tumour 
markers
1.10 Biomarkers
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Tum our
M arker
CA 27.29
CEA
CA 19-9
CA 125
AFP
Normal
Value
< 38 units 
per ml
Primary Tum our (s)
Breast Cancer
<2.5 ng per Colerectal Cancer
ml in non-
smokers
<5 ng per 
ml in
smokers
< 37 units 
per ml
Pancreatic cancer, 
biliary tract cancers
< 35 units Ovarian Cancer 
per ml
Additional Associated Benign Conditions
Malignancies
Colon, gastric, hepatic, lung , Breast, Liver and kidney disorders,
pancreatic, ovarian, prostrate ovarian cysts
cancers
Breast, Lung, gastric, pancreatic. Cigarette smoking, peptic ulcer
bladder, medullary thyroid, head disease, inflammatory bowel disease,
and neck, cervical, and hepatic pancreatitis, hypothyroidism,
cancers, lymphoma, melanoma cirrhosis, biliary obstruction
Colon, esophageal, and hepatic Pancreatitis, biliary disease, cirrhosis
< 5 .4  ng per Hepatocellular 
ml carcinoma, non-
seminomatous germ 
cell tumours
Endometrial, fallopian tube, Menstruation, pregnancy, fibroids,
breast, lung , esophageal, gastric, ovarian cysts, pelvic inflammation,
hepatic, and pancreatic cancers cirrhosis, ascites, pleural and
pericardial effusions, endometriosis
Gastric, biliary and pancreatic Cirrhosis, viral hepatitis, pregnancy
cancers
Sensitivity
Elevated in about 33% of 
early stage breast cancers 
and about 67% of late- 
stag e breast cancers
Elevated in less than 25% 
o f  early-stage colon 
cancers and 75% of late- 
stage colon cancers.
Elevated in 80% to 90% of 
pancreatic cancers and 
60% to 70% o f the late- 
stage colon cancers.
Elevated in about 85% of 
ovarian cancers; elevated 
in only 25% o f early stage 
ovarian cancers
Elevated in 80% of 
heptocellular carcinomas
Table 1.10 Conditions Associated with Elevated Tum our M arker Levels in Serum
CA = cancer antigen; CEA = carcinoembryonic antigen; AFP = alpha-fetoprotein. (Perkins et al., 2003)
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Figure 1.10.1 The roadmap for cancer biom arker development
(Plebani, 2005)
Researchers have proposed sequential phases for cancer biomarker development in the 
form of a road map (see Figure 1.10.1). This takes into consideration the different steps 
that gradually expose the structure, biological relevance and the predictive value o f the 
novel biomarker for the diagnosis and screening of neoplastic disease (Plebani, 2005).
As described previously, tumour cells, in order to establish a metastasis, have to invade 
their surrounding host tissue, enter the circulatory system, arrest in capillary beds o f 
distant organs, invade the host tissue and proliferate. The development of an assay to 
detect these cells before the manifestation of distant metastasis should therefore be 
useful for patient prognosis. There is substantial evidence that Seprase is involved in the 
degradation of the extracellular matrix and subsequent invasion of the surrounding host 
tissue by cancer cells. The cell surface localization of Seprase makes it an ideal 
candidate for targeted therapeutic agents to malignant breast cells, i.e. the selective 
inhibition of Seprase should prevent a critical part of tumour invasion. However, to date, 
the pathophysiologic significance of its expression remains poorly understood.
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Malignant transformation from normal to cancerous tissue is associated with cell-surface 
glycoprotein modifications (Cordero et a l , 2000) These protems can be released in the 
circulation through increased cell turnover, secretion or shedding from the malignant 
cells and have been considered as potential tumour markers for helping in screening, 
diagnosis, staging, prognosis and monitoring of cancer therapy (Cordero et a l , 2000) It 
may be possible that during the early stages of breast cancer, for example, Seprase 
activity becomes over-expressed and starts to appear in the serum in relatively low 
levels Therefore, Seprase would have a huge potential to be a highly specific 
‘biomarker’ for human breast cancer
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The initial objective of this research project was to purify and identify the second Z-Gly- 
Pro-AMC degrading activity found in bovine serum in collaboration with Dr Patrick 
Collins, Dublin City University Previous studies were unsuccessful in purifying this 
second Z-Gly-Pro-AMC degrading activity from bovine serum to a level o f purity and 
quantity required to identify the enzyme by protein sequencing Previous attempts at 
identifying this activity demonstrated that there were contaminating proteins which 
required removal before the enzyme could be identified This would involve developing 
a purification method that would remove these contaminating proteins and to develop a 
method which would allow the native enzyme to be detected in a PAGE gel Upon 
identification of the activity as Seprase, biochemical characterisations studies were 
designed, including investigating the gelatinase activity, the temperature and pH profiles 
of the soluble form of bovine Seprase More detailed substrate specificity studies were 
also designed using a dipeptide library specific for proteases These studies would 
provide valuable insight into the catalytic and structural properties of bovine Seprase 
and open the way for the better design of inhibitors and pharmacological agents This 
project would also involve the further development and optimisation o f the specific 
assay for Seprase
Upon identification of the activity as Seprase, the project also focused on the cloning of 
the human Seprase gene Upon cloning o f the gene, the project would focus on the 
development of an expression system capable of producing catalytically active 
recombinant human Seprase If  expression of active recombinant human Seprase was 
possible in a prokaryotic system, this would enable the rapid production of large 
quantities of the enzyme Alternatively, a mammalian or yeast-based expression system 
would be explored The availability of purified recombinant human Seprase would allow 
a series o f detailed molecular, biochemical and kinetic studies to be carried out Using 
the recombinant Seprase expression system, a series of site-specific mutagenesis 
experiments would be carried out, giving valuable insight into the catalytic and
1 11 Aims of the project
48
structural properties of human Seprase and opening the way for the design o f inhibitors 
and pharmacological agents
Collaboration with BreastCheck and the Symptomatic Breast Care Unit o f the Mater 
Misericordiae Hospital, Dublin was established to analyse clinical samples from patients 
with confirmed breast cancer, in the hope of observing significantly elevated Seprase 
levels in the serum The results from this study could lead to a greater understanding of 
Seprase expression in breast cancer and possibly lead to the identification o f Seprase as 
a specific bio marker and thus the development of a bio marker diagnostic test
To date, Seprase expression has been studied using immunohistochemistry and a 
specific sensitive assay for Seprase has not been developed Such studies as those 
described in this research thesis would significantly add to published data on this 
recently discovered protease, Seprase, and represent the first detailed study o f a soluble 
form of the enzyme from bovine serum This research thesis would also provide a 
specific assay for Seprase which could be used to detect Seprase
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Chapter 2 
Materials and Methods
All chemicals and reagents were obtained from Sigma-Aldrich unless otherwise 
stated
2 1 Protein Concentration 
2 11 Quantitative determination by Biuret Assay
The Biuret assay (Sigma) was used to monitor protein in post column 
chromatography fractions and also to quantify protein in crude serum and post 
chromatography active enzyme pooled sample containing greater than 2 mg/ml 
protein (Gomall et a l , 1949) For protein quantification, all samples were dialysed 
into ultra-pure water and diluted appropriately to achieve a concentration suitably 
determinable by the assay Bovine serum albumin (BSA) standards (2-10mg/ml) and 
enzyme samples were prepared and assayed in triplicate Fifty microlitres o f standard 
or sample was added in triplicate to 200 jal o f Biuret reagent, and allowed stand at 
room temperature for 5 minutes Absorbances were determined at 540nm using a 
Tecan Spectra Plate Reader
2.1 2 Quantitative determination by Standard BCA Assay
The standard bicinchommc acid (BCA) assay (Sigma) was used for protein 
monitoring and quantification in column fractions and pooled samples which 
contained less than 2mg/ml o f protein (Smith et a l , 1985) Samples were prepared as 
outlined m section 2 1 1 and BSA standards in the range 0-2mg/ml were included 
Twenty-five microlitres o f standard or sample was added in triplicate with 200 jil o f 
BCA reagent, and incubated at 37°C for 30 minutes Absorbances were read at 
570nm
2 13 Quantitative determination by Coomassie Plus Assay
The coomassie plus protein assay was used to monitor and quantify protein 
concentration in post column chromatography fractions and pooled samples 
containing between 2 5 and 25 jag/ml protein (Bradford, 1976) Samples were 
prepared as outlined in section 2 1 1 and BSA standards in the range 2 5-25 |ig/ml 
were included One hundred and fifty microlitres o f standard or sample was added in 
triplicate to 150 \x\ o f coomassie plus reagent (Pierce), allowed stand at room 
temperature for 5 minutes and finally read at 595nm
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2 2 Fluorescence Spectrometry using 7-Amino-4-Methyl-Coumarm (AMC) 
2 2 1 AMC Standard Curves
100 jiM stock AMC solution containing 4% v/v methanol was prepared in 100 mM 
potassium phosphate, pH 7 4 All lower AMC concentrations were obtained using 
lOOmM potassium phosphate, pH 7 4 containing 4% v/v methanol as diluent Stock 
solution and standards were stored in the dark at 4°C for up to one month Standard 
curves in the range 0-5 juM and 0-20 |iM AMC were prepared in triplicate by 
combining 25 1^ (100 jal)* of 100 mM potassium phosphate pH 7 4, 100 jlxI (400 
p,l)*of appropriate AMC concentration and 175 jil (1 ml)* of 1 5 M acetic acid 
Fluorimetric analysis of these samples was achieved using a Perkin Elmer LS50 
Fluoresence Spectrophotometer at excitation and emission wavelengths of 370nm 
and 440nm respectively Excitation slit widths were maintained at lOnm while 
emission slit widths were adjusted accordingly for the range being analysed 
* Note Bracketed values represent the volumes used fo r  the cuvette assay
2 2 2 Inner Filter Effect
The inner filter or quenching effect of enzyme samples was determined by 
combining 25 fil (100 |il) of enzyme sample, 100 |il (400 |il) appropriate AMC 
dilution and finally 170 \i\ (1 ml) of 1 5 M acetic acid The filtering effect of crude 
serum samples was assessed in the presence and absence of 5 (il, 2 5x104 M JTP- 
4819* in 10% v/v MeOH The samples were all assayed in triplicate as described in 
section 2 2 1
Note Even though the peptidase under study is named ZIP (Z-Pro-prohnal 
Insensitive Peptidase), JTP-4819 (see Figure 2 2 1), which is also a potent and 
specific inhibitor o f Prolyl Ohgopeptidase, is used throughout this work fo r  
distinguishing between these peptidases This is due to the commercial unavailability 
o f  Z-Pro-prolmal
Figure 2 2 1 Chemical Structure of JTP-4819
(Toide et a l , 1995)
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2 3 Enzyme Assays
2 31 Substrate Preparation
Both Prolyl Oligopeptidase (PO) and Z-Pro-prolinal Insensitive Peptidase (ZIP) 
activities were determined using the fluorimetnc substrate Z-GIy-Pro-AMC, with 
modification o f the original protocol o f Yoshimoto et al (1979) 10 mM Z-Gly-Pro- 
AMC stock was prepared in 100% methanol, aliquoted and stored at -20°C 100 jaM 
substrate containing 4% v/v MeOH was prepared by slowly adding 300 jil MeOH 
and 100 [i\ Z-Gly-Pro-AMC stock to 9 6 ml o f 100 mM potassium phosphate, pH 7 4 
at 37°C Prolyl Oligopeptidase activity was determined with 10 mM DTT in the 
above substrate, while for determination o f ZIP activity 500 mM NaCl was included
2 3 2 Quantitative Zr-Gly-Pro-AMC Degrading Activity Measurements 
2 3 21 Cuvette
Four hundred microhtres o f the 100 jiM substrate was added to 100 jal enzyme 
sample in triplicate and incubated at 37°C for 60 mm Both samples and substrate 
were premcubated for 10 min at 37°C to allow them reach thermal equilibrium 
Reactions were terminated by the addition o f  1 ml o f 1 5 M acetic acid Blanks or 
negative controls were prepared by adding 1 ml o f 1 5 M acetic acid to 100 jal o f  
enzyme sample prior to substrate addition and incubation at 37°C for 60 mm 
Formation o f AMC was measured as described in section 2 2 1 End pomt 
measurements were allowed, as the enzyme assay was linear with respect to time and 
enzyme concentration up to 60 min (Bimey and O’Connor, 2000) Fluonmetric 
intensities observed were converted to nanomole AMC released per minute per ml 
using the appropriate standard curve as outlined in section 2 2 2 One unit o f activity 
is defined as the amount o f enzyme which releases 1 nanomole o f AMC per minute 
at 37°C (see Appendix A for calculations)
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One hundred microlitres o f the 100 yiM substrate was added to 25 jil enzyme sample 
in triplicate and the microtitre plate was incubated at 37°C for 60mins Both samples 
and substrate were pre-incubated at 37°C to allow them reach thermal equilibrium 
Reactions were terminated by the addition o f 175 jil o f 1 5 M acetic acid Blanks or 
negative controls were prepared by adding 175 |il o f 1 5 M acetic acid to 25 jil o f 
enzyme sample prior to substrate addition and incubation at 37°C for 60mins
Fluorimetric analysis o f these samples was achieved using a Perkin Elmer LS50 
Fluorescence Spectrophotometer with plate reader attachment, at excitation and 
emission wavelengths o f 370nm and 440nm respectively Excitation slit widths were 
maintained at lOnm while emission slit widths were adjusted accordingly for the 
range being analysed
End point measurements were allowed, as the enzyme assay was linear with respect 
to time and enzyme concentration up to 60mins Fluorimetric intensities observed 
were converted to nanomole AMC released per minute per ml using the appropriate 
standard curve (Appendix A) Enzyme units were defined as nanomole o f AMC 
released per minute at 37°C
2.3 3 Quantitative Z-Pro-prolinal Insensitive Z-Gly-Pro-AMC (ZIP)
Degrading Activity Measurement
Section 2 3 2 describes the determination o f ZIP activity (which shall henceforth be 
referred to as Seprase) in situations where it was most certainly separated from prolyl 
oligopeptidase activity In crude bovine serum, the following assay modifications 
were necessary to distinguish Seprase activity from PO activity, 25 .^1 (100 jal)* o f 
enzyme sample was pre-mcubated for 15 minutes at 37°C with 5 \i\ (20 jil)* o f  
2 5xl04 M JTP-4819 in 10% v/v MeOH prior to substrate addition Negative 
controls were also included, as in section 2 3 2, incorporating JTP-4819 and 
determinations were carried out in triplicate AMC released was determined 
fluorimetrically, with end point measurements taken as m section 2 3 2 Fluorimetric 
intensities obtained for each sample were converted to nanomole o f AMC released
2 3 2 2 Microtitre Plate
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per minute per ml using the standard curves incorporating JTP-4819, prepared as 
outlined in section 2 2 1 Enzyme units were defined as nanomole of AMC released 
per minute at 37°C
* Note Bracketed values represent the volumes used fo r  the cuvette assay
2 3 4 Non-Quantitative Z-Gly-Pro-AMC Degrading Activity Measurements
A non-quantitative fluorimetnc microtitre plate assay was developed to assist in the 
rapid identification o f Z-GIy-Pro-AMC degrading activities in post-column 
chromatography fractions Two hundred micro litres of 100 jiM Z-Gly-Pro-AMC in 
4% MeOH containing 500 mM NaCl (ZIP) or 10 mM DTT (PO), at 37°C was added 
to 100 |il of sample in each well Post-phenyl sepharose fractions were assayed in the 
presence and absence of 5 jal 2 5x1 O'4 M JTP 4819 in 10% MeOH The microtitre 
plate was incubated at 37°C for 30 minutes AMC released was determined 
fluonmetrically as outlined in section 2 2 1, using the Perkin Elmer LS-50B plate 
reader attachment
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Purification steps were all carried out at 4°C apart from the final size exclusion 
column, which was performed using Bio Rad Biologic HR FPLC at room temperature 
based on the method of Collins and O’Connor (2003)
2 41 Bovine Serum Preparation
Bovine whole blood was collected from a freshly slaughtered animal and stored at 
4°C over 24 hours to allow clot formation The remaining un-clotted whole blood 
was decanted and centrifuged at 6000 rpm for 1 hour at 4°C using a Beckman J2-MC 
centrifuge fitted with JL-10 5 rotor The supernatant and loose cellular debris was 
decanted and re-centrifuged at 20,000 rpm for 15min using a JL-20 rotor The final 
serum was collected and stored at -17°C in 20 ml aliquots
2 4 2 Phenyl Sepharose Hydrophobic Interaction Chromatography
A 20 ml Phenyl Sepharose CL-4B hydrophobic interaction column (2 5cm x 7cm) 
was equilibrated with 100 ml o f 100 mM potassium phosphate containing 200 mM 
ammonium sulphate, pH 7 4 Solid ammonium sulphate was dissolved in 20 ml o f  
bovine serum to give a final concentration o f 200 mM This sample was then applied 
to the equilibrated column followed by a 100 ml wash with 100 mM potassium 
phosphate containing 200 mM ammonium sulphate, pH 7 4 The column was then 
washed with 100 ml o f 100 mM potassium phosphate containing 50 mM ammonium 
sulphate, pH 7 4 Bound protein was eluted isocratically with a 100 ml ultra-pure 
water wash Equilibration o f the column was earned out at a flow rate o f 1 ml/min, 
while all other steps were performed at 2 ml/min Five millilitre fractions were 
collected throughout the procedure and were assayed for Seprase activity according 
to section 2 3 4 Protein content in each fraction was determined using the biuret 
assay according to section 2 11 Fractions containing Seprase activity were pooled to 
yield post-phenyl Sepharose Seprase Enzyme activity and protein content were 
quantified using the fluonmetric assay as outlined in section 2 3 2 and the biuret 
assay as in section 2 11 The phenyl Sepharose resin was regenerated with a 100 ml 
wash o f pure ethanol at 0 5 ml/min, followed by 150 ml o f equilibration buffer
2.4 An Optimised Purification Procedure for Bovine Serum Seprase
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2 4 3 Calcium Phosphate Cellulose Chromatography 
2 4 31 Resin Preparation
One litre o f 500 mM sodium hydrogen phosphate was added (at 6 4 ml/min) to 1 5 L 
o f constantly stirred 500 mM calcium chloride at room temperature Following a 15 
mm agitation, 1 5 ml o f concentrated ammonia solution was added and stirred for a 
further 10 mm The precipitated gel was allowed to settle and the supernatant 
decanted and discarded 1 L of ultra-pure water was added and the stirring continued 
for 5 min Settlmg and decanting was performed and this procedure was repeated 
until the gel was washed with 10 L o f ultra-pure water The washed calcium 
phosphate gel was stored in 1 L of ultra-pure water at 4°C Sigma cellulose type 50 
(lOg) was soaked overnight in 200 ml 500 mM potassium phosphate containing 150 
mM potassium chloride, pH 6 8 The cellulose was washed eight times with ultra- 
pure water and dried overnight at 70°C Washed and dried cellulose (2 g) was 
dissolved in 20 ml 20 mM potassium phosphate, pH 7 4 and added to 24ml o f evenly 
suspended calcium phosphate gel The calcium phosphate cellulose was poured into 
a column (2 5 x 7  0cm) and allowed to settle, yielding 15 ml o f packed resin
2 4 3 2 Column Chromatography
The column was equilibrated at 1 ml/min with 10 mM potassium phosphate, pH 7 4 
The post-phenyl Sepharose Seprase was concentrated to 10 ml and applied to the 
column followed by a 100 ml wash with 10 mM potassium phosphate, pH 7 4 The 
column was then washed with 100 ml o f 170 mM potassium phosphate, pH 7 4 
Bound protein was eluted with 100 ml o f 500 mM potassium phosphate, pH 7 4 
Loading and washing steps were performed at 1 ml/min, while elution was 
performed at 2 ml/min Five millilitre fractions were collected throughout the 
procedure, and again were assayed for Seprase activity according to section 2 3 4 
Protein content in each fraction was determined using the standard BCA assay as 
outlined in section 2 1 2 Fractions containing Seprase activity were pooled to yield 
post calcium phosphate cellulose Seprase Enzyme activity and protein content were 
then quantified as outlined in section 2 3 2 and 2 12
5 7
100 ml o f 20 mM potassium phosphate, pH 7 4 was used to equilibrate a 20 ml 
Cibacron blue 3GA resin The post calcium phosphate cellulose Seprase was 
concentrated and then dialysed overnight against 2 L o f 20 mM potassium phosphate, 
pH 7 4 After sample application, the column was washed with 100 ml o f 20 mM 
potassium phosphate, pH 7 4 to remove any unbound protein Elution was performed 
using a 100 ml linear 0-2M NaCl gradient in 20 mM potassium phosphate, pH 7 4 
Loading, washing and elution were all performed at 1 ml/min Five millilitre 
fractions were collected and assayed for Seprase activity according to section 2 3 4 
Protein content in each fraction was determined using coomassie plus protein reagent 
as in section 2 1 3 Fractions containing Seprase activity were pooled and enzyme 
activity and protein content were quantified as outlined in section 2 3 2 and 2 13
2 4 5 Sephacryl S-300 Size Exclusion Chromatography
A HiPrep 16/60 Sephacryl S-300 High Resolution (HR) size exclusion 
chromatography column (Amersham, GE Healthcare) was attached to a fast protein 
liquid chromatography system The column was equilibrated at 0 8ml/min with 250 
ml o f 100 mM potassium phosphate containing 150 mM NaCl, pH 7 4, which had 
been filtered and degassed The post cibacron blue 3GA Seprase pool was 
concentrated to 2 ml and applied to the column followed by a 150 ml wash with 
equilibration buffer at 0 8 ml/min Five millilitre fractions were collected and 
assayed for Seprase activity as outlined in section 2 3 4 Protein content in each 
fraction was monitored online at 280nm and also using coomassie plus protein 
reagent as outlined in section 2 1 3 Fractions containing Seprase activity were 
pooled and enzyme activity and protein content were quantified as described in 
section 2 3 2 and 2 1 3
2 4 4 Cibacron Blue 3GA Chromatography
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The required amount o f tubing was placed in a 1 L glass beaker and rinsed 
thoroughly with distilled water The beaker was filled with distilled water and ~1 g 
o f EDTA was added The beaker contents were brought to the boil and boiled for 2 
min The water was allowed to cool and then poured off The beaker was re-filled 
with fresh distilled water and boiled again for 2 mm The water was allowed to cool 
and poured off The tubing was thoroughly rinsed with distilled water and was stored 
at 4°C in distilled water
2 4 6 Preparation of dialysis tubing
2 5 Polyacrylamide Gel Electrophoresis
SDS polyacrylamide gel electrophoresis based on the method of Laemmli (1970) was 
employed to determine the effectiveness o f the purification procedure
2 5 1 Preparation of SDS Gels
10% resolvmg and 4 5% stacking gels were prepared as in Table 2 5 1 Gels were 
cast using an ATTO vertical mini electrophoresis system The resolving gel solution 
(Table 2 5 1) was degassed and filtered, TEMED added, mixed and the gel poured 
immediately An overlay o f ethanol/water was placed over the resolving gel After 
polymerisation, the overlay was removed The stacking gel solution (Table 2 5 1) 
was degassed and filtered, TEMED added, mixed and the gel poured immediately A 
comb was placed into the top o f the gel liquid to form loading wells, and the gel was 
allowed polymerise
Solution 10% Resolving Gel 15% Resolving Gel 4% Stacking 
Gel
1 5 M Tns-HCl, pH 8 8 1 625 ml 1 625 ml -
Resolving Gel buffer
0 5  M Tns-HCl, pH 6 8 - - 0 625 ml
Stacking Gel buffer
dH20 2 64 ml 1 56 ml 1 538 ml
Acrylamide/Bis-acrylamide 2 17 ml 3 25 ml 0 335 ml
30%/0 8% (w/v)
10% (w/v) Ammonium 32 5 fil 32 5 fil 12 5 (il
Persulphate
20% (w/v) SDS 32 5 fil 32 5 jal 12 5 (xl
TEMED 3 25 nl 3 25 nl 2 5 jil
Table 2 5 1 SDS PAGE Gel Preparation
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2.5.2 Sam ple Preparation
Samples generated from the different stages o f the purification o f bovine serum 
Seprase (Post-phenyl Sepharose, post-calcium phosphate cellulose, post-cibacron 
blue 3GA and post-S-300 gel filtration) were extensively dialysed overnight into 
ultra-pure water. Each dialysed sample was added to an equal volume o f 2x 
solubilisation buffer which consisted o f 20% v/v glycerol, 4% w/v SDS, 10% v/v 2- 
mercaptoethanol, 0.004% w/v bromophenol blue and 125 mM Tris/HCl, pH 6.8. 
Samples were boiled for 2 minutes and stored on ice until application.
2.5.3 Sample Application
Twenty microlitres o f each prepared sample from section 2.5.2 was applied to the 
10% SDS PAGE gel. The Sigma high molecular weight standards used consisted of 
Myosin (205kDa), P-Galactosidase (116kDa), Phosphorylase B (97kDa), Fructose-6- 
phosphate kinase (84kDa), BSA (66kDa), Glutamic dehydrogenase (55kDa), 
Ovalbumin (45kDa) and Glyceraldehyde-3-phosphate dehydrogenase (36kDa). 
Coloured markers were also used (Figure 2.5.1). Twenty micro litres o f the standards 
solution was also applied to the gel, which was then run at 125V for 2h at room 
temperature. Running buffer was 25 mM Tris/HCl, 192 mM glycine, 0.1% SDS, pH 
8.3.
kDa kDa kDa
201 250220 127 160105
100 — 80 7560
45 40 50
30 m m 31 35
20
12 17 25
15
Figure 2.5.1 Coloured M arkers
Coloured Markers used in SDS analysis. Left: Sigma ColourBurst Markers. Middle:
Kaleidoscope Pre-stained Standards (BioRad). Right'. Full Range Rainbow Markers 
(Amersham). Molecular weight markers are listed.
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Polyacrylamide gels were removed from the electrophoresis chamber and washed 
with dUjO for 5 min Routinely, gels were stained for 60 min in a 0 25% (w/v) 
Coomassie blue solution containing 10% (v/v) Acetic Acid/45% (v/v) methanol and 
then de-stained overnight using 10% (v/v) Acetic Acid/45% (v/v) methanol 
Subsequent soaking in d t^O  enhanced the protein bands further If  this did not 
sufficiently stain the gel, the more intense silver staining method (Blum et a l , 1987) 
was used as outlined in Table 2 5 2 An image o f each stained gel was scanned or 
captured using a Casio Exilim Ex-Z40 digital camera coupled to Casio software
2 5 4 SDS PAGE Gel Staining
Step D uration Reagent
Fix 60 mm 50% ethanol, 12% acetic acid, 0 05% formaldehyde (37% stock)
Wash 3 x 20 mm 50% ethanol
Pre-Treat 1 min 200 1^ of a 5% Na2S20 3 x H20  stock solution m 100 ml dH20
Rinse 2 x 20 s dH20
Impregnate 20 mm 0 lg  AgNC>3, 70 \i\ formaldehyde in 100 ml dH20
Rinse 2 x 20 s dH20
Development 10 mm (max ) 3g Na2C 0 3, 50 [i\ formaldehyde, 4 \i\ Na2S203 x H20  stock 
solution in 100 ml dH20
Stop 5 mm 0 1 M EDTA
Table 2 5 2 Silver Staining Procedure
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2 6 Identification of this Z-Pro-prolinal Insensitive Peptidase
2 61 Determination of N-Terminal Protein Sequence
N-terminal sequencing o f ZIP was performed commercially by Bryan Dunbar’s 
group at the Aberdeen Proteome Facility, University o f Aberdeen, Scotland The 
enzyme sample had to be firstly separated by SDS PAGE, then electroblotted onto 
polyvinylidene difluoride (PVDF) membrane and stained The recommended method 
is shown below (Keen, 2006)
2 6 1 1  SDS Polyacrylamide Gel Electrophoresis
An SDS PAGE gel was precast according to Table 2 5 2 and section 2 5 1 and stored 
overnight at 4°C to prevent N-terminal blocking by free amines Fifty millilitres o f 
bovine serum was purified as in section 2 4 and the final purified ZIP sample was 
dialysed extensively overnight against ultra-pure water and concentrated to 500 [i\ 
using a Thermo Savant DNA110 SpeedVac An equal volume of sample was added 
to an equal volume of solubilisation buffer (see section 2 5 2) and boiled for 2 
minutes Coloured markers were employed as to aid visualising electrophoresis and 
electrotransfer The gel was pre-run at 50V for 30min with 200 |iM thioglycolic acid 
in the upper reservoir in order to provide a scavenger for free radicals The chamber 
was emptied, rinsed with reservoir buffer and further electrophoresis was performed 
at a constant current o f 20 mA for 2hr
2 6 12 PVDF Electroblotting
1 L o f lOx CAPS buffer was prepared and adjusted to pH 11 using sodium 
hydroxide lx  electroblotting buffer in 10% MeOH was prepared and stored at 4°C 
On removal o f the gel it was placed in electroblotting buffer for 1 h, while the PVDF 
membrane was dipped in MeOH for 10 sec and also equilibrated in electroblotting 
buffer for 1 h A transblotting sandwich was made using 8 layers o f pre-soaked filter 
paper, cut to the exact size o f the gel The PVDF membrane was placed on top o f the 
filter paper followed by the gel Eight more layers o f equilibrated filter paper were 
added to complete the sandwich Electroblotting was performed at 0 8mA/cm2 for 1 
h 10mm Removal o f the membrane was followed by a rapid membrane wash in
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ultra-pure water It was then saturated in 100% MeOH for 10 s and stained with 
coomassie blue for 3 mm Destaming in 1% acetic acid was repeated twice, then the 
blot was extensively washed with ultra-pure water and finally allowed to air dry The 
blot was wrapped in clingfilm and sent for sequencing
2 6 2 Protein G Affinity Chromatography
2 5 ml o f protein G resin was equilibrated with 10 ml o f lOOmM potassium 
phosphate containing 200 mM NaCl, pH 7 4 One to two millilitres o f concentrated 
purified ZIP sample was applied to the affinity resin and allowed to shake slowly for 
30 mins at 4°C (Batch bind) The resin was allowed to settle and the supernatant 
removed The resin was then washed with 10 ml with equilibration buffer, allowed 
settle and the supernatant removed A second 10 ml wash o f 100 mM potassium 
phosphate containing 500mM NaCl, pH 7 4 was then performed, the resin again 
allowed to settle and the supernatant removed Each supernatant was pooled and 
assayed for ZIP activity according to section 2 3 4 Bound protein was eluted using a 
10 ml wash with 0 1 M glycine/HCl, pH 2 2
2 6 3 Gelatin Sepharose Chromatography
Five millilitres o f gelatin sepharose was equilibrated with 15 ml 100 mM potassium 
phosphate containing 200 mM NaCl, pH 7 4 The post-protein G ZIP sample was 
concentrated, applied to the resin and allowed to batch-bind slowly for 1 hour at 4°C 
The resin was allowed to settle and the supernatant removed This was followed by a 
wash with 15 ml o f equilibration buffer, the resin allowed to settle and the 
supernatant removed A second 15 ml wash o f 100 mM potassium phosphate 
containing 1 M NaCl, pH 7 4 was performed, with the resin again allowed to settle 
and the supernatant removed Each supernatant was pooled and assayed for ZIP 
activity according to section 2 3 4 Bound protein was eluted with a 15 ml wash o f 4 
M urea, pH 7 0
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2 6 4 UV Zymogram Development
2 6 41 Native Polyacrylamide Gel Electrophoresis
r
A 10% native polyacrylamide gel was prepared as in section 2 5 1 except that no 
SDS was present in the gel and the gels in this case were cast in the large ATTO 
electrophoresis system The cast gels were stored overnight at 4°C Purified ZIP 
sample was dialysed extensively overnight into ultra-pure water and concentrated to 
500 (il using a ThermoSavant DNA 110 SpeedVac
lOx (non-denaturing) solubilisation buffer was prepared as follows 3 2 ml 10% SDS, 
2 ml 0 5M Tris/HCl pH 6 8, 1 6 ml glycerol, 0 05% (w/v) bromophenol blue and 1 2 
ml o f ultra-pure water, in a final volume o f 8 ml This solution was stable for 4-6 
weeks at 4°C, or for months if  stored at -20°C
Running buffer was prepared as in section 2 5 3 without SDS being added 54 jil o f 
concentrated ZIP sample was added to 6 \x\ lOx (non-denaturing) solubilisation 
buffer and applied directly to the gel The gel was run at a constant voltage o f 125 V 
at 4°C for 2 5 h
2 6 4 2 U V Zymogram Assessment
After native PAGE electrophoresis, the gel was rapidly removed and placed in 50 ml 
of 100 jiM Z-Gly-Pro-AMC in lOOmM potassium phosphate pH 7 4 containing 4% 
v/v MeOH and 500 mM NaCl It was incubated with shaking for 10-15 min at 37°C, 
after which excess substrate was removed and the gel placed under ultraviolet light in 
an image analyser for visualisation
2 6 5 Gelatin Zymogram Development
Gelatin zymography was performed to observe enzyme activity against the protein 
substrate, gelatin The gel was prepared by incorporating the protein substrate o f 
interest (gelatm) within the polymerised acrylamide matrix The enzyme sample was 
resolved by 10% native PAGE gel in the presence of 1 mg/ml gelatin The method o f 
Laemmli (1970) was followed, excluding any reducing agents or boiling procedures
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Samples were mixed 3 1 with 4x (non denaturing) solubilisation buffer, which 
consisted o f 16% w/v SDS, 40% v/v Glycerol and 0 08% Bromophenol Blue The 
gels were run at 125V in running buffer (25 mM Tns, 192 mM Glycine) for up to 4 
hours at 4°C After electrophoresis, the gel was washed for 30min in 2 5% Triton X- 
100 at room temperature, with one wash change The gel was then incubated 
overnight at 37°C in reaction buffer (100 mM potassium phosphate, pH 7 4, 500 mM 
NaCl) After staining with Coomassie stain (section 2 5 4) for 2 hours with shaking, 
the gel was destained in water until clear bands were visible Gelatin degrading 
activity was identified as a clear zone o f lysis against a blue background
The identification o f Seprase as a serine protease was also investigated by means o f 
determining the sensitivity o f the enzyme to serine protease inhibitors Prior to 
electrophoresis, enzyme samples were also incubated for 10 minutes in the presence 
o f the serine protease inhibitors PMSF (5 mM), DFP (5^M) and JTP-4819 (2 5x10 
4M - PO specific inhibitor) Samples were mixed as 3 1 with 4x solubilisation buffer 
as previously described
2 6 6 Wheat Germ Agglutinin (WGA) Lectin Affinity Chromatography
Twenty millilitres o f 100 mM potassium phosphate, pH 7 4 containing 200 mM 
NaCl was used to equilibrate a 1 ml WGA lectin resin The purified post-FPLC 
Seprase sample was applied to the resin and allowed to batch-bind slowly for 3 
hours, at 4°C The resin was allowed to settle and the supernatant removed The resin 
was put into a column and washed with 15 ml o f equilibration buffer (100 mM 
potassium phosphate containing 200 mM NaCl, pH 7 4 Bound protein was eluted 
with an 11 ml wash o f 100 mM potassium phosphate containing 0 5 M N-acetyl-D- 
glucosamine and 200 mM NaCl, pH 7 4 Washing and elution were all performed at 
0 5 ml/min One millilitre fractions were collected and assayed for Seprase activity 
according to section 2 3 4 Protein content in each fraction was determined using 
Coomassie plus protein reagent (section 2 1 3 )  Fractions containing Seprase activity 
were pooled and enzyme activity and protein content were quantified as m section 
2 3 2 and 2 1 3
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2 7 Biochemical Studies
2 7 1 Temperature Studies 
2 7 11 Determination of Optimum Assay Temperature
Purified Seprase was assayed in triplicate for 1 h at temperatures ranging from 4- 
70°C, as per section 2 3 2 with the temperature alteration Samples were pre- 
incubated for 15 minutes at the appropnate temperature prior to assay This ensured 
that the observed activity reflected the activity o f the peptidase at the temperature 
under investigation A plot o f Residual activity (%) versus Temperature (°C) was 
constructed Activity levels measured at 37°C were defined as 100%
2.7 1 2 Thermal Profile, (T5o)
This method was used to determine the temperature at which the enzyme begins to 
unfold and lose catalytic activity Temperatures ranging from 4-75°C were used
Seprase was incubated at each temperature for 10 min and then 25 \i\ aliquots of 
enzyme were removed and stored on ice to prevent refolding, until assayed for 
remaining activity The enzyme solution was then placed in the next temperature for 
a further 10 mm Activities were assayed in triplicate under standard conditions 
according to section 2 3 2 A plot o f Residual activity (%) versus Temperature (°C) 
was constructed and the T50 (the temperature where half the residual enzymatic 
activity is lost) determined Activity levels measured at 37°C were defined as 100%
2 7 13  Thermal Stability
Purified Seprase was incubated at temperatures ranging from 4-70°C for up to 3 
hours Aliquots o f enzyme were removed at various time points and stored on ice 
All samples were brought to thermal equilibrium for 15 min at 37°C and assayed 
under standard conditions according to section 2 3 2 Activity levels were plotted as a 
percentage progress from initial activity (To)
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Purified Seprase was maintained at T50 (55°C) in a heated waterbath Aliquots were 
removed at appropnate time intervals and stored on ice All samples were brought to 
thermal equilibrium for 15 mins at 37°C and assayed under standard conditions 
according to section 2 3 2 A plot o f Residual activity (%) versus Time (min) was 
constructed The first order rate constant o f inactivation, was determined by fitting
the data to linear regression plots using Enzfitter® (Biosoft, Cambridge, U K) This 
allowed for the calculation o f the half-life, t y2
2.1.2 Determination of pH optimum
The pH-activity profile o f Seprase was determined by carrying out the standard 
activity assay as described in section 2 3 2 at pH range 6 0-10 5 This range was 
established using the following buffers 100 mM potassium phosphate for pH range 
6 0-8 0, 100 mM Tns-HCl for pH range 7 5-9 5 and 100 mM NaOH/glycine for pH 
range 9 5-10 5 The pH ranges were chosen so that the points overlapped Seprase 
samples were pre-incubated in the above buffers for 10 min at 37°C prior to addition 
of the substrate solution, also prepared in the respective buffers
2 7 14  Thermal Inactivation of Seprase
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2 7 3 Determination of the Second Order Rate Constant, (k2) for DFP 
Inhibition of Seprase
It has been shown that the irreversible and classic serine protease inactivator 
Dnsopropylfluorophosphate (DFP) has a high specificity for the catalytic serine o f  
tissue Seprase, thus catalytically classifying this enzyme as a possible serine 
protease The inhibition o f Seprase by DFP results m an IC50 value o f lOOnM being 
obtained (Collins et a l, 2004) It was decided that the second order rate constant 
should be determined for this inhibitor An enzyme concentration was chosen so that 
both the enzyme and DFP were in equimolar concentrations
A stock substrate o f 200 /iM Z-Gly-Pro-AMC in 8% v/v MeOH and containing 500 
mM NaCl was prepared using 100 mM potassium phosphate, pH 7 4 An inhibitor 
stock of 10 pM DFP and containing 500 mM NaCl was prepared using 100 mM 
potassium phosphate, pH 7 4 Both stocks were pre-incubated at 37°C until 
completely dissolved and thermal equilibrium was reached Equal volumes o f  
substrate stock and inhibitor stock were added together to give a final substrate 
concentration o f 100 pM Z-Gly-Pro-AMC in 4% v/v MeOH containing 500 mM 
NaCl and 5 pM DFP Also, equal volumes o f Seprase and inhibitor stock were added 
together to give a final DFP concentration o f 5 jiM Samples were assayed 
immediately after the addition o f the inhibitor and labelled time zero (T0) A 25 pi 
aliquot o f enzyme inhibitor mixture was added to 225 pi o f substrate inhibitor 
mixture and assayed in triplicate at 37°C for 1 hour Reactions were terminated by 
the addition o f 50 pi o f 1 5 M acetic acid Aliquots were removed from both inhibitor 
mixtures at 1 mm intervals and assayed immediately A plot o f 1/[AMC] Released 
(pmole'1 L) versus Time (mm) was constructed
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Serine protease inhibitors were provided by Dr Peter Kenny, School o f Chemical 
Sciences, DCU These inhibitors were not designed specifically to inhibit Seprase 
They had been developed as part o f a separate research project (Anderson, 2005) and 
they were tested for inhibitory properties using Seprase and Prolyl Oligopeptidase 
purified from bovine serum (see section 2 4 and 2 7 41 respectively) The partial 
purification procedure for bovine serum Prolyl Oligopeptidase was described 
previously by Collins and O’Connor (2003)
2 7 41  Partial Purification Procedure for Bovine Serum Prolyl Ohgopeptidase 
2 7 41  1 Phenyl Sepharose Hydrophobic Interaction Chromatography I
A 20 ml Phenyl Sepharose CL-4B hydrophobic interaction column (2 5 x 7cm) was 
equilibrated with 100 ml o f 100 mM potassium phosphate containing 200 mM 
ammonium sulphate, pH 7 4 Solid ammonium sulphate was dissolved in 20 ml o f  
bovme serum to give a final concentration of 200 mM This sample was then applied 
to the equilibrated column followed by a 100 ml wash with 100 mM potassium 
phosphate containing 200 mM ammonium sulphate, pH 7 4 The column was then 
washed with 100 ml of 100 mM potassium phosphate containing 50 mM ammonium 
sulphate, pH 7 4 Bound protein was eluted with a distilled water wash Equilibration 
of the column was carried out at a flow rate o f 1 ml/min, while all other steps were 
performed at 2 ml/min Five millilitre fractions were collected throughout the 
procedure and were assayed for PO activity according to section 2 3 4 Protein 
content in each fraction was determined using the Biuret assay according to section 
2 1 1 Fractions containing PO activity were pooled to yield post-phenyl Sepharose 
fraction I Enzyme activity and protein content were quantified using the fluorimetric 
assay as outlined in sections 2 3 2 and 2 3 3 and section 2 11 respectively
2 7 4 1.2 Phenyl Sepharose Hydrophobic Interaction Chromatography II
The 20 ml resin used in section 2 7 4 1 1 was regenerated with a 100 ml wash of pure 
ethanol at 0 5 ml/min The column was then equilibrated with 100 ml o f 100 mM 
potassium phosphate containing 1 M ammonium sulphate, pH 7 4 Solid ammonium 
sulphate was dissolved in the concentrated post-phenyl Sepharose I pool (pH was
2 7 4 Inhibition Studies using synthesised Dipeptidyl Phosphonate Esters
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maintained at 7 4 using 1 M NaOH), to give a final concentration o f 1 M The sample 
was then applied to the column followed by a 100 ml wash o f equilibration buffer 
Bound protein was eluted with a 100 ml linear gradient o f 1-0 M ammonium 
sulphate, 100-0 mM potassium phosphate, pH 7 4 The column was then washed 
with 25 ml o f ultra-pure water All steps were performed at a flow rate o f 2 ml/min 
Five millilitre fractions were collected throughout the procedure, and again were 
assayed for PO activity according to section 2 3 4 Protein content in each fraction 
was determined using the standard BCA assay as outlined in section 2 1 2 Fractions 
containing PO activity were pooled to yield post phenyl sepharose fraction II 
Enzyme activity and protein content were then quantified as outlined in sections 
2 3 2 and 2 1 2
2 7 4 1 3 Cibacron Blue 3GA Chromatography
The post phenyl sepharose II pool was concentrated and dialysed overnight against 2 
L o f 20 mM potassium phosphate One hundred millilitres o f 20 mM potassium 
phosphate, pH 7 4 was used to equilibrate a 20 ml cibacron blue 3GA resin After 
sample application the column was washed with 100 ml o f 20 mM potassium 
phosphate, pH 7 4 to remove any unbound protein Elution was performed using a 
100 ml linear 0-2 M NaCl gradient in 20 mM potassium phosphate, pH 7 4 Loading, 
washing and elution were all performed at 1 ml/min Five millilitre fractions were 
collected and assayed for PO activity according to section 2 3 4 Protein content in 
each fraction was determined using coomassie plus protein reagent as in section 
2 1 3 Fractions containing PO activity were pooled and enzyme activity and protein 
content were quantified as outlined in section 2 3 2 and 2 13
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The structures o f the various inhibitors can be seen in Table 2 7 and Figure 2 7
2 7 4 2 Inhibitor Analysis
Compound Ri Rz n M W
g/moi
Compound Ri r 2 n M W
g/moi
8a c a 1 554 53 9a b a 1 526 33
8b c a 2 568 56 9b b a 2 540 55
8c c a 3 582 58 9c b a 3 554 58
8d c b 1 568 56 9d b b 1 540 55
8e c b 2 582 58 9e b b 2 554 58
8 f c b 3 596 61 9 f b b 3 568 61
8g c c 1 492 46 9g b c 1 464 46
8h c c 2 506 49 9h b c 2 478 49
8i c c 3 520 51 9i b c 3 492 51
10a a a 1 492 39 lOd a b 2 520 44
10b a a 2 506 42 10e a c 1 430 32
10c a b 1 50642 lO f a c 2 444 35
Table 2 7 Structure of the Dipeptidyl Phosphonate Esters
n=  1,2 or 3
Figure 2 7 Chemical Structure of the Dipeptidyl Phosphonate esters
A range o f inhibitor concentrations (0-50 jiM) were prepared from a stock 
concentration of 5 mM in 5% v/v DMSO 100 \iM Z-Gly-Pro-AMC in 4% v/v 
MeOH and containing 500 mM NaCl in 100 mM potassium phosphate was used as 
diluent The DMSO concentration was maintained at 4% to ensure the solubility o f
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the inhibitors during the assay Analysis showed that above 5% DMSO, the enzyme 
activity was inhibited Seprase and Prolyl Oligopeptidase from bovine serum were 
isolated and purified using a separation strategy described previously (see sections 
2 4 and 2 7 4 1)
One hundred microhtres o f the substrate inhibitor mixture was added to 25jal 
enzyme Seprase activity was assayed in triplicate as outlined in section 2 3 2 using 
these substrate inhibitor mixtures Suitable negative controls were prepared, 
excluding the inhibitor to determine the effect if any the DMSO and MeOH had on 
the enzyme activity The IC50 value o f each inhibitor for Seprase/Prolyl 
Oligopeptidase was determined
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2.8 Substrate Specificity Studies
2 8 1 Substrate Specificity using a Combinatorial Dipeptide Library
This work was carried out in collaboration with Dr Charles S Craik at the 
University o f California, USA Dr Craik is involved in the study o f substrate 
specificity, catalytic mechanism, structure and biological function o f various 
proteases and their natural inhibitors The lab has developed a method for rapid and 
general profiling o f protease specificity using combinatorial fluorogemc substrate 
libraries (Hams et al 2000)
The substrate specificity o f Seprase was determined using this positional scanning 
synthetic combinatorial dipeptide substrate library The positional scanning library 
used in this study has the general structure Xaa-Xaa-ACC (where Xaa = any amino 
acid) Amide bond hydrolysis occurs between the Xaa-Xaa dipeptide and the 
fluorogemc 7-ammo-4-methylcoumarm, resulting in an mcrease in fluorescence 
This library is composed o f two subhbranes o f 400 compounds each, utilizing the 20 
naturally occurring ammo acids, excluding cysteine and including norleucine (n) 
The Pi sublibrary is composed of 20 separate mixtures in which the Pi position is 
fixed, and the Pi position contains equimolar mixture o f all ammo acids In the Pi 
library, the Pi residue is positionally defined, and the Pi position contains an 
equimolar mixture o f all other ammo acids The results usmg these libraries provide 
a complete understanding o f the specificities of dipeptidases m Si and S2 subsites o f  
the active site
2 8 11 Preparation of the Seprase sample
Seprase from bovme serum was isolated and purified usmg a separation strategy 
described previously (section 2 4) A sample o f this peptidase was prepared for Dr 
Craiks laboratory, for functional characterization Prior to use, the Seprase sample 
was concentrated 80-fold to a protein concentration of 80 \ig!m\ m a Microcon YM- 
10 Centrifugal Filter Unit (Milhpore) Proteolytic activity was measured by the 
continuous fluorimetnc assay with 100 jiM Z-Gly-Pro-AMC (Bachem), prepared in 
100 mM potassium phosphate pH 7 4, containing 250 mM NaCl, 2% (v/v) DMSO 
Assays were carried out at 37°C in 96-well Microfluor 1 Black “ U ” bottomed plates
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(Dynex Technologies) in a Molecular Devices SpectraMax Gemini microplate reader 
fitted with Aex 370 nm and Aem 440 nm filters
2 8.1 2 Construction of a Dipeptide Substrate Library
A Pi-diverse library with bound ACC fluorophore was constructed as outlined by 
Hams and coworkers at the University o f California, San Francisco (Figures 2 8 A- 
E) (Hams et a l, 2000) To introduce the randomized P2 position, a mixture o f Fmoc- 
amrno acids (AnaSpec) [14 8 mmol per well] was pre-activated with 
dnsopropylcarbodiimide (DICI) (390 jil, 2 5 mmol), and 1 -hydroxybenzotnazole 
(HOBt) (340 mg, 2 5 mmol) in dimethylformamide (DMF) (10 ml) An aliquot (0 5 
ml) o f the pre-activated solution was added to each of the wells (Figures 2 8 F) The 
reaction block was agitated for 3 hours, filtered and washed with DMF (three times 
in 0 5 ml) The Fmoc of the P2 amino acid was removed by filtration and the resin 
was washed with DMF (three times with 0 5 ml) and treated with 0 5 ml o f a capping 
solution consisting o f acetic anhydride (2 5 mmol), HOBt (2 5 mmol), and DICI (2 5 
mmol) in DMF (10 ml) After agitation for 4 h at room temperature, the resin was 
washed with DMF (three times with 0 5 ml) and CH2CI2 (three times with 0 5 ml), 
and treated with a solution o f 95 2 5 2 5 TFA/TIS/H20  (Figures 2 8 F-G) After 
incubation for a further 1 h period (room temperature), the reaction block was 
opened and placed on a 96-deep-well microplate and the wells were washed with 
additional TFA/TIS/H2O solution (twice with 0 5 ml)
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Figure 2 8 Diagram illustrating 7-amino-4-carbamoylmethylcoumann 
(ACC)-labelled dipeptide library construction using standard 
Fmoc protocols where SPPS corresponds to solid-phase peptide 
synthesis
2 8 13  Dipeptide Substrate Library Screening
Each dipeptide compound in this library was prepared as a 50 p,M stock solution in 
DMSO Seprase activity was analysed using 0 5 \iM o f each compound under the 
assay conditions described, with fluorescence determined using 350 nm and Aem 
450 nm All assays were performed in triplicate and the formation of free ACC was 
calculated using the conversion (1 RFU se c 1 = 0 0007226 pM sec'1) as determined 
by Harris and colleagues (Hams et a l, 2000)
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Substrate specificity studies on bovine serum Seprase, based on kinetic analysis were 
performed
2 8 2 1 Km Determination For Z-Gly-Pro-AMC
A 300 stock solution o f Z-Gly-Pro-AMC in 5% v/v MeOH containing 500 mM 
NaCl was prepared A range o f substrate concentrations (0-300 ^M) was prepared 
from this stock using 100 mM potassium phosphate, pH 7 4, containing 5% v/v 
MeOH and 500 mM NaCl as diluent Purified Seprase was assayed with each 
concentration in triplicate as outlined in section 2 3 2 The Km of Seprase for the 
substrate Z-Gly-Pro-AMC was estimated when the data obtained was applied to 
various kinetic models (see Appendix A)
2 8 2 2 K ,app Determination Using Selected Synthetic Peptides
The effect o f a variety o f selected synthetic peptides on the kinetic interaction 
between Seprase and the substrate Z-Gly-Pro-AMC was determined Substrate 
concentrations in the range 100-300 juM Z-Gly-Pro-AMC in 60% v/v MeOH 
containing 500 mM NaCl was prepared in the presence o f 200 jiM peptide, each in a 
final volume o f 2 ml The assay MeOH concentration was maintained at 5% The 
peptides studied, and their preparation, are outlined in Table 2 8 Seprase activity 
was assayed in triplicate using these substrate mixtures as outlined in section 2 3 2 
The data obtained was applied to the various kinetic models (see Appendix A), 
where the inhibition constant (K,app) and the type o f inhibition observed were 
determined as outlined in Appendix A
2 8 2 Kinetic Analysis
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Peptide Stock Cone 
(mM)
Solubility Assay Cone 
OiM)
Z-Gly-Met-Phe 5 50% MeOH* 200
Z-Gly-Pro-Phe 5 50% MeOH* 200
Z-Ala-Pro-Phe 5 50% MeOH* 200
Z-Ala-Met-Phe 5 50% MeOH* 200
Z-Ala-Nle-Phe 5 50% MeOH* 200
Z-Gly-Met-Phe-His 5 41% MeOH* 200
Z-Gly-Nle-Phe-His 5 10% MeOH* 200
Z-Ala-Pro-Phe-His 5 10% MeOH* 200
Z-Ala-Nle-Phe-His 5 50% MeOH* 200
Z-His-Pro-Phe-His 5 Ultrapure Water 200
Ala-Ser-Gly-Pro-Ser-Ser 5 10% MeOH* 200
Ala-Ser-Nle-Pro-Ser-Ser 5 10% MeOH* 200
Table 2 8 Peptide Preparation for K ,app Determinations
* Sonication using an ultrasonic water bath was required for complete dissolution
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Bovine tissues and mammalian cell lines in culture were obtained in order to 
determine the presence of Seprase and to create an expression profile for both 
Seprase and Prolyl Ohgopeptidase
2 9 1 Tissue preparation
Tissue samples were obtained from freshly slaughtered cows (Kepak Meats, Clonee, 
Co Meath) and transported to the laboratory on ice Each organ was divided into 
approximately 7 g portions, which were stored at -17°C if not being used 
immediately A 7 g piece o f each tissue was suspended in 30 ml 100 mM potassium 
phosphate buffer, pH7 4 These were homogenised at full speed for 15 s using a 
Sorvall Omni Mixer, followed by 15 s intermission to minimise heating and foaming 
effects Homogenisation o f the samples was continued until the tissue was visually 
disrupted The homogenate (H) was then collected and centrifuged at 15,000 rpm 
(23,667 x g) for 45 mm at 4°C in a Beckman Coulter Allegra 21R refrigerated 
centrifuge fitted with a F0850 rotor The supernatant was decanted and retained (Si) 
The pellet was resuspended in 30 ml 100 mM potassium phosphate buffer, pH7 4, 
and homogenised The second homogenate was then collected and centrifuged as 
previous The supernatant (S2) was again decanted The pellet (P2) was resuspended 
in 30ml 100 mM potassium phosphate buffer, pH 7 4 The pellet and 2 supernatants 
obtained from each tissue were assayed for Seprase and Prolyl Ohgopeptidase 
activity as described in section 2 3 3 The total Z-Gly-Pro-AMC activity present was 
obtained in the absence of the potent inhibitor and PO activity was taken to be the 
residual non-Seprase activity The concentration of protein in each sample was 
measured using the Biuret assay (section 2 11) and specific activities o f Seprase and 
PO were calculated for each tissue
2.9 Tissue Localisation Studies
7 8
Tissue Sample
1 Liver
2 Large Intestine
3 Small Intestine
4 Heart
5 Lungs
6 Brain
7 Serum
8 Kidney
9 Spleen
Table 2 9 1 Bovine Tissue Samples
2 9 2 Preparation of cleared lysate from cultured mammalian cells
A cell pellet containing 6 x 106 cells obtained from the cell culture lab was washed in 
100 mM potassium phosphate buffer, pH 7 4 followed by centrifugation at 2,000 rpm 
(421 x g) for 5 min (using a Beckman Coulter Allegra 21R refrigerated centrifuge 
fitted with a F0850 rotor) The supernatant was discarded and the cells were re­
suspended in 2 ml 100 mM potassium phosphate buffer, pH 7 4, containing 500 mM 
NaCl The cells were disrupted on ice with a 3 mm micro-tip somcator (Somes & 
Materials Inc ) using 2 5 s, 40 kHz pulses for 15 s The cell debris was removed by 
centriiugation at 4,000 rpm for 15 min at 4°C The cleared lysate was transferred to a 
fresh universal and stored at 4°C The cleared lysate was tested for total protein, 
Seprase and Prolyl Oligopeptidase activity as described in section 2 1 2 and 2 3 3 
respectively
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Mammalian Cell Line Source Description
MDA-MB-435 SF Mammary Gland, breast Human breast cancer cell line denved from a 
female with ductal adenocarcinoma
Hs578T Mammary Gland, breast Human breast cancer cell line denved from a 
carcinoma
A549 Lung Human lung carcmoma cell line denved from 
carcinomatous tissue
HeLa (Chang Liver) Liver,
HeLa Contamination
Originally thought to be denved from normal 
liver tissue, but it has now been found to be 
established from HeLa contammation
SK-N-F1 Brain, Neuroblast Neuroblastoma cell line denved from a bone 
marrow metastasis
DG75 Abdominal Lymphoma Lymphoid B cell line denved from an Israeli 
Burkitt-like lymphoma case (Ben-Bassat et a l , 
1977)
L428 Lymphatic tissue Hodgkin’s Lymphoma B-cell line, EBV 
negative
L591 Lymphatic tissue Hodgkin’s Lymphoma B-cell line, EBV 
positive
BAEC Heart Bovine aorta endothelial cell line
BASMC Heart Bovine aortic SMC cell line
SW620 Colon Human colorectal adenocarcinoma cell lme 
established from the lymph node metastasis of 
a male
SW480 Colon Human colorectal adenocarcinoma cell line 
established from the lymph node metastasis of 
a male
HT29 Colon Human colorectal adenocarcinoma cell lme 
established from the primary tumour of a 
female patient
Table 2 9 2 Mammalian Cell Lines
8 0
2 10 Molecular Cloning of Seprase
2 10 1 Bacterial strains, primers and plasmids
The bacterial strains, primers and plasmids used in this work are listed in Tables 2 1 0 1 ,2 1 0  2, 2 103 and 2 10 4 respectively
Strain Genotype Features/Uses Source
Escherichia coli
DH5a F endA 1 recA 1 rei A 1 gyrA 96 supE44 thi-1 
hsdR 17(rK , mK+) mOlacZAM  15 A(lacZYA- 
argF)Ui 69 deoKphoA X
High transformation efficiency Bethesda 
Research Labs
XL 10-Gold A(mcrA)183 A(mcrCB-hsdSMR-mrr)\73
end A l ree A 1 re lA l gyrA96 supE44 thi-1 lac Hte
[F' pro AB lacP ZAM15 Tn 10(ie/R) Amy (camK)]
High transformation efficiency 
Antibiotic resistance 
Expression host
Stratagene
BL2I (DE3) F  dem ompT hsdSB(rB, niß ) gat ¿-(DE3) Protease deficient Expression host
Novagen
Table 2.10 1 Bacterial strains
Name Sequence 
(5’ - 3 ’)
Tm (°C)
Cloning/ Analysis
BamHI-Fapl AAAAAGG AT CCCC ACGCT CT G AAG AC AG AATT 57 9
XhoI-Fap6 AAAAAACT C G AGT C AG ATT CT GAT AC AGGCT 52 3
Fap3 CCAGCAATGATAGCCTCAA 54 5
Fap4 AC AG ACCTT AC ACT CTG AC 54 5
Fap7 for AT G AAG ACTT GGGT AAAAATCG 54 6
BamHl-A-Fap7 for AAAAAGGATCCAATGAAGACTTGGGTAAAAATCG 54 6
BamHl Fap7_for AAAAAGGATCCATGAAGACTTGGGTAAAAATCG 54 6
Fap8_rev TT AGT CT G AC AAAG AG AAAC ACTGC 59 7
Xho-l-Fap8_rev AAAAAACTCGAGTTAGTCTGACAAAGAGAAACACTGC 59 7
Clal-Fap9_rev ACGC AGGGT AAGTGGTATCG 59 4
Clal-FaplO_for GCT AAG AAT CCCGTT GTTCG 57 3
Nco-1 -Fap7_for AAAACCATGGGGATG AAGACTTGGGT AAAAATCG 54 6
Bgl-II-Fap8_rev AAAAAAGATCTTTAGTCTGACAAAGAGAAACACTGC 59 7
BamHl -Koz 1 -Fap7_for AAAAAGG AT CC GCCA rGGGG AT G AAG ACTT GGGT AAAAAT CG 54 6
BamH 1 -Koz2-Fap7_for AAAAAGGATCC GCC4 7GAAGACTTGGGT AAAAATCG 54 6
BamHl-Koz3_for AAAAAGG ATCCGCC^ CCA TOGGG AAG ACTT GGGT AAAAAT CG 50 2
Not-l-Fap8_lrev AAAAAAGCGGCCGCTT AGT CT G AC AAAG AGAAAC ACT GC 59 7
Not-l-Fap8_2rev AAAAAAGCGGCCGC AGTCTGAC AAAGAGAAAC ACT GC 58 4
/3-actin For
DNA clamps are in bold type Restriction sites are underlined Kozak / Ribosome 
Binding Site sequences are in italics 
Tm takes into account only those bases that bind 
Tm = [69 3 + 0 41 (%GC)] -  650/length
G AAAT CGT GCGT G AC ATT AAGG AG AAGCT 65 3
/3-actin Rev T C AGG AGG AGC AAT GAT CTT G A 58 4
Table 2 10 2 Primers (obtained from MWG-Biotech AG)
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Name Sequence
(5’ - 3 ’)
Source
Sequencing
M13rev(-29) CAGGAAACAGCT ATGACC (pCR2 1 forward prim er)
M 1 3 u n i(-2 1 ) T GT AAAACG ACGGCC AGT (pCR2 1 reverse primer)
M13rev(-49) G AGCGGAT AAC AATTTCACACAGG (pCR2 1 forward pnm er)
pQEPfor CCCGAAAAGTGCCACCTG (pQE-30Xa forward pnm er)
pQEPrev GGTCATTACTGGAGTCTTG (pQE-30Xa reverse primer)
pPOBforl CCC AG ACT GGGTTT AT G AAG AGG Internal sequence forward primer
PPOBfor2 CCTCAATTTGACAGATCAAAGAAGTATCCC Internal sequence forward primer
pPOBrevl GGG AT ACTTCTTT GAT CT GTC AAATTG AGG Internal sequence reverse primer
pPOBrev2 CCTCTTC AT AAACCC AGTCTGGG Internal sequence forward primer
CMVfor CGCAAATGGGCGGTAGGCGTG (pIRES forward primer)
T7 T AAT ACGACT C ACT AT AGGG (pIRES forward primer)
SP6 CATTTAGGTGACACTATAG (pIRES reverse pnm er)
pIRES-for AT GGGCGGT AGGCGTGT A (pIRES forward primer)
pIRES-rev ATGCAGTCGTCGAGGAATTG (pIRES reverse pnm er)
Table 2 10.3 Sequencing Pnmers (obtained from MWG-Biotech AG)
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Plasmid Description Source
Vectors
pCR2 1 TA cloning vector Plac, ampR, kanR, lacZa, ColEl origin Figure 2 10 1 Invitrogen
pQE-30-Xa Expression vector T5 promoter/fac operon, ampR, 6xHis sequence at 5’ end of MCS, contains a Factor Xa Protease Qiagen
recognition site, ColEl origin Figure 2 10 2
pBR322 Cloning vector ampR, tetR Roche
pcDNA3 Mammalian Expression vector CMV promoter, ampR, neoR, ColEl origin, fl on Figure 2 10 3 Gifted by Dr Walls,
D C U
pcDNA-3-HA pcDNA expression vector with a HA epitope at the 5’ end of MCS, cloned Hind  III BamHl Figure 2 10 3 D’Souza 2000 / Gifted
by Dr Walls, D C U
pIRES-hrGFP II Mammalian Expression vector CMV promoter, neoR, kanK^ internal ribosome entry site, hrGFP ORF, FLAG epitope Stratagene
Figure 2 10 4
Constructs
pPOB12 pcDNA3-HA containing Seprase ORF This Work
pPOB15 pcDNA3 containing Seprase ORF, subcloned from pPOB12, for expression Contams Eukaryotic Kozak sequence 2 This Work
pPOB16 pcDNA3-HA containing Seprase ORF, subcloned from pPOB12, for expression This Work
pPOB17 pcDNA3 containing Seprase ORF, subcloned from pPOB12, for expression Contams Eukaryotic Kozak sequence 2 This Work
pPOB18 pcDNA3 containing Seprase ORF, subcloned from pPOB12, for expression Contams Eukaryotic Kozak sequence 1 This Work
pQPOB5 pQE-30Xa containing Seprase ORF with 5’ 6xHis sequence fusion, for expression and subsequent purification This Work
pIRPOBl pIRES-hrGFP II containing Seprase ORF, for expression This Work
pIRPOB2 pIRES-hrGFP II containing Seprase ORF with FLAG sequence fusion, for expression and subsequent purification This Work
Table 2 10 4 Plasmids
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Hincim - 235
Figure 2.10.1 pCR2.1 vector
The 3926bp TA cloning vector pCR2.1 (Table 2.10.3). The multiple cloning site (MCS) enzymes are 
indicated. The TA cloning site is situated within the LacZa ORF (green), which is under the control of 
the Piac promoter (yellow). Ampicillin and Kanamycin resistance genes (ampR & kanR) are shown in 
red. Generated using pDRAW32 (Section 2.10.10).
EcoRI - 88
Figure 2.10.2 pQE-30Xa vector
The 3509bp cloning/prokaryotic expression vector pQE-30Xa (Table 2.10.3). The multiple cloning 
site (MCS) enzymes are indicated. The 6xHis coding sequence (green) is situated at the 5’ end of the 
MCS, which in turn is situated downstream of the T5 promoter/lac operon (yellow). Ampicillin 
resistance gene (ampK) is shown in red. Generated using pDRAW32 (Section 2.10.10).
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Figure 2.10.3 pcDNA3 and pcDNA3-HA vectors
The 5446bp cloning/mammalian expression vectors pcDNA3 / pcDNA3-HA (Table 2.10.3). The 
multiple cloning site (MCS) enzymes are indicated. The T7 promoter (yellow) is downstream of the 
CMV promoter (yellow). Ampicillin and neomycin resistance genes (ampR and neoR) are shown in 
red. HA epitope of the vector pcDNA3-HA was cloned in HindUl and BamUl (D’Souza, 2000). 
Generated using pDRAW32 (Section 2.10.10).
Figure 2.10.4 pIRES-hrGFP II vector
The 553 lbp cloning/mammalian expression vector pIRES-hrGFP II (Table 2.10.3). The multiple 
cloning site (MCS) enzymes are indicated. The CMV promoter (yellow) is upstream of the MCS and 
the 3x FLAG epitope (cyan). Kanamycin and neomycin resistance genes (katf' and neoR) are shown in 
red. The internal ribosome entry site (IRES -  blue) is upstream of the hrGFP II ORF (green). 
Generated using pDRAW32 (Section 2.10.10).
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All chemicals and reagents were obtained from Sigma-Aldrich unless otherwise 
stated All chemicals were analytical grade Microbiological media are obtained from 
Oxoid Sterilisation was achieved by autoclaving at 121°C and 15 lb/in2 for 20 min, 
unless otherwise stated
Luna Bertani broth (LB)
Tryptone 10g/L
NaCl lOg/L
Yeast Extract 5 g/L
Adjusted to pH 7 0 with NaOH Sterilised by autoclaving For solid LB, 15 g/L 
Technical Agar No 3 (Oxoid) was included
TE buffer
Tns-HCl 
Na2-EDTA 
pH
TAE buffer (50X)
Tns
Glacial Acetic Acid 
EDTA 
pH
Solution 1 of 1-2-3 method
Glucose 
Na2-EDTA 
Tns-HCl
Solution 2 of 1-2-3 method
NaOH 
SDS
2 10 2 Media, solutions and buffers
10 mM 
1 mM 
8 0
242 g/L 
57 1 ml/L
100 ml/L (of 0 5 M stock EDTA, pH 8 0) 
8 0
50 mM
10 mM (from 0 5 M stock EDTA, pH 8 0) 
25 mM (from 1 M stock Tns-HCl, pH 8 0)
200 mM 
1% (w/v)
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Solution 3 of 1-2-3 method
Potassium acetate 3 M
pH 4 8
To 60ml o f 5M potassium acetate, 11 5ml o f glacial acetic acid and 28 5ml o f dH20  
was added The resulting solution was 3M with respect to potassium and 5M with 
respect to acetate
RF1 buffer
RbCl 100 mM
CaCl2 10 mM
Potassium acetate 30 mM
Glycerol 15% (v/v)
pH (with HC1) 5 8
After the pH had been adjusted MnCl2 was added to 50 mM The solution was filter 
sterilised through a 0 22 jam membrane and stored at 4°C in the dark (MnCl2 is light 
sensitive)
RF2 buffer
RbCl 10 mM
MOPS 10 mM
CaCl2 75 mM
Glycerol 15% (v/v)
pH 68
The solution was filter sterilised through
Transfer buffer
Tns-HCl 25 mM
Glycine 150 mM
Methanol 10% (v/v)
TBS buffer
Tns-HCl 10 mM
NaCl 150 mM
pH 75
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TBS-Tween buffer
Tns-HCl 20 mM 
500 mM 
0 01% (v/v) 
I S
NaCl
Tween 20
pH
Gel loading dye (6X)
Bromophenol Blue 0 25%
Xylene Cyanol 0 25%
Ficoll (Type 400) 15%
Bromophenol Blue and/or Xylene Cyanol were used as appropnate On a 1% agarose 
gel, bromophenol blue and xylene cyanol migrate approximately with the 300 bp and 
4000 bp fragments respectively
Ethidium bromide stain
A 10 mg/ml stock solution in dH20  was stored at 4°C in the dark For the staining o f  
agarose gels, 100 |il o f the stock solution was mixed into 1 L of dH20  The staining 
solution was kept in a plastic tray and covered to protect against light Spent staining 
solution was collected and filtered through a deactivating filter and then treated as 
aqueous waste The filter was destroyed by incineration
Antibiotics
■ Ampicillin was prepared in dH20  at a concentration of 100 mg/ml and stored 
at -20°C The working concentration for E coh was 100 jag/ml
■ Tetracycline was prepared in 50% v/v ethanol at a concentration of 10 mg/ml 
and stored at -20°C The working concentration for E coh was 10 |ig/ml
■ Kanamycin was prepared in dH20  at a concentration of 100 mg/ml and stored 
at -20°C The working concentration for E coh was 50 jag/ml
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2 10 3 Isolation and purification of DNA and RNA
2.10 3.1 Isolation of RNA
RNA was isolated using Trizol Reagent (Invitrogen), a mono-phasic solution o f  
phenol and guanidine isothiocyanate This is a modification o f the method developed 
by Chomczynski and Sacchi (1987) 100 mg of tissue was homogenised m l  ml o f  
Tnzol reagent using a glass-Teflon homogemser (treated with RNase AWAY, 
Molecular i?zoProducts, inc) and transferred to a microfuge tube Alternatively, a 
pellet o f cultured cells was lysed in 1 ml o f Trizol reagent by repeated pipetting The 
sample was incubated at room temperature for 5 min to allow complete dissociation 
of nucleoprotein complexes This was followed by the addition o f 2 0 0  |il o f  
chloroform, mixed briefly by vortexing and incubated at room temperature for 3 min 
The phases were separated by centrifugation at 1 3 ,0 0 0  rpm ( > 1 2 , 0 0 0  x g) for 15  
mm The upper aqueous layer was transferred to a fresh micro fuge tube Then 500jj.1 
of isopropanol was added and mixed by inversion The sample was incubated at 
room temperature for 1 0  mm to precipitate the RNA and then centrifuged at 1 3 ,0 0 0  
rpm ( > 1 2 , 0 0 0  x g) for 1 0  min The supernatant was discarded and the RNA pellet 
was washed with 1ml o f 7 0 %  v/v ethanol The RNA pellet was air-dried and 
dissolved m 3 0  jil RNase-free water Any possible DNA contamination was 
eliminated by treatment with Deoxyribonuclease I (Section 2 1 0  7)
2 10 3 2 Isolation of plasmid DNA
Three procedures for the isolation of plasmid DNA were variably employed The 1- 
2 -3  Method (Section 2  1 0  3 1 1 )  was used for convenient plasmid isolation from 
large numbers o f samples, mostly for the purpose o f screenmg The GenElute 
Plasmid Mmiprep Kit (Sigma, Section 2 1 0  3 2 2)  was used to prepare consistently 
pure and supercoiled plasmid DNA, mostly for the purpose of DNA sequencing The 
Qiagen Plasmid Mini Kit (2  1 0  3 2 3) was used to prepare ultrapure supercoiled 
transfection grade plasmid DNA with high yields
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This method is adapted from the procedure described by Bimholm and Doly (1979) 
Briefly, 1 5 ml o f a bacterial culture in a micro fuge tube was centrifuged at 13,000 
rpm for 5 min to collect the cells The supernatant was discarded and the cell pellet 
re-suspended in 200 |il o f Solution 1 Alternatively, bacterial growth was taken off 
an LB agar culture plate with a sterile loop and re-suspended in 200 jil o f Solution 1 
The re-suspension was left for 5 min at room temperature Then 200 jil o f Solution 2 
was added, the tube was mixed by inversion and placed on ice for 5 min Following 
the addition o f 200 jul o f Solution 3, the tube was mixed by inversion and placed on 
ice for 10 min A clot of chromosomal DNA was collected by centrifugation at
13,000 rpm for 10 min The supernatant was removed to a new micro fuge tube with 
400 jil o f phenol chloroform isoamylalcohol (25 24 1) and mixed by brief vortexing 
Upon centrifugation at 13,000 rpm (>12,000 x g) for 5 mm the mixture is divided 
into an upper aqueous and lower organic layer The aqueous layer was removed to a 
new micro fuge tube with an equal volume o f  iso propanol and mixed by inversion 
The tube was left at room temperature for 5 min and then centrifuged at 13,000 rpm 
(>12,000 x g) for 20 min to pellet the plasmid DNA The pellet was washed with 
70% v/v ethanol and then dried briefly in a SpeedVac (Savant) vacuum centrifuge 
The plasmid DNA was resuspended in 50 jal o f TE buffer and 1 \x\ o f Ribonuclease 
A (Section 2 10 7) was added to digest co-punfied RNA Plasmid DNA was stored at 
4°C
2 10 3 2 2 GenElute plasmid Mmiprep kit
The kit was used according to the manufacturer’s instructions Briefly, 1 5 ml o f a 
bacterial culture in a micro fuge tube was centrifuged at 13,000 rpm (>12,000 x g) 
for 5 mm to collect the cells The supernatant was discarded and the cell pellet was 
completely re-suspended in 200 (il o f re-suspension solution Alternatively, bacterial 
growth was taken off an LB agar culture plate with a sterile loop and re-suspended in 
200 jj.1 o f Solution 1 Then 200 jil o f lysis solution was added and mixed by inversion 
to lyse the cells Following this, 350 jil o f neutralisation/binding buffer was added 
and mixed by inversion to precipitate cell debris, lipids, proteins and chromosomal 
DNA The precipitate was collected by centrifugation at 13,000 rpm (>12,000 x g)
2 10.3 2 1 1-2-3 method
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for 10 min The supernatant was transferred to a spin column in a micro fuge tube and 
centrifuged at 13,000 rpm (>12,000 x g) for 1 min to bind the plasmid DNA The 
flow through was discarded and 750 jil o f washing solution was added followed by 
further centrifugation at 13,000 rpm (>12,000 x g) for 1 min The flow through was 
discarded and the column was centrifuged at 13,000 rpm (>12,000 x g) for 1 min to 
dry the spin column The spin column was transferred to a fresh micro fuge tube and 
50 |il TE buffer was added The DNA was eluted by centrifugation at 13,000 rpm ( >
12.000 x g) for 1 min
2 10 3 2 3 Qiagen plasmid Mini kit
The kit was used according to the manufacturer’s instructions Briefly, 3 ml o f a 
bacterial culture in a micro fuge tube was centrifuged at 13,000 rpm (>12,000 x g) 
for 5 mm to collect the cells The supernatant was discarded and the cell pellet was 
completely re-suspended in 300 |il o f Buffer PI Then 300 jil o f Buffer 2 was added 
and mixed by inversion to lyse the cells Following this 300 \x\ Buffer P3 was added, 
mixed by inversion and incubated on ice for 5 mm to precipitate cell debris, lipids, 
proteins and chromosomal DNA The precipitate was collected by centrifugation at
13.000 rpm ( > 12,000 x g) for 10 mm The supernatant was transferred to a Qiagen- 
tip and allowed to empty by gravity flow The DNA bound to the resin and therefore 
the flow through was discarded 2 x 2 ml o f Buffer QC was applied to the column to 
wash the column 800j l i 1 Buffer QF was added to the column to elute the DNA, 
which was collected in a micro fuge tube Then 560 (il o f isopropanol was added The 
tube was left at room temperature for 5 mm and then centrifuged at 13,000 rpm (>
12.000 x g) for 30 mm to pellet the plasmid DNA The pellet was washed with 1 ml 
70% v/v ethanol and centrifuged at 10,000 rpm (>12,000 x g) for 10mm The 
supernatant was removed and the pellet was then dried briefly m a SpeedVac 
(Savant) vacuum centrifuge The plasmid DNA was resuspended m 30 jil o f  TE 
buffer Plasmid DNA was stored at 4°C
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2 10 3 3 Isolation of DNA from agarose gels
2 10 3 3 1 Glass Wool Gel Extraction
The DNA band to be isolated was excised from the agarose gel using a scalpel The 
gel piece was placed into a PCR tube which had been pierced at the end and 
contained a small piece o f glass wool The PCR tube was then placed in a microfuge 
tube and centrifuged at 13,000rpm (>12,000 x g) for 2 min The solution containing 
DNA was then purified according to section 2 10 3 4
2 12 3 3 2 PerfectPrep kit
The kit was used according to the manufacturer’s instructions The desired DNA 
band was excised from the agarose gel using a scalpel The gel slice was weighed 
and placed in a micro fuge tube The tube was incubated at 65°C for 10 min to 
completely dissolve the agarose in the chaotropic solution One gel slice volume o f  
isopropanol was added and mixed by inversion The solution was transferred to a 
spm column in a micro fuge tube and centrifuged at 13,000 rpm (>12,000 x g) for 1 
min to bind the plasmid DNA The flow through was discarded and 750 jal o f  
washing solution was added followed by further centrifugation at 13,000 rpm ( >
12.000 x g) for 1 mm The flow through was discarded and the column was 
centrifuged at 13,000 rpm (>12,000 x g) for 1 min to dry the spin column The spin 
column was transferred to a fresh micro fuge tube and 30 jal TE buffer was added 
The DNA was eluted by centrifugation at 13,000 rpm (>12,000 x g) for 1 min
2 10 3 4 Purification and concentration of DNA samples
The sample containing the DNA to be precipitated was brought to 500 |il with dH20  
Then 400 |il o f phenol chloroform isoamylalcohol (25 24 1) was added and mixed by 
brief vortexing Upon centrifugation at 13,000 rpm (>12,000 x g) for 5 mm the 
mixture was separated into an upper aqueous and lower organic phase The aqueous 
phase was removed to a new micro fuge tube and an equal volume o f  chloroform was 
added and mixed by brief vortexing The tube was centrifuged at 13,000 rpm (>
12.000 x g) for 5 mm and the aqueous phase was transferred to a new micro fuge 
tube A 1/10 volume o f 3 M sodium acetate was added followed by an equal volume 
of isopropanol and mixed by inversion The tube was left at room temperature for 60
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mm and then centrifuged at 13,000 rpm (>12,000 x g) for 20 min to pellet the DNA 
The pellet was washed with 70% v/v ethanol and then dried briefly in a SpeedVac 
(Savant) vacuum centrifuge The DNA was resuspended in 20-50 jal o f TE buffer
2 10 3 5 Quantification of DNA and RNA
Nucleic Acid concentration was quantified by UV spectrophotometry (Mamatis, et 
al, 1982) A dilution of the sample (typically 1/50) in dH20  was measured for 
absorbance at 260 nm A reading o f 1 0 corresponds to 50 jig/ml o f DNA or 40 
fig/ml o f RNA
2 10 4 Agarose gel electrophoresis
DNA was analysed by electrophoresis through agarose gels in a BioRad horizontal 
gel apparatus according to Mamatis et al (1982) Agarose was added to TAE buffer 
to the required concentration (typically 0 7-2%) and dissolved by boiling The 
agarose solution was poured into plastic trays and allowed to set with a plastic comb 
fitted to create sample wells TAE buffer was used as the running buffer Loading 
dye was mixed with the DNA samples to facilitate loading and to give a visual 
indication o f  migration distance during electrophoresis When RNA samples were 
being analysed, the IX TAE solution was prepared using 0 1% (v/v) DEPC Gels 
were run at 140 volts for 20-40 min depending on size o f gel Gels were stained for 
15 min by immersion in an ethidium bromide staining solution Gels were visualised 
using a UV transilluminator coupled with an image analyser to capture the image to a 
PC On every gel, 0 5 jig o f 1 Kb Plus or 1Kb DNA Ladder (Invitrogen, Figure 
2 10 5) was run as a molecular size marker
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Figure 2 10 5 DNA Ladders
DNA Ladders used (a) 1Kb Plus (b) 1Kb DNA ladders
2 10 5 Competent cells 
2 10 51  Rubidium chloride method
This is an adaptation o f the method outlined by (Hanahan, 1985) Sterile conditions 
were used throughout A 10 ml stenle universal o f LB broth containing the relevant 
antibiotics was inoculated with a single colony o f the desired bacterial strain from a 
plate stock and cultured overnight at 37°C A 1 L flask with 200 ml o f LB broth was 
inoculated with 2 ml o f the overnight culture and incubated at 37°C with shaking at 
225 rpm When the culture had reached an OD600 o f -0  5 (early-mid exponential 
phase) the flask was cooled in ice water All subsequent transactions took place at 
4°C The culture was transferred to a stenle centrifuge bottle The cells were 
collected by centrifugation at 3,000 rpm (1380 x g) for 5 mm (usmg a Beckman JA- 
14 rotor) The supernatant was decanted and the cells gently re-suspended in 60ml o f  
chilled RF1 buffer The suspension was left on ice for 90 mm The cells were again 
collected by centnfugation at 3,000 rpm for 5 mm The supernatant was decanted and 
the cells gently re-suspended m 8ml o f chilled RF2 buffer Aliquots o f 800 |il were 
prepared in stenle 1 5 ml microfiige tubes and flash frozen usmg -80°C ethanol The 
competent cells were stored at -80°C Cells were routinely used within a few weeks
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An aliquot o f competent cells was thawed on ice A 200 jil portion of the cell 
suspension was mixed gently with 1-50 |j,l o f plasmid DNA in a sterile 1 5 ml 
microfuge tube The mixture was left on ice for 30 min The cells were heat-shocked 
at 42°C for 30 seconds and placed back on ice for 2 min Then, 800 |il o f LB broth 
was added to the cells followed by incubation at 37°C for 60 min Following this,
100 [d o f the transformation suspension was spread on an LB agar plate containing 
the relevant antibiotics and incubated at 37°C overnight
2 10 5 3 Determining competent cell efficiency
Competent cell efficiency is defined in terms o f the number o f colony forming units 
obtained per jag o f transformed plasmid DNA A 250 ng/(il stock of pBR322 plasmid 
DNA was diluted to 250 pg/|il, 25 pg/|il and 2 5 pg/jal Then 1 jul o f each dilution was 
transformed as described above The cell efficiency was calculated from the number 
of colonies obtained, taking into account the dilution factor and the fraction o f  
culture transferred to the spread plate
No of Transformants Final Volume at recovery (ml) _ _ _---------------------------- x-----------------------------------------= No Transformants per jug DNAfug of DNA Volume Plated (ml)
2 10 6 Bacterial storage
Bacterial strains were stored as 40% v/v glycerol stocks Mix 750 \xl o f  an overnight 
culture with 750 jil sterile 80% v/v glycerol in a microfuge tube If the bacterial 
strains contained plasmids, the selective antibiotic was included in the culture 
Duplicate stocks were stored at -20°C and -80°C Working stocks streaked on LB 
agar plates, containing antibiotics where appropnate, were stored at 4°C
2 10 5 2 Transformation of competent cells
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All restriction endonucleases, Antarctic Phosphatase, Phusion High Fidelity DNA 
Polymerase and T4 DNA hgase were obtained from Invitrogen Life Technologies or 
New England Biolabs Deoxyribonuclease I, Ribonuclease A (Deoxyribonuclease 
free), M-MLV reverse Transcriptase, REDTaq and REDAccu7ag LA DNA 
polymerases were obtained from Sigma-Aldrich Enzymes were used with their 
relevant buffers according to the manufacturers instructions
2 10 7 1 Reverse transcription
Combine 1 jig o f RNA with 1 [i\ o f  specific reverse primer or ohgo(dT)i5 primer 
(final concentration 1-5 nM) and 1 1^ o f  10 mM dNTP mix The volume was made 
to 10 jil with RNAse free water The mixture was incubated at 70°C for 10 min and 
then placed on ice for 5 min To the mixture was added 1 jil M-MLV reverse 
transcriptase and 2 \i\ specific lOx enzyme buffer The volume was brought to 20 |il 
with RNAse free water The first strand was synthesised at 37°C for 50 mm followed 
by inactivation o f the transcriptase at 95°C for 10 mm Two micro litres o f  the 
reaction was used as template for PCR
2.10 7 2 Polymerase chain reaction
PCR reactions (Mullis and Faloona, 1987) were carried out usmg a Hybaid PCR 
Express Thermocycler The standard PCR reaction volume was 50 jlxI contaming 1 jil 
template (10-100 ng), 1-2 5 mM MgCl2, 0 5 \xM of each primer, 200 jiM of each 
dNTP, 1 unit REDTaq or REDAccuTa# LA DNA polymerase and 5 \x\ specific lOx 
enzyme buffer The standard PCR program was
Stage 1 Step 1 95°C for 10 min
Stage 2 (30 cycles) Step 1 95°C for 1 mm
Step 2 Tann for 30 s
Step 3 72°C for 1 mm per kb to be synthesised 
Stage 3 Step 1 72°C for 10 mm
(Tann was routinely 5°C below the Tm of the pnmers)
2 10 7 Enzymes
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Phusion High-Fidelity DNA Polymerase was used for amplification o f the Seprase 
gene and for subsequent cloning The standard Phusion PCR reaction volume was 50 
jul containing 1 |il template (10-100 ng), 1 5mM MgC^, 0 5 jiM o f each primer, 200 
|jiM of each dNTP, 1 unit High-Fidelity Phusion DNA polymerase and 10 [i\ specific 
5x enzyme buffer The standard PCR program was
Stage 1 Step 1 98°C for 3 min
Stage 2 (30 cycles) Step 1 98°C for 15 s
Step 2 Tann for 30 s
Step 3 72°C for 30 s per kb to be synthesised 
Stage 3 Step 1 72°Cforl0m in
(Tann was routinely 5°C below the Tm of the primers)
2 10 8 Gene manipulation
A variety o f plasmid-based gene cloning approaches such as described by Mamatis et 
al (1987) were used, employing PCR techniques (Section 2 10 7 2), restnction 
endonucleases and DNA ligase (Section 2 10 7)
2 10 81  Antarctic Phosphatase Reaction
Antarctic Phosphatase catalyzes the removal o f 5’ phosphate groups from DNA and 
RNA Phosphatase treated fragments lack the 5’ phosphoryl termini required by 
ligases, therefore, they cannot self-ligate This property was used to decrease the 
vector background in the cloning strategies used One microgram of DNA (restricted 
and extracted according to sections 2 10 7 and 2 10 3 4 respectively) was added to 
IX Reaction Buffer and then 1 jil Antarctic Phosphatase added This mixture was 
mixed and incubated overnight at 37°C The mixture was extracted (section 2 10 3 4) 
and resuspended in 13 |il TE buffer for ligations
98
PCR products were cloned using both prokaryotic and mammalian expression 
vectors (1) pCR2 1 (2) pQE30Xa (3) pcDNA3 (4) pcDNA3-HA (5) pIRES (see 
Table 2 10 3, Figures 2 1 0 1  210  2, 2 1 0 3  and 2 10 4 respectively) The ligation 
was transformed into E coh cells (routinely DH5aor XL-10 Gold strains were used, 
see Table 2 10 1) as described in section 2 10 5 2 Then 100 jal o f the transformation 
reaction was plated on an LB agar plate containing the appropriate antibiotic For 
cloning into pCR2 1 60|il o f 40mg/ml X-gal, to test for «-complementation o f |3- 
galactosidase, was spread onto the agar plate X-gal stock was prepared in DMF and 
stored in the dark at -20°C The lacZa gene encodes the Gf-peptide o f /3-galactosidase, 
which cleaves the X-gal substrate yielding a blue product This allows for positive 
selection o f transformants harbouring plasmids with PCR product inserts Routinely 
a small proportion of colonies are blue It is assumed that these arise as a result o f re- 
circularisation o f the pCR2 1 vector
Colonies arsing from the transformations were routinely screened using the 1-2-3 
Method for Plasmid DNA Isolation (section 2 10 3 2 1), and restriction analysis 
identified transformants with the correct insert o f DNA
2 10 9 DNA sequencing
Recombinant clones were verified by DNA sequencing Commercial sequencing 
services were provided by MWG Biotech AG Suitable sequencing primers (Table 
2 12 2) for standard vectors were provided as part o f the service Samples were 
invariably sent as dried plasmid DNA
2 10 10 Bio-Informatics
Nucleotide and Amino Acid sequences were analysed using a variety o f  web-based 
tools The BLAST programs (Altschul et al, 1997) at the National Centre for 
Biotechnology Information (http //www ncbi nlm mh gov) were used to identify 
homologous sequences deposited in GenBank (Benson et al, 1996) Protein 
sequences, structure files and tools to calculate protein molecular weights and 
isoelectric points were obtained from the Swiss-Prot database (Bairoch and
2 10 8 2 Cloning of PCR products
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Apweiler, 1996) at (http //us expasy org) and the Protein Data Bank (PDB, Berman 
et al, 2000) at (http //www rcsb org/pdb) Alignments o f DNA and Protein 
sequences were performed using the MultAlin program (Corpet, 1988) available at 
(http //prodes toulouse inra fr/multalin/multalin html) and edited using the GeneDoc 
program (Nicholas et al, 1997) available for download at
(www psc edu/biomed/genedoc) Plasmid maps were constructed using the 
pDRAW32 program available for download at (http //www acaclone com) Chemical 
structures were drawn using the ACD/Labs ChemSketch program available for 
download at (http //www acdlabs com) DNA sequences were analysed for restriction 
enzyme sites using the Webcutter 2 0 tool at (http //ma lundberg gu se/cutter2/) 
Tertiary protein structure was analysed and visualised using the DeepView software 
(Guex and Peitsch, 1997) available for download at (http //ca expasy org/spdbv)
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2 1011 Prokaryotic Expression System
2 10 11 1 Protein expression
2 10 11 1 1  Standard expression culture
A 100ml portion o f LB broth was inoculated with 1 ml o f a stationary phase culture 
of E coh that had been transformed with an expression plasmid Selective antibiotics 
were included in the LB broth The culture was incubated at 37°C, shaking at 220 
rpm, until an optical absorbance (A6oo) o f 0 3-0 5 was reached IPTG was added 
(from 10 mM stock) to a final concentration o f 50 |iM to induce expression (if 
required) The culture was allowed to incubate for 4 hours, then centrifuged at 5,000 
rpm (3833 x g) for 5 min (using a Beckman JA-14 rotor) to pellet the cells The 
supernatant was discarded and the pellets were stored at -20°C
2 10 11 1 2 Preparation of cleared lysate
A cell pellet from a 100 ml expression culture was washed in potassium phosphate 
buffer, pH 7 4 followed by centrifugation at 4,000 rpm for 5 min (using a Beckman 
JA-20 rotor) The supernatant was discarded and the cells were re-suspended in 10 
ml potassium phosphate buffer, pH 7 4 The cells were disrupted on ice with a 3 mm 
micro-tip somcator (Somes & Materials Inc) using 2 5 s, 40 kHz pulses for 30 s The 
cell debris was removed by centrifugation at 4,000 rpm for 20 min at 4°C (using a 
Beckman JA-20 rotor) The cleared lysate was transferred to a fresh universal 
container and stored at 4°C
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Immobilised Metal Affinity Chromatography (IMAC) was used to purify 
recombinant human Seprase having an N-terminal 6 xHis tag
2 10 11 2 1 Standard IMAC procedure
One millilitre of nickel-nitrilotriacetic acid resin (Ni-NTA, Qiagen) was gently 
mixed with 10 ml o f cleared lysate for 60 min at 4°C The mixture was poured into a 
0 7 x 15 cm column, allowing the resin to settle The column was washed three times 
with 10 ml potassium phosphate buffer, pH 7 4 containing 20 mM imidazole and 
then eluted with 5 ml potassium phosphate buffer, pH 7 4 containing 200 mM 
imidazole The eluate was dialysed overnight against 1 L potassium phosphate 
buffer, pH 8 0 Samples taken throughout the procedure were analysed by SDS- 
PAGE (Section 2 5) Protein concentration was determined by the standard BCA or 
Coomassie Plus assay (Section 2 1) and Seprase activity was determined by the 
fluonmetnc assay (Section 2 3 3) The purified Seprase sample was stored at 4°C or 
-20°C with 40% glycerol
2 10 11 2 2 Recharging of Ni-NTA resin
This procedure was routinely used before re-using the Ni-NTA Resin The resin was 
poured into a column and washed with 2 column volumes (2 cv) o f distilled water 
followed by 2cv 50% v/v ethanol The resin was then stripped with 3cv 100 mM 
EDTA, pH 8 0 The resin was washed with 2cv 500 mM NaCl followed by 2cv 
distilled water The resin was re-charged with 2cv 100 mM N1SO4 The resin was 
finally washed with 2 cv distilled water, transferred to a plastic container and stored 
at 4°C in 20% v/v ethanol
2 10 11 2 Protein purification using the Standard IMAC procedure
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2 10 12 Mammalian Expression System
2 10 12 1 Cell Culture Methods
All cell culture techniques were performed in a sterile environment using a Holten 
laminar air flow cabinet Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope Cell culture media, supplements and related solutions were 
purchased from Sigma-Aldrich, Dublin, Ireland, unless otherwise stated
Phosphate buffered saline (PBS) (Lennox) was prepared by dissolving five tablets in 
500ml ultra-distilled water (dH20 ) This was then autoclaved at 115°C and 15 lb/in2 
for 20 mm PBS was stored at room temperature IX Trypsin/EDTA solution (T/E) 
was made up as follows 50 ml o f 10X Trypsin and 10 ml o f 1% w/v EDTA were 
added to 440 ml PBS This was aliquoted mto sterile universal contamers and stored 
at -20°C A stock solution o f 1% EDTA can be made up m advance and stored at 
4°C
2 10 12 11 Culture of Cells in Suspension
The cell line DG75 was maintained m supplemented RPMI 1640 medium 
Additional supplements were added to the culture media 10% Fetal Calf Serum 
(FCS), 2 ml L-Glutamme (200 mM), 2 ml pemcilhn/streptomycm (10 mg/ml) 
Cultures were seeded at a density of 2 x 105 to 5 x 105 cells per ml m 25 cm2 flasks 
and expanded m 75 cm flasks Cells were sub-cultured two or three times per week 
by harvestmg mto a sterile centnfuge tube and centrifuged at 1000  x g for 5 mm at 
room temperature The cell pellet was resuspended gently m an appropriate volume 
of fresh media and replaced mto the tissue culture flask All cell lmes were mcubated 
m a humid 5% CO2 atmosphere at 37°C in a Heraeus cell culture mcubator
2 10 12 1 2 Culture of adherent cells
The cell lmes Hs578T and SW480 were maintained in supplemented DMEM For 
Hs578T, high glucose DMEM was supplemented with 5% (w/v) FCS, 5ml 
pemcillin/streptomycm (10 mg/ml), 4 mM L-Glutamme (200 mM stock) and 1 5 ml 
insulin (10 mg/ml) SW480 medium was supplemented with 10% (v/v) FCS, 5ml 
pemcillin/streptomycm As the cells were strongly adherent, trypsmisation was
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required for harvesting prior to sub-cultunng For trypsin is at ion, the medium was 
decanted and the cells were washed with 2 ml o f sterile IX PBS to remove any 
residual FCS which contains a Trypsin-inhibitor activity (a2 -macroglobulin) Then 
2 ml o f 1X T/E solution was placed in each flask and the flasks incubated at 37°C for 
5 mm or until all the cells could be visualized as havmg detached from the flask 
surface The cell suspension was then decanted into a sterile centrifuge tube 
contammg 5 ml o f sterile supplemented medium (FCS inhibits Trypsin) and 
centrifuged at 1000 x g for 5 mm Cells were resuspended m supplemented medium 
at 2 to 5 x 105 cells/ml, usmg 5 ml per 25 cm2 flask and 15 ml per 75 cm2 flask Cells 
were then mcubated as described m section 2 10 12 11
2 10 12 2 Cell Counts
Cell counts were performed usmg an improved Neubauer haemocytometer slide 
Trypan blue exclusion dye was routmely used to determine cell viability Ten 
microhtres o f trypan blue was added to 90 \x\ o f a cell suspension and mixed A 
sample o f  this mixture was added to the counting chamber o f the haemocytometer 
and cells were visualized by light microscopy Viable cells appear clear and do not 
stam, whereas non-viable cells stam blue from the influx o f trypan blue across 
breached membranes
Counting 
Area —
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Notch
Rails
B
Figure 2 10.12.2 Diagram of Haemocytometer
(A) Diagram of haemocytometer with cover slip (B) Illustration of squares on a haemocytometer, 
showing one of the comer quadrants shaded The volume underneath the coverslip of this shaded area 
(or one square) is 0 1 mm3 or 104 ml
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Cells were counted from the four large comer quadrants and the centre square as 
observed under the 10X objective This total number was divided by 5 to give the 
average cell number per square This was multiplied by the dilution factor of 1 1 and 
then by 104, which results in the total cell number per ml
2 10 12 3 Cell Storage and Recovery
Cell stocks were prepared for long term storage as follows Suspension cells 1 x 107 
cells in exponential phase were pelleted and resuspended in 800jil o f supplemented 
RPMI to which lOOjj.1 o f FCS was added, then placed on ice for 10 min DMSO was 
added to a final concentration of 10% (v/v), mixed gently and transferred to a stenle 
cryotube Adherent cells one confluent 75 cm2 flask o f adherent cells was used per 
cell stock Adherent cells were washed with IX PBS followed by trypsimsation and 
resuspended in 900|il o f FCS and 1 OOjlxI of DMSO The cells were mixed gently and 
added to a sterile cryotube The cryotubes were slowly lowered into the gas phase o f  
liquid nitrogen and immersed m liquid nitrogen in a cryofreezer (Cooper 
Cryoservices Ltd) Cells were recovered from liquid nitrogen by thawing rapidly at 
37°C and transferred to a stenle centnfuge tube containing 5ml o f pre-warmed 
supplemented medium The cells were centnfuged at 1000 x g for 5 mm, the pellet 
was resuspended m 5-10ml o f fresh supplemented medium, transferred to a culture 
flask and mcubated at 37°C in 5% C 02
2 10 12 4 Transfection of Cells using Electroporation
In all cases, cells were seeded at a density o f 5 x 105 per ml o f medium 24 h prior to 
transfection Total DNA for transfection was normally purified usmg Qiagen plasmid 
mmi kit accordmg to section 2 10 3 2 3, usmg the same total quantity o f DNA per 
transfection
On the day o f transfection, adherent cells were trypsmised as described in section 
2 10 12 1 2 Suspension cells were centrifuged at 1,000 x g for 5 mm Cells were 
washed twice with cold unsupplemented medium and resuspended at a density o f 4 x 
107 cells per ml o f cold unsupplemented medium For each transfection, 10 jig DNA 
to be transfected (dissolved m 20 |l i 1 T E pH 7 4, section 2 10 2) was added to 200 jul
105
(1 x 107 cells) cold unsupplemented medium cell suspension This cell/DNA 
suspension was then dispensed into labelled pre-cooled cuvettes (BioRad, 0 4 mm) 
and placed on ice Each cell/DNA mix was then pulsed at (1) 250V for DG75 cell 
lines and (2) 100V for SW480 cell lines, with a capacitance of 960p,F (with 
capacitance extender) in a Bio Rad electroporator, and the cuvettes returned to ice 
immediately after electroporation Cells must not stay longer than 10 min on ice 
before being transferred to medium Contents of cuvettes were transferred to culture 
dishes using a micropipette and yellow tip, treating the cells gently Cuvettes were 
washed with warmed supplemented medium from the culture dish, and placed at 
37°C in a 5% C 02 incubator for the required amount o f time
2 10 12 5 Stable Transfections
Stable transfectants were selected by the addition of geneticin (G418) (Sigma) 
Geneticin is an aminoglycoside antibiotic similar in structure to gentamicin, 
neomycin and kanamycin It is a selective antibiotic, used in the selection o f  
mammalian cells, that interferes with the function o f 80S ribosomes and protein 
synthesis A stock solution o f 50 mg/ml was made up in supplemented medium On 
complete dissolution o f G418, the solution was sterile filtered and then stored at - 
20°C The DG75 stably transfected cell lines were maintained under permanent 
selection in supplemented RPMI 1640 containing 1 mg/ml G418 The SW480 stably 
transfected cell lines were maintained m supplemented DMEM containing 1 mg/ml 
G418
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2 10.12 6 Western Blot
Pnor to protein isolation, the viability of the cells was examined and the viable cell 
count determined by trypan blue exclusion as before (section 2 10 12 2) This method 
was employed to isolate total cellular protein (l e cytoplasmic and nuclear proteins) 
and was used for the extraction of Seprase protein Suspensions cells were pelleted at
1,000 x g for 5 min and washed with 5 ml o f ice-cold PBS The cells were then 
transferred to a microfuge tube in 1 ml o f ice-cold PBS, pelleted at 5,000 x g for 5 
min and all o f the supernatant removed Adherent cells were trypsmised according to 
section 2 10 12 12 The cell pellet was washed twice with 5 ml o f ice-cold PBS, and 
then pelleted by centrifugation at 5,000 x g for 5 min and all o f the supernatant 
removed The cell pellet was dispersed in ice-cold suspension buffer (0 1 M NaCl, 
0 01 M Tns-Hcl pH 7 6, 0 001 M EDTA pH 8 0, 1 jig/ml aprotimn, 1 jag/ml 
leupeptin and 100 t^g/ml PMSF), using 200 |il o f suspension buffer for every 5 x 106 
cells An equal volume of 2X SDS gel loading buffer [100 mM Tns-HCl pH 7 6, 4% 
(w/v) SDS, 20% (v/v) glycerol, 10% (v/v) 2-mercaptoethanol, 0 2% (w/v) 
bromophenol blue] was immediately added to the cell suspension, after which the 
sample becomes extremely viscous The sample was then placed in a boiling water 
bath for 10 min and then subjected to sonication for 1 min on full power to shear the 
DNA [2 5 sec, 40kHz pulses] The lysate was clarified by centrifugation at 12,000 x 
g for 10 mm at room temperature The supernatant was aliquoted and stored at -  
20°C Samples were analyzed by SDS-PAGE (section 2 5), loadmg approximately 5 
x 105 cells per lane
2 10 12 6.2 Western Blot Analysis
An SDS-PAGE gel was run as described m section 2 5 Coloured molecular weight 
markers (Sigma ColorBurst, Figure 2 5 1) were mcluded on the gel 6 pieces o f 3 mm 
filter paper (Whatman) and 1 piece o f nitrocellulose membrane (Schleicher and 
Schuell) were cut to the size o f the gel The filter paper sheets, membrane and gel 
were soaked m Transfer Buffer (section 2 10 2) for 15 mm Avoiding air bubbles, 3 
sheets o f filter paper were placed on the cathode o f a horizontal semi-dry electro­
blotter (ATTO), followed by the membrane, the gel, 3 sheets o f filter paper and
2 10 12 6 1 Preparation of Cellular Protein
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finally the anode The protein transfer was allowed to take place at a constant 15V 
for 20 min The membrane was blocked in 30 ml 5% (w/v) Milk Powder in IX TBS- 
T buffer (0 1% (v/v) Tween-20 in TBS) for 60 min, followed by incubation in 20ml 
of Anti-HA (6E2) monoclonal antibody solution (prepared in blocking buffer) 
overnight at 4°C (see Table 2 10 12 6)
P rim ary  Antibody Dilution S econdary Antibody D ilution
HA-Tag (6E2) Mouse Monoclonal 1 1000 Ap-Conjugated Anti Mouse IgG (Promega) 1 5000
Antibody (Cell Signalling
Technology)
M ouse HA Monoclonal Antibody, 1 1000 Alexa Fluor 488 anti-mouse fluorescent 1 400
Clone HA7 (Sigma) antibody (M olecular Probes)
Table 2.10 12 6 Incubation Conditions for Antibodies Used
After overnight incubation, the membrane was washed three times in TBS-T for 15 
min The membrane was then incubated with the appropriate secondary antibody (see 
Table 2 10 12 6) for 90min at room temperature, followed by washing three times 
with TBS-T for 15 min each All o f the above incubations were carried out with 
agitation Membranes were then placed in a clean container and covered with 
BCIP/NBT (Sigma) substrate in the case o f the Ap-conjugated complexes The 
BC1P/NBT container was placed in the dark at room temperature without shaking for 
30 min or longer if required The membranes were then rinsed in distilled water to 
stop the reaction, scanned or photographed, then wrapped in cling film and stored in 
the dark
2 10 12 7 Immunocytochemistry
In order to visually monitor the expression and/or subcellular localisation o f proteins, 
cells were prepared for immunocytochemical analysis as described by Groarke et al 
(2001) with minor modifications Cells were washed twice in phosphate buffered 
saline (PBS) and fixed with 3% v/v formaldehyde for 15 min Cells were 
subsequently washed, permeabihsed for 15 mm with 0 2% Triton X-100 and blocked 
for 30 min in 5% w/v Marvel solution Foliowmg blockmg, cells were mcubated for 
2 h with the primary Mouse HA mAb, Clone HA7 as mdicated m Table 2 10 12 6 
This was followed by 1 hour incubation with 1 400 dilution o f Alexa Fluor 488 anti­
mouse fluorescent secondary antibody (excitation/emission maxima o f 495/519nm)
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Nuclear DAPI staining was routinely performed by incubating cells with 0 5 x 1 O'6 
|ng/ml DAPI for 3 min Cells were sealed with covershps using DAKO mounting 
medium (DAKO Cytomation, Cambridgeshire UK) and visualized by standard 
fluorescent microscopy (Olympus BK50) Suspension cells were centrifuged and 
washed with PBS between each step
2 11 Clinical Research Study of Human Serum
Twenty patients in total were recruited through BreastCheck and the Symptomatic 
Breast Care Unit o f the Mater Misencordiae Hospital over a five month time period 
The study and consent forms were approved by the Research Ethics Committee o f  
the Mater Misencordiae Hospital Ref 1/378/1014 Patients had histologically proven 
Invasive Ductal Carcinoma and were awaiting scheduled excision (10 patients in 
total) This form o f breast cancer was chosen as immunohistochemistry studies have 
shown that Seprase is over expressed in these cases (see Section 1 6) Patients were 
informed o f the study aims on the evening of admission (or at any appropriate pre­
operative time-point) and signed the pertinent Consent Form The patient’s basic 
demographics were recorded pnor to blood sampling (see Table 8 1) Venous blood 
was withdrawn from the patient’s ante-cubital fossa at the time o f  admission and 
prior to any surgical procedure A standard non-heparmised labelled blood bottle was 
used for this purpose The blood was then transferred to the Surgical Laboratory 
where it underwent centrifugation (15,000 rpm x 20min) to isolate the serum The 
serum was removed and transferred to a plastic labelled container which was stored 
in the Surgical Laboratory at -80°C
Clinical samples obtained were analysed for enzyme activity and protein content, 
using the fluonmetnc assay as outlined in section 2 3 3 and the Biuret assay as in 
section 2 1 1 Statistical analysis was performed by Dr Michael Parkinson of the 
School o f Biotechnology, D C U Normal distribution was assessed using the 
Kolmogorov-Smimov test Vanance homogeneity was evaluated by the Levene test 
The statistical significance o f the difference in serum Seprase levels was assessed by 
Student’s t-test performed in the SPSS program for Windows P values <0 05 were 
considered statistically significant (P = statistical significance)
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All additionally relevant patient details were collected when available These 
included (but were not limited to)
(a) Tumour size
(b) Tumour grade
(c) Lymph node status
(d) Lympho-vascular invasion status
(e) ER/PR status
(f) Her2-neu status
Venous samples from a control population (age- and sex-matched) were also 
collected for comparative purposes This population comprised 10 patients admitted 
for elective varicose vein surgery When the blood samples from the entire 
complement o f patients in the study cohort had been accrued, they were transferred 
to the School o f Biotechnology, DCU It was important that all patients included in 
this pilot study be in good health (excluding the presence o f breast cancer/varicose 
veins) prior to recruitment Exclusion criteria incorporated the following
(a) History o f epithelial cancer (esp colomc/gastnc/cervical/melanoma)
(b) Inflammatory disorders (esp rheumatoid arthritis/polyartentis, e tc )
(c) History of recent surgery or trauma
110
Chapter 3
Purification and Identification of Seprase from
Bovine Serum
In the Biuret assay, copper ions in alkaline solution react with peptide bonds to form 
a purple colour with an absorbance maximum at 540nm (Gomall et a l, 1949) The 
linear relationship between protein concentration and absorbance at 540nm is 
observed up to 1 Omg/ml
The BCA assay is similar to the Lowry procedure (Lowry et a l, 1951) but is more 
sensitive than either Biuret or Lowry procedures It also has less variability than the 
Bradford assay Cu2+ is reduced by protein to Cu1+, and it is this reduction that is 
proportional to the amount o f protein present in a sample BCA forms a purple-blue 
complex with Cu1+ thus allowing the reduction of alkaline Cu2+ by proteins to be 
monitored, at 570nm (Smith et a l, 1985)
The Coomassie Plus protein assay is a modification o f the Bradford method 
(Bradford, 1976) It was used for the detection o f low levels o f protein, typically in 
the range o f 2 5 to 25^g/ml The coomassie molecule binds to protein in acidic 
conditions causing a colour change from brown to blue, which maximally absorbs at 
595nm
Protein Standard curves incorporating BSA were prepared as outlined m sections 
2 1 1 , 2 1 2  and 2 1 3 Plots of protein absorbance versus BSA concentration are 
presented in Figures 3 1 1, 3 1 2, 3 1 3 for the Biuret, Standard BCA and Coomassie 
Plus assays respectively
3 1 Protein Determination
BSA Cone (mg/ml)
Figure 3 11 BSA Standard Curve
Plot of absorbance at 540nm versus BSA concentration obtained using the Biuret assay procedure as 
outlined in section 2 1 1 Error bars represent the SEM of triplicate readings
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Figure 3 12  BSA Standard Curve
Plot of absorbance at 570nm versus BSA concentration obtained using the Standard BCA assay 
procedure as outlined in section 2 1 2 Error bars represent the SEM of triplicate readings
BSA Cone (ug/ml)
Figure 3 1 3  BSA Standard Curve
Plot of absorbance at 595nm versus BSA concentration obtained using the Coomassie Plus assay 
procedure as outlmed in section 2 1 3 Error bars represent the SEM of triplicate readings
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ZIP (Seprase) activity studied in this work was determined fluonmetrically by means 
of monitoring AMC release The linear relationship between fluorescence and AMC 
concentration allows for the accurate quantification o f enzyme activity (Appendix 
A)
The synthetic substrate used in this work for the detection o f Seprase activity was Z- 
Gly-Pro-AMC Previously described enzyme assays (Collins et a l , 2004) were 
modified to a microtitre plate assay format This allowed for the use o f minimal 
sample volume, while maintaining the sensitivity and accuracy o f the enzyme assay 
While developing these assays it also had to be considered that Z-Gly-Pro-AMC was 
described as a specific Prolyl Ohgopeptidase substrate (Yoshimoto et al, 1979) A 
specific Prolyl Ohgopeptidase inhibitor, JTP-4819 (instead of Z-Pro-Prolinal) was 
incorporated into the assay as outlined in section 2 3 3 This allowed the 
identification o f Seprase activity in samples that also contained Prolyl 
Ohgopeptidase activity, such as serum and tissue samples Section 2 3 2 describes 
the determination of Seprase activity in situations where it was most certainly free o f  
Prolyl Ohgopeptidase activity
The non-quantitative microtitre plate assay described in section 2 3 4 allowed for the 
rapid identification of Seprase or Prolyl Ohgopeptidase activity in post column 
chromatography fractions, using fewer sample and substrate volumes and requiring 
half the incubation period before analysis
The linearity o f these discontinuous assays, with respect to time and enzyme 
concentration, has been shown previously by Bimey and O’Connor (2001)
3 2 AMC Standard Curve and Inner Filter Effect
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AMC standard curves were prepared as outlined in section 2 2 1 Plots o f fluorescent 
intensity versus AMC concentration are presented in Figures 3 2 1 and 3 2 2
AMC Concentration (uM)
Figure 3 2 1 AMC Standard Curve
900 H 
800 -
AMC Concentration (uM)
Figure 3 2 2 AMC Standard Curve
Plots of fluorescent intensity versus AMC concentration Excitation slit width was maintained at 
lOnm, while the emission slit width was 2 5nm
The inner filter effect (quenching) was also performed according to section 2 2 2 
This was performed to observe the effect on fluorescence o f including crude serum 
or post column pooled fractions in the assay mixture Figures 3 2 3 and 3 2 4 are 
plots o f fluorescent intensity for crude serum and post-Phenyl Sepharose pool Plots
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of the remaining post column pools are not included, as the inner filter effect was not 
observed for these samples
AMC Concentration (uM) 
Figure 3 2 3 Serum Quenched AMC Standard Curve
AMC Concentration (uM)
Figure 3 2 4 Post Phenyl Sepharose Quenched AMC Standard Curve
Plots of fluorescent intensity versus AMC concentration Figure 3 2 3 illustrates the filter effect for 
serum (—) in comparison to unfiltered for buffer ( —} Figure 3 2 4 shows the filter effect for post- 
Phenyl Sepharose Seprase (—) m comparison to buffer (— )
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The purification o f  a target protein from a mixture involves the exploitation o f  a 
number of its physical, chemical and biological characteristics The purpose for 
which the protein is being purified and also the quantity required for future 
characterisation studies, have a significant influence on the purification strategy 
employed
The isolation o f Seprase from bovine serum for biochemical studies required the 
purification o f relatively large quantities o f highly active enzyme The conservation 
of the biological activity o f the enzyme was an important factor to consider when 
developing this purification procedure This purification process was modified by 
Collins and O’Connor (2003) from the original procedure (Birney and O’Connor, 
2001) in order to obtain an increased level o f purity This purification procedure was 
further enhanced in this study by the addition o f affinity columns to remove 
contaminating protein that was interfering with the identification o f the second Z- 
Gly-Pro-AMC degrading activity in serum
Bovine serum was chosen as the starting material for the purification protocol as a 
relatively large volume o f purified enzyme was necessary for the biochemical 
studies Bovine serum was found to have a relatively high content of ZIP (Seprase) 
activity and was a reliable, commercially available source However, it was noted 
that there was batch to batch variation of Seprase and PO activity levels in the serum 
from different bovine sources
Appropriate precautions and considerations were taken throughout the purification 
procedure All steps were earned out at 4°C except the final column, which was 
carried out at room temperature This however didn’t seem to affect the activity o f  
the enzyme Concentration and dialysis steps were kept to the minimum, as these can 
be detnmental to the preservation of activity
3 3 An Optimised Purification Procedure for Bovine Serum Seprase (ZIP)
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3 3.1 Phenyl Sepharose Hydrophobic Interaction Chromatography (HIC)
Proteins are classified as hydrophobic due to the non-polar nature o f their side-chains 
(see Appendix B) A minority o f proteins have hydrophobic groups, such as alanine, 
methionine, tryptophan, and phenylalanine, on their surface Proteins vary with their 
degree o f surface hydrophobicity and it is this characteristic that is exploited with 
HIC Protein fractionation depends on the target protein, the gel matrix and the 
surrounding environment, which is usually aqueous The addition o f neutral salts, in 
this case ammonium sulphate, increases the ionic strength o f the solution thereby 
increasing the hydrophobicity of the protein (Harris and Angel, 1989) Phenyl 
Sepharose was the resin of choice for the first purification step as it is classified as 
having a high binding capacity (20mg/ml), which is required when purifying protein 
from serum
Figure 3 3 1 illustrates the elution profile o f Seprase activity from a phenyl 
Sepharose column which was run according to section 2 4 2 The profile shows the 
presence o f two Z-Gly-Pro-AMC degrading activity peaks (as indicated by —►) 
measured as per section 2 3 4 The first activity peak (Prolyl Oligopeptidase) is 
present in the run through wash, while the second major activity peak (Seprase) 
elutes with the ultra-pure water wash These activities are distinguished according to 
their sensitivity to JTP-4819 (a potent and specific inhibitor o f Prolyl 
Oligopeptidase), which can be observed m Figure 3 3 2 Recently, another group has 
reported similar results in that they observed two distinct Z-Gly-Pro-AMC 
hydrolysing activities when purifying APCE from human plasma, one bound to the 
phenyl column, while the other did not (Lee et a l , 2004) However, using a FRET 
peptide (see Sections 1 8 and 5 1) as a substrate they were able to distinguish 
between the two activities Only the phenyl-bound fraction possessed the proteinase 
activity that cleaved the FRET peptide, which is now known as Seprase
Fractions 42-46 were combined yielding 31ml post Phenyl Sepharose Seprase 
sample This sample was analysed quantitatively for Seprase activity (see section 
2 3 3) and for protein (see section 2 11)
1 1 8
The phenyl sepharose resin was very successful in separating the bulk protein from 
the target protein, Seprase Figure 3 3 1 shows the bulk o f the protein being eluted 
with Prolyl Ohgopeptidase The HIC purification resulted in the substantial loss in 
protein, 1686mg to 64 9mg, a 5 6% loss in activity and a 24-fold purification o f  
Seprase (see Table 3 3 1)
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Figure 3 3 1 Fractionation of the Two Z-Gly-Pro-AMC Hydrolysing Activities 
in Bovine Serum by Phenyl Sepharose Hydrophobic Interaction 
Chromatography
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Figure 3 3 2 Differentiation of the Two Distinct Z-Gly-Pro-AMC Degrading 
Activities (•)  in Bovine Serum by the Inclusion of JTP-4819 (o )
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3 3.2 Calcium Phosphate Cellulose Chromatography
The Hydroxylapatite resin [Caio(P0 4 )6(OH)2] for this purification was produced in 
the laboratory according to modifications to methods previously described ((Bernardi 
et al, 1972, Donlon and Kaufman, 1980, Tiselius et al, 1956) The resin was 
prepared m bulk, eliminating the possibility o f batch to batch variation The 
mechanism o f protein adsorption is thought to involve both Ca2+ and PO4 3 groups on 
the crystal surface (Bemardi et a l, 1972)
After concentration o f the post-phenyl Sepharose pool to 10ml, the sample was 
further purified using calcium phosphate cellulose as outlined in section 2 4 3 Figure 
3 3 3 shows the elution profile o f Seprase activity and protein, measured according to 
sections 2 3 4 and 2 1 2 Seprase bound to the column at a low phosphate 
concentration and eluted on application o f 500mM phosphate The elution profile 
shows the removal o f contaminating protein with 170mM wash step but more 
importantly separating Seprase from Gly-Pro-AMC and Z-Phe-Arg-AMC degrading 
peptidases (Collins and O’Connor, 2003) Fractions 42-45 were pooled yielding 
23ml post calcium phosphate cellulose Seprase sample This sample was analysed 
quantitatively for Seprase activity (see section 2 3 2) and protein (see section 2 12)
This purification step was effective in removing contaminating protein, reducing 
protein from 64 89mg/31ml to lmg/23ml This led to a 63% recovery o f  the overall 
biological activity o f Seprase and purification factor increased to 997-fold (see Table 
3 3 1)
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Figure 3 3 3 Elution Profile of Seprase during Calcium Phosphate Cellulose 
Chromatography
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Cibacron Blue 3GA is a reactive dye or ‘pseudo-ligand’ used in affinity 
chromatography The resin is ideal for binding bovine serum albumin It was 
therefore used in this purification scheme to remove possible bovine serum albumin 
(a major component o f bovine serum) contamination from the Seprase sample
Concentrated and dialysed post calcium phosphate cellulose Seprase was applied to a 
Cibacron blue 3GA column and further purified as outlined m section 2 4 4 Seprase 
bound to the resin and was eluted using an increasing linear gradient o f sodium 
chloride Figure 3 3 4 illustrates the elution profile from the column
3 3 3 Cibacron Blue 3GA Chromatography
2 5
1 0
■D
% 0 5
.cO
E3 0 0 ■Do {n
1000
800
600 -
400 -
200  -
T
I  /
/
/
/
/
/
/
/
/
/i l \
-------------------------------------------------------A
\
.................................
50 100
Fraction Volume (ml)
150
0 46
- 0 44
- 0 42 
- 0  40
0 38
- 0 3 6  8
0 34 d) o
h 0 3 2  I
u>
- 0 30 §
- 0  28 
- 0 26 
0 24
200
Figure 3 3 4 Elution profile of Seprase during Cibacron Blue 3GA 
Chromatography
Fractions 22-24 were pooled yielding the post Cibacron blue 3GA Seprase sample 
This sample was analysed for quantitative Seprase activity (section 2 3 2) and 
quantitative protein (section 2 1 3) determinations
This resin resulted in a further 7 5% loss o f protein, which enabled a 7035-fold 
purification factor Specific Activity also increased to 84 8 Umts/mg (Table 3 3 1)
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Gel permeation chromatography is a form of partition chromatography used for 
separating proteins o f different sizes The HiPrep Sephacryl S-300 HR gel filtration 
column was chosen in this purification procedure due to its fractionation range o f 10- 
1500kDa
2ml o f concentrated post cibacron blue 3GA Seprase was applied to the S-300 
column as outlined in section 2 4 5 Figure 3 3 5 shows the elution profile o f Seprase 
from the gel filtration resin Fractions 11-13 were pooled, yielding the post-S-300 
Seprase sample This sample was analysed for quantitative Seprase activity (section 
2 3 2) and quantitative protein (section 2 13) determinations
The resin was very effective in removing larger and smaller protein contamination 
from the Seprase samples as shown by the protein peaks before and after the Seprase 
activity peak The gel filtration was an ideal purification step, with an 11% loss o f  
the total biological activity, while reducing protein from 80|ig to 30jng
Overall, the purification protocol was extremely successful, conserving 25% of the 
total biological activity o f Seprase, while reducing the total protein from 
1686mg/20ml to 0 03mg/14ml This protocol led to a specific activity 13,805-fold 
higher than that in crude bovine serum (Table 3 3 1)
3 3.4 Sephacryl S-300 HR Size Exclusion Chromatography
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Figure 3 3 5 Elution Profile of Seprase Activity during S-300 Gel Filtration 
Chromatography
125
Purification Step Volume
ml
Total Activity a
Units
Total Protein
mg
Specific Activity
Umts/mg
Purification Factor Recovery
%
Crude Serum 20 20 33 1686 8 0 0121 1 100
Phenyl Sepharose 31 19 20 64 9 0 2960 24 6 94 45
CPC 23 12 20 1 07 12 021 997 2 63 31
Cibacron Blue 18 7 21 0 08 84 80 7,035 35 46
S-300 14 5 0 03 166 41 13,805 24 6
Table 3 3 1 Purification of Seprase from Bovine Serum
The purification table was constructed to assess the overall effectiveness o f the purification procedure
a Based on the enzymatic activity using IOOjiM Z-Gly-Pro-AMC, where Units = nmol mm'1, 1 e Units are expressed as nanomol o f AMC 
released per mmute at 37°C
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3 4 Purity Assessment
Purity assessment o f ZIP using this purification procedure and fluonmetry-based 
analysis has been previously shown (Collins et a l, 2004) The post S-300 purified 
ZIP was shown to have no hydrolysis activity on any substrate other than Z-Gly-Pro- 
AMC The absence o f contaminating peptidases such as Prolyl Oligopeptidase and 
Dipeptidyl Peptidase IV was critical, as these would have interfered with the 
subsequent analysis such as inhibitor and substrate specificity studies
SDS-PAGE was also used to investigate the purity level o f ZIP in the purified 
sample Figures 3 4 1 and 3 4 2 represent images o f the coomassie stained and silver 
stamed polyacrylamide gels respectively Figure 3 2 1 illustrates the progression o f  
the purification procedure (lanes 2-5) and the concurrent loss o f protein, indicated by 
the reduction of protein bands There is no visible band present for the target protein 
ZIP at 97kDa Silver staining this gel (Figure 3 4 2) shows some contaminating 
protein in the final sample (post S-300) However, a molecular weight band of 97kDa 
is still not visible in this final purified sample (lane 5)
Based on the previously obtained fluorimetry results and on the SDS-PAGE analysis, 
the purity of the post S-300 sample was considered to be acceptable for further 
studies
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Figure 3 4 1 SDS-Gel of Purification Procedure
SDS gel stained using coomassie blue stain as per section 2 5 4 Lane (1) Sigma High Range Marker, 
(2) Crude Serum, (3) Post Phenyl Sepharose, (4) Post Calcium Phosphate, (5) Post S-300 Gel 
Filtration, (6) WGA Affinity Column, (7) Sigma High Range Marker, (8) Colourburst Marker, (9) 
Kaleidoscope Marker
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Figure 3 4 2 SDS-Gel of Purification Procedure
SDS gel stained using Silver stain procedure as per section 2 5 4 Lane (1) Sigma High Range Marker, 
(2) Crude Serum, (3) Post Phenyl Sepharose, (4) Post Calcium Phosphate, (5) Post S-300 Gel 
Filtration (6) WGA Affinity Column, (7) Sigma High Range Marker, (8) Colourburst Marker
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The primary structure o f a protein plays a major role in determining its three- 
dimensional structure. This in turn leads to the specific functionality o f the protein 
i.e. its distinct biological activity. It was very important to this study to obtain the 
amino acid sequence data for ZIP, by N-terminal or internal sequencing. This would 
ultimately confirm exactly what protein ZIP is and thus finally identify the 
protein/protease responsible for the second Z-Gly-Pro-AMC hydrolysing activity in 
bovine serum.
50ml o f bovine serum was purified to obtain sufficient ZIP sample for sequence 
analysis. SDS PAGE was performed (see section 2.6.1.1) and the gel electroblotted 
to a PVDF membrane (see section 2.6.1.2 and Figure 3.5.1). The blot was sent to Dr. 
Bryan Dunbar, Aberdeen Proteome Facility, University o f Aberdeen, Scotland for N- 
terminal sequencing. This facility has 2 Applied Biosystem protein sequencers for 
Edman sequencing. The blot showed a possible faint band close to the previously 
reported molecular weight o f ZIP, 95KDa (Bimey and O'Connor, 2001). However, 
there were also a number o f other minor contaminating bands present; possibly due 
to the requirement to purify relatively large amounts o f starting material to observe a 
Seprase band.
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Figure 3.5.1 Coomassie-Stained PVDF Membrane Blot
Lane (1) and (2), Purified post-S-300 bovine Seprase from 50ml serum; (3) Coloured marker
3.5 Identification of the Z-Pro-prolinal Insensitive peptidase
1 2 9
This sequencing attempt failed due to an inadequate amount o f protein present For 
clarification purposes, the strong band seen just above the 52KDa was sequenced and 
determined to be BSA
Another larger sample was prepared and purified over the first three columns in the 
purification procedure This partially purified ZIP sample was concentrated and sent 
to the Proteomics Department, University o f Dundee for internal sequencing Figure 
3 5 2 shows that using the larger volume of starting materials and only partially 
purifying the sample led to increased contamination by other proteins It was thought 
that by removing a purification step, there would be more o f the target protein 
present to obtam sequencing data Internal sequencing o f the band below 55KDa 
marker identified seven proteins with the major protein identified being bovine heavy 
chain IgG (Collins and O’Connor, 2003) All other sequence data obtained had no 
link to the protease activity o f ZIP
l 2
\L
Figure 3 5 2 SDS PAGE Gel of partial purified ZIP Sample
Lane (1) Sigma High Range Molecular Weight Markers, (2) Partially purified post-Cibacron Blue 
bovine Seprase
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These results showed that, without knowledge o f the exact location o f the ZIP band 
under denaturing conditions, it was not possible to sequence and identify the protein 
o f interest As can be seen from the results, this was made more difficult when trying 
to purify large volumes o f starting material in order to obtain enough target protein, 
as it resulted in increased amounts o f minor protein contamination
In order to be sure that the correct protein o f interest was being sequenced, an in-gel 
(zymogram) assay for ZIP was developed There were no reports o f this technique 
having been performed previously using this enzyme A highly concentrated ZIP 
sample was separated on a 10% native polyacrylamide gel, prepared and run 
according to section 2 6 4 The presence o f native ZIP hydrolysing the substrate Z- 
Gly-Pro-AMC is illustrated in Figure 3 5 3, which was observed under ultraviolet 
light
z ip  — ► ■ !
3 5 1 UV Zymogram Development
Figure 3 5 3 Native PAGE Analysis of ZIP Proteolytic Analysis
Zymogram clearly shows the fluorescent band (—+) which appears m the region of Z-Gly-Pro-AMC 
substrate hydrolysis after visualisation under ultraviolet light
The fluorescent bands were excised and placed in ultra-pure water overnight at 4°C, 
so that the protein present would diffuse out o f the bands into solution Due to the 
presence of a small amount of protein in the bands, this technique did not work 
Another fluorescent band which had been excised from the same gel was sent to the 
University o f Dundee for internal sequence analysis Due to such a low level o f 
target protein, it was difficult to identify the protein(s) present However, two 
proteins were identified by this approach, fibronectin and IgG Fibronectin was o f 
interest at first, as its plasma form is known to have potential proteolytic activity 
(Unger and Tschesche, 1999) It was important to remove these two proteins from
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the sample if they were contaminants, but if the activity was caused by fibronectin, to 
try and remove it by gelatin chromatography.
80ml o f  bovine serum was purified, in 20ml batchs as described in section 2.4. The 
enzyme activity from each purification was pooled and concentrated. 
Chromatography was performed using protein G affinity resin as outlined in section
2.6.2. This resin failed to bind ZIP and any IgG present in the sample was removed 
successfully. Next, the post-Protein G sample was applied to the gelatin Sepharose 
resin according to section 2.6.3. The ZIP activity failed to bind to this resin also, thus 
eliminating the involvement of fibronectin in our protease activity. Therefore, both 
IgG and Fibronectin were contaminating proteins co-migrating with ZIP on the 
native gel.
The final sample was prepared and run on a native PAGE gel, analysed using the 
zymogram assay and silver stained (see sections 2.6.4 and 2.5.4 respectively).
kDa kDa
Figure 3.5.4 UV Zymogram and Silver Staining of native ZIP
The fluorescent band in Figure 3.5.4 was excised and sent to Harvard 
Micro chemistry Facility where sequence analysis was performed by micro capillary 
reverse-phase HPLC nano-electrospray tandem mass spectrometry (^iLC/MS/MS) on 
a Finnigan LCQ DEÇA XP Plus quadrupole ion trap mass spectrometer.
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This procedure identified the ZIP protein as Seprase. Seprase is a known serine 
protease, associated with the small group o f serine integral membrane peptidases. 
The peptides sequenced and identified are shown in Figure 3.5.5 and Figure 3.5.6. 
Table 3.7.1 compares some important biochemical properties o f both ZIP and 
Seprase.
Qit 16933540 MS/MS Spectra; 12 Sum TIC: 4 le8  Avq TIC; J 4o7
fibroblast activation protein, dipt* subunit; integral membrane seiine ptotease, seprase [Homo sapiens] yi 1924982 yb|AAC516G3.il integral 
membrane serine protease Seprase [Homo sapiens] gi|20072811|gb|AAH2&250.1| fibroblast activation protein, alpha [Homo sapiens]
Sequence Reference TIC Ions Scan
(-) KLGVYEVEDQITAVR gi 116933540 +3 5 4e7 22/28 899
(-) KLGVYEVEDQITAVR gi| 16933540 +3 l l e 8 35/56 897
(-) LAYVYQNNIYLK gil 16933540 +5 3 le 7 17/22 858
(-} IFNGIPDWVYEEEM*LATK gi| 16933540 +3 1.7e7 20/34 1243
(-) FIEM’ GFIDEKR gil 16933540 *3 6.6e6 16/20 734
(-} NVDYLLIHGTADDNVHFQNSAQIAK gi 116933540 >6 1 2e6 25/96 1260
(-) YALWWSPNGK gil 16933540 +2 3.2e6 14/18 1019
(-) IFNGIPDWVYEEEMLATK gil 16933540 +3 8.9e6 16/34 1263
Figure 3.5.5 Peptides sequenced and identified as Seprase
This is an example of the results obtained from the Harvard Microchemistry Facility and therefore is 
not an exhaustive list.
gi 11924982 : MKTWKIVF&VATSAVLALLVHCIVLRPSRVHNSXKNTMRALTLKDILNGTFSYKTFFPHWISGQKYI.HQSAI>NiriVLYJIIBT&QSYTILSNRTHKSVNAS : 101 
gi 11924982 : HYGLSPDRQFVYLESDYSKLWRYSYTATYYIYDLSNGEFVRGNELPRPIQYLCVSPVGSKLAYVYQNHIYLKQRPGDPPFQITniGRElJKIFNGIPDWYE : 202
gi 11924982 : HEMLATKYALlilffSPir&KFLAYAEFIJDTDIPVIAYSYYCDEQYPRTINIPYPKACAKWPWRIFIIDTTYPAYV&PQEVPVPJUIIASSDYYFSVLTWTDER : 303
gi 11924982 : VCLQWLKRVQ1JVSVLSICDFRED¥QTTOCPKTQEHIEESRTGWAGGFFVSTPVFSYDAISYYKIFSDKDGYKHIHYIKI>TVEHAIQITSGIWEAINIFRVT : 404
giI1924982 : QDSLFYSSNBFEHYPGRElilYRISIGSYPPSKKCVTCHLRKIRCQYYTASFSDYAKYYALVCYGPGIPISTLHDGRTDQIIKILKJliKELINALKNIQLPK : SOS 
gi 11924982 : KKIKKLKVr>HITLWYKKILPPQFDRSKKYPLLIQVYGGPCSQSVRSVFAVH¥I£5YLA3KRi.HVIAUVDGR0IAFQM>KLLYAVYRKLGVYEVEDQITAVRK : 606
gi 11924982 : FIKHGFIDEKRIAIWG¥SYGGYVSSLALASGTGLFKCGIAVAPVSSWBYYASVYTERFHGIiPTKl>DHI.EHYKNSTVHARAEYFRNVDYLLIHGTAI>DNVHF : 70?
gi 11924982 : QNS AQIAKALWAQVT>FQAHWYS£>QNHGLS GL STNHLYTHMTHFLKQCFSLSD : 760
Figure 3.5.6 Seprase amino acid sequence
Seprase amino acid sequence (GI: 1924982) with identified sequencing peptides marked.
133
Seprase is known to exhibit gelatinase activity (Aoyama and Chen, 1990; Monsky et 
al., 1994; Pineiro-Sanchez et al., 1997); therefore, it was important that gelatin 
zymographic analysis be performed on purified ZIP/Seprase for this potential 
activity. Gelatin zymography was performed according to section 2.6.5. Figure 3.6.1 
(A) illustrates a gelatin zymogram with a clear zone o f lysis where the purified 
sample showed enzymatic activity towards gelatin.
kDa kDa 1 2 3 4 5
205->
IIP->
3.6 Gelatin Zymography
100->
Figure 3.6.1 Gelatinolytic Activity of Seprase, detected by Zymography
(A) Purified ZIP/Seprase was loaded on a 10% native gel incorporating 1 mg/ml gelatin and activity 
subsequently detected using gelatin zymography. (B) Identification of Seprase as a serine protease. 
Purified ZIP/Seprase pre-incubated with the appropriate inhibitor was loaded on a 10% native gel 
incorporating 1 mg/ml gelatin and activity subsequently detected using gelatin zymography. Lane 1, 
Kaleidoscope Marker; Lane2, Seprase, Lane 3, Seprase incubated with PMSF; Lane 4, Seprase 
incubated with DFP; Lane 5, Seprase incubated with JTP-4819. Molecular masses (kDa) of standard 
proteins are indicated on the left.
This result also shows that Seprase, apart from having an exopeptidase activity 
(cleaves Z-Gly-Pro-AMC), also has an endopeptidase activity. To date, no 
physiological substrate has clearly been defined for this protease but its ability to 
effectively degrade gelatin suggests a candidate protein substrate in vivo and a 
possible role in extracellular matrix protein degradation. Complete inhibition o f  the 
soluble form o f Seprase gelatinase activity was observed for the serine protease 
inhibitors PMSF and DFP (see Figure 3.6.1 (B)), as reported for the membrane- 
associated Seprase (Aoyama and Chen, 1990). The Prolyl Oligopeptidase-specific 
inhibitor JTP-4819 did not have any effect on this activity. This inhibition study 
suggests that Seprase contains a catalytically active serine residue.
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3 7 Wheat Germ Agglutinin (WGA) Lectin Affinity Chromatography
Lectins are a family o f carbohydrate binding proteins/glycoproteins They are 
capable o f binding glycoproteins even in the presence o f  various detergents The 
agglutination activity o f these highly specific carbohydrate-binding molecules is 
usually inhibited by a simple monosaccharide Wheat germ agglutinin has a sugar 
specificity for yV-acetyl-/3-D-glucosamine
Seprase has been shown to bind to the Wheat Germ Agglutinin lectm affinity resin 
(Aoyama and Chen, 1990, Pmeiro-Sanchez et a l, 1997) This affinity resin was 
investigated using purified ZIP/Seprase, with the thought that it would improve the 
standard purification procedure detailed in section 2 4
The post Sephacryl S-300 Seprase was applied to the WGA lectm column as per 
section 2 6 6 Bound Seprase was eluted usmg 0 5M N-acetyl-D-glucosamine Figure 
3 7 1 illustrates the elution profile o f Seprase Fractions 13-17 were pooled to yield 
the post WGA Seprase sample This sample was analysed for quantitative Seprase 
activity (section 2 3 2) and quantitative protein (section 2 1 3) determinations
The resin was very effective m removmg more protein contamination from the 
Seprase sample, as shown by the protem peaks before and after the Seprase activity 
peak The affinity resm resulted m a 15% loss o f the total biological activity, while 
reducmg protem from 30^g to 7jig
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Figure 3 71  Elution Profile of Seprase Activity during WGA Lectin Affinity 
Chromatography
Overall, the purification protocol was extremely successful, conserving almost 10% 
o f the total biological activity of Seprase, while reducing the total protein from 
1686mg/ml to 0 007mg/ml This protocol led to a specific activity 21,483-fold higher 
than that in crude bovine serum (Table 3 7 1)
This column did show its effectiveness in binding Seprase and would be useful when 
purifying Seprase from other sources, such as mammalian expression systems that do 
not contain as much protein contamination as bovine serum
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Purification Step Volume
ml
Total Activity a
Units
Total Protein
mg
Specific Activity
Umts/mg
Purification Factor Recovery
%
Crude Serum 20 20 33 1686 8 0 0121 1 100
Phenyl Sepharose 31 19 20 64 9 0 2960 24 5 94 45
CPC 23 12 20 1 07 12 021 997 2 63 31
Cibacron Blue 18 7 21 0 08 84 80 7,035 35 46
S-300 14 5 0 03 166 41 13,805 24 60
WGA Lectin 5 5 1 95 0 007 258 96 21,483 9 58
Table 3.7 1 Purification of Seprase from Bovine Serum with the addition of WGA Affinity Lectin Column
The purification table was constructed to assess the overall effectiveness o f the purification procedure
a Based on the enzymatic activity using IOOjiM Z-Gly-Pro-AMC, where Units = nmol mm 1 le  Units are expressed as nanomol o f AMC 
released per mmute at 37°C
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ZIP Seprase
MW (Native) kDa 174* 170
MW (Monomer) kDa 95-96 97
pi 5 68* ~5
pH (Optimum) 7 4-8 0* 78
Assay Temp (°C) 37* 37
Catalytic Type Serine protease* Serine protease
Reaction Catalysed Endopeptidase*, Endopeptidase,
proline specific proline specific
Inhibitors DFP, AEBSF* DFP, AEBSF
Gelatinase activity Yes Yes
Reference *(Rimey and O'Connor, (Pineiro-Sanchez et a l ,
2001) 1997)
Table 3 7 2 Comparison of Important Biochemical Properties of both 
enzymes
Table 3 7 2 compares some of the important biochemical properties o f both ZIP and 
Seprase This study presents the first identification o f a serum/soluble form o f this 
protease (Collins et a l , 2004), as it displays a strong similarity with the primary 
structure (see Figure 3 5 6) and similar catalytic activity to the cell associated serine 
integral membrane peptidase Seprase A second group has recently identified the 
soluble form o f Antiplasmin Cleaving Enzyme (APCE) as Seprase (Lee et a l, 
2005a)
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Chapter 4 
Biochemical Analysis of Seprase
4.1 Temperature Studies
Enzymes are sensitive to their environmental conditions Up to a point, the rate o f the 
reaction will increase as a function o f temperature because the substrate molecules 
will collide more frequently with the active site These sets o f experiments were 
designed to investigate the effects o f temperature on the enzymatic activity o f 
Seprase
4 1 1  Determination of Optimum Assay Temperature
Each enzyme has an optimal temperature that favours the native conformation for 
maximum activity The influence o f temperature on the activity o f Seprase was 
investigated As outlined in section 2 7 1 1, the standard activity assay was carried 
out at a range o f temperatures The resulting optimum assay temperature profile is 
shown in Figure 4 1 1
The physiological temperature o f a healthy human, range from 36 2 to 37 2°C and for 
a bovine animal is 38 9°C (Prendeville et a l, 2002) Most metabolic enzymes 
function with an optimal temperature near body temperature, but this is not always 
the case In this study, an increase in residual Seprase activity (%) was observed up 
to 40°C, which is not unexpected considering that the source o f Seprase is bovme 
Despite this observation, it was decided to continue using 37°C as the standard assay 
temperature, considering the mammalian origins o f this enzyme Seprase purified 
from the chicken embryo was reported to have a temperature optimum o f 37°C 
(Kelly, 1999)
T em p e ra tu re  ( ° C )
Figure 4.1.1 Determination of the Optimum Assay Temperature for Seprase
Activity levels measured at 37°C were defined as 100% Error bars shown represent SEM o f triplicate readings
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4 12  Thermal Profile, (T50)
Above the enzyme’s optimum temperature, the enzyme degrades as the noneovalent 
interactions that stabilise the native conformation are disrupted This method was 
used to determine the temperature at which the enzyme begins to unfold and lose 
catalytic activity The assay was carried out at temperatures ranging from 4°C to 
75°C according to section 2 7 12
The apparent activity increased with temperature up to 40°C, above which the 
activity started to decline The half-inactivation temperature o f Seprase was 
estimated by inspection as 55°C
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Figure 4 12  Thermal Profile of Seprase
Activity levels measured at 37°C were defined as 100% Error bars shown represent SEM of triplicate 
readings
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4.1.3 Thermal Stability
Figure 4.1.3 illustrates the effect o f temperature on the stability o f  Seprase. Stability 
o f this mammalian enzyme would be expected at temperatures up to 37°C, and this 
was clearly the case. After 3 hours o f incubation at 37°C, 90% of Seprase activity 
remained. It was found that Seprase remained stable up to 40°C during this time 
frame. Above this temperature, Seprase activity was found to decline rapidly. 
However, 60% of Seprase activity was found to remain after incubation at 50°C for 
60 minutes. At physiological temperature Seprase seems to be activated, increasing 
activity.
0
Time (mm)
Figure 4.1.3 Determination of the Thermal Stability of Seprase
Dilute protein solutions are often unstable, due to adsorption to surfaces and 
dissociation o f subunits. Relatively high thermostability can be attributed to the 
presence o f other proteins ‘protecting’ the peptidase. These proteins increase 
interactions between water molecules, thus strengthening hydrophobic interactions. 
This explains why BSA is often added to purified enzyme samples (Harris and 
Angel, 1989). Progression o f a purification scheme removes these stabilising 
proteins, thereby causing the protein o f interest to become more heat-labile. 
Although the Seprase sample was extremely pure (13,805-fold, Table 3.3.1, section 
3.3), there was no requirement for the addition of protein due to its excellent 
thermostability profile.
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4 1 4  Thermal Inactivation of Seprase
Thermal inactivation o f Seprase was carried out at 55°C (T50), for up to 90mins 
Activity losses o f 50% were obtained after 16 minutes o f incubation as illustrated by 
Figure 4 1 4
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Figure 4 14  Thermal inactivation of Seprase
Error bars shown represent SEM of triplicate readings
The first 50 time points fitted satisfactorily to the first order process, showing that 
Seprase lost activity progressively according to first order kmetics (data were fitted 
using Enzfitter®) This allowed for an estimation o f an apparent or pseudo half-life 
The first order rate constant o f inactivation was determined to be 0 0436 ± 0 00143s
In 21 The half-life o f this reaction was calculated using the equation f, = -----  to be
2 k
15 9s
It seems a pseudo-two-state unfolding mechanism is contributing to the loss o f  
Seprase activity It seems that one inactivation process dominates over the first 40 
minutes and then a second at longer time periods The active form o f Seprase is a 
dimer and the loss o f activity may proceed initially via the dissociation o f the two 
subunits followed by their unfolding
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As with temperature, each enzyme has an optimal pH which is favourable to the 
native conformation for maximal activity. The pH effect results due to critical amino 
acids at the active site o f the enzyme that participate in substrate binding and 
catalysis. The ionic or electric charge on the active site amino acids can enhance and 
stabilize interactions with the substrate. In addition, the ability o f the substrate and 
enzyme to donate or receive a H+ is affected by pH.
The influence o f pH on the activity of Seprase was investigated as outlined in section
2.7.2. Figure 4.2 shows the pH profile for purified Seprase.
4.2 Influence of pH
pH
Figure 4.2 Influence of pH on Seprase activity
Residual enzyme activity over pH range 6.0 to 10.5. Different buffers used for specific ranges as 
described in Section 2.7.2. pH values of 8.0 were taken to be 100%. Error bars shown represent SEM 
of triplicate readings.
Seprase was found to remain stable over a pH range o f 7.0 to 9.5 in the various 
buffering systems. It is clear from Figure 4.2 that the maximum Z-Gly-Pro-AMC 
hydrolysing activity occurred at pH 8.0 in the phosphate buffer system. By 
comparison, in the Tris buffer system, the relative activity was found to decrease by 
27%. Previous studies have reported pH optima of Seprase to be 7.0, 8.5, 7.5 and 7.6 
(see Table 1.4) (Aoyama and Chen, 1990; Bimey and O'Connor, 2001; Kelly, 1999; 
Sun et al., 2002).
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The phosphate buffering system was chosen for most assay and storage protocols 
The Tns buffer system was less effective in maintaining optimum enzyme activity 
and has also been found to interfere with a number o f protein assays due to primary 
amine presence
4 3 Determination of the Second Order Rate Constant, (k2) for DFP 
Inhibition of Seprase
The activity o f Seprase is irreversibly inhibited by the serine protease inhibitor 
dusopropyl fluorophosphate, which specifically and stoichiometncally reacts with 
Seprase at Ser624, demonstrating that this residue represents the active site 
nucleophile Inhibition o f the soluble form o f Seprase resulted in an IC50 o f lOOnM 
(Collins et a l , 2004)
In many reactions, the rate o f reaction changes as the reaction progresses Initially 
the rate o f reaction is relatively large, while after a period of time the rate o f reaction 
decreases to zero (at which point the reaction is complete) In order to characterise 
the kinetic behaviour o f a reaction, it is desirable to determine how the rate of 
reaction varies as the reaction progresses
A rate law is a mathematical equation that describes the progress o f the reaction 
There are two forms o f rate law for chemical kinetics the differential rate law and 
then integrated rate law
The differential rate law describes how the rate o f reaction varies with the 
concentration of various species, usually reactants, in the system The rate o f reaction 
is proportional to the rates o f change in concentrations o f the reactants and the 
products, that is, the rate is proportional to the derivative o f the concentration Each 
rate law contains a constant, k, called the rate constant For the second-order reaction, 
the rate o f reaction (r) is directly proportional to the square o f the concentration o f  
one o f the reactants [A]2
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The differential rate law for a second order reaction is,
r = k [ A \
^  = k[A]2 dt
And the integrated rate law,
[A][A] 1 + kt[A]0
The rate constant o f inhibition for DFP was determined under second-order 
conditions based on the equation,
1 1 1 f 1—  = --------------- or —  = kt + ------[A] ([A]0 +k)t [A] [A]0
(y = mx + b)
with the molar ratio or Seprase to DFP at 1 1
The second-order rate constant k, has units o f L mole 1 s '1 or M 1 s 1
Equimolar amounts o f Seprase and DFP were incubated according to section 2 7 3 
for varying periods o f time Fluorescent intensity was converted to [AMC] released 
using the calculations according to Appendix A The second order rate constant for
DFP was determined using the plot o f 1 / [AMC] released (|im ol)1 L versus Time
(mm)
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AMC Cone (uM)
Figure 4.3 1 Standard Curve for DFP Analysis
Error bars shown represent SEM o f triplicate readings
U§  <
Time (nun)
Figure 4 3 2 k2 determination for DFP Inhibition of Seprase
Error bars shown represent SEM of triplicate readings
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The second order rate constant (fe), o f inhibition o f DFP against Seprase was 
calculated, from the slope o f the line, to be 3 31x103 M ls"1 This kinetic constant 
indicates very good inhibition o f Seprase
The second order rate constant, fe, determined for DFP inhibition o f porcine brain 
prolyl endopeptidase (PO) was estimated to be 825 M ]s 1 (Rennex et a l, 1991) 
Seprase displays a 4-fold higher sensitivity to DFP inhibition to that obtained for PO 
This indicates strongly that although both Seprase and PO cleave the substrate Z- 
Gly-Pro-AMC, the substrate specificity o f both enzymes is different
Recent studies o f dipeptide proline diphenyl phosphonates found that Gly-Prop(Oh)2 
exhibited an overall second order rate constant o f inactivation o f 177 M ls 1 and 8 7 x 
103 M ]s 1 against Seprase and DPPIV respectively (Gilmore et a l , 2006) The data 
from this study suggests that both enzymes have a similar inhibition profile, and 
there exists subtle differences in their binding affinities This irreversible inhibitor 
displays an 18 7 fold lower inactivation rate o f Seprase than DFP However, DFP is 
an extremely toxic serine protease inactivator and it is understandable that Seprase 
would have an increased sensitivity to it
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4 4 Inhibition Studies
Serine protease inhibitors were provided by Dr Peter Kenny, School o f Chemical 
Sciences, DCU They were tested for inhibitory properties using purified Seprase 
(section 2 4) and Prolyl Ohgopeptidase (section 2 7 4 1) from bovine serum
4 4 1 Partial Purification Procedure for Bovine Serum Prolyl Ohgopeptidase
Prolyl Ohgopeptidase was partially purified from bovine serum as outlined in section 
2 7 4 1 This enabled comparative inhibitory studies with Seprase Enzyme assays for 
Prolyl Ohgopeptidase were performed as described in section 2 3 2, with the addition 
of DTT in the substrate preparation as outlined in section 2 3 1
4 4 11 Phenyl Sepharose Hydrophobic Interaction Chromatography I
The first step in Prolyl Ohgopeptidase purification from bovine serum is the same 
step discussed in section 3 3 1 for the isolation o f Seprase This step is extremely 
important for both purification procedures in that it critically separates the two Z- 
Gly-Pro-AMC hydrolysing activities found in bovine serum, from each other Figure 
4 4 1 shows the elution profile o f PO activity from Phenyl Sepharose column, run 
according to section 2 7 4 1 The first activity peak, which is present m the run 
through and is inhibited by JTP-4819, is Prolyl Ohgopeptidase
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Figure 4 4 1 Elution profile of PO activity during Phenyl Sepharose 
Hydrophobic Interaction chromatography I
Elution profile shows the differentiation of the two distinct Z-Gly-Pro-AMC degrading activities (•)
in bovine serum by the inclusion of JTP-4819 (o )
Fractions 3-9 were pooled yielding 30ml post phenyl sepharose I PO sample This 
sample was analysed for quantitative PO activity (section 2 3 2) and quantitative 
protein determinations (section 2 11)
83% of PO activity was retained with this purification step, most likely due to the 
fact that the enzyme did not bind and was present in the run through The co-elution 
o f contaminating protein (793mg) explains the poor purification factor o f 2 16-fold 
obtained
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4 4 12  Phenyl Sepharose Hydrophobic Interaction Chromatography II
The first chromatography step in the purification o f Prolyl Ohgopeptidase was 
applied to separate Seprase and PO A second hydrophobic interaction column was 
employed to further purify PO A higher ammonium sulphate concentration (1M) 
was used during this second phenyl Sepharose column for binding o f Prolyl 
Ohgopeptidase Figure 4 4 2 illustrates the elution profile o f PO, during a linear 
decreasing ammonium sulphate concentration gradient PO seems to leak off the 
column, prior to the elution gradient This was possibly due to the inefficient 
equilibration of the hydrophobic column
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Figure 4 4 2 Elution profile of PO during purification using Phenyl Sepharose 
Hydrophobic Interaction Chromatography II
Fractions 37-42 were pooled yielding 35ml post Phenyl Sepharose II PO sample 
This sample was analysed quantitatively for PO activity (see section 2 3 2) and 
protein (see section 2 12)
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Table 4 4 1 shows a loss of 99% of the total applied protein This was an extremely 
significant loss o f protein, which resulted in a 67% decrease in the total applied 
enzyme activity This second purification step resulted in a 58-fold purification 
factor It is possible that, along with this removal o f contaminating protein, as well as 
the concentration and addition of ammonium sulphate to the post-phenyl Sepharose I 
sample, has led to 32% of the original biological activity remaining Compared to the 
Seprase purification scheme, after two purification steps, 60% of biological activity 
remained (see Table 3 3 1) Another possible reason for the loss o f PO activity is that 
it has been reported to be rather unstable during purification (Cunningham and 
O’Connor, 1997, Dowling, 1998)
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4 4 13  Cibacron Blue 3GA Chromatography
This resin was employed as in the Seprase purification to remove BSA present in the 
sample (section 2 7 4 1 3) and to purify PO to a greater extent
Concentrated and dialysed post Phenyl Sepharose II PO was applied to the Cibacron 
Blue 3GA column Prolyl Oligopeptidase did not bind to the Cibacron Blue 3GA and 
was present in the run through as illustrated in Figure 4 4 3 This is the total opposite 
o f Seprase, which was bound to this resin, as shown in section 3 3 3
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Figure 4 4 3 Cibacron Blue 3GA Chromatography of PO Activity
Fractions 4-6 were pooled yielding 9ml post-Cibacron Blue 3GA PO sample This 
sample was analysed for quantitative PO activity (section 2 3 2) and quantitative 
protein determinations (section 2 13)
This resin was successful in removing a further 11 lmg o f contaminating protein 
resulting in an overall 96% reduction in protein A 313-fold purification factor along 
with 6 4% retention o f biological activity was obtamed This was deemed 
satisfactory for a partial purification of Prolyl Oligopeptidase from bovine serum
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Purification Step Volume
ml
Total Activity a
Units
Total Protem
mg
Specific Activity
Umts/mg
Purification Factor Recovery
%
Crude Serum 25 16 145 2052 61 0 0079 1 100
Phenyl Sepharose I 30 13 493 793 52 0 0170 2 16 83 57
Phenyl Sepharose II 35 5 258 11 53 0 4561 58 32 57
Cibacron Blue 9 1 033 0 42 2 463 313 6 4
Table 4 4 1 Partial Purification of Prolyl Okgopeptidase from Bovine Serum
The purification table was constructed to assess the overall effectiveness o f the purification procedure
a Based on the enzymatic activity usmg IOOjiM Z-Gly-Pro-AMC, where Units = nm olm in'1, 1 e Units are expressed as nanomol o f AMC 
released per mmute at 37°C
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It can be seen from Figures 4 4 5, 4 4 6 and 4 4 7 that the inhibitor compounds tested 
(as described in section 2 7 4 2) had little or no inhibitory effect on Seprase and PO 
A
activities over the concentration range used Compound 8h (Figure 4 4 5 and Table 
4 4 2) showed some signs o f inhibitory effects by reducing Seprase activity to 53% 
activity, while Prolyl Oligopeptidase activity was reduced to 85%
4 4 2 Inhibitor Analysis
Figure 4 4.4 Structure of 8h Inhibitor
Due to the lack o f inhibition, the IC50 value o f each inhibitor for Seprase/PO could 
not be determined A higher concentration o f inhibitor would be required for this 
analysis If, however, a higher concentration o f inhibitor compound were to be 
tested, a higher concentration o f DMSO would be required to maintain the inhibitor’s 
solubility However the concentration o f DMSO in the reaction had to be kept at a 
minimum m order to retain enzyme activity If  further work were planned on testing 
these dipeptides, it would be required to make the inhibitor compounds more water- 
soluble
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8a Inhibitor Concentration (uM)
8c Inhibitor Concentration (uM)
8b Inhibitor Concentration (uM)
8d Inhibitor Concentration (uM)
1 2 0  -i
20 40
8e Inhibitor Concentration (uM) 8f Inhibitor Concentration (uM)
8g Inhibitor Concentration (uM) 8h Inhibitor Concentration (uM)
Seprase — Prolyl Oligopeptidase
8i Inhibitor Concentration (uM)
Figure 4.4.5 Inhibitor Profile Effect of the Compound 8 Series
Enzyme activities are expressed as a percentage of uninhibited enzyme. Error bars shown represent SEM of 
triplicate readings.
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9a Inhibitor Concentration (uM)
9c Inhibitor Concentration (uM)
9e Inhibitor Concentration (uM)
9b Inhibitor Concentration (uM)
9d Inhibitor Concentration (uM)
9f Inhibitor Concentration (uM)
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9g Inhibitor Concentration (uM)
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Figure 4.4.6 Inhibitor Profile Effect of the Compound 9 Series
Enzyme activities are expressed as a percentage o f uninhibited enzyme. Error bars shown represent SEM of 
triplicate readings.
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10b Inhibitor Concentration (uM)
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Figure 4.4.7 Inhibitor Profile Effect of the Compound 10 Series
Enzyme activities are expressed as a percentage o f uninhibited enzyme. Error bars shown represent SEM o f 
triplicate readings.
1 5 8
Compound % Residual 
Activity 
Seprase PO
Compound % Residual 
Activity 
Seprase PO
Compound % Residual 
Activity 
Seprase PO
8a 99 87 9a 85 92 10a 102 95
8b 85 96 9b 87 87 10b 97 96
8c 101 101 9c 81 91 10c 109 100
8d 80 84 9d 91 87 lOd 106 97
8e 79 87 9e 85 87 lOe 105 98
8f 79 80 9f 86 95 lOf 108 95
8g 97 93 H 101 103
8h 53 85 9h 101 94
8i 102 90 9i 101 89
Table 4 4 2 Overall Inhibitory Studies on Seprase and Prolyl Ohgopeptidase
Enzyme activities are expressed as a percentage of uninhibited enzyme Residual Activities (%) are 
shown for the effect of each compound (50|iM) on both Seprase and PO
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Chapter 5 
Substrate Specificity Studies
Substrate specificity studies of an enzyme are extremely important and can ultimately 
lead to an understanding of the possible physiological significance of an enzyme It is 
known that the substrate specificity of a protease is not just determined by the two amino 
acid residues at either side of the scissile bond of a substrate (Si and Si’) but can also be 
influenced by the other factors such as peptide length and conformation
Initial work on the substrate specificity o f Seprase (Bimey and O'Connor, 2001) studied 
a number o f proline containing peptides as potential substrates Collins and colleagues 
(2004) determined that bovine Seprase releases Z-Gly-Pro from the synthetic substrate 
Z-Gly-Pro-AMC with high efficiency However, no cleavage of Gly-Pro-AMC or Pro- 
AMC occurs, indicating intolerance at the Pi and P2 -sites for free a-amine groups (see 
Figure 5 1 1 for nomenclature) Recent studies have shown that Seprase tolerates other 
N-bloeking groups such as N-methyl-, formyl, and succinyl- (Edosada et a l , 2006b)
Hydrolysis of Z-Gly-Pro-AMC by Seprase was profiled in the presence of proline- 
contammg peptides with variations in the ammo acid residues located at the C-terminal 
site o f the scissile bond (position P i’) in addition to variations m conformation and 
length All peptides contained the constant sequence of Z-Gly-Pro-, which inhibited 
Seprase either m a mixed or non-competitive mode The lowest K x ^  values were 
obtained for peptides Z-Gly-Pro-Phe and Z-Gly-Pro-Met Highest Kx app values occurred 
m substrates with His, Glu and Ala m the Pi’ position Kinetic analysis of Seprase 
revealed greatest affinity for large hydrophobic residues m the Pi' position, and reduced 
affinity for acidic, basic and small ammo acids in this position (Collins et a l , 2004) 
More detailed substrate specificity studies were earned out on punfied Seprase and were 
performed as outlmed in section 2 8
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5 1 Substrate Specificity using Combinatorial Dipeptide Library
Dr Craik’s laboratoiy developed a method for rapid and general profiling of protease 
specificity using combinatorial fluorogenic libraries Initially it was proposed to use a 
positional scanning library that would analyse Pj -  P4 position However, after numerous 
attempts, no results were obtained from this analysis It was then decided to use the 
positional scanning synthetic combinatorial dipeptide substrate library This dipeptide 
library was synthesised using the bifunctional fluorogenic leaving group 7-ammo-4- 
carbamoylmethylcoumann (ACC) similar to the tetrapeptide library constructed by 
Hams and colleagues (Hams et a l , 2000) However, A^-terminal acetylation o f the P2 
residue produced a library with the general composition, Ac-Xaa-Xaa-ACC (Figure 2 8), 
where Xaa is any ammo acid Amide bond hydrolysis occurs between the Xaa-Xaa 
dipeptide and ACC, result mg m an mcrease in fluorescence
This library was composed of two sub-libraries (P| and P2) consisting o f 400 compounds 
each, utilizing the 20 naturally occurring ammo acids, but excludmg cysteine and 
including norleucine The Pi sub-library was composed of 20 separate mixtures m which 
the Pi position was fixed and the P2 position contained an equimolar mixture o f all o f the 
other ammo acids In the P2 sub-library, the P2 residue is positionally defined, and the Pi 
position contains an equimolar mixture of all other ammo acids The results using these 
libraries provide a complete understanding of the specificities o f Seprase in Si and S2 
subsites of the active site
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The Schechter and Berger nomenclature
Figure 5.1.1 Schematic Representation of an Enzyme-Substrate Complex
Residues of the substrate and enzyme subsites are numbered according to their distance from the scissile 
bond and their location on the N- or C-terminal side of the cleavage site (Schechter and Berger, 1967).
In this study, positional scanning of the Pi ACC library determined that Seprase has a 
marked preference for proline in the Si subsite, but appears to tolerate all other amino 
acids with the exception of tryptophan (Figure 5.1.2). When fluorescence was 
normalized as a percentage of Pi-proline released (i.e. Ac-Xaa-Pro-ACC = 100%), ACC 
was not released from peptides with amino acids other than pro line in the Pi position at a 
rate greater than 24%. Lowest activity was observed with Pi aromatic residues, such as 
phenylalanine, tyrosine and tryptophan. These results indicate that the Si subsite o f 
Seprase is therefore designed to specifically fit proline residues. A recent study based on 
the cleavage site in c^ APpro, confirmed that Seprase requires a Pro line in the Pi position 
(Edosada et al., 2006a).
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Figure 5.1.2 Pi Positional Scanning Profile for Seprase
Positional scanning of bovine Seprase using a combinatorial dipeptide library assayed at the P] position. 
The X-axis gives the standard single letter code for amino acids where n = norleucine. Amino acids are 
arranged in the order of basic (K,R,H), acidic (D,E), polar (N,Q,S,T), special (G,P), aromatic (F,W,Y) and 
aliphatic (A,V,I,L,n,M) groups. Free ACC fluorescence of 1 RFU sec'1 was calculated to be equivalent to 
0.0007226 pM sec1. (100% scale)
Data obtained during screening of the P2 sub-library revealed a much broader specificity 
in the S2 binding pocket of bovine Seprase. However, the catalytic rates are relatively 
low in comparison to cleavage after Pi-proline. Comparing Figure 5.1.3 and 5.1.4 
together, it appears that the initial reaction at the P2 position for each amino acid may be 
related to the presence in each well of Pi-Pro (1 /20th of each substrate). Therefore, even 
if the enzyme does not favour a particular amino acid at P2, cleavage will still occur due 
to the presence o f Pi-Pro in the well. After the first 12 minutes, Pi-Pro has been used up 
and Seprase then begins to cleave the other substrates with much lower processing (see 
Figure 5.1.4).
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P2 Library
Figure 5.1.3 P2 Positional Scanning profile from 0-60 minutes for Seprase
Positional scanning of bovine Seprase using a combinatorial dipeptide library assayed at the P2 position. 
The X-axis gives the standard single letter code for amino acids where n = norleucine. Amino acids are 
arranged in the order of basic (K,R,H), acidic (D,E), polar (N,Q,S,T), special (G,P), aromatic (F,W,Y) and 
aliphatic (A,V,I,L^,M) groups. Free ACC fluorescence of 1 RFU sec1 was calculated to be equivalent to 
0,0007226 pM sec'1. (100% scale)
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Figure 5.1.4 P2 Positional Scanning profile from 12-60 minutes for Seprase
Positional scanning of bovine Seprase using a combinatorial dipeptide library assayed at the P2 position. 
The X-axis gives the standard single letter code for amino acids where n = norleucine. Amino acids are 
arranged in the order of basic (K,R,H), acidic (D,E), polar (N,Q,S,T), special (G,P), aromatic (F,W,Y) and 
aliphatic (A,V,I,L,n,M) groups. Free ACC fluorescence of 1 RFU sec'1 was calculated to be equivalent to 
0.0007226 pM sec'1. (100% scale)
In the S2 subsites, this study shows that Seprase has a preference for Norleucine (Nle), 
Alanine (Ala), Leucine (Leu), Glycine (Gly), Arginine (Arg), Methionine (Met), and 
does not tolerate aromatic, strongly basic or acidic residues. Using substrates that span 
the P4-P2’ positions, recent studies showed that Seprase has a preference for Glycine at 
the P2 position (Edosada et al., 2006a). Using longer peptides confers a certain amount 
of conformational restriction on the amino acid entering the S2 site of the enzyme, as 
their positions will affect the position of the P2 amino acid. Kinetic studies have shown 
that Seprase has a preference for Ala-Pro-AFC over Gly-Pro-AFC as a substrate with 
kcat/Km values o f 5.8 x 104 M 'V 1 and 2.3 x 104 M’V 1 respectively (Edosada et al., 
2006b). However, Z-Gly-Pro-AMC has a 2-3-fold higher affinity for Seprase than does 
Ala-Pro-AFC (Km 101 jiM and 323\iM respectively) (see Table 1.8) (Lee et al., 2005a).
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As discussed previously, Gly-Prop(Oh)2 was most effective m inhibiting Seprase 
activity, exhibiting an overall second order rate constant of inactivation of 177 M lsec 1 
against Seprase (see Section 1 9 2) (Gilmore et a l , 2006) This is in keeping with 
Seprase having a preference for P2-Glycine However, this group did not investigate the 
effect of Ala-Prop(Oh)2 on Seprase activity Seprase was also found to have a broader 
specificity at the P4, P3, Pi’ and P2’ positions (see section 1 8) (Edosada et a l , 2006a) 
Kinetic analysis o f Seprase using a FRET peptide has shown this peptide to have high 
affinity and kinetic efficiency, indicating that residues in the P4-P4’ region contribute to 
the substrate specificity (see Section 1 8) (Lee et a l , 2005a)
A similar study to that reported in this work, used a P2-Pro-AMCC library and an Ac-P2- 
Pro-AMCC library to identify the peptide motifs for Seprase-selective inhibitor design 
(Edosada et a l , 2006b) With the P2-Pro-AMCC library, Seprase showed a preference 
for lie, Pro and Arg at the P2 position By contrast, the second library Ac-P2-Pro-AMCC 
found Seprase only cleaved Ac-Gly-Pro-AMCC This library is o f similar structure to 
that reported in this research thesis, however, the latter study shows that Seprase has a 
broader specificity at the P2 position The source of Seprase used in these studies may be 
a possible reason for the slight variation in the results The study mentioned used 
recombinantly expressed human Seprase with an N-terminal FLAG tag, whereas our 
study used the novel bovine serum form of Seprase
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These results for Seprase can be compared to DPPIV (Figure 5 1 5), to which Seprase 
shows considerable sequence similarity at 52% (Goldstein et a l , 1997) DPPIV also has 
a preference for Proline in the Pi position However, Alanme is the next most preferred 
residue, albeit with greatly reduced efficiency DPPIV has a highly indiscriminate S2 
subsite, with all residues well tolerated (Leiting et a l , 2003), provided that the terminal 
amino group is protonated (Gilmore et a l , 2006) Inhibitory studies have shown, 
however, that the P2 residue of the inhibitor has an effect on the second order rate 
constant (see Section 1 9 2) (Gilmore et a l , 2006) Detailed comparison o f Seprase and 
DPPIV revealed that the Ala657 residue in Seprase, instead of Asp663 as in DPPIV, 
reduces the acidity m this pocket, and this change could explain the lower affinity for N- 
terminal amines by Seprase (see Figure 1 4 4) (Aertgeerts et a l , 2005) In contrast to 
Seprase, DPPIV has been shown to have a marked preference for a substrate with a free 
N-terminus (Edosada et a l , 2006b)
Pi
DPP-VII ;
K M X F P S T W Y V A R N O E Q G H I L
DPP-II i III
K M X F P S T W Y V A R N D E Q G H I L
DPP-IV
K M X F P S T W Y V A R N D E Q G H I L
Figure 5 1 5  Positional Scanning combinatorial dipeptide library profiles
Positional scanning combinatorial dipeptide library data for recombinant Gly30 DPP-VII, human placenta 
DPP-II and human recombinant DPP-IV Amino acid residues are shown m single letter code X 
represents norleucine (Leiting et a l , 2003)
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5 2 Kinetic Analysis
Kinetic analysis can lead to a better understanding of the mechanism of action of an 
enzyme and the physiological importance of the enzyme m vivo Substrate specificity 
studies by Collins et al (2004) suggest that Seprase has an extended substrate-binding 
region in addition to the primary specificity site, Si It is possible that the substrate 
binding region is comprised of three sites located at the ammo-terminal site (Si, S2, S3) 
and two sites at the carboxyl site from the scissile bond Si’ and S2’ Edosada et al 
(2006a) recently carried out specificity studies (P4 -  P2) on Seprase They designed 
peptides based on the Serpase cleavage site of o-antiplasmin TSGP-NQ They 
determined that Seprase had a high affinity for the peptide ASGP-SS Usmg these 
studies and the results from the combinatonal dipeptide library, peptides were designed 
to fully profile the substrate-binding region o f Seprase
5 2 1 Km Determination for ZrGly-Pro-AMC
The kinetic behaviour o f purified Seprase was mvestigated using Z-Gly-Pro-AMC Km 
values for the hydrolysis of the substrate Z-Gly-Pro-AMC were determined according to 
section 2 8 2 1 The resulting Michaelis-Menten curve for purified Seprase is shown in 
Figure 5 2 1 Data obtained was applied to the Lineweaver-Burk, Eadie-Hofstee and 
Hanes-Woolf kinetic models for analysis (Appendix A) These data were also fitted by 
linear regression using Enzfitter (a non-linear regression data analysis program) From 
these plots, the maximal enzyme velocity (Vmax) and the Michaehs constant (Km) were 
determined, which are given in Table 5 2 1 Also given in Table 5 2 1 is the turnover 
number (kcat) for purified Seprase, which was determined as described in Appendix A 
High catalytic activity and high specificity for substrates, can be described kinetic ally by 
the constants such as kcat and k^t / Km
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[ZrQy-Pro-AMC j (uM)
Figure 5 2 1 Mich aehs-Men ten curve for purified Sep rase
Plot of substrate concentration [Z-Gly-Pro-AMC] (fiM) versus reaction rate, represented by fluorescent 
intensity (FI), for purified Seprase Data obtained by the procedure described in Section 2 8 2 1 Error bars 
shown represent SEM of triplicate readings
1 / [Z-Gly-Pro-AMC] (ulVf1)
Figure 5 2 2 Lineweaver-Burk plot for purified Seprase
Data from Figure 5 2 1 fitted to the Lineweaver-Burk model for the determination of kinetic parameters, 
as outlined in Appendix A Equation and regression are shown Km and Vmax values given in Table 5 2 1 
Error bars shown represent SEM of triplicate readings
170
160 T
0 i 1 11 1 I 11 1 1 I 1 -*- L- 1 I 1 11 I 1 1 ‘ 1 I 1 ‘- 1 ' I 1 1 ' ' i 1 1 1 ' I L 1 1 1 I -1 1 1 1 I 
0 01 02 03 04 05 06 07 08 09 1
n/[Z-Gly-Pro-AMC] (uM *)
Figure 5 2 3 Eadie-Hofstee plot for punfied Sep rase
Data from Figure 5 2 1 fitted to the Eadie-Hofstee model for the determination of kinetic parameters, as 
outlined in Appendix A Equation and regression are shown and values given in Table 5 2 1 
Error bars shown represent SEM of triplicate readings
[ZrGly-Pro-AMC| (uM"1)
Figure 5 2 4 Hanes-Woolf plot for punfied Seprase
Data from Figure 5 2 1 fitted to the Hanes-Woolf model for the determination of kinetic parameters, as 
outlined in Appendix A Equation and regression are shown Km and values given in Table 5 2 1 
Error bars shown represent SEM of triplicate readings
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Lineweaver-
Burk
Eadie-Hofstee Hanes-Woolf Enzfitter Average
K m (fiM) 83 33 79 946 65 100 13 82 10
V ma\ (Units/ml) 125 128 121 95 135 127 49
kcat (sec1) 8 823 9 035 8 608 - 8 822
kcat / K m ( M 's ') 1 06 x 105 1 13 x 105 1 32 x 10s - 1 17 x 10s
Table 5 21  Kinetic parameters for Seprase
Km and V ,^  values obtained from Figures 5 2 2 to 5 2 4 kcat values were determined according to 
Appendix A
The Michaehs-Menten curve (Figure 5 2 1) shows that up to about 80jaM Z-Gly-Pro- 
AMC, the Seprase substrate concentration is limiting to the enzymatic reaction For this 
reason, the standard activity assay used m this work (Section 2 3 2) used lOOjaM Z-Gly- 
Pro-AMC, ensuring a substrate excess A higher concentration of substrate could also 
have been used, but it was deemed unnecessary
The kmetic data in Table 5 2 1 shows that relatively little variance was observed 
between the three kinetic models plotted m Figures 5 2 1 to 5 2 4 and that using 
Enzfitter The average Km determined for purified Seprase was 82 1 O i^M This value is 
~1 5-fold higher than the Km value o f 54^iM reported previously for Seprase by Bimey 
and O’Connor (2001) and ~3 3-fold lower than 270^M reported by Collins et al (2004) 
This work, unlike those mentioned, used the microplate assay (section 2 3 2) to analyse 
these kinetic parameters This led to a decrease in experimental error due to lapses in 
time initiating/terminating each reaction and the subsequent analysis o f samples 
Recently published results for human APCE and Seprase show a Km o f 101 jiM and 
124^iM toward Z-Gly-Pro-AMC respectively (see Table 1 8) (Lee et a l , 2005a) These 
results are on average ~1 4-fold higher than the Km obtained in this study for bovine 
Seprase
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While the Km is independent of enzyme concentration, Vmax is not Since the 
concentration of purified Seprase was known, the turnover number (kcat), the number of 
substrate molecules converted into product by one enzyme molecule per second, could 
be calculated as 8 822s 1 kcat is a measure of the maximum potential catalytic activity o f 
an enzyme The ratio of kcat / Km is the second order rate constant for the reaction o f 
enzyme and substrate to form products Therefore, kaU / Km can be described as a 
specificity constant for an enzyme and provides a measure of how rapidly an enzyme 
can work at low substrate concentration Since an enzyme and substrate cannot combine 
more rapidly than diffusion permits, there is what is called a 'limit o f  efficiency \ an 
upper limit on enzyme catalysis The value of kcat / Km cannot be greater than 1 x 109 s 1 
M 1 Those enzymes that have values that approach the diffusion limit indicate extreme 
efficiency in binding substrate and in converting it to a product Seprase was found to 
have an average kcat / Km ratio of 1 17 x 105 M ]s 1 for cleavage o f Z-Gly-Pro-AMC 
Other groups have reported values of 5 3 x 104 M ls ] and 7 4 x 103 M !s 1 (see Table 1 8) 
(Aertgeerts et a l , 2005, Edosada et a l, 2006a) The substrate Z-Gly-Pro-AMC is 
however, not cleaved by DPPIV (Aertgeerts et a l , 2005)
5 2 2 Competitive inhibition of Seprase by synthetic peptides
A ligand-induced change in the effective value of Km is one way of regulating the 
activity o f an enzyme By measuring the effects of different compounds on Km, it is 
possible to identify physiologically important inhibitors and activators The K iapp values 
obtained in this study will be regarded as the affinity constants of the enzyme Seprase 
for that particular peptide
The competitive influence of selected tn- and tetra-peptide substrates (Table 2 8) on the 
Z-Gly-Pro-AMC degrading activity of Seprase was investigated as described in Section 
2 8 2 2 The resulting data sets were applied to the aforementioned Lineweaver-Burk, 
Eadie-Hofstee and Hanes-Woolf kinetic models for analysis (Appendix A) From these 
plots the apparent Km (Kmapp) and Vmax (Vmaxapp) were determined m the presence of each 
peptide These Kmapp values were used to calculate the dissociation constants (K ,app) as 
outlined in Appendix A, which are given in Table 5 2 2 For example the Kmapp for Z- 
Gly-Met-Phe, calculated from the kinetic model in Figure 5 2 5, was 95 26|iM Usmg 
the formula described in Appendix A the was calculated to be 1247 72^M
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1 / [Zr-dy-Pro-AIVIC] (ulVf‘)
Figure 5.2.5 K \app determination for ZrGly-Met-Phe using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Gly-Met-Phe. Error bars shown represent SEM of triplicate readings.
l/[Z-Qy-Pro-AM C] (ulVf1)
Figure 5.2.6 Kjapp determination for Z-Gly-Pro-Phe using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent K™ (Km*™). Non-inhibited data plotted in blue. Equations 
and regressions are shown. K japp values are given in Table 5.2.2. Plot illustrates the uncompetitive 
inhibition of Seprase by Z-Gly-Pro-Phe. Error bars shown represent SEM of triplicate readings.
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1 /[Z-Gly-Pro-AMC] (uM*1)
Figure 5.2.7 K \ app determination for ZrAla-Pro-Phe using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Ala-Pro-Phe. Error bars shown represent SEM of triplicate readings.
l/[Z-Qy-Pro-AM C] (ulVf1)
Figure 5.2.8 Kiapp determination for Z-Ala-Met-Phe using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the non-competitive 
inhibition of Seprase by Z-Ala-Met-Phe. Error bars shown represent SEM of triplicate readings.
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1 / [ZrQy-Pro-AMC] (ulVf1)
Figure 5.2.9 K*app determination for Z-Ala-Nle-Phe using Lineweaver-Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Km3*515). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kj app values are given in Table 5.2.2. Plot illustrates the uncompetitive 
inhibition of Seprase by Z-Ala-Nle-Phe. Error bars shown represent SEM of triplicate readings.
1/| ZrGly- Pro-A MC1 (ulVT1)
Figure 5.2.10 Ksapp determination for ZrGly-Met-Phe-His using Lineweaver-Burk 
plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Gly-Met-Phe-His. Error bars shown represent SEM of triplicate readings.
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Figure 5.2.11 Kjapp determination for Z-Gly-Nle-Phe-His using Lineweaver-Burk 
plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Km3*515). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Gly-Nle-Phe-His. Error bars shown represent SEM of triplicate readings.
1 /[ ZrGly-Pro-AMCJ (uIVT1)
Figure 5.2.12 Kiapp determination for ZrAla-Pro-Phe-His using Lineweaver-Burk 
plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Ala-Pro-Phe-His. Error bars shown represent SEM of triplicate readings.
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Figure 5.2.13 Kjapp determination for Z-Ala-Nle-Phe-His using Lineweaver-Burk 
plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the mixed inhibition of 
Seprase by Z-Ala-Nle-Phe-His. Error bars shown represent SEM of triplicate readings.
l/[Z-Gly-Pro-AMCJ (u M ')
Figure 5.2.14 Kiapp determination for Z-His-Pro-Phe-His using Lineweaver-Burk 
plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kjapp values are given in Table 5.2.2. Plot illustrates the competitive inhibition 
of Seprase by Z-His-Pro-Phe-His. Error bars shown represent SEM of triplicate readings.
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Figure 5.2.15 Kiapp determination for Ala-Ser-Gly-Pro-Ser-Ser using Lineweaver- 
Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. K japp values are given in Table 5.2.2. Plot illustrates the non-competitive 
inhibition of Seprase by Ala-Ser-Gly-Pro-Ser-Ser. Error bars shown represent SEM of triplicate readings.
Figure 5.2.16 Kiapp determination for Ala-Ser-Nle-Pro-Ser-Ser using Lineweaver- 
Burk plot
Data from peptide competition assays (Section 2.8.2.2) fitted to Lineweaver-Burk model, as outlined in 
Appendix A, for the determination of apparent Km (Kmapp). Non-inhibited data plotted in blue. Equations 
and regressions are shown. Kj app values are given in Table 5.2.2. Plot illustrates the mixed non­
competitive-uncompetitive inhibition of Seprase by Ala-Ser-Nle-Pro-Ser-Ser. Error bars shown represent 
SEM of triplicate readings.
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Peptide Kmapp (jiM)
Lineweaver-Burk Eadie-Hofstee Hanes-Woolf
Average K1app^ M ) V m ax
Average
Inhibition Type
Z-Gly Pro-AMC 83 33 79 946 65 82 10* - 127 49* -
Z-Gly Pro-Phe 200 128 93 120 149 64 243 12 149 17 Uncompetitive
Z-GIy Met-Phe 105 26 90 52 90 95 26 1247 72 136 70 Mixed
Z-Ala-Pro-Phe 111 11 99 523 95 101 87 830 55 130 30 Mixed
Z-Ala-Met-Phe 83 33 75 983 90 83 10 16420 105 26 Non-competitive
Z-AIa-NIe-Phe 181 82 145 31 120 149 04 245 29 206 10 Uncompetitive
Z-Gly-Met-Phe-His 196 08 62 71 94 117 60 462 53 148 Mixed
Z-Gly Nle-Phe-His 178 57 168 9 160 169 16 188 60 202 03 Mixed
Z-Ala-Pro-Phe-His 172 41 136 74 159 156 05 222 04 183 14 Mixed
Z-Ala-Nle-Phe-His 344 82 45 434 159 183 08 162 60 173 08 Mixed
Z-His-Pro-Phe-His 357 14 117 85 125 200 139 27 162 86 Competitive
Ala-Ser-Gly-Pro-Ser-Ser 83 33 - - 83 33 13349 90 90 Non-competitive
Ala-Ser-Nle-Pro-Ser-Ser 250 120 155 7 155 7 223 10 120 16 Mixed
Table 5 2 2 values for selected peptides
Kmapp values obtained from Figures 5 2 5 to 5 2 17 K,app calculated as outlined in Appendix A 
* Average values calculated as per Table 5 2 1
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5 2 2 1 Effect of Tn- and Tetra peptides on Seprase Activity
Using the dipeptide substrate Pi library, results show that Seprase will cleave Pro line 
preferentially over Norleucine and Methionine respectively These residues will 
however fit into the Si site of Seprase The tn-peptide Z-Gly-Pro-Phe was altered using 
these results to see the effect of different conformations of amino acids on the affinity of 
Seprase for the particular peptide Changmg the Pi Proline to Methionine in the peptide 
Z-Gly-X-Phe (X being the substituted amino acid), decreased affinity 5-fold (243 1 2 j i M  
to 1247 72jaM respectively) Methionine is obviously not in the right configuration for 
the binding pocket at this position Methionine, which is non-polar, is larger than Proline 
and it has quite a long side chain which extends away from the a-carbon o f the ammo 
acid This is quite a different configuration compared to that of the pyrrolidine ring of 
Proline While it is a bulky residue and can cause kinks m a polypeptide chain, the Si 
binding site in Seprase is capable of accommodating Prolme
The change from Glycine to Alanine in the peptide Z-X-Pro-Phe affected the affinity by 
decreasing it 5 fold This demonstrates that P2-S2 is also an important site for the 
specificity of Seprase Both amino acids are similar m size and conformation but the 
decrease in affinity is possibly due to the change from a hydrophilic to a hydrophobic 
residue It is possible that the configuration and arrangement that Proline confers on the 
P2 residue places it into close proximity to other residues that may or may not be 
favourable to hydrophobicity This result does show that for this peptide, Seprase has a 
preference for a hydrophilic residue in the P2 position By altering this peptide further, 
changing the Proline to a Methionine (Z-Ala-X-Phe), led to an almost 20 fold decrease 
in affinity This is understandable when it is taken into consideration that Proline is the 
preferred residue in the Si subsite, and the conformation o f Methionine as discussed 
previously The long side cham of Methionine may not allow the P2 Alanme access to 
the S2 subsite, thereby decreasing the affinity constant
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A further alteration to this peptide, substituting Norleucine for Methionine (Z-Ala-X- 
Phe) led to a 67-fold increase in affinity (245 29^M and 16420^M respectively) 
Norleucine also has a long side chain, albeit not as long as Methionine, but it may be the 
orientation of the NH2 group that is having an effect on the affinity of the substrate for 
accessing the binding pocket By substituting Prolrne back into this peptide (Z-Ala-Pro- 
Phe), the affinity constant is decreased 3-fold from 245 29^M to 830 55jiM An 
extension of the peptide Z-Gly-Met-Phe by the addition of a Histidine to the P2’ position 
led to a 2 7-fold increase in the apparent affinity of Seprase for the substrate
Collins et al (2004) found that a 2-fold increase in affinity was observed in going from 
Z-Gly-Pro-Phe to Z-Gly-Pro-Phe-His By adding a charged Histidine residue in the P2 
position the affinity constant, Km decreased from 461 53^M to 206 88fiM, indicating 
increased affinity This study was unable to analyse the peptide Z-Gly-Pro-Phe-His as 
there wasn’t sufficient peptide remaining from the previous study Therefore, in order to 
compare the effect of substituting Proline with Norleucine in the peptide Z-Gly-Pro-Phe- 
His, the K,app values obtained between this study and that o f Collins et al (2004) had to 
be analysed to determine the degree of variation They reported a Km o f 270^M for Z- 
Gly-Pro-AMC which is over 3-fold higher than that obtained from the Enzfitter results 
in this study (82 IO i^M) Comparing the Kiapp results for Z-Gly-Pro-Phe from both 
studies shows that there is a ~2 fold difference (461 53^M and 243 12^iM respectively) 
On average, there seems to be a ~2 5 fold difference between the two studies Collins et 
al (2004) reported a K?w of 206^iM for Z-Gly-Pro-Phe-His Takmg this -2  5-fold 
difference into account, substituting Pro line with Norleucine seemed to lead to a 
decrease in affinity [ (188 60|iM x 2 5 ) = 471 5|iM from 206|iM] This comparison 
comes with a caveat as it is not a direct comparison and it would be advisable to 
determine the K i(app) for both peptides concurrently with the same batch of enzyme
The lowest K,app of 139 27^M was observed with the substitution o f Glycine with 
Histidine in the peptide Z-X-Pro-Phe-His By replacing the P2 residue with Alanine led 
to a decrease in affinity to 222 04|iM This is possibly due to the Proline residue 
restricting the orientation of Alanine, thus not allowing access to the site or causing the
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hydrophobic residue to react unfavourably in the binding pocket (there may be stenc 
clashes between the different residues) It seems that Seprase tolerates a large positively 
charged residue at the P2 position The increased affinity observed by substituting 
Proline with Norleucine m the peptide Z-Ala-X-Phe-His, may be due to Norleucine 
allowing Alanine to have greater access to the binding pocket It is possible that 
Norleucine gives greater flexibility to the peptide than prohne-allowmg for a greater 
tolerance of peptides that may not be as favourable to the Seprase binding pocket
Substitution of Glycine with Alanine at the P2 position of the peptide Z-X-Nle-Phe-His, 
resulted in an increased K,app from 188 60jiM to 162 60[iM The addition of Norleucine 
at the Pi position seems to allow a better tolerance of the hydrophobic residue Alanine at 
the P2 position, as was discussed earlier with other peptides These results concur with 
those from the P2 dipeptide library (Figures 5 1 3 and 5 1 4), in that Seprase shows a 
better tolerance for Alanine than Glycine This does seem to depend however, on the 
ammo acid in the Pi position
By altering the P] position in the peptide Z-Gly-X-Phe-His from Norleucine to 
Methionine the Kiapp increased over 2-fold from 188 60^iM to 462 53(iM This result 
confirms that although the P2 substrate library results show that Seprase can tolerate 
Methionine in the St subsite, the amino acid does not have the correct confirmation for 
the binding pocket and the extended substrate binding region
Edsouda et al (2006a) determined that Seprase had a high affinity for the peptide ASGP- 
SS (Km 4 3^M and kcat/Km 1 3 x 106 M ls !) This peptide was analysed with the bovine 
Seprase along with a second peptide that had Norleucine instead of Glycine at the P2 
position By changing the Glycine residue the K,3^  increased 60-fold, from 13349^iM to 
233 1 OjiM This peptide showed more flexibility and affinity in the binding pocket The 
results from the P2 library (Figure 5 1 3 and 5 1 4) show that Norleucine is the preferred 
ammo acid to Glycine This is shown in the markedly improved affinity constants 
described here Both peptides show competitive inhibition towards the hydrolysis of Z- 
Gly-Pro-AMC by Seprase (Figures 5 2 15 and 5 2 16) The reported results, using the
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dipeptide library, show that the specificity of P2 is not as strict as that reported by 
Edosada in 2006a Their library defined FAP as an endopeptidase of strict Gly-Pro 
cleaving specificity Another group looking at potent irreversible inhibitors of Seprase, 
report that the S2 binding pocket appears to be capable of accommodating a wide variety 
of amino acid residues as our P2 library results suggest (Gilmore et a l , 2006)
It seems from these results and those of Collins et al (2004), that it is necessary for Pj- 
Sj, P2-S2 Pi’-Si’ and P2J-S2’ to be filled for relatively good affinity There was better 
affinity when multiple substrate binding sites were occupied The results do show that 
Seprase did, however, have a lower affinity for these peptides than for Z-Gly-Pro-AMC 
The study of the Pi site shows that it is designed to fit proline but it does tolerate other 
ammo acids as does Prolyl Oligopeptidase, provided they do not exceed the size of the 
Prolines pyrrolidine ring (Edosada et a l , 2006a) I would recommend the analysis of Z- 
Gly-Pro-Phe-His and Z-Ala-Pro-Phe-His with the same batch of enzyme to fully 
determine the P2 preference, when Proline is in the Pi position
Overall, from these results, Seprase shows that it has clear specificity for Proline in the 
Pi position The peptidase has a preference for hydrophobic residues in the P2 position 
and a bulky hydrophobic residue in the P3 position Previous results by Collins et al 
(2004) have shown an evident preference for a hydrophobic residue at the C-terminal 
end o f the scissile bond (PT)
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Chapter 6 
Localisation Studies
Both bovine tissues and mammalian cell culture cell lines were used to determine the 
expression profile for Seprase and PO The result o f which would ascertain the tissue 
of ongm of the two serum Z-Gly-Pro-AMC degrading peptidases and/or establish the 
optimum source for future study o f these enzymes A previous tissue localisation 
study (Bimey and O’Connor, 2001) did not perform as extensive a profile as that 
described here
6 1 1  Bovine Tissue Studies
Bovme tissue samples were obtained from freshly slaughtered cows and prepared as 
outlmed in section 2 9 1 The pellet (P2) and both supernatants (Si and S2) obtained 
from the tissues listed in Table 2 9  1 were analysed quantitatively for enzyme 
activity and protein content as outlmed m section 2 3 3 and 2 1 1 respectively The 
total Z-Gly-Pro-AMC activity present was obtamed m the absence o f the potent 
inhibitor JTP-4819 and PO activity was taken to be the residual non-Seprase activity 
The inner filter effect as discussed m section 2 2 2 was observed with the coloured 
homogenised tissue samples, therefore, filtered AMC standard curves were prepared 
for each tissue extract (Si, S2 and P2)
The Total Activity (Unit) and Specific Activity (Umt/mg) were calculated for each 
tissue fraction accordmg to Appendix A Figures 6 11, 6 12, 6 13 and 6 1 4 
illustrate these calculated activities for Seprase and PO obtamed for each tissue
6 1 Localisation Studies
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Total Activity was calculated according to Appendix A. Error bars shown represent SEM of triplicate 
readings.
Figure 6.1.1 Total Seprase Activity in Bovine Tissue
&
Figure 6.1.2 Specific Activity of Seprase in Bovine Tissue
Specific activity is a ratio of total enzyme activity to total protein and was calculated according to 
Appendix A. Error bars shown represent SEM of triplicate readings
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Figure 6.1.3 Total Prolyl Oligopeptidase Activity in Bovine Tissue
Total Activity was calculated according to Appendix A. Error bars shown represent SEM of triplicate 
readings.
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Figure 6.1.4 Specific Activity of Prolyl Oligopeptidase in Bovine Tissue
Specific activity is a ratio of total enzyme activity to total protein and was calculated according to 
Appendix A. Error bars shown represent SEM of triplicate readings.
Extraction of soluble proteins from animal tissues is relatively straightforward due to 
the weakness o f the cell membranes and the absence o f a cell wall. For all tissue 
samples, the bulk peptidase activity was determined to be in the SI fraction (Figures
6.1.1 and 6.1.3) and, therefore, the focus will be on the specific activities calculated 
in these supernatants.
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Figure 6.1.5 Specific Activity of Seprase in Si Fraction
Error bars shown represent SEM o f triplicate readings.
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Figure 6.1.6 Specific Activity of Prolyl Oligopeptidase in Si Fraction
Error bars shown represent SEM o f triplicate readings.
Figures 6.1.1 and 6.1.5 clearly illustrate the positive identification o f Seprase activity 
in bovine large intestine, serum, kidney, liver and spleen extracts with total activities 
o f 0.92, 0.91, 0.15, 0.1 and 0.07 Units respectively. Figure 6.15 illustrates a reduction 
in the apparent activity o f Seprase in these extracts. This is due to the protein content 
in these extracts. Serum had the highest protein content, followed by liver and the 
spleen (85.19, 23.81 and 15.7 mg respectively). The large intestine contained 7.2 mg
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protein, thereby allowing for quite a high specific activity o f 0 128 units/mg Figures 
6 12  and 6 1 6 illustrate the identification of PO activity in bovine large intestine, 
kidney, spleen, brain, liver and lung with total activities o f 33 22, 25 85, 25 40, 8 19, 
0 1 and 0 06 Units respectively
Using the developed highly specific fluorimetnc microplate assay, both enzymes 
seem to be ubiquitously expressed, although PO to a greater extent These results are 
comparable to those reported by Bimey and O’Connor (2001) Bovine large and 
small mtestme and heart were mcluded m this research study and, as can be seen in 
Figures 6 15 and 6 1 6, the large mtestme has the highest specific activity for both 
Seprase and PO (0 128 umts/mg and 4 61 umts/mg respectively) Although Figure 
6 1 5 shows that the large mtestme has the highest specific activity (0 128 umt/mg) 
o f Seprase, Table 6 1 1 shows that this activity only represents 13% of the total Z- 
Gly-Pro-AMC hydrolysmg activities m the organ The large mtestme reabsorbs water 
and any digested materials which have not already passed into the bloodstream The 
localisation o f Seprase m the large mtestme could mdicate a role for Seprase m the 
digestive system, possibly proteolytically cleaving prohne-contaming peptides or 
protems This is the first report o f Seprase expression in the large mtestme and 
kidney
Tissue
S j Samples
Seprase Activity
%
PO Activity
%
Liver
l 99
Large Intestine
13
1
87
Small Intestine 99
Heart
3 97
Lung
2 98
Brain
1 99
Serum
56 44
Kidney
10 90
Spleen
1 99
Table 6 1 1  Levels of Seprase and PO Activities in Various Bovine Samples
Activities are expressed as a percentage o f the total Z-Gly-Pro-AMC degrading activity (100%)
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In general, Seprase specific activity levels were considerably lower than those for PO 
m the same tissue extracts, except for serum This table shows that serum has the 
highest percentage o f Seprase activity out of all the other tissue samples tested
As mentioned above, Figure 6 1 6 clearly shows that PO activity was most abundant 
m bovme large mtestme extracts The second most abundant source o f PO was the 
bram with 99% of the total Z-Gly-Pro-AMC hydrolysmg activity Bimey and 
O’Connor (2001) found that the bram had 94% PO activity
The large mtestme is certainly a possible source for both Seprase and PO, with high 
specific activities and low protein content Table 6 1 1 also shows that another 
alternative source would be kidney However, extractmg the enzymes from tissues 
mvolves a much more labour intensive process, employing a combmation o f 
mechanical and centrifugal forces
These results correlate well with those reported for Seprase m literature Seprase has 
been shown to be expressed in the liver (Levy et a l , 1999) and also m mtestmal- and 
diffuse-type gastnc carcinomas (Okada et a l , 2003) This could explain the high 
activity levels o f Seprase found m the large mtestme (Okada et a l , 2003)
Bovme bram or kidney would also appear to be good sources o f PO, bemg rich in 
enzyme activity and both are commonly employed m the extraction o f prolyl 
ohgopeptidase (Dehm and Nordwig, 1970, Yoshimoto et a l , 1983)
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Mammalian cell lines were also used to determine the expression profile o f Seprase 
and PO.
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6.1.2 Cell Localisation Studies
Figure 6.1.7 Z-Gly-Pro-AMC Hydrolysing Activity Profile for M am m alian 
Cells
□  Total Z-Gly-Pro-AMC Hydrolysing A ctiv ity  
■  Total Seprase Activ ity
Error bars shown represent SEM o f triplicate readings.
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Figure 6.1.8 Total Seprase Activity in Mammalian Cell Lines
Error bars shown represent SEM o f triplicate readings.
193
Figure 6 1 7 clearly shows that the breast cancer cell lines Hs578T and MDA- 
MB435 SF express Seprase Seprase activity represents 64% and 85% o f the total Z- 
Gly-Pro-AMC hydrolysing activity o f these cell lines, respectively Seprase activity 
has also been identified by others in breast cancer cell lines such as MCF-7 
(Goodman et a l , 2003) This is the first report of Seprase expression m the breast 
cancer cell lines Hs578T and MDA-MB435 SF The cell lines A549 (lung), Chang 
(liver) and SK-N-FI (brain) did not show any Z-Gly-Pro-AMC hydrolysmg activity 
The remamder o f the cell lmes showed varying degrees o f PO activity The breast 
cancer cell line Hs578T shows a high degree o f Seprase activity and, therefore, was 
chosen for use m clonmg the Seprase gene (Section 7 0)
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Chapter 7 
Molecular Cloning of Seprase
The objective o f this work was to clone the Homo sapiens (human) Seprase gene 
from cDNA (Section 2 10 3 1 and 2 10 7 1) and subsequently develop a recombmant 
expression system (Section 2 10 11 and 2 10 12), capable o f producmg catalytically 
active recombmant human Seprase at relatively high levels, which could be purified 
for further biochemical and functional studies
Cell pellets (-1 x 107 cells) o f three human cancer cell lines, MDA-MB-435 SF, 
SW480 and Hs578T (American Type Culture Collection No HTB-129, CCL-228 
and HTB-126 respectively) were a kmd gift from the laboratones o f Dr Rosaleen 
Devery and Dr Susan McDonnell (DCU, Ireland) MDA-MB-435 SF is derived 
from a metastatic ductal adenocarcmoma SW480 was derived from a primary 
adenocarcmoma of the colon Hs578T was derived from a carcinoma of the breast 
The SW480 cells were found to be negative for Seprase activity (0 0007 Units) as 
determined by the method described m Section 2 9 2 In contrast, the MDA-MB-435 
SF and Hs578T cells were found to be positive for Seprase activity (0 97 and 1 76 
Units respectively) Total RNA was isolated from a fresh Hs 578T cell pellet as 
described in Section 2 10 3 1 Figure 7 1 1 shows analysis o f this RNA by agarose 
gel electrophoresis (Section 2 10 4) Sharp, clear 28S and 18S nbosomal RNA 
(rRNA) bands were an indication that the RNA preparation had not been degraded to 
any significant extent
1 2 3
f 2MS 
18S
71.1 Cloning of human Seprase gene
Figure 7 1 1  RNA Analysis
1% agarose gel Lane 1, D N A Ladder, Lane 2, RNA isolated from Hs578T cells (Section 2 10 3 1) 
treated w ith Ribonuclease A  (Section 2 10 7), Lane 3, RNA isolated from Hs578T cells Prominent 
18S and 28S rRNA bands are indicated using arrows
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The sequence for human Seprase mRNA (NM_004460, GI 16933539, Figure 7.1.4) 
was obtained from GenBank. The 2788bp sequence contains a 2283bp open reading 
frame (ORF) for human Seprase. The initial aim o f this work was to clone the 
Seprase gene into pCR2.1, thereby providing a DNA template for further cloning 
applications. cDNA was generated from the Hs578T RNA using the oligo(dT)i5 
primer as described in section 2.10.7.1. The cDNA was used as template for PCR 
(Section 2.10.7.2) using primers i?awHI-Fapl and X/zoI-Fap6 and REDAccu7b# LA 
DNA polymerase. The ZtamHI-Fapl and A7zoI-Fap6 (Table 2.10.2) were designed 
external to this ORF to amplify the Seprase gene (Figure 7.1.4) as a 2366bp 
fragment. The resulting PCR product, analysed by agarose gel electrophoresis (see 
Section 2.10.4), is shown in Figure 7.1.2 (A). A relatively faint band corresponding 
to the expected size o f 2366bp was obtained. Some non-specific bands were also 
present. Several attempts were made to increase the specificity o f  the PCR and 
eliminate these bands by increasing the annealing temperature during the PCR 
reaction (see Figure 7.1.2. (A)). However, these attempts proved unsuccessful. The 
PCR Optimisation Kit (Sigma) containing PCR buffers with varying pH and Mg++ 
concentrations were used to further enhance the PCR. It was found that Buffer G o f 
the kit increased the amount o f PCR product formed although it was unable to 
increase the primer specificity, leading to the production o f non-specific bands 
(Figure 7.1.2 (B)).
A 1 2 3 4 5 6 7 8 9  10 11 B 1 2 3 4 5
Figure 7.1.2 Cloning of human Seprase gene
0.7% agarose gels. (A ) Lane 1, DNA Ladder; Lane 2-11, temperature gradient products o f  RT-PCR on 
Hs578T RNA using primers ZtawHI-FAPl, A7joI-FAP6, REDAccuTa# LA  for temperatures 52.1°C, 
52.5°C, 53.3°C, 54.7°C, 56.4°C, 58.4°C, 60.3°C,62.3°C, 64.6°C, 66.0°C. (B) Lane 1, DNA Ladder; 
Lane 2-5, products o f RT-PCR on Hs578T RNA using primers ¿tawHI-FAPl, A7wI-FAP6 
REDAccu7a<7 L A  and Buffer G (2.5mM M gC^). Annealing temperatures used were 54.6°C, 53.4°C, 
52.5°C and 52.1°C respectively. A  red arrow indicates the band corresponding to the expected 2344bp 
Seprase gene product, while a black arrow indicates non-specific bands.
12,000bp
2.000bp
l,650bp
l.OOObp
850bp
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Figure 7 13  Control PCR Reactions
Control RT-PCR reactions performed on Hs578T RNA using (A) /3-actin primers jS-actin For and &- 
actm Rev (Table 2 10 2), yielded 360bp product, (B) Fap3 and Fap4 pnmers yielded the 836bp 
fragment o f Seprase Control reactions were performed on all PCR reactions (Section 2 10 7 1) to 
determine that it was successful in making good quality cDNA
The PCR products shown in Figure 7 1 2 (B) were extracted from the gel accordmg 
to Section 2 10 3 3 1, restricted with the respective enzymes (Section 2 10 7), and 
cloned mto the clonmg vector pCR2 1 as described m Section 2 10 8 2 Several white 
colonies were purified and plasmid DNA was isolated (Section 2 10 3 2 1) 
Screenmg for a clone having the desired ~2366bp recombmant Seprase insert, was 
carried out by enzymatic restriction analysis with EcoR\ (Section 2 10 7) The site 
for the insertion o f PCR products in the pCR2 1 vector is bounded by EcoRl sites 
that function as diagnostic restriction sites The clones were found to contain a 
smaller fragment than the ~2366bp expected fragment
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9 1 1 1 6 9 3 3 5 3  :  A A T T C A A G T G T A T G G T G G T C C C T G C A G T C A G A G T G T A A G G T C T G T A T T T G C T G T T A A T T G G A T A T C T T A T C T T G C A A G T A A G G A A G G G A T G G T C A T T G C C T  :  1 9 1 9
9 1 1 1 6 9 3 3 5 3  :  T G C T G G A T G G T C G A G G A A C A G C T T T C C A A C C T G A C A A A C T C C T C T A T G C A G T G T A T C G A A A G C T G G G T G T T T A T G A A G T T C A A G A C C A G A T T A C A G C T G T C  :  2 0 2 0"v----------------------F«p4
9 1  |  1 6 9 3 3 5 3  :  A G A A A A T T C A T A G A A A T G G G T T T C A T T G A T U A A A A A A G A A T A & C C A T A T G & G C C T G G T C C T A T G G A C C A T A C G T T T C A T C A C T C C C C C T T C C A T C T G G A A C  :  2 1 2 1
9 1 1 1 6 9 3 3 5 3  :  T G G T C T T T T C A A A T G T G G T A T A G C A G T G G C T C C A C T C T C C A G C T G G C A A T A T T A C G C G T C T G T C T A C A C A & A G A G A T T C A T C G G T C T C C C A A C A A A C C A T G  :  2 2 2 2
9 1  I  1 6 9 3 3 5 3  :  A T A A T C T T C A C C A C T A T A A G A A T T C A A C T G T C A T C C C A A C A G C A C A A T A T T T C A G A A A T G T A G A C T A T C T T C T C A T C C A C G C A A C A G C A G A T G A T A A T G T C  :  2 3 2 3
9 1 1 1 6 9 3 3 5 3  :  C A C T T T C A A A A C T C A G C A C A C A T T G C T A A A C C T C T C C T T A A T C C A C A A C T C C A T T T C C A C C C A A T G T G C T A C T C T G A C C A G A A C C A C G G C T T A T C C G C C C T  :  2 4 2 4
9 1 1 1 6 9 3 3 5 3  :  C T C C A C G A A C C A C T T A T A C A C C C A C A T C A C C C A C T T C C T A A A C C A C T C T T T C T C T T T G T C A G A C T A A A A A C G A T G C A G A T C C A A G C C T C T A T C A C * - * - T C T C  :  2 5 2 5
^  FapS F«p6
g i  I  1 6 9 3 3 5 3  :  A A A A C C T T A T A T A A A C C C C T C A G A C A G T T T G C T T A T T T T A T T T T T T A T G T T G T A A A A T G C T A G T A T A A A C A A A C A A A T T A A T G T T G T T C T A A A G G C T G T T A  :  2 6 2 6
9 1 1 1 6 9 3 3 5 3  :  A A A A A A A G A T G A G G A C T C A G A A G T T C A A G C T A A A T A T T G T T T A C A T T T T C T G G T A C T C T G T G A A A & A A G A G A A A A G G G A G T C A T G C A T T T T G C T T T G G A C A  :  2 7 2 7  
9 1 1 1 6 9 3 3 5 3  :  C A G T G T T T T A T C A C C T G T T C A T T T G A A G A A A A A T A A T A A A G T C A G A A G T T C A A A A A A A A A A  :  2 7 8 8
Figure 7.1.4 Human Seprase mRNA sequence
Nucleotide sequence GI 16933539: human Seprase mRNA. ORF is highlighted in blue. Binding 
locations o f  primers are indicated. C la l recognition site indicated in red. Illustrated using GenDoc 
(Section 2.10.10).
1 9 9
Variations o f different forward and reverse primers were used for RT-PCR reactions 
to try and amplify the full Seprase gene. These were unsuccessful (possibly due to 
the large size o f the gene) and therefore it was decided to clone the Seprase gene in 
two parts.
The Seprase gene has a unique Clal recognition site at 800bp from the start codon. 
Primers were designed to amplify Seprase in two parts. Figure 7.1.5 (A) illustrates 
the strategy employed. The Seprase gene was amplified using REDAccu7flg LA and 
the products formed were run on an agarose gel (Figure 7.1.5 (B)). The PCR 
products were concentrated using the method described in Section 2.10.3.4 and 
restricted with the respective endonuclease restriction enzymes according to Section 
2.10.7. The vector pCR2.1 (Figure 2.10.1) was restricted using BamHl and Xhol and 
treated using Antarctic Phosphatase (Section 2.10.8.1). The two restricted inserts 
were ligated with the treated vector and transformed into the E. coli strain XL-10 
Gold according to Section 2.10.5.2. A candidate clone (pPOBl) was identified and 
further analysed by PCR using BamH\-¥apl and A7zoI-Fap8 (Table 2.10.2). A band 
corresponding to the expected 2283bp recombinant Seprase (rSeprase) gene product 
was obtained, as shown in Figure 7.1.5. C.
1 2 3 1 2
Seprase Gene
flo/wHI-Fap7 C/aI-Fap9 C/al-Fap 10 A7ioI-Fap8
flij/wHIFap7-(7aIFap9 C/ii I Fap 10-AV/o I Fap8
820bp 1515bp
1515bp 
820bp
Figure 7.1.5 The Cloning of rSeprase in two parts strategy
The Seprase gene was cloned into the vector pCR2.1 in two parts utilising the unique C la l recognition 
site in the gene (at 800bp) and amplification strategy in (A). RT-PCR was performed on RNA isolated 
from Hs578T. PCR was performed on this cDNA using REDAccu7a^ LA  DNA polymerase and the 
products visualised on a 1% agarose gel (B). Lane 2 shows the 820bp fragment (blue) and Lane 3 
shows the 1515bp fragment (green). (C) 0.7% agarose gel; Lane 1: DNA Ladder; Lane 2; product o f  
PCR on pPOB5 using primers 5amHI-Fap7 and A7zoI-Fap8 (Table 2.10.2). The band corresponding to 
the expected 2283bp Seprase gene product is indicated by the red arrow.
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A restriction digest o f this clone (pPOBl) analysed by agarose gel electrophoresis is 
shown in Figure 7 1 6 Restriction with BamHi and Xhol produces a band 
corresponding to the expected 2283bp fragment containing the rSeprase sequence 
Single restriction with BamHl, Xhol and EcoRl produced bands corresponding to the 
expected 6132pb linearised plasmid Restriction with Hind\\\ produced bands 
corresponding to the expected 424bp and 5708bp Restnction with Pstl produced 
bands corresponding to the expected 2947bp, 1765bp and 1420bp The sequence o f 
pPOBl was confirmed by DNA sequencing (Section 2 10 10) The sequencing data 
is given m Figure 7 1 8 A map of pPOBl is shown m Figure 7 17
1 2 3 4 5 6 7 8  1 2 3 4 5 6 7 8
Figure 7 1 6  Verification Digest of pPOBl
Restriction digest o f pPOBl analysed on 1% agarose gel (A) Lane 1, lkb DNA ladder, Lane2, 
pPOBl uncut, Lane 3, BamHi, Lane 4, Xhol, Lane 5, EcoRl, Lane 6, Hindlll, Lane 7, Pstl, Lane 8, 
BamHi and ücoRI (B) Lane 1, lk b  D N A ladder, Lane 2, pPOBl cut w ith BamHl, Lane 3, pPOB5 cut 
w ith Xhol, Lane 4, pPOBl cut with BamHi & Xhol, Lane 5, pPOBl cut w ith BamHi & Clal, Lane 6, 
pPOB5 cut w ith Clal & Xhol, Lane 7, PCR fragment i?flf/HFQ-Fap7--CZaI-Fap9, Lane 8, PCR fragment 
C/al-Fap 10—A7zoI-Fap8
<— 1515 bp 
<— 820bp
<— pCR2 I ■<— vSeprase
A B
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Hiiidm 235
Xliol 2536
Figure 7.1.7 pPOBl Plasmid Map
The rSeprase gene fragment (blue) is inserted into the vector pCR2.1. The la c Z a  ORF (green) is 
under the control o f the lac promoter (yellow). Am picillin  and Kanamycin resistance genes (ampK &  
kanR) are shown in red. Generated by pDRAW32 (Section 2.10.10).
Figure 7.1.8 illustrates the alignment of pPOBl with the FAP/Seprase mRNA 
sequence GI 16933539. The alignment illustrates a frame shift mutation at the 3’ end 
o f the rSeprase sequence, thereby altering the codon sequence and the last 3 amino 
acids.
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V i  I 1 6 9 3 3 5 3  A TGAACAC TTGGCTAAAAATCCTXTTT C - C A C T T  GC CAC CTC T GC T GTCC T  T GC CT T A T TGCT C - A T GT& CATTCTCTTACGCCCTTCAACACItCAT A A C t c  10
t> J> OB 1  AT GAAGAC T T GCGTAAAAAT C CTAT T T C-CACI ItC CA UC TCICC TCICC TTC-C C TTAT TC CI CAT G-T CCATTCT C T TAC G-CCCTT CAACACTTCATAJkC T C 1 0
I I S 9 3 S Í 3  r«iLÍ«JUAJi.TACAjkTCAM,ClCA.CTCACAgTCAACCA.Ii.TTTTAAJLTC;CAJlCATTTTgTTATjUÜUlC*TTTTTTCCAAACTCCJlTtTCA.IÍCJk.CJUlCJU.TJlTC 20
p p g B l  TGAAGAAAATACAATGAGAGCACTCACACTGAAGCATATTTTAAATGGAACATTTTCTTATAAAACATTTTTTCCAAACTCCATTTCAGCACAAGAATATC Z O
9 Í I 1 6 9 3 3 5 3  XICATCAAT C T CCACATAACAATATACTACTT TAIAATAT T CAAACACCACAA.I CATATA C C ATT T T GAGT AATACAAC CAT CAAAA&T GT CAA TCCTTCA 3 0
p P D S l  T T CAT CAATC T  CC ACATAACAATATACT AC TT TAT AATAT T  CAAACACCACAAICATATAC C ATT T T GAGT AATACAAC C JlT CAAAAGT GT GAAT GCTTCA 3 0
Hi. I 1 6 9 3 3 5 3  AATTACGGCTTATCACCTCATCGGCAATTTGTATATCTACAAACTCATTATTCAAAGCTTTGGACATACTCTTACACAGCAACATATTACATCTATGACCT 4 0pPOBJ. AATTAC GGC T TAT CACCT GAT C CCCAAT T T CT A TA TC TA C A M C I CAT TAT T C AAACC TTT GCACATACT C T TAC AC AGC AAC AT AT T ACATC TAT CAC C T 4 0
g i  I 1 6 9 3 3 6 3  TAGCAATCCACAATTTGTAACACCAAATCACGTTCC TCGTCCAATTCACTATTTATGCTCCTCCCCTCTT&CCAGTAAATTAUCATATGTCTATCAAAACA 6 0
p p OS 1 T AGCAAT GGACAAT T TCTAACACCAAAICACC TTCCTCCTC CAAT TCACTATT TATCCT GGT CCCCTGTT &CCACIAAAT TAGCATAT GT C TAT C AAAACA 5 O
w± I 1 6 9 3 3 6 3  ATATCTATTTCAAACAAAGACCACGACATCCACCTTTTCAAATAACATTTAATGCAAGAGAAAATAAAATATTTAATGGAATCCCAGACTGGGTTTATCAA 6 0
p P O B l ATATCTATTTGAAACAAA&ACCACGACATCCACCTTTTCAAATAACATTTAATCGAACACAAAATAAAATATTTAATGGAa TCCCAGACTCGCTTT ATCAA 6 0
O I | 1 6 9 3 3 5 3  G A G G A A A T G C T T C C T A C A A A A T A T G C T C T C T G C T G G T C T C C T A A T C C A A A A T T T T T G G C A T A T C C G C A A T T T A A T C A T A C G G A T A T A C C A C T T A T T G C C T A  7 0P P O S 1  GACCAAAT GC TTCC TACAAAATAT GC T C TC H rC T tC T  CT C C TAAT GGJLAAAT T T TTGGCAT AT CC CCAAT T TAAT GAT AC CCATATAC CACT TAT T GC C T A  7 0
g l  I 1 6 9 3 3 5 3  TTCCTATTATGCCGATCAACAATATCCTAGAACAATAAATATTCCATACCCAAAGGCTGGAGCTAAGAATCCCGTTGTTCIGOATATTTATTATCCATACCA 8 01
p P O S l  TTCCTATTATGCCCATGAACAATATCCTAGAACAATAAATATTCCATACCCAAAGGCTGGAGCTAACAATCCCGTTGTTCCGATATTTATTATCGATACCA 8 01
g j .  1 1 6 9 3 3 5 3  C T T A C C C T G C G T A T C T A G C T C c e C A G G A A G T G C C T G T T C C A C C A A T G A T A C C C T e A A G T G A T T A T T A T T T C A C T T G G C T C A C C T C C G T T A C T C A T G A A C G A  9 0
pPQSl C T T A C C C T G C G T A T G T A G G T C C C C A G G A A G T G C C T G T T C C A G C A A T G A T A G C C T C A A G T G A T T A T T A T T T C A G T T G G C T C A C C T G C C T T A C T G A T C A A C G A  9 0
|  1 6 9 3 3 6 3  G T A T e T T T G C A C T C G C T A A A A A G A G T C C A G A A T G T T T C C G T C C T C T r T A T A T C T C A C T r C A G C C A A G A C T G G C A G A C A T G G G A T T C T C C A A A G A C C C A G G A  1 0 1
p P D B l  G T A T G T T T C C A G T G G C T A A A A A G A G T C G A C A A T G T T T C C G T C C T O T C T A T A T G T C A C T T C A G C G A A G A C T G G C A G A C A T G G G A T T G T C C A A A G A C C C A G C A  1 Q X
9 ±  |  1 É 9 3 3 S 3  GCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAACACCAGTTTTCAGCTATGATGCCATTTCGTACTACAAAATATTTAGTGACA 1 1 1
p P O B l GCATATAGAAGAAAGCAGAACTGGAT g g g c t g g t g g a t t c t t t  g t t t c a a c a c c a g t t t t c a g c t a t g a t g c c a t t  t c g t a c t ACAAAATATT t a c t  c a c a  1 1 1 .
g ±  1 1 6 9 3 3 5 3  AGGATGGCT AC AAACATAT TCACT AT AT CAAAGACAC TGTGGAAAATGCTATT C AAAT TAC AAGT GGCAAGTGGGACGC CAT AAAT AT ATTCAGAGT AACA 1 2 1
P  p O B  1 ACGAT GGC TAC AAACATAT T CACTAT AT CAAAGACAC TCT GCAAAATGC TAT T C AAAT TAC AAGT GGCAAGTCCGAC GC C AT AAAT AT AT T CAGAGT AACA 1 2 1 !
g i  I 1 6 9 3 3 5 3  CAGGATTCACTGTTTTATTCTAGCAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGCAAGCTATCCTCCAACCAAGAAGTG 1 3 1 :
p P D B l CACCATTCACTGTTTTATTCTACCAATGAATTTGAAGAATACCCTCCAAGAAGAAACATCTACACAATTACCATTCGAAGCTATCCTCCAAGCAAGAACTG 1 3 1 :
g i  | 1 6  9 3 3 5 3  TGTTACTTGCCATCTAAGGAAAGAAA&GTGCCAATATTACACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCeCAGGCATCC 1 4 1
p P O B l T GT TAC T T GC C AT C T AAGGAAAC AAAGGTGC C AATAT TAC AC AGC AAGT T T C AGCGAC TACGC CAAGTACT ATGCACTTGTCTGC TAC GCC C C ACGC AT C C 1 4 1
Cf± | 1 6 9 3 3 5 3  CCATTTCCACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTGGAAGAAAACAAGGAATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTAAA 1 5 1
p P O B l CCATTTCCACCCTTCATCATGGACGCACTGATCAAGAAATTAAAATCCTGCAACAAAACAAGGAATTCCAAAATGCTTTCAAAAATATCCACCTGCCTAAA 1 £ 1
I 1 6 9 3 3 5 3  GAGCAAATTAAGAAACTT GAAGTAGAT GAAAT TACT TTATGGTACAAGATGAT TCTTCC TCCT CAATTTGACAGATCAAAGAAGTATCCCTTGCT AATTCA 1 6 1p P O B l GAGGAAAT TAAGAAACTTGAAGTAGAT GAAAT TACT TTATGCTACAAGATGAT T CTTC C TCCTCAATTTGACAGATCAAAGAACTATCCCTTGCT AATTCA 1 6 1
g ±  | 1 6 9 3 3 5 3  AGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCTGTATTTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTGGTGG 1 7 1
p P O B l AGTCTATCGTCCTCCCTGCAGTCAGAGTGTAAGGTCTGTATTTCCTGTTAATTGGATATCTTATCTTCCAAGTAACGAAGGGATGGTCATTGCCTTGCTCG 1 7 1
ga. 1 1 6 9 3 3 5 3  ATCCTCGAGGAACACCT T T CCAACCT GACAAACTC CTCTATGCAGTGTATCGAAACCT GCCTCTTTATCAAGTT GAAGAC CAGAT TACACCTCTCACJlAAA 1 B 1
p P O B l a t g g t c g a g g a a c a g c t t t c c a a g g t c a c a a a c t c c t c t a t g c a g t g t a t c g a a a g c t g g g t g t t t a t g a a g t t g a a g a c c a g a t t a c a g c t g t c a g a a a a  101
<s± I 1 6 9 3 3 5 3  TTCATACAAATCCCTITCATTCATBAAAAAACAATA&CCATATC&COCTOOTCCTATCCASCATACCTTTCATCACTO&CCCTTCgATCTCCAACTWTCT 1 9 1 .p p p B i  t  t  c a t a g a a a t  c c c t  t  t c a t t c j l t  g a a a a a a  c a a t  a c c  c a t a t  c c c g c t g g t  c  c  t  a t  g g a g - g a t a c  g t  t  t  c  a t  c a c  t  g c c  c  c  t  t  g c a t  c  t  c c a a c t  c c t  c  t  i  9  i
<a± l 1 6 9 3 3 5 3  TTTCAAATGTGGTATACCAGTGGCTCCAGTCTCCAGCTGCGAATATTACGCGTCTCTCTACACACAGAGATTCATCGGTCTCCCAACAAACGATGATAATC 2 0 2p P D B l  T T  TCAAAT GT GGTATAGC ACT GGC T C CAGTCT C CAGC TGGGAAT ATTAC GC GT C TGTC TAC ACAGAGAGAT T  CATCGCT C T C C CAAC AAAGGA T GATAAT C 2 0 2
i 1693353 t t g a g c a c t a t a a g a a t t c a a c t g t g a t c c c a a g a g c a g a a t a t t t c a g a a a t g t a c a c t a t c t t c t c a t c c a c g g a a c a g c a g a t g a t a a t g t g c a c t t t  2. 1 2 .
p P O B i t t g a g c a c t a t a a g a a t t c a a c t g t g a t g g c a a g a g c a g a a t a t t t c a g a a a t g t a g a c t a t c t t c t c a t c c a c g g a a c a g c a g a t g a t a a t g t g c a c t t t  2 1 2
c f i  1 1 6 9 3 3 5 3  CAAAACTCAGCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCTGACCAGAACCACGGCTTATCCGGCCTGTCCAC 2 2 2
p P O B l c a a a a c t c a g c a c a g a t t g c t a a a c c t c t c g t t a a t c c a c a a g t g g a t t t c c a c g c a a t c t g g t a c t c t g a c c a g a a c c a c g g c t t a t c c c g c c t g t c c a c  222
|  1 6  9  3 3 5 3  C A A C  C A C  T  T  A T  A C  A C  C  C A C A T C A C  C C A C T T C C  T A A A G C A G T  G T  T  T  C  T C T  T | i j | d i i Ü ¿ U u Ü £  2 2 0 3
Figure 7 1 8  DNA Sequencing of pPOBl
Sequence o f pPOBl aligned w ith that o f Seprase (GI 16933539) The alignment illustrates a frame 
shift at the 3 ’ end o f the sequence (highlighted m grey) Illustrated using GenDoc (Section 2 10 10)
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While analysing the pPOBl sequence (Figure 7 1 8), the cloned gene product was 
aligned with various FAP/Seprase published sequences, which led to some 
mterestmg observations Analysis o f the various published FAP/Seprase mRNA 
sequences displayed differences between them at the mRNA levels
Figure 7 1 9 illustrates the differences at mRNA level between FAP (GI 16933539 
and GI 1888315) and Seprase (GI 1924981) A total o f 5 base changes were 
observed at mRNA level (see Figure 7 1 9 (A)), two of which conserved the ammo 
acid residues at the protem level (see Figure 7 1 9 (B), marked *) The remaining 3 
base changes altered Ala207-Pro207, Tyr229-Lys229 and Tyr354-Arg354 (marked as 1, 2, 3 
respectively m Figure 7 1 9) The addition of Pro line at position 207 does not change 
the hydrophobic nature o f that position but it would cause a ‘kink’ m the sequence, 
possibly altering the tertiary structure o f the protem Proline is also a larger ammo 
acid than Alanme Tyrosine was replaced by the smaller charged residue Lysme 
Tyrosine altered to Arginine led to the addition o f a much larger and charged residue 
at position 354 The long extended side chams of Lysme and Arginine obviously do 
not hmder the folding or the activity o f the protem This can also be said for the 
addition o f Prohne207 Obviously adding a ‘kink’ m the sequence at that position does 
not hmder the folding or the activity o f Seprase
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A
*
9 1 1 1 6 9 3 3 5 3  T T C A T C A A T C T G C A G A T A A C A A T A T A G T A C T T T A T A A T A T T C A A A C A G g J c A A T C A T A T A C C A T T T T G A G T A A T A G A A C C A T G A A A A G T C T G A A T G C T T C A  3 0 3
g i  119 2 4 9 8 1  t t c a t c a a t c t g c a g a t a a c a a t a t a g t a c t t t a t a a t a t t g a a a c a g g S c a a t c a t a t a c c a t t t t g a g t a a t a c a a c c a t g a a a a c t & t g a a t g c t t c a  3 0 3
g i I 1 8 8 8 3 1 5  T T C A T C A A T C T G C A G A T A A C A A T A T A G T A C T T T A T A A T A T T G A A A C A C G A C A A T C A T A T A C C A T T T T G A G T A A T A G A A C C A T G A A A A G T G T G A A T G C T T C A  3 0 3
g i .  1 1 6 9 3 3 5 3  
9 1 1 1 9 2 4 9 8 1  
g i  1 1 8 8 8 3 1 5
g i | 1 6 9 3 3 5 3  
g i 1 1 9 2 4 9 8 1  
g i  1 1 8 0 8 3 1 5
7 0 7
7 0 7
7 0 7
1 2
g a g g a a a t  g c  t  t § c  t a c a a a a t a t  g c  t  c  t  c  t  g  g t  g g t  c  t  c  c  t  a a t g g a a a a t  t  t  t  t  g  g c  a t a t  g  c  g g a a t t t a a t  g a t  a S g g a t a t a c c a g t t a t t g c c t a  
G A G G A A A T G C T I & C T A C A A A A T A T G C T C T C T G G T G G T C T C C I A A T G G A A A A T T T T T G G C A T A T G C G G A A T T T A A T G A T A C G G A T A T A C C A G I T A T T & C C T A
g a g g a a a t g c t t S c t a c a a a a t a t g c t c t c t g g t g g t c t c c t a a t g g a a a a t t t t t g g c a t a t g c g g a a t t t a a t g a t a S & g a t a t a c c a g t t a t t g c c t a
G C  A T  A T  A G A A G A A A G C  A G A A C  T G G A T G G G C T G G T G G A T T C T T T G T T T  C  A f c j j A C  C A G T T T T C A G C T A T G A T G C C A T T T C G T A C T A C  A A A A T  A T T T A G T G A C A  1 1 1 1
G C A T A T A G A A G A A A G C A G A A C  T  G G A T G G G C  T  G G I G G A T  T C T  T T  G T  T  T C A A C A C  C A G T T T  T  C A G C T A T  G A T G C  C A T T  T  C  G T A C  T A C A A A A T A T  T  T A G T G A C A  1 1 1 1
G  C A T  A T  A  G A A G A A A G C A G A A C  T  G G A T  G G G C  T  G G  T  G G A T  T  C  T  T  T  G T  T  T  C A A ^ A C  C A C T T T T C A G C T A T G A T G C C A T T T C G T A C  T  A C  A A A A T  A T T T A G T G A C A  1 1 1 1
g i | 1 6 9 3 3 5 3  C a H a A C T C A G C A C A G A T T C C T A A A G C T C T G G T T A A T C C A C A A G T C C A T T T C C A G G C A A T G T G G T A C T C T G A C C A G A A C C A C G G C T T A T C C G G C C T G T C C A C  2 2 2 2
g i 1 1 9 2 4 9 8 1  C  A g A A C T C A G C A C A G A T T  G C T A A A G C T C T G G I T A A T G C A C A A G T G G A T T T C C A G G C A A T G T G G T A C T C I G A C C A G A A C C A C G G C T T A T C C G G C C T G T C C A C  2 2 2 2
g i  1 1 8 8 8 3 1 5  C A A A A C T C A G C A C A G A T T G C T A A A G C T C T G G T T A A T C C A C A A G T G G A T T T C C A G G C A A T G T G G T A C T C T G A C C A G A A C C A C G G C T T A T C C G G C C T G T C C A C  2 2 2 2
B
1 2
gi1 1 6 9 3 3 5 3  B E M L S t K Y A L B W S  P N G K F L A Y A B  FMD^DI P V I A Y S Y Y G D  E Q Y P R T I H I P Y P K A G A K H P W R I F I I D  T  T Y P A Y V G P Q E V P V P A M I A S  S D Y Y F  S U L T W V T D K  R  303
gi1 1 9 2 4 9 8 1  2 E H L A T K Y A L H U S  P H G K 7  L A Y A E F H D T D I P V I A Y S Y Y G D  B Q  Y P R T I H I P Y P K A G A K H P W R I  F I I D  T  T Y P A Y V G P  Q B V P V P A M I A S S D Y Y F S W L T W V T D B  R  303
gi 1 1 8 8 8 3 1 5  B E H L Q T K Y A L W U S P H G K F L A Y A E F H D j D I P V I A Y S Y Y & D B Q Y P R T I H I P Y P K A G A K H P W R I F I i r i T T Y P A Y V & P Q B V P V P A H I A S S D Y Y y S U L T W V T D B R  303
3
g i 11693353 VC L Q V L K R V Q N V S V L S I CD F RKDWQ TTODC PKTQ EHI B  E  S RT GWAGCF F V S ^ P V F S Y D A I S Y Y K I F  S D K D C Y K H I H Y I K D T V E N A I Q I TS G K U K A I N I F R V T  404
gi 11924981 VCL Q l i T L K R V Q N V S V L S  I C D F R K D W Q T WDCPKTQEHIBBSRTGWAGGF F V S T P V F S Y D A I S Y Y K I F SDKDCYKHIHYIi® T V B N A I QI T S G K W B A I N I F R V T  404
gi 11888315 V C L Q W L K R V O i r V S V L S I C D F R E D U Q T W D C P K T Q B H I B I S R T G W A G C F F V s g p V F S Y D A I S Y Y K l F S D K D G Y K H I H Y I K D T V K H A I Q I T S G K H S A I W I F R V T  404
Figure 7 19  Alignments of Sequences
(A) Seprase (GI 1924981) and F A P  mRNA (GI 16933539 and GI 1888315) sequences aligned This 
Figure illustrates the 5 altered bases between the sequences (shaded m grey) (B) The respective 
Seprase and FAP protein sequences for the mRNA sequences indicated in (A) are aligned The two 
base changes seen m Seprase GI 1924981 (marked *) conserved the amino acid residues o f FAP (GI 
16933539) The 3 base changes observed in GI 1888315 (marked 1, 2, 3) however altered the ammo 
acid sequence Illustrated usmg GenDoc (Section 2 10 10)
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A new high fidelity polymerase called Phusion High-Fidelity DNA Polymerase was 
supplied by NEB This polymerase generates PCR products with accuracy and speed 
even on more difficult and long templates, such as Seprase The error rate o f Phusion 
DNA polymerase is 50 fold lower than that o f Thermits aquaticus DNA polymerase 
The use o f Phusion also has the added advantage o f reduced extension and cycling 
times
Phusion DNA Polymerase, instead of REDAccuTai/ LA, was therefore employed to 
clone the Seprase gene, as the PCR and cloning strategy to date illustrated the 
difficulty o f the DNA template Clonmg strategies were developed for clonmg the 
Seprase gene into (1) pcDNA3, (2) pcDNA3-HA and (3) pQE30-Xa (Figures 2 10 3 
and 2 10 2 respectively) A further clonmg strategy was developed for clonmg the 
Seprase gene into pIRES-hrGFP II (Figure 2 10 4)
7 1 2  Cloning of human Seprase gene into pcDNA3 and pcDNA3-HA
The mammalian expression vectors pcDNA3 and pcDNA3-HA (Table 2 10 3 and 
Figure 2 10 3) were chosen to clone and express the Seprase gene Both vectors were 
restricted with BamHl and Xhol, treated with Antarctic Phosphatase accordmg to 
Section 2 10 8 1 and concentrated accordmg to Section 2 10 3 4 cDNA was 
generated from the Hs578T RNA usmg the ohgo(dT)i5 pnmer as described m section 
2 10 7 1 The primers BamHl-A-Fapl (5’ end o f the gene) and XAoI-Fap8 (3’ end o f 
the gene) were designed to amplify the full length Seprase gene (see Figure 7 1 4 and 
Table 2 10 2) in order to clone it into pcDNA3/pcDNA3-HA vectors The Seprase 
gene was amplified usmg this cDNA as a template for PCR with Phusion DNA 
Polymerase (Section 2 10 7 2) and the primers BamHl^A-Fapl and Xhol-Fzp$ The 
products formed were run on an agarose gel (Figure 7 1 9 (B)) The PCR products 
were concentrated usmg the method described m Section 2 10 3 4 and restncted with 
the respective endonuclease restriction enzymes (BamHl and XhoY) accordmg to 
Section 2 10 7 The restncted PCR fragments were then ligated with the treated 
pcDNA3/pcDNA3-HA vector and transformed accordmg to 2 10 5 2, into the E coli 
strain XL-10 Gold
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Clones were screened according to Section 2 10 3 2 1 and a candidate clone was 
further analysed by restnction analyseis A restriction digest o f this clone (pPOB12) 
analysed by agarose gel electrophoresis is shown in Figure 7 110 Restnction with 
BamHl and Xhol produces a band corresponding to the expected 2283bp fragment 
contammg the rSeprase (recombinant Seprase) sequence Smgle restriction with 
BamHl and EcoRl produced bands corresponding to the expected 7692pb linearised 
plasmid Restnction with Pstl produced bands corresponding to the expected 
1420bp,
2007bp and 3983bp There also seems to be some uncut and partially cut vector 
DNA m Lane 7 (Figure 7 110 (A)) The successful clonmg o f rSeprase was 
confirmed by DNA sequencing (Section 2 1010) The sequencmg data is given in 
Figure 7 112 and Appendix C A map of pPOB12 is shown m Figure 7 111
7l26bp F6108 bp }
5090bp i
4072bp r
3054bp t
2036bp
1636bp £■;
1018bp
506bp
4072bp
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2036bp 
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10l8bp
B
Figure 7 110 Verification Digest of pPOB12
Restriction digest o f pPOB12 analysed on 0 7% agarose gel (A) Lane 1, lkb  DNA ladder, Lane2, 
pcDNA3-HA uncut, Lane 3 &  4, pPOB12 uncut, Lane 5, Bam Hl, Lane 6, ÆcoRI, Lane 7, Pstl, Lane 
8, Bam Hl and £coRI (B) Lane 1, lkb  DNA ladder, Lane 2, PCR fragment B a m H l-A -F a p l-X h o l-  
Fap8, Lane 3, PCR fragment itawffl-Kosl-Fap7--A7joI-Fap8, Lane 4, PCR fragment BamHI-Kos2- 
Fap7—XhoI-Fap8
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Figure 7.1.11 pPOB12 Plasmid Map
The rSeprase gene fragment (purple) is inserted into the vector pcDNA3-HA. The C M V and T7 
promoter (yellow) are up stream o f the inserted gene fragment. Am picillin  and Neomycin resistance 
genes (ampR &  neoR) are shown in red. HA epitope o f  the vector is cloned in H in d U l and Bam Ul 
(D ’Souza et al. 2000). Generated using pDRAW32 (Section 2.10.10).
Figure 7.1.12 illustrates the alignment o f pPOB12 with FAP (GI 16933539). The 
sequencing results confirm the ORF o f FAP with no base changes or frame shift 
errors. pPOB12 was used as a template for further cloning procedures.
I 16933S3 
pPOBIZ
ATCAAGAC T T GCCTAAAAAT C CTATT T CCACT T CC CAC CICTCCTCICCTTCCCTTATT CCT CAT M CCAIICTCTTJLCCC C CT T C AACACT TC ATAAC T C AT CAACAC T T CCCT AAAAATC CT ATT T CCACT TCCCAC C T C T CC T CT CCT T GC CT T AT T GCT CAT CTCCAT T CT C TIACCC C CT T C AACACT TC ATAAC T C
I16933S3 
p P 0 B 1 2
t g a a g a a a a t a c a a t c a c a c c a c t c a c a c t g a a g g a t a t t t t a a a t c g a a c a t t t t c t t a t a a a a c a t t t t t t c c a a a c t g g a t t t c a c g a c a a g a a t a t c
TGAACAAAATACAATGACAGCACTCACACTCAAGGATATTTTAAATGGAACATTTTCTTATAAAACATTTTTTCCAAACTGCATTTCACCACAACAATATC
giI 1693353 
p P O B IZ
T t c a t c a a t  c  t  g c a g a t a a c a a t a t a c t a c  t  t  t a t  AATATT g a a a c  a c c a c a a t  c a t  a t a c  c  a t  t  t  t  c a c t  a a t a g a a c  c a t  c a a a a c t  CT C - A A T  C C r T C A
t t c a t c a a t c t g c a g a t a a c a a t a t a g t a c t t t a t a a t a t t g a a a c a g g a c a a t c a t a t a c c a t t t t g a g t a a t a g a a c c a t g a a a a g t g t g a a t g c t t c a
3 0 3303
I  1 6 3 3 3 5 3  
pPOBIZ
a a t t a c c c c t t a t c a c c t c a t c g g c a a t t t c t a t a t c t a c a a a c t c a t t a t t c a a a g c t t t g c a g a t a c t c t t a c a c a g c a a c a t a t t a c a t c t a t c a c c tAAT TAC CCC T t a t  CAC CT CAT C GGCAAT T TGTATATC TAGAAAGT CAT TAT T CAAACC T TT CCA CAT AC TC T TACACACCAAC AT AT TAC AT CTAT CACC T
ga.I1693353 pPOBIZ TAGCAATGGAGAATTTGTAAGAGCAAATCACCTTCCTCGTCCAATTCACTATTTATGCTCGTeCCCTGTTGGGAGTAAATTAGCATATCTCTATCAAAACAt a c c a a t g g a g a a t t t g t a a c a c c a a a t c a g c t t c c t c g t c c a a t t c a g t a t t t a t g c t g g t c c c c t g t t c c c a g t a a a t t a g c a t a t g t c t a t c a a a a c a 5 OS 60-5
gl I L6933S3 
pPOB12
a t a t c t a t t t g a a a c a a a g a c g a g g a g a t c c a c c t t t t c a a a t a a c a t t t a a t g g a a g a g a a a a t a a a a t a t t t a a t g g a a t c c c a g a c t g g g t t t a t g a a  
ATATCTATTTGAAACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAATATTTAATGGAATCCCACACTGGGTTTATGAA
I 1693353 
pPDBIZ
CACCAAAT GC TT GC TACAAAATAT CC T C T CT CCT CCT C T CCT AAT CCAAAAT T TT T CGCAT AT CC CCAAT T TAAT CATACCCAT AT AC C ACT TAT T CCC T A CACCAAAT GC TT GC TACAAAATAT CCT C T CT CGT CCT C T CCT AAT CCAAAAT T TT T GGCAT AT CC CCAAT T TAAT GATAC CCAT AT AC CACT TAT T GC C T A
«i I1«93353 
pPOBIZ
TTCCTATTATGGCGATGAACAATATCCTAGAACAA.TAAATATTCCATACCCAAAGGCTGGAGCTAA.GAATCCCGTTGTTCCCATATTTATTATCCATACCA TTC CTAT TATCCC GATGAACAATATCCTACAACAATAAATATTCCATACCCAAAGGC T CCACC TAJLCAATCCCCTT CTTCCCATAT T TAT TATCCA TACCA
I 1Í933S3 
pPOB12
CTTACCCTCCGTATCTAGCTCCCCACCAAGTGCCTCTTCCAGCAATGATAGCCrCAAGrCATTATTArTTCACTTGGCTCACGTGGGTTACTCATCAACGA
c t t a c c c t g c g t a t c t a c g t c c c c a c g a a g t g c c t g t t c c a g c a a t g a t a c c c t c a a g t g a t t a t t a t t t c a c t t g g c t c a c g t g c g t t a c t g a t c a a c g a
I 1693353 
pPDBIZ
CTAT CT t  t g c a c t  g c c  t a a a a a c a c t  c c a g a a t  C TTT C CCT C C T c t c  t a t  a t  c t c a c  t t  c a c g g a a c a c t  c c c a c a c a t  g c g a t t c t  c c a a a c a c  c c a c c a  
g t a t g t t t g c a g t g g c t a a a a a g a g t c c a c a a t g t t t c g g t c c t g t c t a t a t c t g a c t t c a g -c c a a g a c t g g c a g a c a t g g g a t t g t c c a a a g a c c c a g g a
ga. I 1693353 
pPQElZ
c c a t a t a g a a  g a a a  g c a c a a c  t c c a t c c g c t c g t g g a t t c t t t c t t t  c a a c a c c a g  t t t t  c a g  c t a t  g a t  c c  c a t  t t c c t a c  t ACa a a a t a t t t a c t g a c aCCATATAGAAGAAACCACAAC T CCA T CCC C T CCT CCAT TCTTTCTTT CAACAC CACT T T T C ACCTAT GATCC CAT T T CCTAC TACAAAATAT T TACT CAC A
tji I 1693353 
pPOBIZ
a g g a t g g c t a c a a a c a t a t t c a c t a t a t c a a a g a c a c t g t g g a a a a t g c t a t t c a a a t t a c a a g t g g c a a g t g c g a g g c c a t a a a t a t a t t c a c a g t a a c a
a c g a t g c c t a c a a a c a t a t t c a c t a t a t c a a a g a c a c t c t c g a a a a t c c t a t t c a a a t t a c a a g t g c c a a g t g g c a g g c c a t a a a t a t a t t c a g a c t a a c a
gi|i6933S3
pPOBli
CACCAT T CAC TCT T T TAT T C TACCAAT CAAT T T &AACAATAC C C TCCAACAAGAAAC ATCT AC ACAAT TACCAT T G-GAACC T ATCC T CC AAGC AACAACT C 
CACCAT T CAC TCT T T TAT T CTAGCAAT GAA TT T CAA CAA TACCC T GGAAGAAGAAAC AT CT ACACAA T TACCAT T CCAACC TAT CC T CCAACC AACAACT C 13131313
?3. I 1693363 
pPOBXZ
TGTTACTTGCCATCTAACCAAACAAAGGTGCCAATATTACACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTCTCTCCTACGGCCCAGGCATCC 
TCT TACTTCCCATCTAAGGAAAGAAACCT CCCAATAT TACACAGCAAGTTTCAGCCACTACGCCAAGTACTATGCACTTCTCTGCTACCCCCCAGGCATCC
gl I 1693353 
pPOBIZ
c c a t  t  t  c  c  a c  c c  t  T c a t  g a t  CCAC GCAC t  g a t  c a a g a a a t t  a a a a t  c  c  t  g g a a g a a a a c a a g - g a a t  t  g g a a a a t  g c  t  t  t  g a a a a a t  a t  c  c  a g c  t  c c  c  t  a a a  
c c a t t t c c a c c c t t c a t g a t c c a c g c a c t g a t  c a a g a a a t t a a a a t c c t g c a a g a a a a c a a g c a a t t g c a a a a t g c t t t g a a a a a t a t c c a g c t g c c t a a a
I 1693353 
pPOBIZ
CACCAAAT TAACAAAC TT CAACT ACAT CAAAT TJLC TT TAT CCT ACAAC AT CAT TC T T C C TC C T CAAT T T CACACAT CAAACAACT AT CCCTT GC T AAT T C A 
CACCAAAT TAACAAAC T T CAACT ACAT CAAAT TAC TT T AT CCTACAACAT GAT TCT T CCTCCT CAAT T T CACACAT CAAACAACT AT CCCTT GC T AAT T C A
gi I 1693353 
pPOBIZ
ACT GTATGGT GGTC CCT GCACT CAGAGT GTAAGGTCTGTATTTCCTCTTAAT T GGATATCT TATCTTGCAAGTAAGGAAGGGATCCT CAT T CCCT T GGTGG
a c t g t a t g c t g g t c c c t g c a c t c a c a g t g t a a g c t c t c t a t t t g c t g t t a a t t g g a t a t c t t a t c t t g c a a g t a a g c a a c g g a t g g t c a t t g c c t t g g t g g
* 1 I 1 6 9 3 3  5 3  
p P O B IZ
AT CGT C CACCAAC ACC TT T C CAACCT CACAAACICCTC TAT CCACT CTAT C CAAACC T CCCT CTT TAT CAACT T CAACACC ACAT TAC ACC T CT CACAAAA 
ATCGTCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAGAAAA
«1 I 1 6 9 3 3 5 3  
pPOBIZ
t t c a t a c a a a t c c c t t t c a t t c a t c a a a a a a c a a t a c c c a t a t c c c c c t c c t c c t a t g c a c c a t a c c t t t c a t c a c t g c c c c t t c c a t c t c c a a c t g c t c t
T T CATACAAAT CCCTT T CATTCAT GAAAAAA CAAT ACC CAT AT CCCCC T CCT C C TAT CCACCA TAC CT T T CAT CAC ICCCC C TT CC AT C T CCJlAC T CCTC T
gA I 1693353 
pPOBIZ
t t t c a a a t g t g c t a t a c c a g t g g c t c c a g t c t c g a c c t g g g a a t a t t a c c c c t c t g t c t a c a c a c a g a g a t t c a t &g g t c t c c c a a c a a a g g a t g a t a a t c
t t t c a a a t c t g g t a t a g c a g t c g c t c c a g t c t c c a g c t g g g a a t a t t a c g c c t c t g t c t a c a c a g a c a c a t t c a t g g g t c t c c c a a c a a a g c a t g a t a a t c
I16933S3 
pPOBIZ
t t g a g c a c  t a t a a c a a t t  c a a c t  c t c a t  c c c a a g a c c  a c a a t  a t  t  t  c a  c a a a t  c t a c a c  t a t  c  t t c  t  c a t  c c a c  c g a a c a c c a c a t  c a t a a t  c t  c c  a c  t  t  tTTCACCAC TATAACAATT CAAC T CTCAT GCCAACACC AGAAT AT T T C ACAAAT CTACAC TAT C TTC T CAT C CAC CCAACACCACAT CATAAT CTCCAC T T T
yi I16933S3 
pFDBIZ
CAAAACTCAGCACAGATTCCTAAAGCTCTCCTTAATGCACAAGTCCATTTCCAGCCAATGTGCTACTCTGACCAGAACCACCGCTrATCCGCCCTCTCCAC
CAAAACTCAGCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATCTGCTACTCTGACCAGAACCACGGCTTATCCGCCCTGTCCAC
I1È933S3 
pPOBIZ
GJLAC CACTTATACACCCACATCACCCACTTCCTAAAGCAGTCTTTCTCTTTCTCACAC t a a  
GAACCACTTATACACCCACATGACCCACTTCCTAAAGCAGTGTTTCTCTTTGTCAGACTAA 2203Z2B3
Figure 7.112 DNA Sequencing of pPOB12
Sequence ofpPOB12 aligned w ith that o f Seprase DNA sequencing confirms the successful cloning 
o f  rSeprase Illustrated usmg GenDoc (Section 2 10 10) Sequencing data is given in Appendix C
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The primers ÆawHI-Kozl-Fap7 and 2to/nHI-Koz2-Fap7 were designed (Table 
2 10 2) so that they contained a Kozak sequence, 5’-GCC(A/G)CCATGG-V for 
initiation o f translation o f the protem Figure 7 1 10 (B) shows the amplified Seprase 
gene fragments usmg pPOB12 as template, Phusion DNA Polymerase and the 
primers ÆamHI-Kozl-Fap7, ÆamHl-Koz2-Fap7 and XAoI-Fap8 The fragments were 
concentrated accordmg to Section 2 10 3 4 and restncted with BamHl and Xhol The 
restricted PCR fragments were then ligated with the treated pcDNA3-HA and pc- 
DNA3 vectors and transformed accordmg to 2 10 5 2, mto the E coh stram XL-10 
Gold The use o f the two vectors would distinguish the effect, if any, the HA tag 
would have on the refolding and activity o f the enzyme
Clones were screened accordmg to Section 2 10 3 2 1 and candidate clones were 
further analysed by restriction analyses A restriction digest o f these clones 
(pPOB15, 16, 17, 18) analysed by agarose gel electrophoresis is shown m Figure 
7 113 Restriction with BamHl and Xhol produces a band corresponding to the 
expected 2283bp fragment contammg the rSeprase sequence Single restriction with 
BamHl and EcoRI produced bands corresponding to the expected 7692pb linearised 
plasmid Restriction with Hindlll produced bands corresponding to the expected 
376bp and 7316bp Restriction with Pstl produced bands corresponding to the 
expected 1420bp, 2007bp and 3983bp There also seems to be some uncut and 
partially cut vector DNA m Lane 7 (Figure 7 110) The successful clonmg o f 
rSeprase was confirmed by DNA sequencing (Section 2 10 10) The sequencmg data 
is given m Appendix C A map o f pPOB15-18 is shown m Figure 7 1 14 
1 2 3 4 5 6 7 8
5090bp 
4072bp 
3054bp 
2036bp 
I636bp 
1018bp
506bp
Figure 7 1 13 Verification Digest for pPOB15-18
Restriction digest o f pPOB15-18 analysed on 0 7% agarose gel (A) Lane 1, lkb  D N A  ladder, Lane2, 
pcDNA3-HA/pcDNA3 uncut, Lane 3, pPOB15-18 uncut, Lane 4, B a m H l, Lane 5, E c o F l,  Lane 6, 
H in d lll, Lane7, P stl, Lane 8, Bam Hl and £coRI
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Figure 7.1.14 pPOB15-18 Plasmid Map
The rSeprase gene fragment (purple) is inserted into the vectors pcDNA3/pcDNA3-HA. The C M V 
and T7 promoter (yellow) are up stream o f the inserted gene fragment. Am pic illin  and Neomycin 
resistance genes (ampR &  neoR) are shown in red. HA epitope o f the vector is cloned in H in d lll and 
Bam Ul (D ’Souza, 2000). Generated using pDRAW32 (Section 2.10.10).
The mammalian constructs pPOB12, pPOB15, pPOB16, pPOB17, pPOB18 and the 
vector pcDNA3 were transfected into the DG75 cell line according to Section
2.10.12.4. Stable transfectants were then tested for Seprase activity according to 
Section 2.9.2. Table 7.1.1 identifies the DG75 cell line and respective transfected 
construct. Figure 7.1.15 illustrates the expression profile o f the various cell lines. 
Results show that none o f the transfectants display Seprase activity, although they do 
express active Prolyl Oligopeptidase. It was necessary to reveal the reason why 
Seprase activity was not detected. The expression o f Seprase was investigated firstly 
at the transcription level to ensure the efficient transcription o f the Seprase gene and 
then at the translation level.
C lone Cloning
V ector
C loning Sequence 
F orw ard  P rim er
A ctual C loning 
V ector
A ctual Sequence
5 ’
F ram e T ransfected  
C ell Line
pPO B12 pcDNA3-HA 5amHI-A-Fap7 pcDNA3-HA ZtomHI-A-Fap7 In frame with 
HA tag
DG75-1
pPO B IS pcDNA3 ZtomHI-Koz2-Fap7 pcDNA3-HA Z?a/wHI-Koz2-Fap7 Out of frame 
with HA tag
DG75-2
pPO B16 pcDNA3-HA ÆamHI-Kozl-Fap7 pcDNA3-HA /tamHI-A-Fap7 In frame with 
HA tag
DG75-3
pPO B17 pcDNA3-HA £aroHI-Koz2-Fap7 pcDNA3-HA £amHI-Koz2-Fap7 In frame with 
HA tag
DG75-4
pPOB18 pcDNA3 ZtomHI-Kozl-Fap7 pcDNA3-HA 5amHI-Kozl-Fap7 Out of frame 
with HA tag
DG75-5
- pcDNA3 - pcDNA3-HA - - DG75-6
Table 7.1.1 Summary of cloning strategy of pcDNA3 and pcDNA3-HA 
vectors
Table shows the planned cloning procedure for each construct. The constructs listed were transfected 
into the DG75 cell line. Sequences containing varying Kozak sequences were cloned into the 2 
vectors. pcDNA3 and pcDNA3-HA were used to determine if the HA tag effected the refolding and 
activity of the Seprase protein.
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Figure 7.1.15 Expression profile of transfected cell lines
Transfected cell lines are indicated with their respective transfected plasmid. The transfected cell lines 
were tested for Seprase activity and Prolyl Oligopeptidase activity. PO activity was detected at the 
same level in all cell lines. DG75-1, containing the plasmid pPOB12, showed some Seprase activity 
but that may be residual PO activity not inhibited by JTP-4819. The levels of Seprase activity would 
lead to the conclusion that the stable transfectants did not express active Seprase activity.
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In order to investigate the efficient transcription of rSeprase, RNA extracted from the 
stable transfectants (Section 2 10 3 1) was treated with Deoxyribonuclease I (DNase 
I) according to Section 2 10 7 to remove any DNA contammation PCR of /3-actin 
and full length Seprase gene was performed on the treated RNA to ensure that the 
DNA was digested thoroughly No bands were present when the PCR products were 
run on an agarose gel RT-PCR was then performed on the treated mRNA and the 
result mg PCR fragments were run on an agarose gel illustrated m Figure 7 1 16 
Figure 7 116 (A) illustrates the PCR of full length Seprase gene Lanes 2-6 show the 
PCR fragments corresponding to the Seprase gene (2283bp fragment) run on an 
agarose gel, illustrating that Seprase mRNA is present m the transfected cell lmes 
DG75-1-5 Lane 7 is lackmg a band corresponding to the Seprase fragment, 
illustrating that DG75-6 does not contain Seprase mRNA This was expected as 
DG75-6 only contains the vector pcDNA3-HA Figure 7 1 16 (B) illustrates the RT- 
PCR o f /3-actin, housekeeping gene Lanes 2-7 show the PCR fragments 
corresponding to the 0-actin fragment (360bp) run on an agarose gel This confirms 
that the RT-PCR reaction was successful m producmg good quality cDNA and that 
/?-actin mRNA is present m the transfected cell lmes DG75-1-6
1 2 3 4 5 6 7 8  1 2 3 4 5 6 7 8
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Figure 7 1 16 mRNA Analysis of stable transfected cell lines
Analysis o f mRNA from the stable transfectants mRNA extracted from the cell lines was treated w ith 
DNase I to digest DNA (A) PCR o f the frill length Seprase gene using the DNase I treated mRNA 
PCR fragments produced were run on 0 7% agarose gel Lane 1, Ikb  DNA ladder, Lane 2, DG75-1, 
Lane 3, DG75-2, Lane 4, DG75-3, Lane 5, DG75-4, Lane 6, DG75-5, Lane 7, DG75-6, Lane 8, 1 kb 
D N A ladder (B) PCR o f /3-Actin using the DNase I treated mRNA PCR fragments produced were 
run on 1% agarose gel Lane 1, lkb  D N A ladder, Lane 2, DG75-1, Lane 3, DG75-2, Lane 4, DG75-3, 
Lane 5, DG75-4, Lane 6, DG75-5, Lane 7, DG75-6, Lane 8, 1 kb DNA ladder
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Analysis o f Seprase protein expression was performed using western blot analysis. 
Western blot analysis was carried out on lysates from the transfectants (DG75 1-6), 
according to Section 2.10.12.6.2. The western blot would confirm if Seprase protein 
was being expressed, albeit in an inactive form. Figure 7.1.17 shows multiple protein 
bands reacting with the HA-Tag (6E2) Mouse Monoclonal antibody (Table 
2.10.12.6). This was unexpected as the membrane had been washed to avoid any 
non-specific binding o f the antibody. It was also observed that the transfectants 
containing the pcDNA3 vector (Lane 4, Lane 7, Lane 8) also reacted to the same 
extent as those containing the pcDNA3-HA vector (Lane 3, Lane 5, Lane 6).
250kDa 
160kDa 
105kDa
75kDa
127kDa
80kDa
40k Da
31kDa
20k Da
Figure 7.1.17 Western Blot Analysis of rSeprase expression
Western blot analysis o f DG75 stable transfectants. Lane 1, Full Range Rainbow Marker; Lane 2, 
ColourBurst Marker; Lane 3, DG75-1; Lane 4, DG75-2; Lane 5, DG75-3; Lane 6, DG75-4; Lane 7, 
DG75-5; Lane 8, DG75-6; Lane 9, Kaleidoscope Pre-stained Standards.
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The 5’ region upstream of the cloned Seprase sequences o f vectors pcDNA3, 
pcDNA3-HA, pPOB12-18 were analysed using DNA sequencing. This established 
that all vectors contained the HA epitope (Figure 7.1.18) and that the original vectors 
had been mislabeled prior to being gifted. Table 7.1.1 lists the actual sequences o f 
the constructs transfected into the DG75 cell line. The sequencing also showed if the 
rSeprase sequences cloned into the pcDNA3-HA vector were in frame with the HA 
start codon and Kozak sequence.
Figure 7.1.18 also illustrates that all constructs were cloned into the pcDNA3-HA 
with either Kozak sequence (Kozl or Koz2) as planned. However, the pPOB16 
construct lacked the Kozak 1 sequence and the pPOB17 construct contained an extra 
Cytosine (C) base. Sequencing also confirmed the frame o f the Seprase gene. The 
constructs pPOB12, pPOB16 and pPOB17 were found to be in frame with the HA 
epitope. Therefore, the respective stably transfected cell lines DG75-1, DG75-3 and 
DG75-4 should have expressed the Seprase protein fused to the HA tag. However, 
the stably transfected cell lines DG75-2 and DG75-5 contained constructs that were 
out o f frame with the N-terminal HA tag. They did however contain a Kozak 
sequence, so therefore they should also have expressed the Seprase protein which 
was not fused to the HA epitope.
pPOBIZ : GCTTGICGACCAT&GGTTACCCATACGATGTTCCAGAnACGCTA&CTT&GGGGATCCA— ATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACC : 98
pPOBIS : GCTTGTCGACCATGGGTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGGGATCCGCC-ATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACC : 100
pP0B16 : GCTTGTCGACCATGGGTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGGGATCCA ATCJLAGACTT&GGTAAÀÀATCGTATTTGGAGTTGCCACC : 98
pP0B17 : GCTT&TCGACCATGGGTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGGGATCCGCCCATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACC : 101 
pP0B18 : GCTTGTCGACCATGGGTTACCCATACGATGTTCCAGATTACGCTAGCTTGGGG&ATCCGCC-ATGGGGATGAAGACTTGGTAAAAATCGTATTTGGAGTTG : 100
RBS HA Tag BamHI rSeprase gem
Figure 7.1.18 Alignment of Mammalian Expression Clones 5’ Upstream 
Sequence
The 5’ region o f the Seprase cloned fragment was sequenced to determine the frame and sequence o f 
the region. Sequencing determined that all constructs contain the HA tag (amino acid sequence 
YPYDVPDYA). The ribosome binding site (RBS -  Kozak sequence) is indicated, containing the start 
codon (ATG) for the HA tag epitope. The Bam Ul cloning restriction site is indicated in red. The start 
codon o f the Seprase gene is indicated in blue.
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The cell lines DG75-1 and DG75-6 were chosen to be analysed using 
immunocytochemistry according to Section 2 10 12 7 and illustrated in Figure 
7 1 19 DG75-1 and DG75-6 nuclei were stained with DAPI, which identified the 
cells under the fluorescent microscope and can be seen in Figure 7 119 (A) and (C) 
The same cells were then analysed for bmdmg of the secondary Alexa Fluor 488 
antibody Figure 7 1 19 (B) shows that the DG75-1 cells are fluorescing, indicating a 
positive reaction o f the secondary antibody bmdmg with the HA tag fused to protem 
Figure 7 1 18 (D) shows that the DG75-6 cells do not bmd the secondary antibody 
These results suggest that the Seprase protem has been expressed m the DG75-1 cell 
lme fused to the N-termmal HA tag, albeit at very low levels
B D
Figure 7 1 19 Immunocytochemistry of stably transfected cell lines
Immunocytochemistry was performed on the transfected cell lmes DG75-1 and DG75-6 (A) and (B) 
relate to DG75-1 (A) DG75-1 cells nuclei stamed w ith DAPI (B) DG75-1 cells fluorescing w ith the 
secondary Alexa Fluor 488 antibody Shows positive binding w ith the HA tag (C) DG75-6 cells 
nuclei stained with DAPI (D) DG75-6 cells fail to fluoresce w ith the secondary Alexa Fluor 488 
antibody Shows negative binding with the HA tag
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Overall, these results illustrate that transcription o f Seprase mRNA from the 5 
constructs is occurring Western blot analysis o f the stable transfectants did not 
provide any conclusive results with regards to translation o f the Seprase mRNA mto 
protem Immunocytochemistry results do suggest, however, that the Seprase mRNA 
is translated into protem, albeit m an mactive form
7 1 3  Cloning of human Seprase gene into pQE30-Xa
Although there was some probability that catalytically active recombmant human 
Seprase (rSeprase) would not be expressed m E coh, it was decided to mvestigate 
this possibility Previous studies have shown that it is possible to express a 
catalytically active mammalian protem, PAP1, in E coh (Vaas, 2005) The 
prokaryotic expression vector pQE30-Xa (Table 2 10 3 and Figure 2 10 2) was 
chosen to clone and express the Seprase gene The vector pQE30-Xa features an 
optimised hybrid promoter-operator element consisting o f the phage T5 
transcriptional promoter and a lac operator sequence, which mcreases lac protem 
(LacI) bmdmg, enabling repression of this strong promoter Associated with this 
operator region is a synthetic ribosome bmdmg site (RBS) designed for high 
translation rates The vector encodes a Factor Xa Protease recognition site which is 
found 3’ o f the 6xHis-tag and 5’ o f the multiple clonmg site Factor Xa Protease 
treatment results in a recombmant protem free o f the vector-derived 6xHis-tag at the 
N-terminus
The vector was restricted with BamYil and Sail, treated with Antarctic Phosphatase 
accordmg to Section 2 10 8 1 and concentrated accordmg to Section 2 10 3 4 The 
primers BamHl~V3.pl and Xhol-Fzp& were designed and were used to amplify the 
Seprase gene with BamRl and Xhol restriction endonuclease sites and to clone the 
Seprase gene mto pQE30-Xa vector The Seprase gene was amplified usmg pPOB12 
as a template for PCR, with the primers ZtamFII-Fap7 and _A7ioI-Fap8 and usmg 
Phusion DNA Polymerase (Section 2 10 7 2) The products formed were run on an 
agarose gel (Figure 7 1 20) The PCR products were concentrated usmg the method 
described m Section 2 10 3 4 and restricted with the respective endonuclease 
restriction enzymes (BamWl and Xhol) accordmg to Section 2 10 7 The restncted
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PCR fragments were then ligated with the treated pQE30-Xa vector and transformed 
accordmg to 2 10 5 2, into the E colt stram XL 10-Gold
Clones were screened accordmg to Section 2 10 3 2 1 and a candidate clone was 
further analysed by restnction analyses A restriction digest o f this clone (pQPOB5) 
analysed by agarose gel electrophoresis is shown in Figure 7 1 20 Single restnction 
with BamYW and Xhol produced bands corresponding to the expected 5764pb 
linearised plasmid Restnction with EcoRl produced bands corresponding to the 
expected 2187bp and 3577bp Restriction with Hindlll produced bands 
corresponding to the expected 1891bp and 3873bp Restriction with Pstl produced 
bands corresponding to the expected 609bp, 1420bp and 3735bp The successful 
clonmg o f rSeprase was confirmed by DNA sequencing (Section 2 10 10) A map o f 
pQPOB5 is shown in Figure 7 1 21 The sequencmg data is given m Figure 7 1 22 
and Appendix C
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4072bp 
3054bp 
2036bp 
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1018bp 
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Figure 7 1 20 Verification digest of pQPOBS
(A) 0 7% agarose gel Lane 1, lk b  DNA ladder, Lane 2, PCR fragment 5amHI-Fap7--A7ioI-Fap8 (B) 
0 7% agarose gel Lane 1, 1 kb DNA ladder, Lane 2, pQE30-Xa uncut, Lane 3, pQPOB5 uncut, Lane 
4, Bam  HI, Lane 5, X h o l, Lane 6, £ ’coRI, Lane 7, H in d lll, Lane 8, Pstl, Lane 9, 1 kb D N A ladder
218
T5 Promoter / lac operon j B a in H I - 193PstI 457
HiiiclHI - 599
EcoRI 88
Pstl 18*
EcoRI 22“*5 
Sail - 247€
PstI 2486 
Hiii<UH - 2490
Figure 7.1.21 pQPOB5 Plasmid Map
The rSeprase gene fragment (purple) is inserted into the expression vector pQE30-Xa. T5 promoter 
(yellow) is up stream o f the inserted gene fragment. The 6xHis coding sequence (green) is situated at 
the 5’ end o f the MCS. Am picillin  resistance gene (<ampK) is shown in red. Generated using 
pDRAW32 (Section 2.10.10).
giI1693353 : .....................................................   ATGAAGACTTGGGTAAA : 17
pQPOBS : ATCAGAGGATCGailCiCCAiaW SCATCKGGATCTGCCTCIGGATCTCCTHBHHÄ^UTGC^ACtCGATCC......................................... : 101^ s / ' /   ^ _ /
Start Codon 6 x His Tag Factor X aRS Factor XaC.S. BaaHI rSeprase gene
giI1693353 : AATCGTAITTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCATAACTCTGAAGAAAATACAATGA : 118
pQPOBS : ....................................................................................................................................................................................................................................................... : 202
Figure 7.1.22 Sequence of pQPOB5 aligned with that of Seprase.
D NA sequencing confirms the successful cloning o f rSeprase in the expression vector pQE30-Xa. 
Figure illustrates only the 5’ region o f the Seprase gene. Dots (...)  indicate that the nucleic acid base 
at that position is conserved in the alignment. Start codon o f pQE30-Xa vector is indicated (ATG) 
upstream o f the N-terminal 6xHis Tag. The Factor Xa recognition site (R.S.) is highlighted in | H I  
followed by the Factor Xa cleavage site (C.S.). The B a m R l recognition site used for cloning o f the 
Seprase gene into the vector pQE30-Xa is indicated in blue. Illustrated using GenDoc (Section 
2.10.10). Sequencing data is given in Appendix C.
2 1 9
Expression o f recombinant Seprase protem (rSeprase) m both XL10-Gold and BL21
(DE3) was earned out (Section 2 10 11) and the enzyme was purified usmg IMAC
q(Section 2 10 11 2) The XL 10-Gold stram contams F factors, which carry the lacl 
qallele The lacl allele is a promoter mutation that expresses the Lacl repressor 
protem at high levels, resultmg in strong repression o f the lac promoter unless the 
mducer IPTG is added, which bmds and inactivates Lacl and thus mduces 
transcription from the lac promoter BL21 is a stram deficient m the OmpT87 
protease, purportedly allowing higher recovery o f heterologous recombmant 
protems
The cleared lysate and purification fractions obtamed from these expression cultures 
were analysed by SDS-PAGE (Section 2 5) and are shown in Figure 7 1 23 The 
clear lysate o f both expression cultures was assayed for Seprase activity accordmg to 
Section 2 3 3 Neither o f the clear lysates had Seprase activity (data not shown) 
Figure 7 1 23 clearly shows that there was no expression o f Seprase protem m either 
E coh stram The elution fractions m both purification schemes (see Figure 7 1 23) 
contams many protems o f varying molecular weights, none o f which correspond to 
the 97kDa Seprase protem subunit
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Figure 7 1 23 Expression and Purification of rSeprase in E coh XL 10-Gold and 
BL21 (DE3)
Analysis o f rSeprase expression and purification in E  colt from pQPOB5 (Figure 7 121) by 10% 
SDS-PAGE (A) XLIO-Gold Lane 1, High Range Sigma Marker, Lane 2, Clear lysate, Lane 3, Flow 
through, Lane 4, First wash, Lane 5, Second wash, Lane 6, Third wash, Lane 7, First elution, Lane 8, 
Second elution, Lane 9, Third elution, Lane 10, Fourth elution, Lane 11, F ifth elution, Lane 12, Wide 
Range Sigma Marker (B) BL21 (DE3) Lane 1, High Range Sigma Marker, Lane 2, Clear lysate, 
Lane 3, Flow through, Lane 4, First wash, Lane 5, Second wash, Lane 6, First elution, Lane 7, Second 
elution, Lane 8, Third elution, Lane 9, Fourth elution, Lane 10, Fifth elution, Lane 11, Wide Range 
Sigma Marker, Lane 12, Kaleidoscope Marker
Genes in both prokaryotes and eukaryotes exhibit a non-random usage o f 
synonymous codons (a codon table is given m Appendix D) This means there is a 
bias toward one or two codons m most degenerate codon families The frequency o f  
codon usage is usually reflected by the abundance o f the associated tRNAs in 
different cell backgrounds This implies that recombmant heterologous genes 
enriched with codons rarely used in E coh may experience poor translation 
efficiency (Makndes, 1996) Arginine codons AGG and AGA are the least frequently 
used m E coh and the tRNAs that recognise them are among the least abundant 
Consecutive AGG or AGA codons can lead to a high level o f frame shifting 
(Rosenberg et a l , 1993) If the DNA sequence encoding the recombmant protem 
contams several such codons, a variety o f truncated protem products, particularly 
from large recombmant protems, is likely to be synthesised Figure 7 1 24 shows the 
nucleotide sequence coding for rSeprase, as it is found on the pQPOB5 construct 
Codons o f mmimal usage m E coh have been indicated, according to international 
DNA sequence databases (Nakamura, 2000)
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Figure 7 1 24 clearly shows that the Seprase gene contains 82 rare codons and 
consecutive AGG or AGA codons are indicated (*) It is possible that Seprase was 
being expressed in truncated forms This could explam the numerous protein bands 
visualised m the elution fractions visualised m Figure 7 1 23 A possible solution 
would be to place the 6xHis affinity tag at the C-terminus, and therefore only full 
length protems will bmd to the Ni-NTA resin durmg the purification procedure, the 
truncated forms will not bmd and will be removed m the flow-through and the wash 
fractions However, m the case o f active Seprase expression, the C-terminal 6xHis 
tag could affect the foldmg of the protein and the subsequent dimerisation
E coh Rosetta is a derivative o f the stram BL21 carrying the pRARE plasmid 
pRARE (Novy et a l , 2001) encodes genes for six tRNAs that recognise codons 
considered rare m E coh The use o f pRARE durmg the expression of heterologous 
proteins is one strategy to overcome a possible codon bias o f E coh This system 
does not provide for all the rare codons but it could be used to express the 97kDa 
subunit o f Seprase
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rS tp rass  - AXGAAGACTXGGGXAAAAAXCGTATXT|^ BgTTGCCACCTCXGCXGTGCXXGCCXTAXXGGXGATGTGCAXXGTCXXACGCCCXTCaMHgTXCAXAACXC : lOl 
. M .  - K .  .  T .  .  W .  .  V .  . K .  .  I .  .  V .  .  F .  .  C .  .  V .  .  A .  . T .  .  S .  .  A .  . V .  .  L .  .  A .  .  I .  .  L .  .  V .  . M .  .  C .  .  I .  .  V .  .  L .  .  R .  .  P .  .  S .  .  R .  .  V .  . H .  - M .  .  S  ;  3 4
r S a p x r a . s e  .  T G A A G A A A A X A C A A T C ^ H C C A C X C A C  A C T C A A G G A T A T T T T A A A T ^ B a C A X X X X C T X A T A A A A C A X T X X T T C C A A A C X G G A X T X C a B B c A A G A A X A X C  :  2 0 2
B E - . N - T . H _  . R . . A . . L . . T . . L . . K . . D . . I . . L . . H . . G .  . T . . F . . 3 . . Y . . K . - X . . F . . F . . P . . N . . W - . I . . S . . G . . Q . . R . . Y . .  :  6 7
r S a p n i t  :  T T C A T C A A T C T G O X D A T A A C A A t H g T A C T Ï T A T A A T A T T G A A A C a H c A A T C A T A T A C C A T T T T C A D T A A T | H a C C A T G A A A A G T C T D A A T D C T T C A  :  3 0 3
:  L . . H . . Q . . 3 . . A .  . D . . N .  - M .  - I . . V .  . L . . Y . . N .  . I . . 1 . . I . . G . . Q . . 3 . . Y . . I . . X . . L . . S . . N .  R .  . X . . M . . K .  . 3 . . V . . H . . A .  . 3 .  :  1 0 1
r S t p i u a  ;  A A T X A C & G C X X A X C A C C X G A X ^ H C A A T X I G X A X A T H B C A A A G T G A X X A X X C A A A G C X X X G C ® ^ A C T C X X A C A C A G C A A C A X A X X A C A X C X A T G A C C X  ;  4 0 4
N .  .  Y .  .  G .  .  L .  .  S .  .  P .  -  D .  .  R .  .  Q .  -  F .  .  V .  .  Y .  .  L .  .  B .  .  S .  . D .  .  Y .  .  S .  . K .  .  I . .  . W .  .  R .  .  Y .  .  3 .  .  Y .  - X .  .  A .  .  X .  .  Y .  .  Y .  . X _  .  Y .  .  D .  L  :  1 3 5
r S a p r x *  -  T A G C A A T H i & A A T 7 T G T A ^ j B A A T G A G C T T C C T C G T C C A A T T C A G T A T I T A T G C T G G T C G C C T G T T B * t J T A A * T T * c c A T A T f t T C T A T C A A A A C A  :  S O S
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r S e p r a . s e  :  X X C C X A X X A X G C C C A X G A A C A A X A X C C X ^ H A C A | ^ H A A X A X X C C A T A C C C A A A G C C X ^ H G C X A A G A A X | | G X X G X X | | ^ ^ H X X X A X X A X C G A X A C C A  :  8 0 8
:  S . . Y .  .  Y  .  .  G .  . D . . B . . Q . . Y . . P . . R . . T . . I . . H .  . X . . P  . Y .  P . . K . . A . . G .  .  A .  K .  .  N .  .  P  .  .  V .  .  V .  .  R .  . I . . F . . I . . I . . D . . T . .  :  2 6 9
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Figure 7.1.24 E. coli codon bias relative to rSeprase
Nucleotide sequence coding for rSeprase, as found on pQPOB5. It clearly shows that the Seprase 
gene contains 82 rare codons and consecutive AGG or AG A codons are indicated (*). Am ino acids 
corresponding to each codon are specified. Codons considered rare in E. coli are highlighted red. For 
amino acid information see Appendix D. Illustrated using GenDoc (Section 2.11).
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7 14  Cloning of human Seprase gene into pIRES-hrGFP II
The cloning strategy involving mammalian expression vector pcDNA3-HA failed to 
produce an active form o f the protease Seprase Therefore the mammalian expression 
vector pIRES-hrGFP II (Table 2 10 3 and Figure 2 10 4) was chosen to re-clone and 
express Seprase The primer £a/nHI-Koz3_for was designed (Table 2 10 2) so that it 
contained a Kozak sequence, 5’-GCCACCA TGG-3’ for initiation o f translation o f 
the protem Figure 7 1 23 (B) shows the amplified Seprase gene fragments usmg 
pPOB12 as template, Phusion DNA Polymerase and the primers £amHI-Koz3_fbr, 
7Vctf-I-Fap8_lrev and AfoM-Fap8_2rev The fragments were concentrated according 
to Section 2 10 3 4 and restncted with BamHl and Xhol The restricted PCR 
fragments were then ligated with the treated pIRES-hrGFP II vector and transformed 
accordmg to 2 10 5 2, mto the E coh stram XL-10 Gold The primer Afo/-I-Fap8_lrev 
provides a stop codon (TAA) allowing for the Seprase gene to be expressed without 
a C-terminal fused FLAG tag The 7Voi-I-Fap8_2rev primer however allows for the 
Seprase gene to be expressed fused to the FLAG tag The two reverse primers would 
distinguish the effect, if any, the C-terminal FLAG tag would have on the refoldmg 
and activity o f the enzyme
Clones were screened accordmg to Section 2 10 3 2 1 and candidate clones were 
further analysed by restriction analyses A restriction digest o f these clones 
(pIRPOBl and pIRPOB2) analysed by agarose gel electrophoresis is shown in Figure 
7 1 25 (A) Smgle restnction with Bam H l, Clal and EcoRl produced bands 
corresponding to the expected 7776bp linearised plasmid Restnction with Hindlll 
produced bands corresponding to the expected 444bp, 3 021 bp and 4311 bp 
Restnction with Pstl produced bands corresponding to the expected 405bp, 1420bp, 
2130bp and 3821 bp The successful clonmg o f rSeprase was confirmed by DNA 
sequencmg (Section 2 10 10) The sequencmg data is given m Figure 7 1 26 and 
Appendix C A map of pIRPOBl and pIRPOB2 is shown in Figure 7 1 25
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Figure 7.1.25 Verification Digest for pIRPOBl and pIRPOB2
Restriction digest o f pIRPOBl/2 analysed on 0.7% agarose gel: (A) Lane 1, lkb  DNA ladder; Lane2, 
pIRES-hrGFP II uncut; Lane 3, pIRPOBl/2 uncut; Lane 4, Bam Hl; Lane 5, C la l; Lane 6, ZscoRI; 
Lane 7, H in d lll; Lane8, P stl; Lane 9, lkb  DNA ladder. (B) Lane 1, lkb  DNA ladder; Lane 2, PCR 
fragment ZtamHI-Koz3_for--7Vo/I-Fap8_lrev; Lane 3, PCR fragment itawHI-Koz3_for--A/M -  
Fap8_2rev.
Hindm 691
Figure 7.1.26 pIRPOBl and pIRPOB2 Plasmid Map
The rSeprase gene fragment (purple) is inserted into the vector pIRPOBl and pIRPOB2. C M V 
promoter (yellow) is up stream o f the inserted gene fragment. The 3xFLAG epitope (green) is situated 
3 ’ o f the inserted gene. Neomycin and Kanamycin resistance genes (neoR and kanK) are shown in red. 
Generated using pDRAW32 (Section 2.10.10).
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gi 11693353 : ........ ....ATG— AAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTC : 86
pIRPOBl : GGATCCGCCACC—  GGG........................................................................................  : 101
pIRP0B2 : GGATCCGCCACC...GGG........................................................................................  : 101
Bam Hl RBS Start of iSepiase
gi 11693353
pIRPOBl
pIRP0B2
gi11693353
pIRPOBl
pIRPOBZ
ATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCACTTCCTAAAGCAGTGTTTCTCTTTGTCAGACTAA- : 2283
..GCGGCCGCGACTACAAGGATGACGA : 2323 
.GCGGCCGCGACTACAAGGATGACGATG : 2323
TGACAAGGAT TACAAAGACGAC GAT GATAAGGAC TATAAGGATG 
ACAAGGAT TACAAAGACGACGAT GATAAGGAC TATAAGG-----
2367
2362
Start o f FLAG T ag sequence
Figure 7.1.27 Alignment of pIRES-hrGFP II Mammalian Expression Clones
The Seprase cloned fragment was sequenced to determine the frame and sequence o f the region. The 
Figure illustrates only the 5’ and 3 ’ regions o f  the Seprase gene. Dots (...)  indicate that the nucleic 
acid base at that position is conserved in the alignment.The Bam Hl cloning restriction site is indicated 
in red The ribosome binding site (RBS -  Kozak sequence) is indicated (green), containing the start 
codon (ATG). Sequencing determined that the pIRPOBl contained the stop codon and pIRPOB2 
construct is in frame with the FLAG tag (amino acid sequence DYKDDDDK).
The mammalian constructs pIRES-hrGFP II, pIRPOBl and pIRPOB2 constructs 
were transfected into the SW480 cell line according to Section 2.10.12.4. Seprase has 
been shown to be expressed in colon cancer therefore SW480 was chosen as an 
expression system as the cell line was derived from a colorectal carcinoma, and it has 
been found not to express Seprase (Figure 6.1.8). It was thought that by using a colon 
cell line, Seprase would be expressed in an active form. However, after numerous 
attempts at transfection by electroporation, no transfectants were obtained. Therefore 
the procedure for the transfection into the SW480 cell line must be optimised. It may 
also be necessary to use alternative methods such as transient transfection using 
lipofection. An alternative to the SW480 cell line should also be sought, as this cell 
line has recently shown difficulty in other transfection experiments performed by 
other research groups (data not shown).
Active recombinant human and mouse Seprase has been expressed in mammalian 
and insect expression systems (Niedermeyer et al., 1997; Park et al., 1999; Scanlan et 
al., 1994) and these systems have shown to produce low yields o f Seprase (Lee et al., 
2005a). Active recombinant Seprase proteins have been expressed with both fused 
N- and C-terminal tags. A soluble Seprase fusion protein was produced with an N- 
terminal murine CD8a extracellular domain (ECD) (Park et al., 1999). This fusion 
protein was shown to have both dipeptidyl peptidase and gelatinase activity. Another
2 2 6
group has also produced the extracellular domain o f Seprase fused N-terminally to 
6xHis tag and C-terminally to a FLAG tag (Cheng et a l , 2002) It appears from these 
reports that the addition of an N- or C-terminal fusion tag to the Seprase protein does 
not affect the folding, dimerisation and, therefore, the activity o f the enzyme
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Chapter 8
Clinical Research Study of Human Serum
Currently there are no ideal tumour markers and most are restricted to momtonng 
cancers once they have been detected and diagnosed using other methods There are also 
no tumour markers currently recommended for screening of the general population 
Most tumour markers have too many false positives from benign conditions to make 
screening feasible Many only clearly identify malignancy once the cancer is sufficiently 
advanced to make this detection of limited use
There is currently no early detection tumour marker test for breast cancer The aim of 
this clinical research project was to determine if Seprase levels in serum are a useful 
breast cancer diagnostic marker By assay mg the serum samples for Seprase activity it 
was possible to obtain strong data confirming that patients with breast cancer have an 
elevated level of this enzyme, as has been shown previously m studies using tissue
The test could be used during the initial assessment process of patients, in conjunction 
with the clinical investigation and mammogram/ultrasound It could also be very 
valuable m situations where mammography cannot detect the breast cancer By using 
this highly sensitive assay to detect this putative breast cancer serum marker (Seprase), it 
could be possible to identify patients with early stages of breast cancer, thereby 
mcreasing their chances o f a better prognosis The initial assessment of patients would 
not require an mvasive procedure such as a biopsy A minimal sample of blood (eg 1-2 
ml serum) or a saliva sample is all that would be required to carry out the Seprase 
biomarker test
Seprase could be used as another important prognostic factor, indicating the possibility 
of metastasis, not only in breast cancer patients but also for the other epithelial cancers 
mentioned previously The test could also be used to monitor a patient’s response to 
treatment
Patients were recruited from BreastCheck and the Symptomatic Breast Care Unit o f the 
Mater Misencordiae Hospital (see section 2 11 and Appendix D) The study and consent 
forms were approved by the Research Ethics Committee o f the Mater Misencordiae
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Hospital Ref 1/378/1014 The two patient populations consisted o f 20 patients 10 
patients that have confirmed mvasive ductal carcinoma (IDC) and a control cohort of 10 
patients, who were undergoing varicose vein surgery Clinical samples were processed 
according to section 2 11 and were analysed for enzyme activity and protein content, 
usmg the fluorimetnc assay as outlined in section 2 3 3 and the Biuret assay as in section 
2 1 1 Additional relative patient information was collected and is shown in Table 8 1
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S am ple No Age Sex Diagnosis Size
(cm)
N ode status ER/PR G rad e T um ou r
M arkers
Staging L iver US/ 
Bone Scan
Surgery Follow Up
11 59 F IDC, ILC 09 0/1
(-)
+/+ 2 CEA = I N o M D W G WLE and sn biopsy N A
12 61 F IDC 1 9 0/1
(-)
+/+ 2 CEA = 1 
CA 153= 104
N o M D W G WLE and sn biopsy N A
13 58 F IDC 1 1 2/2
(+)
+/+ 1 N D N o M D W G WLE and sn biopsy Further Axillary 
Clearance
14 61 F IDC 08 0/1 +/+ 2 N D N D W G WLE and sn biopsy N A
15 54 F IDC 4 10/16
(+)
+/+ 3 CEA = 3 2 Liver ok Metastatic 
deposit left femur
Mastectomy and axillary 
clearance
N A
16 49 F IDC 25 6/23
(+)
N A 1 CEA = 1 0 N o M D W G WLE and sn biopsy Further
mastectomy and 
axillary clearance
17 58 F IDC 1 1
(-)
+/+ 2 N D NoM D Mastectomy and axillary 
clearance
N A
18 52 F IDC 7 0/10
(-)
+/+ 2 N D NoM D Mastectomy and axillary 
clearance
Reconstruction
19 65 F IDC 07 0/1
(-)
+/+ 1 N D N o M D W G WLE and sn biopsy N A
20 N A F N A N A N A N A N A N A N A N A N A
Table 8 1 Characteristics of the patient cohort supplying serum samples
Sample Numbers are listed as they appear in Figure 8 1 and Figure 8 2 N D not determined N A not available IDC infiltrating ductal carcinoma ILC infiltrating lobular carcinoma CEA normal 
level 0-5 CA15 3 normal level 0-40 Node status number o f nodes positive for tumour cells/number of nodes examined ER estrogen receptor PR progesterone receptor No M D No metastatic 
disease WG WLE Wire guided WLE
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Figure 8.1 Total Activity of Serum Samples from full cohort of patients
The control samples are numbered 1-10 (blue). Those patients with confirmed cases o f IDC are numbered 
11-20 (red) (see Table 8.1).
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Figure 8.2 Specific Activity of Serum Samples from full cohort of patients
The control samples are numbered 1-10 (blue). Those patients with confirmed cases o f IDC are numbered 
11-20 (red) (see Table 8.1).
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Statistical analysis of both population data sets show that is was normally distributed 
(see Table 8.2) and, therefore, the Student’s t-test was chosen to determine significance. 
A summary of the statistical analysis o f the clinical data is shown in Tables 8.2, 8.3 and
8.4. Analysis shows that there is a highly significant difference between the control and 
cancer patients for both Total Activity (p = 0.005) and Specific Activity (p = 0.004) of 
Seprase in serum (see Table 8.4). Therefore, it can be concluded from this that Seprase 
levels are elevated in cancer patients with invasive ductal carcinoma and that the specific 
Seprase assay described was able to detect this difference.
Diagnosis Kolmogorov-Smirnov(a)
Statistic d f Sig.
Total A ctiv ity  Cancer 0.211 10 0.200
Control 0.239 10 0.109
Specific A ctiv ity  Cancer 0.165 10 0.200
Control 0.243 10 0.097
Table 8.2 Test of Normality of Clinical Samples
Diagnosis N Mean Std. Deviation Std. E rro r  Mean
Total A ctiv ity Cancer 10 0.09752 0.042259 0.013364
Control 10 0.04695 0.019200 0.006072
Specific A ctiv ity Cancer 10 0.00157058 0.000796097 0.000251748
Control 10 0.00062619 0.000221251 0.000069966
Table 8.3 Group Statistics of Clinical Samples
t-test fo r Equality o f Means
t d f Sig. Mean Std. e rro r 95% Confidence
(2-tailed) Difference Mean Interval of the 
Difference 
Lower Upper
Total E q u a l variances not 3.445 12.564 0.005 0.05057 0.01468 0.0004 0.0015
A ctiv ity assumed
Specific E q u a l variances not 3.614 10.382 0.004 0.00094 0.00026 0.0004 0.0015
A ctiv ity assumed
Table 8.4 Independence Samples Test
2 3 3
To date there is no serum or saliva tumour marker(s) for breast cancer screening The 
current methods of screenmg for breast cancer, as described m section 1 10, have shown 
that they are not without disadvantages However until a suitable bio marker for breast 
cancer is discovered and developed, these screemng methods remam at the forefront of 
patient diagnosis
The assay described m this research thesis is the only highly sensitive and specific assay - 
developed for Seprase The assay has the unique ability to distinguish between the two 
Z-Gly-Pro-AMC hydrolysing activities found m serum Now that the assay has shown 
that Seprase levels are elevated in breast cancer patients, the study should be expanded 
to investigate and monitor the expression pattern of Seprase m serum and biopsy 
samples from patients with various types (e g normal, bemgn, in situ cancer, invasive 
ductal and lobular) and in various stages of breast cancer Serum samples would be 
taken from patients prior to surgery and at various stages post surgery This will give a 
more detailed analysis on the expression levels of Seprase at all stages of the cancer 
This assay was subject to invention disclosure and has been submitted for patent 
application A further expansion of the study would extend beyond breast cancer and 
would encompass the other cancers in which Seprase levels have been shown to be 
elevated (including colorectal, ovarian, bladder and lung carcinomas) This assay has the 
potential to be used initially as kit for breast cancer (1) screenmg, (2) diagnosis, and (3) 
for monitoring the progression of the disease It is envisaged that this test would be 
available m all hospitals and cancer clinics
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Chapter 9 
Summary and Recommendations
This research thesis describes the successful purification o f the second Z-Gly-Pro- 
AMC hydrolysing activity m bovine serum using a highly effective purification 
procedure The development of the UV zymogram enabled the identification of this 
activity as Seprase (Chapter 3) Biochemical studies performed usmg the soluble 
serum form o f Seprase have shown that the enzyme has both exopeptidase (cleaves 
Z-Gly-Pro-AMC) and endopeptidase (cleaves gelatm) activity This soluble form o f 
Seprase was also shown to bind to the WGA lectin affinity column
Further biochemical analysis o f Seprase (Chapter 4) and substrate specificity 
profiling provided valuable insight mto the catalytic and structural properties o f 
bovme Seprase (Chapter 5) The expression profile study identified the large 
intestme and the breast cancer cell lme Hs578T as possible sources o f Seprase 
(Chapter 6) This also allowed for the gene for human Seprase to be successfully 
cloned mto both a prokaryotic and mammalian expression system (Chapter 7) The 
clinical study confirmed that Seprase levels were elevated m serum samples from 
patients with mvasive ductal carcinoma (Chapter 8) These studies have greatly 
added to the growing amount o f published data on this recently discovered protease, 
Seprase
The role o f Seprase m cancer still awaits experimental proof Some additional studies 
on Seprase that could provide more clarity on the enzyme and also on the 
relationship between the structure and function are hereby outlmed
Further work is required to express Seprase m both the prokaryotic and mammalian 
expression systems The expression o f Seprase m the prokaryotic system requires 
optimisation to express the full length protem The transfection o f  mammalian cells 
also requires further optimisation This could mvolve vary mg the electroporation 
conditions or possibly usmg an alternative method such as transient transfection 
usmg hpofection An alternative to the SW480 cell lme should also be sought, as this 
cell lme has recently shown difficulty m other transfection experiments performed by 
other research groups (data not shown) This may mvolve clonmg and expressmg the 
soluble form o f Seprase, lacking the transmembrane domam
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Once an active form of Seprase is expressed it would be possible to perform 
mutational analysis Comparative biochemical and structural studies usmg the 
recombinant protem would provide information on the relationship between structure 
and function o f the enzyme These studies would mclude those mentioned m this 
thesis and also the effects o f giycosylation on both the exopeptidase and 
endopeptidase activity o f Seprase The role o f Seprase m cancer could be elucidated 
usmg function/knockdown approach (1 e by specific inhibitors or RNAi) and results 
o f quantitative expression profiling studies (usmg real-time PCR)
The identification o f Seprase in the bovine large intestine has created the opportunity 
to clone the bovine Seprase gene and to determine the ammo acid sequence o f the 
bovme protease A recombinant bovme form o f the enzyme could be expressed and 
compared to the human Seprase recombinant protem
The substrate specificity studies could be expanded by analysmg the hydrolysis o f  
the synthetic peptide substrates by Seprase usmg HPLC and identifying the products 
usmg LC-MS
The clinical study should also be expanded to investigate and monitor the expression 
pattern of Seprase m serum and biopsy samples from patients with various types (e g 
normal, benign, in situ cancer, invasive ductal and lobular and in various stages o f 
breast cancer Serum samples would be taken from patients prior to surgery and at 
various stages post surgery This will give a more detailed analysis on the expression 
levels o f  Seprase at all stages o f the cancer A further expansion o f the study would 
extend beyond breast cancer and would encompass the other cancers m which 
Seprase levels have been shown to be elevated including colorectal, ovarian, bladder 
and lung carcinomas
Finally, this work now provides some useful tools for the contmued research o f 
Seprase and its in vivo role The clone presents a probe, which can be used m various 
tissue and array-hybndisation studies and to investigate possible tissue-specific 
forms and expression o f the enzyme Also, antibodies can be raised agamst the 
purified recombinant protem and subsequently used in immunohistochemical 
investigations and m applications such as high-resolution tissue microscopy coupled 
with immunocytochemical amplification
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Appendix A 
Activity & Kinetics
One unit o f activity is defined as the amount o f enzyme which releases 1 nanomole 
of AMC per minute at 37°C (unit = nmoles min'1)
AMC released (X) is defined as fluorescent intensity (Fi) divided by the slope o f the 
appropriate AMC standard curve is
Fi— = X ¿¿moles L 1 = X jiMm
The reaction volume is 125x10^ L and duration is 60 min
X(125x 1 0 6) , T.lTAMC released =  —--------nmoles L ¿m inoU
Reaction uses 25 xl 0”6 L enzyme
JW„ , . .  X(125 x lO 6) , r ,AMC released by enzyme = —-------------- -  umoles min L60(25 xlO )
Quantification of Seprase Activity (Microplate Method 1)
X(125 x l 0 6)(1000) , ,----------------7----------nmoles mm ml60(25 xlO )(1000)
x— units ml 
12
fll H units ml
12m
When expressing units as /¿moles min' 1 this formula changes to A1 unifS
12000m  ^ m
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One unit o f activity is defined as the amount o f enzyme which releases 1 nanomole 
o f AMC per minute at 37°C (unit = nmoles mm ’)
AMC released (X) is defined as fluorescent intensity (Fi) divided by the slope o f the 
appropriate AMC standard curve is
Fi i— = X /¿moles L = X \iM
Quantification of Seprase Activity (Microplate Method 2)
m
The reaction volume is 250x1 O'6 L duration is 60 min
AMC released
The reaction uses 25 xlO"6 L enzyme
X(250 x l 0 6)(1000) 
60(25 xl0~6)(1000) nmoles min 1 ml 1
1—units ml
6
 units ml 16m
When expressing units as /¿moles m in1 this formula changes to A1 units ml 16000m
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Calculation of the Second Order Rate Constant, k2 for DFP
Charactenstic Kinetic Plot for the second order rate constant
1—  vs t [A]
Slope of Kinetic Plot is k2, L m ole1 sec1 
[A] = [AMC] is calculated from
One unit o f activity is defined as the amount o f enzyme which releases 1 nanomol o f  
AMC per minute at 37°C (unit = nmol min'1)
AMC released (X) is defined as fluorescent intensity (Fi) divided by the slope o f the 
appropriate AMC standard curve
F i i— = X /¿moles L = X jiMm
The reaction volume is 250x1 CT6 L
AMC released = X  (250 x 10“6) pmoles U x L
The reaction uses 25 xl 0 6 L enzyme
AMC released by enzyme = X(250 xlO ) . r-i
(25 xlO“6)
= \0 X  ¡moles L
fjmoles L 1m
From Kinetic Plot
(¡mole) 1 L
min
= juM 1 mm 1 
Slope x 106
60 M sec"
= k2 M 1 sec 1
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Purification Table Calculations
Total activity (unit) Units o f enzyme activity, calculated from fluorescent intensity 
as described in section 6 1
Total protein (mg) mg/ml o f protein estimated from appropriate BSA standard 
curve x volume o f sample in mis
Specific activity (unit/mg) Total activity/Total protein
Purification factor Specific activity o f sample/Specific activity o f starting sample 
(serum)
Recovery (%) (Total activity of sample/Total activity o f starting sample) x 100
Error Bars
Error bars on all enzyme activity graphs represent the standard error o f the mean o f  
triplicate fluorescence values The standard error (SE) o f the mean is defined as
SE = a/Vn
Where
a  is the standard deviation i e Vvanance (variance = (a2 + b2 + c2)/3 , where a, b & c 
are the triplicate values)
n is the number o f repeat values measured (three in this case)
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Kinetic Analysis
Km Determination
The Michaelis constant, or Km as it is usually known, is defined as the substrate 
concentration which gives rise to a velocity equal to half the maximal velocity This 
constant can be analysed by measuring reaction velocity (V) at various 
concentrations o f substrate, the data giving rise to the well-known Michaelis-Menten 
hyperbola curve In the case o f Seprase, activity is determined by measuring 
fluorescent intensity (Fi) resulting at various concentrations o f the substrate Z-Gly- 
Pro-AMC, as described in Section 2 8 2 1 A plot o f Fi versus [Z-Gly-Pro-AMC] 
yields the Michaelis-Menten curve Once an enzyme-catalysed reaction follows 
normal Michaelis-Menten kinetics, data can be applied to a number o f kinetic models 
such as
Lineweaver-Burk Plot of 1/fluorescent intensity versus 1/substrate concentration 
The intercept o f the line on the y-axis gives a direct readout o f 1/Vmax and the 
intercept o f the line on the x-axis gives -1/Km The slope o f the line is equal to Km/V
Eadie-Hofstee Plot o f fluorescent intensity versus fluorescent intensity/substrate 
concentration The intercept on the y-axis represents 1 / V max, while the slope is given 
as -Km
Hanes-Woolf Plot o f substrate concentration/fluorescent intensity versus substrate 
concentration The intercept on the x-axis gives -Km, and on the y-axis Km/Vmax The 
slope is 1 /V
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Determination of kcat
The turnover constant (kcat) o f an enzyme can be determined if the Vmax and total 
enzyme (Et) are known
mol min ml 1 , k------------- □------ = mm (s )mol ml
In the case o f Seprase, Vmax (nmoles mm 1 m l1 or units m ll) is determined 
experimentally as described above Et (moles m l!) can be calculated from the 
molecular weight (gm ole1) and amount o f enzyme used (g m l]) The molecular 
weight o f Seprase is 170,000 g mole as deduced from the ammo acid sequence
262
K, Determinations
The inhibition constant (K^, or dissociation constant for the enzyme-inhibitor 
complex, can be determined by measuring the apparent Km (Kmapp) observed in the 
presence o f an inhibitor at a specific concentration ([I]), as described in Section 
2 8 2 2 and applied to the following equation
K, for competitive inhibition is calculated as follows,
K  ~ K "'[I]' K°:p-K m
Where
K, is the inhibition constant
Km is the Michaelis constant with no inhibitor present 
[I] is the inhibitor concentration
Kmapp means the new or “apparent” value o f Km in the presence o f I, the inhibitor 
Measured as for Km
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Types of Reversible Inhibition
Inhibitors can be divided into two groups, reversible and irreversible Reversible 
inhibition involves noncovalent forces that bind inhibitors to enzymes There are 
several types o f reversible inhibition competitive, uncompetitive, non competitive 
and mixed Distinguished, using the Lineweaver-Burk plot, by determining the effect 
of inhibitor on Km? Vmax and ICm/Vmax
Competitive Inhibition Involves the binding o f an inhibitor to the enzyme forming 
an enzyme-inhibitor complex The inhibitor bearing a structural and chemical 
similarity to the substrate binds to the active site thus competing with it for substrate
In competitive inhibition, the slope of the Lineweaver-Burk plot increases The Km 
value also increases but the Vmax value is unchanged This type o f inhibition is 
recognised by plots intersecting at a common point on the positive y-axis
Uncompetitive inhibition Involves binding only to the enzyme-substrate complex 
to prevent catalysis
This type o f inhibition causes a decrease in Km and Vmax There is no change in the 
slope o f the Lineweaver-Burk plot It is identified by the presence o f parallel lines in 
the Lineweaver-Burk plot
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Non-competitive inhibition Involves binding equally to enzyme and enzyme- 
substrate complex
This type o f inhibition causes a decrease in Vmax along with Km remaining the same 
The slope o f the Lineweaver-Burk plot increases and is recognisable by plots 
intersecting at a common pomt on the negative x-axis
Mixed Inhibition' These inhibitors bind unequally to both enzyme and enzyme- 
substrate complex There can be two cases with these inhibitors,
Mixed competitive-non-competitive increase Km and decrease Vmax They cause an 
increase in the Lineweaver-Burk slope and are identified by plots intersecting above 
the negative portion o f the x-axis
Mixed non-competitive-uncompetitive decrease both Km and Vmax The Lineweaver- 
Burk plot slope is increased and plots intersecting below the negative portion o f the 
x-axis identify this type o f inhibition
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Appendix B 
Amino Acids
Tiny
Charged
Ammo acid properties
Venn diagram presenting properties of the 20 amino acids
Alanine Ala A
Arginine Arg R
Asparagine Asn
Aspartic acid Asp
Cysteine
N
D
Cys C
Glutamic acid Glu E
Glutamine Gin Q
ch3
nh2
NHo O
OH
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Glycine
Histidine
Isoleucine
Leucine
Lysine
Methionine
Phenylalanine
Pro line
Serine
Threonine
Tryptophan
Tyrosine
Valine
G1y G
NH,
His H
Ile I
Leu L
Lys K
Met M
Phe F
Pro
Ser S
Thr T
Trp W
Tyr
Val
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Second Letter of Codon
U C A G
UUUPhe UUC Ser UAUTyr UGU Cysu UUC Phe UCC Ser UAC Tyr UGC CysUUALeu UCA Ser UAA Stop UGA StopUUG Leu UCG Ser UAG Stop UGGTrp
First letter CUU Leu CCU Pro CAU His CGUArg
of Codon C CUC Leu CCC Pro CAC His CGC Arg
(5’ end) CUALeu CCA Pro CAA Gin CGAArgCUGLeu CUG Pro CAGGm CGGArg
AUUIle ACU Thr AAUAsn AGUserA AUC lie ACC Thr AAC Asn AGC serAUA lie ACA Thr AAA Lys AGAAi^AUG Mel ACG Thr AAGLys AGG Arg
GUUVal GCU Ala GAUAsp GGU GlyG GUC Val GCC Ala GAC Asp GCG GlyGUAVai GCA Ala GAAGlu GGA GlyGUGVal GCGAla GAG Glu GGG Gly
Genetic code
Ammo acid codons applicable to both H  sapiens and E coh
Appendix C 
Sequence Data
>pPOBl (labelled pP0B5 in fridge)
ATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTG
GTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCATAACTCTGAAGAAAATACAATGAGA
GCACTCACACTGAAGGATATTTTAAATGGAACATTTTCTTATAAAACATTTTTTCCAAACT
GGATTTCAGGACAAGAATATCTTCATCAATCTGCAGATAACAATATAGTACTTTATAATA
TTGAAACAGGACAATCATATACCATTTTGAGTAATAGAACCATGAAAAGTGTGAATGCTT
CAAATTACGGCTTATCACCTGATCGGCAATTTGTATATCTAGAAAGTGATTATTCAAAGC
TTTGGAGATACTCTT ACACAGCAACAT ATT ACATCTATGACCTTAGC AATGGAGAATTTG
TAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGGTCGCCTGTTGGGAGTA
AATTAGCATATGTCTATCAAAACAATATCTATTTGAAACAAAGACCAGGAGATCCACCTT
TTCAAATAACATTTAATGGAAGAGAAAATAAAATATTTAATGGAATCCCAGACTGGGTTT
ATGAAGAGGAAATGCTTGCTACAAAATATGCTCTCTGGTGGTCTCCTAATGGAAAATTTT
TGGCATATGCGGAATTTAATGATACGGATATACCAGTTATTGCCTATTCCTATTATGGCG
ATGAAC AAT ATCCT AG AACAAT AAAT ATTCC AT ACCC AAAGGCTGGAGCT AAGAATCCC
g t t g t t c g g a t a t t t a t t a t c g a t a c c a c t t a c c c t g c g t a t g t a g g t c c c c a g g a a g t g c
CTGTTCCAGCAATGATAGCCTCAAGTGATTATTATTTCAGTTGGCTCACGTGGGTTACTGA
TGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCAGAATGTTTCGGTCCTGTCTATATG
TGACTTCAGGGAAGACTGGCAGACATGGGATTGTCCAAAGACCCAGGAGCATATAGAAG
AAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAACACCAGTTTTCAGCTATGATG
CCATTTCGTACTACAAAATATTTAGTGACAAGGATGGCTACAAACATATTCACTATATCA
AAGACACTGTGGAAAATGCTATTCAAATTACAAGTGGCAAGTGGGAGGCCATAAATATA
TTCAGAGTAACACAGGATTCACTGTTTTATTCTAGCAATGAATTTGAAGAATACCCTGGA
AGAAGAAACATCTACAGAATTAGCATTGGAAGCTATCCTCCAAGCAAGAAGTGTGTTAC
TTGCCATCT AAGGAAAG AAAGGTGCC AAT ATT AC ACAGC AAGTTTCAGCG ACT ACGCC A
AGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCCCATTTCCACCCTTCATGATGGAC
GCACTGATCAAGAAATTAAAATCCTGGAAGAAAACAAGGAATTGGAAAATGCTTTGAAA
AATATCC AGCTGCCTAAAGAGGAAATT AAG AAACTTG AAGT AG ATG AA ATT ACTTT ATG
GTACAAGATGATTCTTCCTCCTCAATTTGACAGATCAAAGAAGTATCCCTTGCTAATTCA
AGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCTGTATTTGCTGTTAATTGGATATCT
TATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCGAGGAACAGCTTTC
CAAGGTGACAAACTCCTCTATGCAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAAGAC
CAGATTACAGCTGTCAGAAAATTCATAGAAATGGGTTTCATTGATGAAAAAAGAATAGC
CATATGGGGCTGGTCCTATGGAGGATACGTTTCATCACTGGCCCTTGCATCTGGAACTGG
TCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGCGTCTGTC
TACACAGAGAGATTCATGGGTCTCCCAACAAAGGATGATAATCTTGAGCACTATAAGAA
TTCAACTGTGATGGCAAGAGCAGAATATTTCAGAAATGTAGACTATCTTCTCATCCACGG
AACAGCAGATGATAATGTGCACTTTCAAAACTCAGCACAGATTGCTAAAGCTCTGGTTAA
TGCACAAGTGGATTTCCAGGCAATGTGGTACTCTGACCAGAACCACGGCTTATCCGGCCT
GTCCACGAACCACTTATACACCCACATGACCCACTTCCTAAAGCAGTGTTTCTCTTGTCA
GACTAA
>pPOB12
ATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCACCTCTGCTGTGCTTGCCTTATTG
GTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCATAACTCTGAAGAAAATACAATGAGA
GCACTCACACTGAAGGATATTTTAAATGGAACATTTTCTTATAAAACATTmTCCAAACT
GGATTTCAGGACAAG AATATCTTCATCAATCTGCAGATAACAAT AT AGT ACTTTAT AAT A
TTGAAACAGGACAATCATATACCATTTTGAGTAATAGAACCATGAAAAGTGTGAATGCTT
CAAATTACGGCTTATCACCTGATCGGCAATTTGTATATCTAGAAAGTGATTATTCAAAGC
TTTGGAGATACTCTTACACAGCAACATATTACATCTATGACCTTAGC AATGGAGAATTTG
TAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGGTCGCCTGTTGGGAGTA
AATTAGCATATGTCTATCAAAACAATATCTATTTGAAACAAAGACCAGGAGATCCACCTT
TTCAAATAACATTTAATGGAAGAGAAAATAAAATATTTAATGGAATCCCAGACTGGGTTT
ATGAAGAGGAAATGCTTGCTACAAAATATGCTCTCTGGTGGTCTCCTAATGGAAAATTTT
TGGCATATGCGGAATTTAATGATACGGATATACCAGTTATTGCCTATTCCTATTATGGCG
ATGAACAAT ATCCT AG AACAATAAATATTCCATACCCAAAGGCTGGAGCT AAGAATCCC
GTTGTTCGGATATTTATTATCGATACCACTTACCCTGCGTATGTAGGTCCCCAGGAAGTGC
CTGTTCCAGCAATGATAGCCTCAAGTGATTATTATTTCAGTTGGCTCACGTGGGTTACTGA
TGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCAGAATGTTTCGGTCCTGTCTATATG
TGACTTCAGGGAAGACTGGCAGACATGGGATTGTCCAAAGACCCAGGAGCATATAGAAG
AAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAACACCAGTTTTCAGCTATGATG
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CCATTTCGTACTACAAAATATTTAGTGACAAGGATGGCTACAAACATATTCACTATATCA
A AGACACT GT GG AAAATGCT ATT CAA ATT ACAAGTGGCAAGTGGGAGGCCAT AAAT AT A
TTCAGAGT AACACAGGATTCACTGTTTT ATTCT AGCAATGAATTTG AAGAAT ACCCTGGA
AGAAGAAACATCTACAGAATTAGCATTGGAAGCTATCCTCCAAGCAAGAAGTGTGTTAC
TTGCCATCTAAGGAAAGAAAGGTGCCAATATTACACAGCAAGTTTCAGCGACTACGCCA
AGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCCCATTTCCACCCTTCATGATGGAC
GCACTGATCAAGAAATTAAAATCCTGGAAGAAAACAAGGAATTGGAAAATGCTTTGAAA
AATATCCAGCTGCCTAAAGAGGAAATTAAGAAACTTGAAGTAGATGAAATTACTTTATG
GTACAAGATGATTCTTCCTCCTCAATTTGACAGATCAAAGAAGTATCCCTTGCTAATTCA
AGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCTGTATTTGCTGTTAATTGGATATCT
TATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTGGTGGATGGTCGAGGAACAGCTTTC
CAAGGTGACAAACTCCTCTATGCAGTGTATCGAAAGCTGGGTGTTTATGAAGTTGAAGAC
CAGATTACAGCTGTCAGAAAATTCATAGAAATGGGTTTCATTGATGAAAAAAGAATAGC
CATATGGGGCTGGTCCTATGGAGGATACGTTTCATCACTGGCCCTTGCATCTGGAACTGG
TCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTCCAGCTGGGAATATTACGCGTCTGTC
TACACAGAGAGATTCATGGGTCTCCCAACAAAGGATGATAATCTTGAGCACTATAAGAA
TTCAACTGTGATGGCAAGAGCAGAATATTTCAGAAATGTAGACTATCTTCTCATCCACGG
AACAGCAGATGATAATGTGCACTTTCAAAACTCAGCACAGATTGCTAAAGCTCTGGTTAA
TGCACAAGTGGATTTCCAGGCAATGTGGTACTCTGACCAGAACCACGGCTTATCCGGCCT
GTCCACGAACCACTTATACACCCACATGACCCACTTCCTAAAGCAGTGTTTCTCTTTGTCA
GACTAA
>pPOB15
TTACGCTAGCTTGGGGGATCCGCCATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCC
ACCTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCATA
ACTCTGAAGAAAATACAATGAGAGCACTCACACTGAAGGATATTTTAAATGGAACATTTT
CTT AT A A A AC ATTTTTT CC AAACT GG ATTTC AGG ACAAGAAT AT CTTC AT C AAT CT GC AG
ATAACAATATAGTACTTTATAATATTGAAACAGGACAATCATATACCATTTTGAGTAATA
G AACC AT G AAAAGTGTG AAT GCTTC AA ATTACGGCTT ATCACCTG AT CGGC AATTT GT AT
ATCTAGAAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCT
ATGACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATT
TATGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATATCTATTTGA
AACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAATA
TTTAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCTC
TGGTGGTCTCCTAATGGAAAATmTGGCATATGCGGAATTTAATGATACGGATATACCA
GTTATTGCCTATTCCTATTATGGCGATGAACAATATCCTAGAACAATAAATATTCCATAC
CCAAAGGCTGGAGCTAAGAATCCCGTTGTTCGGATATTTATTATCGATACCACTTACCCT
GCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGCAATGATAGCCTCAAGTGATTATTAT
TTCAGTTGGCTCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTC
CAGAATGTTTCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTGT
CCAAAGACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTGT
TTCAACACCAGTTTTCAGCTATGATGCCATTTCGTACTACAAAATATTTAGTGACAAGGA
TGGCTACAAACATATTCACTATATCAAAGACACTGTGGAAAATGCTATTCAAATTACAAG
TGGCAAGTGGGAGGCCATAAATATATrCAGAGTAACACAGGATTCACTGTTTTATTCTAG
CAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGGAAGCT
AT CCTCC AAGC A AG AAGTGT GTT ACTT GCCATCT AAGG AAAG AAAGGT GCC AAT ATT AC
ACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATC
CCCATTTCCACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTGGAAGAAAAC
AAGGAATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTAAAGAGGAAATTAAGAAACT
TGAAGTAGATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATTTGACAGATC
AAAGAAGTATCCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTC
TGTATTTGCTGTT AATTGG ATAT CTT ATCTTGC AAGTA AGG A AGGG AT GGT C ATT GCCTTG
GTGGATGGTCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGTGTATCGAAA
GCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAGAAAATTCATAGAAATGG
GTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTGGTCCTATGGAGGATACGTTTCAT
CACTGGCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTC
CAGCTGGGAATATTACGCGTCTGTCT ACACAGAGAGATTCATGGGTCTCCCAACAAAGG
ATGATAATCTTGAGCACTATAAGAATTCAACTGTGATGGCAAGAGCAGAATATTTCAGA
AATGTAGACTATCTTCTCATCCACGGAACAGCAGATGATAATGTGCACTTTCAAAACTCA
GCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCT
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GACCAGAACCACGGCTTATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCAC
TTCCTAAAGCAGTGTTTCTCTTTGTCAGACTAACTCGAGCATGCATCTAGAGGGC
>pPOB16
TTACGCTAGCTTGGGGGATCCAATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGCCAC
CTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCATAAC
TCTGAAGAAAATACAATGAGAGCACTCACACTGAAGGATATTTTAAATGGAACATTTTCT
TATAAAACATTTTTTCCAAACTGGATTTCAGGACAAGAATATCTTCATCAATCTGCAGAT
AACAATATAGTACTTTATAATATTGAAACAGGACAATCATATACCATTTTGAGTAATAGA
ACCATGAAAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTATAT
CTAGAAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCTAT
GACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATTTA
TGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATATCTATTTGAAA
CAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAATATT
TAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCTCTG
GTGGTCTCCTAATGGAAAATTTTTGGCATATGCGGAATTTAATGATACGGATATACCAGT
TATTGCCTATTCCT ATTAT GGCG ATG AAC AATATCCT AG AAC AAT AAATATTCC AT ACCC
AAAGGCTGGAGCTAAGAATCCCGTTGTTCGGATATTTATTATCGATACCACTTACCCTGC
GTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGCAATGATAGCCTCAAGTGATTATTATTT
CAGTTGGCTCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCA
GAATGTTTCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTGTCC
AAAGACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTTT
CAACACCAGTTTTCAGCTATGATGCCATTTCGTACTACAAAATATTTAGTGACAAGGATG
GCTACAAACATATTCACTATATCAAAGACACTGTGGAAAATGCTATTCAAATTACAAGTG
GC AAGTGGGAGGCC AT AAAT AT ATTCAG AGT AAC AC AGG ATTC ACTGTTTTATTCT AGC A
ATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGGAAGCTAT
CCTCCAAGCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAAGGTGCCAATATTACAC
AGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCC
CATTTCCACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTGGAAGAAAACA
AGG AATTGGAAAATGCTTTGAAAAAT ATCC AGCTGCCT AAAG AGGAAATT AAG AAACTT
GAAGTAGATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATTTGACAGATCA
AAGAAGTATCCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCT
GTATTTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTG
GTGGATGGTCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGTGTATCGAAA
GCTGGGTGTTT AT GAAGTT GAAGACCAGATT ACAGCTGTC AG AAAATTC AT AGAAATGG
GTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTGGTCCTATGGAGGATACGTTTCAT
CACTGGCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTC
CAGCTGGGAATATTACGCGTCTGTCTACACAGAGAGATTCATGGGTCTCCCAACAAAGG
ATGATAATCTTGAGCACTATAAGAATTCAACTGTGATGGCAAGAGCAGAATATTTCAGA
AATGTAGACTATCTTCTCATCCACGGAACAGCAGATGATAATGTGCACTTTCAAAACTCA
GCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCT
GACC AG AACC ACGGCTT ATCCGGCCTGTCC ACGAACCACTT AT AC ACCC ACAT GACCC AC
TTCCTAAAGCAGTGTTTCTCTTTGTCAGACTAACTCGAGCATGCATCTAGAGGGCCCTATT
C
>pPOB17
TTACGCTAGCTTGGGGGATCCGCCCATGAAGACTTGGGTAAAAATCGTATTTGGAGTTGC
CACCTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTCAAGAGTTCAT
AACTCTGAAGAAAATACAATGAGAGCACTCACACTGAAGGATATTTTAAATGGAACATT
TTCTTATAAAACATTTTTTCCAAACTGGATTTCAGGACAAGAATATCTTCATCAATCTGCA
GAT AACAAT AT AGT ACTTT AT AAT ATTGAAAC AGGAC AATC AT AT ACC ATTTTGAGT AAT
AGAACCATGAAAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTA
TATCTAGAAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATC
TATGACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTAT
TTATGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATATCTATTTG
AAACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAAT
ATTTAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCT
CTGGT GGTCTCCTAATGGAAAATTTTTGGCATATGCGG AATTT AATG AT ACGG AT AT ACC
a g t t a t t g c c t a t t c c t a t t a t g g c g a t g a a c a a t a t c c t a g a a c a a t a a a t a t t c c a t a
CCCAAAGGCTGGAGCTAAGAATCCCGTTGTTCGGATATTTATTATCGATACCACTTACCC
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TGCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGCAATGATAGCCTCAAGTGATTATTA
TTTCAGTTGGCTCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGT
CCAGAATGTTTCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTG
TCCAAAGACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTG
TTTCAACACCAGTTTTCAGCTATGATGCCAnTCGTACTACAAAATATTTAGTGACAAGG
ATGGCTACAAACATATTCACTATATCAAAGACACTGTGGAAAATGCTATTCAAATTACAA
GTGGCAAGTGGGAGGCCATAAATATATTCAGAGTAACACAGGATTCACTGTTTTATTCTA
GCAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGGAAGC
TATCCTCCAAGCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAAGGTGCCAATATTAC
ACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATC
CCCATTTCCACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTGGAAGAAAAC
AAGGAATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTAAAGAGGAAATTAAGAAACT
TGAAGTAGATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATTTGACAGATC
AAAGAAGTATCCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTC
TGTATTTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTG
GTGGATGGTCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGTGTATCGAAA
GCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAGAAAATTCATAGAAATGG
GTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTGGTCCTATGGAGGATACGTTTCAT
CACTGGCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTC
CAGCTGGGAATATTACGCGTCTGTCTACACAGAGAGATTCATGGGTCTCCCAACAAAGG
ATGATAATCTTGAGCACTATAAGAATTCAACTGTGATGGCAAGAGCAGAATATTTCAGA
AATGTAGACTATCTTCTCATCCACGGAACAGCAGATGATAATGTGCACTTTCAAAACTCA
GCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGTGGTACTCT
GACCAGAACCACGGCTTATCCGGCCTGTCCACGAACCACTTATACACCCACATGACCCAC
TTCCTAAAGCAGTGTTTCTCTTTGTCAGACTAACTCGAGCATGCATCTAGAGGGC
>pPOB18
GATTACGCTAGCTTGGGGGATCCGCCATGGGGATGAAGACTTGGGTAAAAATCGTATTTG
GAGTTGCCACCTCTGCTGTGCTTGCCTTATTGGTGATGTGCATTGTCTTACGCCCTTCAAG
AGTTCATAACTCTGAAGAAAATACAATGAGAGCACTCACACTGAAGGATATTTTAAATG
GAACATTTTCTTATAAAACATTTTTTCCAAACTGGATTTCAGGACAAGAATATCTTCATCA
ATCTGC AGAT AACAAT AT AGT ACTTT AT AATATTG AAAC AGG AC AATC AT AT ACC ATTTT
GAGTAATAGAACCATGAAAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCA
ATTTGT AT ATCT AGAAAGTGATT ATTCAAAGCTTTGGAGAT ACTCTT AC AC AGC AAC AT A
TTACATCTATGACCTTAGCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAAT
TCAGTATTTATGCTGGTCGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATAT
CTATTTGAAACAAAGACCAGGAGATCCACCmTCAAATAACATTTAATGGAAGAGAAA
ATAAAATATTTAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAAT
ATGCTCTCTGGTGGTCTCCTAATGGAAAATTTTTGGCATATGCGGAATTTAATGATACGG
ATATACCAGTTATTGCCTATTCCTATTATGGCGATGAACAATATCCTAGAACAATAAATA
TTCCATACCCAAAGGCTGG AGCT AAG AATCCCGTTGTTCGGAT ATTT ATTATCG AT ACCA
CTTACCCTGCGTATGTAGGTCCCCAGGAAGTGCCTGTTCCAGCAATGATAGCCTCAAGTG
ATTATTATTTCAGTTGGCTCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAA
AAAGAGTCCAGAATGTTTCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACAT
GGGATTGTCCAAAGACCCAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGG
ATTCTTTGTTTCAACACCAGTTTTCAGCTATGATGCCATTTCGTACTACAAAATATTTAGT
GACAAGGATGGCTACAAACATATTCACTATATCAAAGACACTGTGGAAAATGCTATTCA
AATTACAAGTGGCAAGTGGGAGGCCATAAATATATTCAGAGTAACACAGGATTCACTGT
TTTATTCTAGCAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCA
TTGGAAGCTATCCTCCAAGCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAAGGTGC
CAATATTACACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGC
CCAGGCATCCCCATTTCCACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTG
GAAGAAAACAAGGAATTGGAAAATGCTTTGAAAAATATCCAGCTGCCTAAAGAGGAAAT
TAAGAAACTTGAAGTAGATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATT
TGACAGATCAAAGAAGTATCCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAG
TGTAAGGTCTGTATTTGCTGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGT
CATTGCCTTGGTGGATGGTCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGT
GTATCGAAAGCTGGGTGTTTATGAAGTTGAAGACCAGATTACAGCTGTCAGAAAATTCAT
AGAAATGGGTTTCATTGATGAAAAAAGAATAGCCATATGGGGCTGGTCCTATGGAGGAT
ACGTTTCATCACTGGCCCTTGCATCTGGAACTGGTCTTTTCAAATGTGGTATAGCAGTGGC
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TCCAGTCTCCAGCTGGGAATATTACGCGTCTGTCTACACAGAGAGATTCATGGGTCTCCC
AACAAAGGATGATAATCTTGAGCACTATAAGAATTCAACTGTGATGGCAAGAGCAGAAT
ATTTCAGAAATGTAGACTATCTTCTCATCCACGGAACAGCAGATGATAATGTGCACTTTC
AAAACTCAGCACAGATTGCTAAAGCTCTGGTTAATGCACAAGTGGATTTCCAGGCAATGT
GGTACTCTGACCAGAACCACGGCTTATCCGGCCTGTCCACGAACCACTTATACACCCACA
t g a c c c a c t t c c t a a a g c a g t g t t t c t c t t t g t c a g a c t a a c t c g a g c a t g c a t c t a g a g
g g c c c t a t t c
> PQPOB5
a t g a g a g g a t c g c a t c a c c a t c a c c a t c a c g g a t c t g g c t c t g g a t c t g g t a t c g a g g g a
a g g c c t t a t a a t g g a a c t g g a t c c a t g a a g a c t t g g g t a a a a a t c g t a t t t g g a g t t g c c
a c c t c t g c t g t g c t t g c c t t a t t g g t g a t g t g c a t t g t c t t a c g c c c t t c a a g a g t t c a t a
a c t c t g a a g a a a a t a c a a t g a g a g c a c t c a c a c t g a a g g a t a t t t t a a a t g g a a c a t t t t
c t t a t a a a a c a t t t t t t c c a a a c t g g a t t t c a g g a c a a g a a t a t c t t c a t c a a t c t g c a g
ATAACAATATAGTACnTATAATATTGAAACAGGACAATCATATACCATTTTGAGTAATA
g a a c c a t g a a a a g t g t g a a t g c t t c a a a t t a c g g c t t a t c a c c t g a t c g g c a a t t t g t a t
ATCTAGAAAGTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCT
a t g a c c t t a g c a a t g g a g a a t t t g t a a g a g g a a a t g a g c t t c c t c g t c c a a t t c a g t a t t
TATGCTGGTCGCCTGTTGGGAGT AAATT AGC AT ATGTCTATCAAAACAAT ATCT ATTTG A 
AACAAAGACCAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAATA 
TTTAATGGAATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCTC 
TGGTGGTCTCCTAATGG AAAATTTTTGGC AT ATGCGG AATTT a a t g  a t  a c g g  a t  a t  a c c a
g t t a t t g c c t a t t c c t a t t a t g g c g a t g a a c a a t a t c c t a g a a c a a t a a a t a t t c c a t a c
c c a a a g g c t g g a g c t a a g a a t c c c g t t g t t c g g a t a t t t a t t a t c g a t a c c a c t t a c c c t
g c g t a t g t a g g t c c c c a g g a a g t g c c t g t t c c a g c a a t g a t a g c c t c a a g t g a t t a t t a t
t t c a g t t g g c t c a c g t g g g t t a c t g a t g a a c g a g t a t g t t t g c a g t g g c t a a a a a g a g t c
c a g a a t g t t t c g g t c c t g t c t a t a t g t g a c t t c a g g g a a g a c t g g c a g a c a t g g g a t t g t
c c a a a g a c c c a g g a g c a t a t a g a a g a a a g c a g a a c t g g a t g g g c t g g t g g a t t c t t t g t
t t c a a c a c c a g t t t t c a g c t a t g a t g c c a t t t c g t a c t a c a a a a t a t t t a g t g a c a a g g a
TGGCT AC AAAC AT ATTCACTAT ATC AAAGAC ACTGTGGAAAATGCT ATTCAAATT AC AAG
t g g c a a g t g g g a g g c c a t a a a t a t a t t c a g a g t a a c a c a g g a t t c a c t g t t t t a t t c t a g
CAATGAATTTGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGGAAGCT
a t c c t c c a a g c a a g a a g t g t g t t a c t t g c c a t c t a a g g a a a g a a a g g t g c c a a t a t t a c
ACAGCAAGTTTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATC
c c c a t t t c c a c c c t t c a t g a t g g a c g c a c t g a t c a a g a a a t t a a a a t c c t g g a a g a a a a c
AAGGAATTGGAAAATGCTTTGAAAAATATCC AGCTGCCT AAAGAGGAAATT AAG AAACT
t g a a g t a g a t g a a a t t a c t t t a t g g t a c a a g a t g a t t c t t c c t c c t c a a t t t g a c a g a t c
a a a g a a g t a t c c c t t g c t a a t t c a a g t g t a t g g t g g t c c c t g c a g t c a g a g t g t a a g g t c
t g t a t t t g c t g t t a a t t g g a t a t c t t a t c t t g c a a g t a a g g a a g g g a t g g t c a t t g c c t t g
g t g g a t g g t c g a g g a a c a g c t t t c c a a g g t g a c a a a c t c c t c t a t g c a g t g t a t c g a a a
g c t g g g t g t t t a t g a a g t t g a a g a c c a g a t t a c a g c t g t c a g a a a a t t c a t a g a a a t g g
g t t t c a t t g a t g a a a a a a g a a t a g c c a t a t g g g g c t g g t c c t a t g g a g g a t a c g t t t c a t
c a c t g g c c c t t g c a t c t g g a a c t g g t c t t t t c a a a t g t g g t a t a g c a g t g g c t c c a g t c t c
c a g c t g g g a a t a t t a c g c g t c t g t c t a c a c a g a g a g a t t c a t g g g t c t c c c a a c a a a g g
a t g a t a a t c t t g a g c a c t a t a a g a a t t c a a c t g t g a t g g c a a g a g c a g a a t a t t t c a g a
a a t g t a g a c t a t c t t c t c a t c c a c g g a a c a g c a g a t g a t a a t g t g c a c t t t c a a a a c t c a
g c a c a g a t t g c t a a a g c t c t g g t t a a t g c a c a a g t g g a t t t c c a g g c a a t g t g g t a c t c t
g a c c a g a a c c a c g g c t t a t c c g g c c t g t c c a c g a a c c a c t t a t a c a c c c a c a t g a c c c a c
t t c c t a a a g c a g t g t t t c t c t t t g t c a g a c t a a
> pIRPOBl
g g a t c c g c c a c c a t g g g g a a g a c t t g g g t a a a a a t c g t a t t t g g a g t t g c c a c c t c t g c t
g t g c t t g c c t t a t t g g t g a t g t g c a t t g t c t t a c g c c c t t c a a g a g t t c a t a a c t c t g a a g
AAAATACAATGAGAGCACTCACACTGAAGGATATTTTAAATGGAACATnTCTTATAAAA
CATTTTTTCCAAACTGGATTTCAGGACAAGAATATCTTCATCAATCTGCAGATAACAATA
TAGTACTTTATAATATTGAAACAGGACAATCATATACCATTTTGAGTAATAGAACCATGA
AAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTATATCTAGAAA
GTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCTATGACCTTA
GCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGGT
CGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATATCTATTTGAAACAAAGAC
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CAGGAGATCCACCTTTTCAAATAACATTTAATGGAAGAGAAAATAAAATATTTAATGGA
ATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCTCTGGTGGTCT
c c t a a t g g a a a a t t t t t g g c a t a t g c g g a a t t t a a t g a t a c g g a t a t a c c a g t t a t t g c c
t a t t c c t a t t a t g g c g a t g a a c a a t a t c c t a g a a c a a t a a a t a t t c c a t a c c c a a a g g c t
g g a g c t a a g a a t c c c g t t g t t c g g a t a t t t a t t a t c g a t a c c a c t t a c c c t g c g t a t g t a
g g t c c c c a g g a a g t g c c t g t t c c a g c a a t g a t a g c c t c a a g t g a t t a t t a t t t c a g t t g g
c t c a c g t g g g t t a c t g a t g a a c g a g t a t g t t t g c a g t g g c t a a a a a g a g t c c a g a a t g t t
t c g g t c c t g t c t a t a t g t g a c t t c a g g g a a g a c t g g c a g a c a t g g g a t t g t c c a a a g a c c
c a g g a g c a t a t a g a a g a a a g c a g a a c t g g a t g g g c t g g t g g a t t c t t t g t t t c a a c a c c
a g t t t t c a g c t a t g a t g c c a t t t c g t a c t a c a a a a t a t t t a g t g a c a a g g a t g g c t a c a a
a c a t a t t c a c t a t a t c a a a g a c a c t g t g g a a a a t g c t a t t c a a a t t a c a a g t g g c a a g t g
g g a g g c c a t a a a t a t a t t c a g a g t a a c a c a g g a t t c a c t g t t t t a t t c t a g c a a t g a a t t
t g a a g a a t a c c c t g g a a g a a g a a a c a t c t a c a g a a t t a g c a t t g g a a g c t a t c c t c c a a
g c a a g a a g t g t g t t a c t t g c c a t c t a a g g a a a g a a a g g t g c c a a t a t t a c a c a g c a a g t
TTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCCCATTTCC
a c c c t t c a t g a t g g a c g c a c t g a t c a a g a a a t t a a a a t c c t g g a a g a a a a c a a g g a a t t
GGAA AATGCTTTG AAAAATATCCAGCTGCCT AAAGAGG AAATTAAGAAACTTGAAGT AG
a t g a a a t t a c t t t a t g g t a c a a g a t g a t t c t t c c t c c t c a a t t t g a c a g a t c a a a g a a g t
a t c c c t t g c t a a t t c a a g t g t a t g g t g g t c c c t g c a g t c a g a g t g t a a g g t c t g t a t t t g c
t g t t a a t t g g a t a t c t t a t c t t g c a a g t a a g g a a g g g a t g g t c a t t g c c t t g g t g g a t g g
t c g a g g a a c a g c t t t c c a a g g t g a c a a a c t c c t c t a t g c a g t g t a t c g a a a g c t g g g t g t
t t a t g a a g t t g a a g a c c a g a t t a c a g c t g t c a g a a a a t t c a t a g a a a t g g g t t t c a t t g a
t g a a a a a a g a a t a g c c a t a t g g g g c t g g t c c t a t g g a g g a t a c g t t t c a t c a c t g g c c c t
t g c a t c t g g a a c t g g t c t t t t c a a a t g t g g t a t a g c a g t g g c t c c a g t c t c c a g c t g g g a
a t a t t a c g c g t c t g t c t a c a c a g a g a g a t t c a t g g g t c t c c c a a c a a a g g a t g a t a a t c t
t g a g c a c t a t a a g a a t t c a a c t g t g a t g g c a a g a g c a g a a t a t t t c a g a a a t g t a g a c t
a t c t t c t c a t c c a c g g a a c a g c a g a t g a t a a t g t g c a c t t t c a a a a c t c a g c a c a g a t t g
c t a a a g c t c t g g t t a a t g c a c a a g t g g a t t t c c a g g c a a t g t g g t a c t c t g a c c a g a a c c
a c g g c t t a t c c g g c c t g t c c a c g a a c c a c t t a t a c a c c c a c a t g a c c c a c t t c c t a a a g c
a g t g t t t c t c t t t g t c a g a c t a a g c g g c c g c g a c t a c a a g g a t g a c g a t g a c a a g g a t t a
c a a a g a c g a c g a t g a t a a g g a c t a t a a g g a t g
> pIRPOB2
g g a t c c g c c a c c a t g g g g a a g a c t t g g g t a a a a a t c g t a t t t g g a g t t g c c a c c t c t g c t
g t g c t t g c c t t a t t g g t g a t g t g c a t t g t c t t a c g c c c t t c a a g a g t t c a t a a c t c t g a a g
a a a a t a c a a t g a g a g c a c t c a c a c t g a a g g a t a t t t t a a a t g g a a c a t t t t c t t a t a a a a
c a t t t t t t c c a a a c t g g a t t t c a g g a c a a g a a t a t c t t c a t c a a t c t g c a g a t a a c a a t a
T AGT ACTTT AT AAT ATTG AAACAGGAC AATC AT AT ACCATTTTG AGT AAT AG AACC ATGA
AAAGTGTGAATGCTTCAAATTACGGCTTATCACCTGATCGGCAATTTGTATATCTAGAAA
GTGATTATTCAAAGCTTTGGAGATACTCTTACACAGCAACATATTACATCTATGACCTTA
GCAATGGAGAATTTGTAAGAGGAAATGAGCTTCCTCGTCCAATTCAGTATTTATGCTGGT
CGCCTGTTGGGAGTAAATTAGCATATGTCTATCAAAACAATATCTATTTGAAACAAAGAC
CAGGAGATCCACCnTTCAAATAACATTTAATGGAAGAGAAAATAAAATATTTAATGGA
ATCCCAGACTGGGTTTATGAAGAGGAAATGCTTGCTACAAAATATGCTCTCTGGTGGTCT
CCTAATGGAAAArmrTGGCATATGCGGAATTTAATGATACGGATATACCAGTTATTGCC
TATTCCT ATT ATGGCGATGAAC AAT ATCCT AGAACAATAAAT ATTCC AT ACCC AAAGGCT
GGAGCTAAGAATCCCGTTGTTCGGATATTTATTATCGATACCACTTACCCTGCGTATGTA
GGTCCCC AGGAAGTGCCTGTTCCAGC AAT GAT AGCCTCAAGT GATT ATT ATTTC AGTTGG
CTCACGTGGGTTACTGATGAACGAGTATGTTTGCAGTGGCTAAAAAGAGTCCAGAATGTT
TCGGTCCTGTCTATATGTGACTTCAGGGAAGACTGGCAGACATGGGATTGTCCAAAGACC
CAGGAGCATATAGAAGAAAGCAGAACTGGATGGGCTGGTGGATTCTTTGTTTCAACACC
AGTTTTCAGCTATGATGCCATTTCGTACTACAAAATATTTAGTGACAAGGATGGCTACAA
ACATATTCACTATATCAAAGACACTGTGGAAAATGCTATTCAAATTACAAGTGGCAAGTG
GGAGGCCATAAATATATTCAGAGTAACACAGGATTCACTGTTTTATTCTAGCAATGAATT
TGAAGAATACCCTGGAAGAAGAAACATCTACAGAATTAGCATTGGAAGCTATCCTCCAA
GCAAGAAGTGTGTTACTTGCCATCTAAGGAAAGAAAGGTGCCAATATTACACAGCAAGT
TTCAGCGACTACGCCAAGTACTATGCACTTGTCTGCTACGGCCCAGGCATCCCCATTTCC
ACCCTTCATGATGGACGCACTGATCAAGAAATTAAAATCCTGGAAGAAAACAAGGAATT
GGAAAATGCTTTGAAAAATATCCAGCTGCCTAAAGAGG AAATTAAGAAACTTGAAGTAG
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ATGAAATTACTTTATGGTACAAGATGATTCTTCCTCCTCAATTTGACAGATCAAAGAAGT
ATCCCTTGCTAATTCAAGTGTATGGTGGTCCCTGCAGTCAGAGTGTAAGGTCTGTATTTGC
TGTTAATTGGATATCTTATCTTGCAAGTAAGGAAGGGATGGTCATTGCCTTGGTGGATGG
TCGAGGAACAGCTTTCCAAGGTGACAAACTCCTCTATGCAGTGTATCGAAAGCTGGGTGT
TT ATGAAGTTGAAGACCAGATT ACAGCTGTC AG AAAATT CAT AGAAAT GGGTTT C ATTGA
TGAAAAAAGAATAGCCATATGGGGCTGGTCCTATGGAGGATACGTTTCATCACTGGCCCT
TGCATCTGGAACTGGTCTTTTCAAATGTGGTATAGCAGTGGCTCCAGTCTCCAGCTGGGA
ATATTACGCGTCTGTCTACACAGAGAGATTCATGGGTCTCCCAACAAAGGATGATAATCT
t g a g c a c t a t a a g a a t t c a a c t g t g a t g g c a a g a g c a g a a t a t t t c a g a a a t g t a g a c t
a t c t t c t c a t c c a c g g a a c a g c a g a t g a t a a t g t g c a c t t t c a a a a c t c a g c a c a g a t t g
c t a a a g c t c t g g t t a a t g c a c a a g t g g a t t t c c a g g c a a t g t g g t a c t c t g a c c a g a a c c
a c g g c t t a t c c g g c c t g t c c a c g a a c c a c t t a t a c a c c c a c a t g a c c c a c t t c c t a a a g c
a g t g t t t c t c t t t g t c a g a c t g c g g c c g c g a c t a c a a g g a t g a c g a t g a c a a g g a t t a c a
a a g a c g a c g a t g a t a a g g a c t a t a a g g
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